DrugMAP Full Data Download File
Title - DrugMAP drug information in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
College of Pharmaceutical Sciences
Zhejiang University
https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)
ID: Drug ID
DN: Drug Name
HS: Highest Status
SN: Synonymous
CP: Company
TC: Therapeutic Class
DT: Drug Type
SQ: Sequence
PC: PubChem CID
MW: Molecular Weight
FM: Formula
IC: InChI
CS: Canonical SMILES
IK: InChIKey
IU: IUPAC Name
CA: CAS Number
CB: ChEBI ID
DE: Disease Entry
DMMHNU2 ID DMMHNU2
DMMHNU2 DN (S)-(+)-Dimethindene maleate
DMMHNU2 HS Approved
DMMHNU2 SN UNII-J43ZL3WTLN; J43ZL3WTLN; 136152-65-3; DSSTox_RID_83231; DSSTox_CID_28966; DSSTox_GSID_49040; Dimethindene maleate, (+)-; CAS-1217457-81-2; NCGC00025158-01; 121367-05-3; Dimethindene maleate, (S)-(+)-; DTXSID8049040; CHEMBL2356801; MolPort-023-276-095; HMS3267J12; Tox21_113582; AKOS024456589; Tox21_113582_1; NCGC00025158-02; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1S)-1-(2-pyridinyl)ethyl)-, (2Z)-2-butenedioate (1:1); B6734; (S)-(+)-Dimethindene maleate, > UNII-6LL60J9E0O component
DMMHNU2 TC Antiinflammatory Agents
DMMHNU2 DT Small molecular drug
DMMHNU2 PC 56972160
DMMHNU2 MW 408.5
DMMHNU2 FM C24H28N2O4
DMMHNU2 IC InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m1./s1
DMMHNU2 CS C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMMHNU2 IK SWECWXGUJQLXJF-HFNHQGOYSA-N
DMMHNU2 IU (Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1S)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
DMMHNU2 CA CAS 136152-65-3
DMMHNU2 DE Pruritus
DMIAHVU ID DMIAHVU
DMIAHVU DN 2-deoxyglucose
DMIAHVU HS Approved
DMIAHVU SN 154-17-6; Deoxyglucose; 2-Deoxy-D-mannose; 2-Deoxy-D-arabinohexose; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; arabino-Hexose, 2-deoxy-; D-Glucose, 2-deoxy-; 9G2MP84A8W; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; AK-44445; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; d-2-glucodesose; D-2dGlc; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; 2-INNo-D-AEIIC; SCHEMBL7670; AC1L33KH; KSC175S5P; 4-01-00-04282 (Beilstein Handbook Reference); Jsp003004; CHEMBL2074932; CTK0H5957; MolPort-002-317-302; 2-deoxy-D-glucose
DMIAHVU CP Threshold Pharmaceuticals
DMIAHVU DT Small molecular drug
DMIAHVU PC 108223
DMIAHVU MW 164.16
DMIAHVU FM C6H12O5
DMIAHVU IC InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
DMIAHVU CS C(C=O)[C@H]([C@@H]([C@@H](CO)O)O)O
DMIAHVU IK VRYALKFFQXWPIH-PBXRRBTRSA-N
DMIAHVU IU (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal
DMIAHVU CA CAS 154-17-6
DMIAHVU DE Solid tumour/cancer
DMYFBMS ID DMYFBMS
DMYFBMS DN 99mTc-fanolesomab
DMYFBMS HS Approved
DMYFBMS SN LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody
DMYFBMS CP Palatin Technologies
DMYFBMS DT Antibody
DMYFBMS DE Appendicitis
DMVZO01 ID DMVZO01
DMVZO01 DN 99mTc-sestamibi
DMVZO01 HS Approved
DMVZO01 SN Sestamibi; RP-30; Tc-MIBI; Technetium-99m sestamibi
DMVZO01 CP Bristol-Myers Squibb Pharma Co
DMVZO01 DT Small molecular drug
DMVZO01 PC 9832136
DMVZO01 MW 777.9
DMVZO01 FM C36H66N6O6Tc+7
DMVZO01 IC InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+7/i;;;;;;1+1
DMVZO01 CS CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc+7]
DMVZO01 IK ZGDBEIODOXIKGQ-KTTJZPQESA-N
DMVZO01 IU 1-isocyano-2-methoxy-2-methylpropane;technetium-99(7+)
DMVZO01 DE Breast cancer
DMMN36E ID DMMN36E
DMMN36E DN Abacavir
DMMN36E HS Approved
DMMN36E SN Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
DMMN36E CP GlaxoSmithKline
DMMN36E TC Anti-HIV Agents
DMMN36E DT Small molecular drug
DMMN36E PC 441300
DMMN36E MW 286.33
DMMN36E FM C14H18N6O
DMMN36E IC InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
DMMN36E CS C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO
DMMN36E IK MCGSCOLBFJQGHM-SCZZXKLOSA-N
DMMN36E IU [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
DMMN36E CA CAS 136470-78-5
DMMN36E CB CHEBI:421707
DMMN36E DE Human immunodeficiency virus infection
DMOERGM ID DMOERGM
DMOERGM DN Abaloparatide
DMOERGM HS Approved
DMOERGM SN Tymlos
DMOERGM CP Radius Health
DMOERGM DT Recombinant protein
DMOERGM SQ Abaloparatide N-terminal peptide sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA
DMOERGM PC 76943386
DMOERGM MW 3961
DMOERGM FM C174H300N56O49
DMOERGM IC InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
DMOERGM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMOERGM IK BVISQZFBLRSESR-XSCWXTNMSA-N
DMOERGM IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMOERGM CA CAS 247062-33-5
DMOERGM DE Postmenopausal osteoporosis
DM2RX0I ID DM2RX0I
DM2RX0I DN Abametapir
DM2RX0I HS Approved
DM2RX0I SN 5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl
DM2RX0I DT Small molecular drug
DM2RX0I PC 15664
DM2RX0I MW 184.24
DM2RX0I FM C12H12N2
DM2RX0I IC InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3
DM2RX0I CS CC1=CN=C(C=C1)C2=NC=C(C=C2)C
DM2RX0I IK PTRATZCAGVBFIQ-UHFFFAOYSA-N
DM2RX0I IU 5-methyl-2-(5-methylpyridin-2-yl)pyridine
DM2RX0I CA CAS 1762-34-1
DM2RX0I DE Head and body lice
DM5WFNP ID DM5WFNP
DM5WFNP DN Abarelix
DM5WFNP HS Approved
DM5WFNP SN Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10
DM5WFNP CP Speciality European Pharma
DM5WFNP TC Anticancer Agents
DM5WFNP DT Small molecular drug
DM5WFNP PC 16131215
DM5WFNP MW 1416.1
DM5WFNP FM C72H95ClN14O14
DM5WFNP IC InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
DM5WFNP CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM5WFNP IK AIWRTTMUVOZGPW-HSPKUQOVSA-N
DM5WFNP IU (2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DM5WFNP CA CAS 183552-38-7
DM5WFNP CB CHEBI:337298
DM5WFNP DE Prostate cancer
DMSA8RU ID DMSA8RU
DMSA8RU DN Abatacept
DMSA8RU HS Approved
DMSA8RU SN Orencia (TN)
DMSA8RU CP Bristol-Myers Squibb
DMSA8RU TC Antirheumatic Agents
DMSA8RU SQ Abatacept monomer sequence: MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSA8RU DE Rheumatoid arthritis
DMJO6GV ID DMJO6GV
DMJO6GV DN Abciximab
DMJO6GV HS Approved
DMJO6GV SN ReoPro (TN)
DMJO6GV CP Eli Lilly
DMJO6GV TC Anticoagulants
DMJO6GV DT Monoclonal antibody
DMJO6GV SQ 1TXV:H ReoPro-like antibody Heavy Chain 1: EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 1DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >1TXV:H ReoPro-like antibody Heavy Chain 2EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 2DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
DMJO6GV DE Angina pectoris
DM8V75C ID DM8V75C
DM8V75C DN ABIRATERONE
DM8V75C HS Approved
DM8V75C SN Abiraterone (AR inhibitor)
DM8V75C DT Small molecular drug
DM8V75C PC 132971
DM8V75C MW 349.5
DM8V75C FM C24H31NO
DM8V75C IC InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
DM8V75C CS C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
DM8V75C IK GZOSMCIZMLWJML-VJLLXTKPSA-N
DM8V75C IU (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8V75C CA CAS 154229-19-3
DM8V75C CB CHEBI:68642
DM8V75C DE Prostate cancer
DMANBZI ID DMANBZI
DMANBZI DN Abiraterone acetate
DMANBZI HS Approved
DMANBZI SN CB-7630; JNJ-212082; Zytiga
DMANBZI TC Anticancer Agents
DMANBZI DT Small molecular drug
DMANBZI PC 9821849
DMANBZI MW 391.5
DMANBZI FM C26H33NO2
DMANBZI IC InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
DMANBZI CS CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
DMANBZI IK UVIQSJCZCSLXRZ-UBUQANBQSA-N
DMANBZI IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMANBZI CA CAS 154229-18-2
DMANBZI CB CHEBI:68639
DMANBZI DE Prostate cancer
DMZT2P0 ID DMZT2P0
DMZT2P0 DN Abobotulinum toxin A
DMZT2P0 HS Approved
DMZT2P0 SN AbobotulinumtoxinA; Azzalure; Dysport; Reloxin; Abobotulinum toxin A for injection; CNT-52120
DMZT2P0 CP Ipsen
DMZT2P0 DE Cervical cancer
DM7GCVW ID DM7GCVW
DM7GCVW DN Acalabrutinib
DM7GCVW HS Approved
DM7GCVW SN Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
DM7GCVW CP AstraZeneca/Acerta Pharma
DM7GCVW PC 71226662
DM7GCVW MW 465.5
DM7GCVW FM C26H23N7O2
DM7GCVW IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM7GCVW CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM7GCVW IK WDENQIQQYWYTPO-IBGZPJMESA-N
DM7GCVW IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM7GCVW CA CAS 1420477-60-6
DM7GCVW DE Chronic lymphocytic leukaemia; Mantle cell lymphoma
DMO381I ID DMO381I
DMO381I DN Acamprosate
DMO381I HS Approved
DMO381I SN AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid
DMO381I TC Alcohol Deterrents
DMO381I DT Small molecular drug
DMO381I PC 71158
DMO381I MW 181.21
DMO381I FM C5H11NO4S
DMO381I IC InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)
DMO381I CS CC(=O)NCCCS(=O)(=O)O
DMO381I IK AFCGFAGUEYAMAO-UHFFFAOYSA-N
DMO381I IU 3-acetamidopropane-1-sulfonic acid
DMO381I CA CAS 77337-76-9
DMO381I CB CHEBI:51041
DMO381I DE Alcohol dependence
DMRM3AW ID DMRM3AW
DMRM3AW DN Acarbose
DMRM3AW HS Approved
DMRM3AW SN acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369
DMRM3AW CP Bayer
DMRM3AW TC Hypoglycemic Agents
DMRM3AW DT Small molecular drug
DMRM3AW PC 41774
DMRM3AW MW 645.6
DMRM3AW FM C25H43NO18
DMRM3AW IC InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1
DMRM3AW CS C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
DMRM3AW IK XUFXOAAUWZOOIT-UGEKTDRHSA-N
DMRM3AW IU (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
DMRM3AW CA CAS 56180-94-0
DMRM3AW CB CHEBI:2376
DMRM3AW DE Diabetic complication; Cardiovascular disease
DM0TI4U ID DM0TI4U
DM0TI4U DN Acebutolol
DM0TI4U HS Approved
DM0TI4U SN Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
DM0TI4U CP Promius Pharma Llc
DM0TI4U TC Antihypertensive Agents
DM0TI4U DT Small molecular drug
DM0TI4U PC 1978
DM0TI4U MW 336.4
DM0TI4U FM C18H28N2O4
DM0TI4U IC InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
DM0TI4U CS CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
DM0TI4U IK GOEMGAFJFRBGGG-UHFFFAOYSA-N
DM0TI4U IU N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide
DM0TI4U CA CAS 37517-30-9
DM0TI4U CB CHEBI:2379
DM0TI4U DE Hypertension
DMOLNCZ ID DMOLNCZ
DMOLNCZ DN ACECLIDINE
DMOLNCZ HS Approved
DMOLNCZ SN (-)-aceclidine; R-(-)-aceclidine; GTPL288; ZB016005; [(8R)-1-azoniabicyclo[2.2.2]octan-8-yl] acetate
DMOLNCZ DT Small molecular drug
DMOLNCZ PC 1979
DMOLNCZ MW 169.22
DMOLNCZ FM C9H15NO2
DMOLNCZ IC InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
DMOLNCZ CS CC(=O)OC1CN2CCC1CC2
DMOLNCZ IK WRJPSSPFHGNBMG-UHFFFAOYSA-N
DMOLNCZ IU 1-azabicyclo[2.2.2]octan-3-yl acetate
DMOLNCZ CA CAS 827-61-2
DMOLNCZ CB CHEBI:93847
DMOLNCZ DE Glaucoma/ocular hypertension
DMZDF0B ID DMZDF0B
DMZDF0B DN Aceclofenac
DMZDF0B HS Approved
DMZDF0B SN Airtal; Barracan; Biofenac; Bristaflam; Falcol; Gerbin; Preservex; YT-919
DMZDF0B CP Almirall Prodesfarma SA
DMZDF0B DT Small molecular drug
DMZDF0B PC 71771
DMZDF0B MW 354.2
DMZDF0B FM C16H13Cl2NO4
DMZDF0B IC InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
DMZDF0B CS C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMZDF0B IK MNIPYSSQXLZQLJ-UHFFFAOYSA-N
DMZDF0B IU 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid
DMZDF0B CA CAS 89796-99-6
DMZDF0B CB CHEBI:31159
DMZDF0B DE Inflammation
DMH75KV ID DMH75KV
DMH75KV DN Acenocoumarol
DMH75KV HS Approved
DMH75KV SN Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
DMH75KV TC Anticoagulants
DMH75KV DT Small molecular drug
DMH75KV PC 54676537
DMH75KV MW 353.3
DMH75KV FM C19H15NO6
DMH75KV IC InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
DMH75KV CS CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O
DMH75KV IK VABCILAOYCMVPS-UHFFFAOYSA-N
DMH75KV IU 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one
DMH75KV CA CAS 152-72-7
DMH75KV CB CHEBI:53766
DMH75KV DE Thrombosis
DM1SRQT ID DM1SRQT
DM1SRQT DN Aceprometazine
DM1SRQT HS Approved
DM1SRQT SN Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB
DM1SRQT TC Antihistamines
DM1SRQT DT Small molecular drug
DM1SRQT PC 26035
DM1SRQT MW 326.5
DM1SRQT FM C19H22N2OS
DM1SRQT IC InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
DM1SRQT CS CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C
DM1SRQT IK XLOQNFNTQIRSOX-UHFFFAOYSA-N
DM1SRQT IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone
DM1SRQT CA CAS 13461-01-3
DM1SRQT CB CHEBI:53770
DM1SRQT DE Sleep-wake disorder
DMUIE76 ID DMUIE76
DMUIE76 DN Acetaminophen
DMUIE76 HS Approved
DMUIE76 SN acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet
DMUIE76 CP Beximco Pharma
DMUIE76 TC Analgesics
DMUIE76 DT Small molecular drug
DMUIE76 PC 1983
DMUIE76 MW 151.16
DMUIE76 FM C8H9NO2
DMUIE76 IC InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
DMUIE76 CS CC(=O)NC1=CC=C(C=C1)O
DMUIE76 IK RZVAJINKPMORJF-UHFFFAOYSA-N
DMUIE76 IU N-(4-hydroxyphenyl)acetamide
DMUIE76 CA CAS 103-90-2
DMUIE76 CB CHEBI:46195
DMUIE76 DE Pain
DM1AF5U ID DM1AF5U
DM1AF5U DN Acetazolamide
DM1AF5U HS Approved
DM1AF5U SN Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox
DM1AF5U TC Anticonvulsants
DM1AF5U DT Small molecular drug
DM1AF5U PC 1986
DM1AF5U MW 222.3
DM1AF5U FM C4H6N4O3S2
DM1AF5U IC InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
DM1AF5U CS CC(=O)NC1=NN=C(S1)S(=O)(=O)N
DM1AF5U IK BZKPWHYZMXOIDC-UHFFFAOYSA-N
DM1AF5U IU N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
DM1AF5U CA CAS 59-66-5
DM1AF5U CB CHEBI:27690
DM1AF5U DE Glaucoma/ocular hypertension
DM4SJ5Y ID DM4SJ5Y
DM4SJ5Y DN Acetic Acid, Glacial
DM4SJ5Y HS Approved
DM4SJ5Y SN ethanoic acid; 64-19-7; Ethylic acid; Acetic acid glacial; Acetic acid, glacial; Methanecarboxylic acid; Glacial acetic acid; Vinegar acid; Acetasol; Acide acetique; Essigsaeure; Aci-jel; Azijnzuur; Vinegar; Kyselina octova; Acido acetico; Octowy kwas; Pyroligneous acid; HOAc; Azijnzuur [Dutch]; Ethanoic acid monomer; acetyl alcohol; Aceticum acidum; Essigsaeure [German]; ethoic acid; Caswell No 003; Otic Tridesilon; Octowy kwas [Polish]; Otic Domeboro; Acetic acid (natural); Kyselina octova [Czech]; Acide acetique [French]; Orlex; Vosol; Acetic Acid 025% In Plastic Container
DM4SJ5Y CP Actavis Mid Atlantic Llc
DM4SJ5Y TC Antiinfective Agents
DM4SJ5Y DT Small molecular drug
DM4SJ5Y PC 176
DM4SJ5Y MW 60.05
DM4SJ5Y FM C2H4O2
DM4SJ5Y IC InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
DM4SJ5Y CS CC(=O)O
DM4SJ5Y IK QTBSBXVTEAMEQO-UHFFFAOYSA-N
DM4SJ5Y IU acetic acid
DM4SJ5Y CA CAS 64-19-7
DM4SJ5Y CB CHEBI:15366
DM4SJ5Y DE infection in the ear canal
DMR6N7H ID DMR6N7H
DMR6N7H DN Acetohexamide
DMR6N7H HS Approved
DMR6N7H SN Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
DMR6N7H TC Hypoglycemic Agents
DMR6N7H DT Small molecular drug
DMR6N7H PC 1989
DMR6N7H MW 324.4
DMR6N7H FM C15H20N2O4S
DMR6N7H IC InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
DMR6N7H CS CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
DMR6N7H IK VGZSUPCWNCWDAN-UHFFFAOYSA-N
DMR6N7H IU 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
DMR6N7H CA CAS 968-81-0
DMR6N7H CB CHEBI:28052
DMR6N7H DE Diabetic complication
DMYX7NI ID DMYX7NI
DMYX7NI DN Acetohydroxamic Acid
DMYX7NI HS Approved
DMYX7NI SN AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)
DMYX7NI TC Antiinfective Agents
DMYX7NI DT Small molecular drug
DMYX7NI PC 1990
DMYX7NI MW 75.07
DMYX7NI FM C2H5NO2
DMYX7NI IC InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
DMYX7NI CS CC(=O)NO
DMYX7NI IK RRUDCFGSUDOHDG-UHFFFAOYSA-N
DMYX7NI IU N-hydroxyacetamide
DMYX7NI CA CAS 546-88-3
DMYX7NI CB CHEBI:27777
DMYX7NI DE Urinary tract infection
DMZV2PJ ID DMZV2PJ
DMZV2PJ DN Acetophenazine
DMZV2PJ HS Approved
DMZV2PJ SN Acephenazinum; Acetophenazina; Acetophenazinum; Tindal; Acetophenazine [INN]; Acetophenazina [INN-Spanish]; Acetophenazinum [INN-Latin]; Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine
DMZV2PJ TC Antipsychotic Agents
DMZV2PJ DT Small molecular drug
DMZV2PJ PC 17676
DMZV2PJ MW 411.6
DMZV2PJ FM C23H29N3O2S
DMZV2PJ IC InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3
DMZV2PJ CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMZV2PJ IK WNTYBHLDCKXEOT-UHFFFAOYSA-N
DMZV2PJ IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMZV2PJ CA CAS 2751-68-0
DMZV2PJ CB CHEBI:2401
DMZV2PJ DE Bipolar disorder
DMDF79Z ID DMDF79Z
DMDF79Z DN Acetylcholine
DMDF79Z HS Approved
DMDF79Z SN acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e
DMDF79Z CP Novartis Pharmaceuticals Corp
DMDF79Z TC Cardiovascular Agents
DMDF79Z DT Small molecular drug
DMDF79Z PC 187
DMDF79Z MW 146.21
DMDF79Z FM C7H16NO2+
DMDF79Z IC InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1
DMDF79Z CS CC(=O)OCC[N+](C)(C)C
DMDF79Z IK OIPILFWXSMYKGL-UHFFFAOYSA-N
DMDF79Z IU 2-acetyloxyethyl(trimethyl)azanium
DMDF79Z CA CAS 51-84-3
DMDF79Z CB CHEBI:15355
DMDF79Z DE Cataract
DMHAUO0 ID DMHAUO0
DMHAUO0 DN Acetyldigitoxin
DMHAUO0 HS Approved
DMHAUO0 SN Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CP Norvatis Phamaceuticals Corporation
DMHAUO0 TC Cardiotonic Agents
DMHAUO0 DT Small molecular drug
DMHAUO0 PC 5284512
DMHAUO0 MW 807
DMHAUO0 FM C43H66O14
DMHAUO0 IC InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
DMHAUO0 CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O
DMHAUO0 IK HPMZBILYSWLILX-UMDUKNJSSA-N
DMHAUO0 IU [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CA CAS 1111-39-3
DMHAUO0 CB CHEBI:53773
DMHAUO0 DE Congestive heart failure
DMYLOVR ID DMYLOVR
DMYLOVR DN Aciclovir
DMYLOVR HS Approved
DMYLOVR SN acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir
DMYLOVR CP GlaxoSmithKline
DMYLOVR TC Antiviral Agents
DMYLOVR DT Small molecular drug
DMYLOVR PC 135398513
DMYLOVR MW 225.2
DMYLOVR FM C8H11N5O3
DMYLOVR IC InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
DMYLOVR CS C1=NC2=C(N1COCCO)N=C(NC2=O)N
DMYLOVR IK MKUXAQIIEYXACX-UHFFFAOYSA-N
DMYLOVR IU 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one
DMYLOVR CA CAS 59277-89-3
DMYLOVR CB CHEBI:2453
DMYLOVR DE Virus infection; Herpes simplex virus infection
DM8BKU9 ID DM8BKU9
DM8BKU9 DN Acitretin
DM8BKU9 HS Approved
DM8BKU9 SN Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 TC Keratolytic Agents
DM8BKU9 DT Small molecular drug
DM8BKU9 PC 5284513
DM8BKU9 MW 326.4
DM8BKU9 FM C21H26O3
DM8BKU9 IC InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
DM8BKU9 CS CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC
DM8BKU9 IK IHUNBGSDBOWDMA-AQFIFDHZSA-N
DM8BKU9 IU (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 CA CAS 55079-83-9
DM8BKU9 CB CHEBI:50173
DM8BKU9 DE Psoriasis vulgaris
DMLFZHD ID DMLFZHD
DMLFZHD DN Aclarubicin
DMLFZHD HS Approved
DMLFZHD SN Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
DMLFZHD TC Anticancer Agents
DMLFZHD DT Small molecular drug
DMLFZHD PC 451415
DMLFZHD MW 811.9
DMLFZHD FM C42H53NO15
DMLFZHD IC InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
DMLFZHD CS CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
DMLFZHD IK USZYSDMBJDPRIF-SVEJIMAYSA-N
DMLFZHD IU methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
DMLFZHD CA CAS 57576-44-0
DMLFZHD CB CHEBI:77980
DMLFZHD DE Acute myeloid leukaemia
DM7JT24 ID DM7JT24
DM7JT24 DN Acocantherin
DM7JT24 HS Approved
DM7JT24 SN Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DM7JT24 TC Cardiotonic Agents
DM7JT24 DT Small molecular drug
DM7JT24 PC 439501
DM7JT24 MW 584.7
DM7JT24 FM C29H44O12
DM7JT24 IC InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DM7JT24 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DM7JT24 IK LPMXVESGRSUGHW-HBYQJFLCSA-N
DM7JT24 IU 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM7JT24 CA CAS 630-60-4
DM7JT24 CB CHEBI:472805
DM7JT24 DE Heart failure; Atrial fibrillation
DMTIGA0 ID DMTIGA0
DMTIGA0 DN Acrivastine
DMTIGA0 HS Approved
DMTIGA0 SN Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
DMTIGA0 CP Pfizer Pharmaceuticals
DMTIGA0 TC Antiinflammatory Agents
DMTIGA0 DT Small molecular drug
DMTIGA0 PC 5284514
DMTIGA0 MW 348.4
DMTIGA0 FM C22H24N2O2
DMTIGA0 IC InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
DMTIGA0 CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O
DMTIGA0 IK PWACSDKDOHSSQD-IUTFFREVSA-N
DMTIGA0 IU (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
DMTIGA0 CA CAS 87848-99-5
DMTIGA0 CB CHEBI:83168
DMTIGA0 DE Allergic rhinitis
DMQMV1B ID DMQMV1B
DMQMV1B DN Adalimumab
DMQMV1B HS Approved
DMQMV1B SN Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
DMQMV1B CP Abbott Laboratories
DMQMV1B TC Antirheumatic Agents
DMQMV1B DT Antibody
DMQMV1B SQ Light chain:: DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC > Heavy chain:EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
DMQMV1B DE Rheumatoid arthritis
DMX2358 ID DMX2358
DMX2358 DN Adapalene
DMX2358 HS Approved
DMX2358 SN Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
DMX2358 CP Galderma Laboratories
DMX2358 TC Dermatologic Agents
DMX2358 DT Small molecular drug
DMX2358 PC 60164
DMX2358 MW 412.5
DMX2358 FM C28H28O3
DMX2358 IC InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMX2358 CS COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMX2358 IK LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMX2358 IU 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMX2358 CA CAS 106685-40-9
DMX2358 CB CHEBI:31174
DMX2358 DE Acne vulgaris
DMM278X ID DMM278X
DMM278X DN Adefovir
DMM278X HS Approved
DMM278X SN ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
DMM278X DT Small molecular drug
DMM278X PC 60172
DMM278X MW 273.189
DMM278X FM C12H14Cl2N2
DMM278X IC InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
DMM278X CS C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O
DMM278X IK FIKAKWIAUPDISJ-UHFFFAOYSA-L
DMM278X IU 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
DMM278X CA CAS 106941-25-7
DMM278X CB CHEBI:2469
DMM278X DE Hepatitis B virus infection; Herpes simplex virus infection
DMMAWY1 ID DMMAWY1
DMMAWY1 DN Adefovir dipivoxil
DMMAWY1 HS Approved
DMMAWY1 SN Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV
DMMAWY1 CP Gilead Sciences
DMMAWY1 TC Antiviral Agents
DMMAWY1 DT Small molecular drug
DMMAWY1 PC 60871
DMMAWY1 MW 501.5
DMMAWY1 FM C20H32N5O8P
DMMAWY1 IC InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
DMMAWY1 CS CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C
DMMAWY1 IK WOZSCQDILHKSGG-UHFFFAOYSA-N
DMMAWY1 IU [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMMAWY1 CA CAS 142340-99-6
DMMAWY1 CB CHEBI:31175
DMMAWY1 DE Hepatitis B virus infection
DMYQDBO ID DMYQDBO
DMYQDBO DN Ademetionine
DMYQDBO HS Approved
DMYQDBO SN Ceritan; Samyr; Transmetil; Ademetionine butandisulphonate; Ademetionine disulfate tosylate; Ademetionine sulfate tosilate; FD-1561; FO-1561
DMYQDBO CP Bioresearch SpA
DMYQDBO DT Small molecular drug
DMYQDBO PC 34755
DMYQDBO MW 398.4
DMYQDBO FM C15H22N6O5S
DMYQDBO IC InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
DMYQDBO CS C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMYQDBO IK MEFKEPWMEQBLKI-AIRLBKTGSA-N
DMYQDBO IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate
DMYQDBO CA CAS 29908-03-0
DMYQDBO CB CHEBI:67040
DMYQDBO DE Cerebrovascular ischaemia; Hepatic fibrosis
DMZLHKJ ID DMZLHKJ
DMZLHKJ DN Adenine
DMZLHKJ HS Approved
DMZLHKJ SN ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine
DMZLHKJ TC Dietary supplement
DMZLHKJ DT Small molecular drug
DMZLHKJ PC 190
DMZLHKJ MW 135.13
DMZLHKJ FM C5H5N5
DMZLHKJ IC InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
DMZLHKJ CS C1=NC2=NC=NC(=C2N1)N
DMZLHKJ IK GFFGJBXGBJISGV-UHFFFAOYSA-N
DMZLHKJ IU 7H-purin-6-amine
DMZLHKJ CA CAS 73-24-5
DMZLHKJ CB CHEBI:16708
DMZLHKJ DE Malnutrition
DMM2NSK ID DMM2NSK
DMM2NSK DN Adenosine
DMM2NSK HS Approved
DMM2NSK SN Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
DMM2NSK TC Antiarrhythmic Agents
DMM2NSK DT Small molecular drug
DMM2NSK PC 60961
DMM2NSK MW 267.24
DMM2NSK FM C10H13N5O4
DMM2NSK IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMM2NSK CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMM2NSK IK OIRDTQYFTABQOQ-KQYNXXCUSA-N
DMM2NSK IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMM2NSK CA CAS 5536-17-4
DMM2NSK CB CHEBI:16335
DMM2NSK DE Paroxysmal supraventricular tachycardia
DMNIJT0 ID DMNIJT0
DMNIJT0 DN Adenosine monophosphate
DMNIJT0 HS Approved
DMNIJT0 SN ASMP; Adenovite; Adenyl; Adenylate; Cardiomone; Lycedan; Monophosphadenine; Muskeladenylsaeure; Myoston; PAdo; Phosaden; Phosphaden; Phosphentaside; AMP dianion; Adenine polynucleotides; Adenosine phosphate; Adenosini phosphas; Adenylic acid; Ergadenylic acid; Fosfato de adenosina; Muscle adenylic acid; POLY A; Polyadenylic acids; Vitamin B8; A-5mp; AMP (VAN); AMP (nucleotide); Adenosine Monophosphate (Amp); Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas [INN-Latin]; Adenyl (TN); Adenylic acid (VAN); Ado5'P; Fosfato de adenosina [INN-Spanish]; Muskeladenosin-phosphorsaeure; Phosphate d'adenosine; Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; My-B-Den; Phosphate d'adenosine [INN-French]; ADENOSINE-5'-PHOSPHATE; Adenosine 5'-(dihydrogen phosphate); Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5-monophosphate(2-); GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb
DMNIJT0 TC Dietary supplement
DMNIJT0 DT Small molecular drug
DMNIJT0 PC 6083
DMNIJT0 MW 347.22
DMNIJT0 FM C10H14N5O7P
DMNIJT0 IC InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMNIJT0 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMNIJT0 IK UDMBCSSLTHHNCD-KQYNXXCUSA-N
DMNIJT0 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMNIJT0 CA CAS 61-19-8
DMNIJT0 CB CHEBI:16027
DMNIJT0 DE Malnutrition
DM79F6G ID DM79F6G
DM79F6G DN Adenosine triphosphate
DM79F6G HS Approved
DM79F6G SN Adenylpyrophosphate; Triphosadenine; Triphosadenine (DCF); Adenosine 5'-triphosphate(4-); [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
DM79F6G TC Dietary supplement
DM79F6G DT Small molecular drug
DM79F6G PC 5957
DM79F6G MW 507.18
DM79F6G FM C10H16N5O13P3
DM79F6G IC InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DM79F6G CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DM79F6G IK ZKHQWZAMYRWXGA-KQYNXXCUSA-N
DM79F6G IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM79F6G CA CAS 56-65-5
DM79F6G CB CHEBI:15422
DM79F6G DE Bradycardia; Heart disease; Malnutrition
DMBHO9Y ID DMBHO9Y
DMBHO9Y DN Adinazolam
DMBHO9Y HS Approved
DMBHO9Y SN Adinazolamum; Deracyn; Adinazolam [USAN]; U 41123; Adinazolamum [INN-Latin]; Deracyn (TN); U 41,123;U-41123; Adinazolam (USAN/INN); Adinazolam [USAN:BAN:INN]; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
DMBHO9Y TC Antidepressants
DMBHO9Y DT Small molecular drug
DMBHO9Y PC 37632
DMBHO9Y MW 351.8
DMBHO9Y FM C19H18ClN5
DMBHO9Y IC InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
DMBHO9Y CS CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMBHO9Y IK GJSLOMWRLALDCT-UHFFFAOYSA-N
DMBHO9Y IU 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
DMBHO9Y CA CAS 37115-32-5
DMBHO9Y CB CHEBI:251412
DMBHO9Y DE Anxiety disorder
DMVWHTG ID DMVWHTG
DMVWHTG DN Afamelanotide
DMVWHTG HS Approved
DMVWHTG SN [Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH
DMVWHTG DT Small molecular drug
DMVWHTG PC 16197727
DMVWHTG MW 1646.8
DMVWHTG FM C78H111N21O19
DMVWHTG IC InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMVWHTG CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMVWHTG IK UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMVWHTG IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVWHTG CA CAS 75921-69-6
DMVWHTG DE Vitiligo; Erythropoietic porphyrias
DMT3D5I ID DMT3D5I
DMT3D5I DN Aflibercept
DMT3D5I HS Approved
DMT3D5I SN Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
DMT3D5I CP Sanofi
DMT3D5I SQ Protein sequence for aflibercept: SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMT3D5I DE Metastatic colorectal cancer
DMPOD47 ID DMPOD47
DMPOD47 DN Ajmalicine
DMPOD47 HS Approved
DMPOD47 SN MLS000111555; methyl 19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate; NSC72115; SMR000107477; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19.alpha.)-; 6474-90-4; WLN: T F6 D5 C666 EM ON SO TU& TTTJ R1 UVO1; Isoarteril; Oxayohimban-16-carboxylic acid,17-didehydro-19-methyl-, methyl ester, (19
DMPOD47 DT Small molecular drug
DMPOD47 PC 441975
DMPOD47 MW 352.4
DMPOD47 FM C21H24N2O3
DMPOD47 IC InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1
DMPOD47 CS C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMPOD47 IK GRTOGORTSDXSFK-XJTZBENFSA-N
DMPOD47 IU methyl (1S,15R,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMPOD47 CA CAS 483-04-5
DMPOD47 CB CHEBI:2524
DMPOD47 DE Circulatory disorder
DMDJW5K ID DMDJW5K
DMDJW5K DN Ajmaline
DMDJW5K HS Approved
DMDJW5K SN (17R,21
DMDJW5K DT Small molecular drug
DMDJW5K PC 6100671
DMDJW5K MW 326.4
DMDJW5K FM C20H26N2O2
DMDJW5K IC InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16-,17-,18+,19+,20+/m0/s1
DMDJW5K CS CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C
DMDJW5K IK CJDRUOGAGYHKKD-RQBLFBSQSA-N
DMDJW5K IU (1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMDJW5K CA CAS 4360-12-7
DMDJW5K DE Atrial fibrillation
DML6SRO ID DML6SRO
DML6SRO DN Alacepril
DML6SRO HS Approved
DML6SRO SN Cetapril (TN)
DML6SRO CP Dainippon
DML6SRO DT Small molecular drug
DML6SRO PC 71992
DML6SRO MW 406.5
DML6SRO FM C20H26N2O5S
DML6SRO IC InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
DML6SRO CS C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DML6SRO IK FHHHOYXPRDYHEZ-COXVUDFISA-N
DML6SRO IU (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DML6SRO CA CAS 74258-86-9
DML6SRO CB CHEBI:31182
DML6SRO DE Cardiovascular disease
DMYZ57N ID DMYZ57N
DMYZ57N DN Albendazole
DMYZ57N HS Approved
DMYZ57N SN Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
DMYZ57N CP GlaxoSmithKline
DMYZ57N TC Antiprotozoal Agents
DMYZ57N DT Small molecular drug
DMYZ57N PC 2082
DMYZ57N MW 265.33
DMYZ57N FM C12H15N3O2S
DMYZ57N IC InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMYZ57N CS CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMYZ57N IK HXHWSAZORRCQMX-UHFFFAOYSA-N
DMYZ57N IU methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
DMYZ57N CA CAS 54965-21-8
DMYZ57N CB CHEBI:16664
DMYZ57N DE Worm infection
DM1JEGF ID DM1JEGF
DM1JEGF DN Albiglutide
DM1JEGF HS Approved
DM1JEGF CP GSK
DM1JEGF SQ Albiglutide sequence: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
DM1JEGF PC 122173812
DM1JEGF MW 3284.6
DM1JEGF FM C148H223N39O46
DM1JEGF IC InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1
DM1JEGF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N
DM1JEGF IK OGWAVGNOAMXIIM-VTAHJYCESA-N
DM1JEGF IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1JEGF CB CHEBI:78425
DM1JEGF DE Type-2 diabetes
DM5JTPU ID DM5JTPU
DM5JTPU DN Albumin Human
DM5JTPU HS Approved
DM5JTPU SN Albumin (Human); Kedbumin
DM5JTPU CP Ge Healthcare
DM5JTPU DE Hypoalbuminemia
DM5J1NH ID DM5J1NH
DM5J1NH DN Alcaftadine
DM5J1NH HS Approved
DM5J1NH SN Lastacaft (TN)
DM5J1NH CP Vistakon Pharmaceuticals
DM5J1NH DT Small molecular drug
DM5J1NH PC 19371515
DM5J1NH MW 307.4
DM5J1NH FM C19H21N3O
DM5J1NH IC InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3
DM5J1NH CS CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1
DM5J1NH IK MWTBKTRZPHJQLH-UHFFFAOYSA-N
DM5J1NH IU 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
DM5J1NH CA CAS 147084-10-4
DM5J1NH CB CHEBI:71023
DM5J1NH DE Allergic conjunctivitis
DMAE84F ID DMAE84F
DMAE84F DN Alclometasone
DMAE84F HS Approved
DMAE84F SN Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone
DMAE84F CP GlaxoSmithKline
DMAE84F TC Antiinflammatory Agents
DMAE84F DT Small molecular drug
DMAE84F PC 5311000
DMAE84F MW 408.9
DMAE84F FM C22H29ClO5
DMAE84F IC InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
DMAE84F CS C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl
DMAE84F IK FJXOGVLKCZQRDN-PHCHRAKRSA-N
DMAE84F IU (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMAE84F CA CAS 67452-97-5
DMAE84F CB CHEBI:53776
DMAE84F DE Inflammation
DM2U4XQ ID DM2U4XQ
DM2U4XQ DN ALCURONIUM
DM2U4XQ HS Approved
DM2U4XQ SN Alcuronium
DM2U4XQ DT Small molecular drug
DM2U4XQ PC 21158560
DM2U4XQ MW 666.9
DM2U4XQ FM C44H50N4O2+2
DM2U4XQ IC InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1
DM2U4XQ CS C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\\CO)/C1)CC2
DM2U4XQ IK MUQUYTSLDVKIOF-CHJKCJHBSA-N
DM2U4XQ IU (2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol
DM2U4XQ CA CAS 23214-96-2
DM2U4XQ CB CHEBI:55313
DM2U4XQ DE Anaesthesia
DM4YMIS ID DM4YMIS
DM4YMIS DN Aldesleukin
DM4YMIS HS Approved
DM4YMIS SN Proleukin (TN)
DM4YMIS CP Chiron
DM4YMIS TC Anticancer Agents
DM4YMIS SQ Aldesleukin sequence: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DM4YMIS DE Renal cell carcinoma; Non-hodgkin lymphoma
DM9S2JW ID DM9S2JW
DM9S2JW DN Aldosterone
DM9S2JW HS Approved
DM9S2JW SN ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocortene; Aldocorten; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum; Aldosterona; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 18-Aldocorticosterone; Aldosterone [INN:BAN:DCF]; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB; Aldocorten; D-Aldosterone; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosterone, (+-)-Isomer; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
DM9S2JW TC Antihypertensive Agents
DM9S2JW DT Small molecular drug
DM9S2JW PC 5839
DM9S2JW MW 360.4
DM9S2JW FM C21H28O5
DM9S2JW IC InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
DM9S2JW CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O
DM9S2JW IK PQSUYGKTWSAVDQ-ZVIOFETBSA-N
DM9S2JW IU (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde
DM9S2JW CA CAS 52-39-1
DM9S2JW CB CHEBI:27584
DM9S2JW DE Hypertension
DMP1I6Y ID DMP1I6Y
DMP1I6Y DN Alectinib
DMP1I6Y HS Approved
DMP1I6Y SN 1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2; Alectinib; 9-ethyl-6,6-dimethyl-
DMP1I6Y DT Small molecular drug
DMP1I6Y PC 49806720
DMP1I6Y MW 482.6
DMP1I6Y FM C30H34N4O2
DMP1I6Y IC InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
DMP1I6Y CS CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C
DMP1I6Y IK KDGFLJKFZUIJMX-UHFFFAOYSA-N
DMP1I6Y IU 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
DMP1I6Y CA CAS 1256580-46-7
DMP1I6Y CB CHEBI:90936
DMP1I6Y DE Lung cancer; Non-small-cell lung cancer
DMMYPWO ID DMMYPWO
DMMYPWO DN Alefacept
DMMYPWO HS Approved
DMMYPWO SN Amevive (TN)
DMMYPWO TC Analgesics
DMMYPWO SQ Alefacept heavy chain : CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Alefacept light chainMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN
DMMYPWO DE Pain
DMZL3IV ID DMZL3IV
DMZL3IV DN Alemtuzumab
DMZL3IV HS Approved
DMZL3IV SN Campath (TN); MabCampath (TN); Campath-1H (TN)
DMZL3IV CP Bayer Schering Pharma
DMZL3IV TC Anticancer Agents
DMZL3IV DT Antibody
DMZL3IV SQ 1CE1:H CAMPATH-1H:Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 1DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1CE1:H CAMPATH-1H:Heavy Chain 2QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 2DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV >1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMZL3IV DE Chronic lymphocytic leukaemia; Multiple sclerosis
DMY2KX9 ID DMY2KX9
DMY2KX9 DN Alendronate
DMY2KX9 HS Approved
DMY2KX9 SN Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
DMY2KX9 CP Teva Pharmaceuticals
DMY2KX9 TC Bone Density Conservation Agents
DMY2KX9 DT Small molecular drug
DMY2KX9 PC 2088
DMY2KX9 MW 249.1
DMY2KX9 FM C4H13NO7P2
DMY2KX9 IC InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
DMY2KX9 CS C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
DMY2KX9 IK OGSPWJRAVKPPFI-UHFFFAOYSA-N
DMY2KX9 IU (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
DMY2KX9 CA CAS 66376-36-1
DMY2KX9 CB CHEBI:2567
DMY2KX9 DE Paget's disease; Osteoporosis
DMCKPUR ID DMCKPUR
DMCKPUR DN Alfaferone
DMCKPUR HS Approved
DMCKPUR SN Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha)
DMCKPUR CP Alfa Wassermann SpA
DMCKPUR DE Hairy cell leukaemia
DMVO0UB ID DMVO0UB
DMVO0UB DN Alfentanil
DMVO0UB HS Approved
DMVO0UB SN Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
DMVO0UB CP Janssen Pharmaceutica
DMVO0UB TC Anesthetics
DMVO0UB DT Small molecular drug
DMVO0UB PC 51263
DMVO0UB MW 416.5
DMVO0UB FM C21H32N6O3
DMVO0UB IC InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
DMVO0UB CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC
DMVO0UB IK IDBPHNDTYPBSNI-UHFFFAOYSA-N
DMVO0UB IU N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
DMVO0UB CA CAS 71195-58-9
DMVO0UB CB CHEBI:2569
DMVO0UB DE Anaesthesia
DMZVMKF ID DMZVMKF
DMZVMKF DN Alfuzosin
DMZVMKF HS Approved
DMZVMKF SN Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
DMZVMKF CP Sanofi-Aventis
DMZVMKF TC Antihypertensive Agents
DMZVMKF DT Small molecular drug
DMZVMKF PC 2092
DMZVMKF MW 389.4
DMZVMKF FM C19H27N5O4
DMZVMKF IC InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
DMZVMKF CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DMZVMKF IK WNMJYKCGWZFFKR-UHFFFAOYSA-N
DMZVMKF IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
DMZVMKF CA CAS 81403-80-7
DMZVMKF CB CHEBI:51141
DMZVMKF DE Benign prostatic hyperplasia
DM4LOD0 ID DM4LOD0
DM4LOD0 DN Alglucosidase alfa
DM4LOD0 HS Approved
DM4LOD0 SN Lumizyme (TN); Myozyme (TN)
DM4LOD0 CP Genzyme Corporation
DM4LOD0 TC Enzyme Replacement Agents
DM4LOD0 SQ Alglucosidase alfa: AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
DM4LOD0 DE Pompe disease
DM1BV7W ID DM1BV7W
DM1BV7W DN Aliskiren
DM1BV7W HS Approved
DM1BV7W SN Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]
DM1BV7W CP Norvatis Phamaceuticals Corporation
DM1BV7W TC Antihypertensive Agents
DM1BV7W DT Small molecular drug
DM1BV7W PC 5493444
DM1BV7W MW 551.8
DM1BV7W FM C30H53N3O6
DM1BV7W IC InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
DM1BV7W CS CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
DM1BV7W IK UXOWGYHJODZGMF-QORCZRPOSA-N
DM1BV7W IU (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
DM1BV7W CA CAS 173334-57-1
DM1BV7W CB CHEBI:601027
DM1BV7W DE Hypertension
DMME8LH ID DMME8LH
DMME8LH DN Alitretinoin
DMME8LH HS Approved
DMME8LH CP Ligand Pharmaceuticals
DMME8LH TC Anticancer Agents
DMME8LH DT Small molecular drug
DMME8LH PC 449171
DMME8LH MW 300.4
DMME8LH FM C20H28O2
DMME8LH IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+
DMME8LH CS CC1=C(C(CCC1)(C)C)/C=C/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C
DMME8LH IK SHGAZHPCJJPHSC-ZVCIMWCZSA-N
DMME8LH IU (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMME8LH CA CAS 5300-03-8
DMME8LH CB CHEBI:50648
DMME8LH DE Kaposi sarcoma
DMB4HFI ID DMB4HFI
DMB4HFI DN Alkavervir
DMB4HFI HS Approved
DMB4HFI CP 3m Pharmaceuticals Inc
DMB4HFI TC Cardiovascular Agents
DMB4HFI DE High blood pressure
DMNLHAC ID DMNLHAC
DMNLHAC DN Allopregnanolone
DMNLHAC HS Approved
DMNLHAC SN 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
DMNLHAC DT Small molecular drug
DMNLHAC PC 92786
DMNLHAC MW 318.5
DMNLHAC FM C21H34O2
DMNLHAC IC InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
DMNLHAC CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMNLHAC IK AURFZBICLPNKBZ-SYBPFIFISA-N
DMNLHAC IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMNLHAC CA CAS 516-54-1
DMNLHAC CB CHEBI:50169
DMNLHAC DE Postpartum depression; Essential tremor or related tremors; Status epilepticus seizure; Depression
DMLPAOB ID DMLPAOB
DMLPAOB DN Allopurinol
DMLPAOB HS Approved
DMLPAOB SN Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP
DMLPAOB CP GlaxoSmithKline
DMLPAOB TC Antimetabolites
DMLPAOB DT Small molecular drug
DMLPAOB PC 135401907
DMLPAOB MW 136.11
DMLPAOB FM C5H4N4O
DMLPAOB IC InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
DMLPAOB CS C1=NNC2=C1C(=O)NC=N2
DMLPAOB IK OFCNXPDARWKPPY-UHFFFAOYSA-N
DMLPAOB IU 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
DMLPAOB CA CAS 315-30-0
DMLPAOB CB CHEBI:40279
DMLPAOB DE Hyperuricaemia
DM0SYAN ID DM0SYAN
DM0SYAN DN Almitrine
DM0SYAN HS Approved
DM0SYAN SN Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN TC Antiinflammatory Agents
DM0SYAN DT Small molecular drug
DM0SYAN PC 33887
DM0SYAN MW 477.6
DM0SYAN FM C26H29F2N7
DM0SYAN IC InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
DM0SYAN CS C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DM0SYAN IK OBDOVFRMEYHSQB-UHFFFAOYSA-N
DM0SYAN IU 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN CA CAS 27469-53-0
DM0SYAN CB CHEBI:53778
DM0SYAN DE Chronic obstructive pulmonary disease
DM7I64Z ID DM7I64Z
DM7I64Z DN Almogran
DM7I64Z HS Approved
DM7I64Z SN Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
DM7I64Z CP Almirall Prodesfarma
DM7I64Z TC Antimigraine Agents
DM7I64Z DT Small molecular drug
DM7I64Z PC 123606
DM7I64Z MW 335.5
DM7I64Z FM C17H25N3O2S
DM7I64Z IC InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
DM7I64Z CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
DM7I64Z IK WKEMJKQOLOHJLZ-UHFFFAOYSA-N
DM7I64Z IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
DM7I64Z CA CAS 154323-57-6
DM7I64Z CB CHEBI:520985
DM7I64Z DE Migraine
DMFG5ST ID DMFG5ST
DMFG5ST DN Almotriptan malate
DMFG5ST HS Approved
DMFG5ST SN Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510
DMFG5ST PC 123607
DMFG5ST MW 469.6
DMFG5ST FM C21H31N3O7S
DMFG5ST IC QHATUKWEVNMHRY-UHFFFAOYSA-N
DMFG5ST CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O
DMFG5ST IK 1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)
DMFG5ST IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine;2-hydroxybutanedioic acid
DMFG5ST CA CAS 181183-52-8
DMFG5ST CB CHEBI:53781
DMFG5ST DE Migraine
DM8WI3R ID DM8WI3R
DM8WI3R DN Alogliptin
DM8WI3R HS Approved
DM8WI3R SN 850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203; UNII-JHC049LO86
DM8WI3R CP Takeda
DM8WI3R DT Small molecular drug
DM8WI3R PC 11450633
DM8WI3R MW 339.4
DM8WI3R FM C18H21N5O2
DM8WI3R IC InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
DM8WI3R CS CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
DM8WI3R IK ZSBOMTDTBDDKMP-OAHLLOKOSA-N
DM8WI3R IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
DM8WI3R CA CAS 850649-61-5
DM8WI3R CB CHEBI:72323
DM8WI3R DE Type-2 diabetes
DML2A03 ID DML2A03
DML2A03 DN Alosetron
DML2A03 HS Approved
DML2A03 SN Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
DML2A03 CP Prometheus Laboratories Inc
DML2A03 TC Gastrointestinal Agents
DML2A03 DT Small molecular drug
DML2A03 PC 2099
DML2A03 MW 294.35
DML2A03 FM C17H18N4O
DML2A03 IC InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
DML2A03 CS CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
DML2A03 IK JSWZEAMFRNKZNL-UHFFFAOYSA-N
DML2A03 IU 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DML2A03 CA CAS 122852-42-0
DML2A03 CB CHEBI:253342
DML2A03 DE Irritable bowel syndrome
DMEXMYK ID DMEXMYK
DMEXMYK DN Alpelisib
DMEXMYK HS Approved
DMEXMYK SN alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
DMEXMYK CP Novartis
DMEXMYK DT Small molecular drug
DMEXMYK PC 56649450
DMEXMYK MW 441.5
DMEXMYK FM C19H22F3N5O2S
DMEXMYK IC InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
DMEXMYK CS CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
DMEXMYK IK STUWGJZDJHPWGZ-LBPRGKRZSA-N
DMEXMYK IU (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
DMEXMYK CA CAS 1217486-61-7
DMEXMYK CB CHEBI:93752
DMEXMYK DE Solid tumour/cancer; Breast cancer
DMXC1K9 ID DMXC1K9
DMXC1K9 DN Alpha 1-PI
DMXC1K9 HS Approved
DMXC1K9 SN Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine
DMXC1K9 DT Small molecular drug
DMXC1K9 PC 3689
DMXC1K9 MW 325.4
DMXC1K9 FM C21H27NO2
DMXC1K9 IC InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
DMXC1K9 CS CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
DMXC1K9 IK UYNVMODNBIQBMV-UHFFFAOYSA-N
DMXC1K9 IU 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
DMXC1K9 CA CAS 23210-56-2
DMXC1K9 CB CHEBI:93829
DMXC1K9 DE Alpha-1 antitrypsin deficiency; Cancer related pain
DMAS02L ID DMAS02L
DMAS02L DN Alpha-acetyldigoxin
DMAS02L HS Approved
DMAS02L SN Dioxanin (TN); Lanatilin (TN); Sandolanid (TN)
DMAS02L DT Small molecular drug
DMAS02L PC 11765960
DMAS02L MW 823
DMAS02L FM C43H66O15
DMAS02L IC InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMAS02L CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)OC(=O)C)O
DMAS02L IK HWKJSYYYURVNQU-DXJNJSHLSA-N
DMAS02L IU [(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-3-hydroxy-2-methyloxan-4-yl] acetate
DMAS02L CA CAS 5511-98-8
DMAS02L DE Cardiovascular disease
DMN7Y9K ID DMN7Y9K
DMN7Y9K DN Alpidem
DMN7Y9K HS Approved
DMN7Y9K SN ALPIDEM; 82626-01-5; Ananxyl; Alpidemum [Latin]; UNII-I93SC245QZ; SL 80.0342-00; 2-(6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide; 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide; CHEMBL54349; I93SC245QZ; S-800342; NCGC00182850-01; 6-Chlor-2-(4-chlorphenyl)-N,N-dipropylimidazol(1,2-a)pyridin-3-acetamid; DSSTox_RID_83237; DSSTox_CID_28972; DSSTox_GSID_49046; Alpidemum; 6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide
DMN7Y9K DT Small molecular drug
DMN7Y9K PC 54897
DMN7Y9K MW 404.3
DMN7Y9K FM C21H23Cl2N3O
DMN7Y9K IC InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
DMN7Y9K CS CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMN7Y9K IK JRTIDHTUMYMPRU-UHFFFAOYSA-N
DMN7Y9K IU 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
DMN7Y9K CA CAS 82626-01-5
DMN7Y9K CB CHEBI:135649
DMN7Y9K DE Anxiety disorder
DMC7XDN ID DMC7XDN
DMC7XDN DN Alprazolam
DMC7XDN HS Approved
DMC7XDN SN Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CP Pfizer Pharmaceuticals
DMC7XDN TC Hypnotics and Sedatives
DMC7XDN DT Small molecular drug
DMC7XDN PC 2118
DMC7XDN MW 308.8
DMC7XDN FM C17H13ClN4
DMC7XDN IC InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
DMC7XDN CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMC7XDN IK VREFGVBLTWBCJP-UHFFFAOYSA-N
DMC7XDN IU 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CA CAS 28981-97-7
DMC7XDN CB CHEBI:2611
DMC7XDN DE Anxiety disorder; Epilepsy
DMWH7NQ ID DMWH7NQ
DMWH7NQ DN Alprostadil
DMWH7NQ HS Approved
DMWH7NQ SN Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
DMWH7NQ CP Pfizer Pharmaceuticals
DMWH7NQ TC Vasodilator Agents
DMWH7NQ DT Small molecular drug
DMWH7NQ PC 5280723
DMWH7NQ MW 354.5
DMWH7NQ FM C20H34O5
DMWH7NQ IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
DMWH7NQ CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMWH7NQ IK GMVPRGQOIOIIMI-DWKJAMRDSA-N
DMWH7NQ IU 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMWH7NQ CA CAS 745-65-3
DMWH7NQ CB CHEBI:15544
DMWH7NQ DE Erectile dysfunction; Diabetic foot ulcer
DMB47TQ ID DMB47TQ
DMB47TQ DN Alseroxylon
DMB47TQ HS Approved
DMB47TQ TC Antihypertensive Agents
DMB47TQ DE Hypertension
DMRJ3YX ID DMRJ3YX
DMRJ3YX DN Alteplase
DMRJ3YX HS Approved
DMRJ3YX SN Activase (TN)
DMRJ3YX CP Boehringer Ingelheim Ltd
DMRJ3YX TC Thrombolytic Agents
DMRJ3YX SQ Alteplase sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMRJ3YX DE Pulmonary embolism
DMKLAYG ID DMKLAYG
DMKLAYG DN Altretamine
DMKLAYG HS Approved
DMKLAYG SN Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG TC Anticancer Agents
DMKLAYG DT Small molecular drug
DMKLAYG PC 2123
DMKLAYG MW 210.28
DMKLAYG FM C9H18N6
DMKLAYG IC InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
DMKLAYG CS CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
DMKLAYG IK UUVWYPNAQBNQJQ-UHFFFAOYSA-N
DMKLAYG IU 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG CA CAS 645-05-6
DMKLAYG CB CHEBI:24564
DMKLAYG DE Ovarian cancer
DMO9WDS ID DMO9WDS
DMO9WDS DN Altropane
DMO9WDS HS Approved
DMO9WDS SN Carbon-11-Altropane; Iodine-123-Altropane; 11C-Altropane; 123I-Altropane
DMO9WDS CP Harvard University
DMO9WDS DT Small molecular drug
DMO9WDS PC 6440180
DMO9WDS MW 429.3
DMO9WDS FM C18H21FINO2
DMO9WDS IC InChI=1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1
DMO9WDS CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)F
DMO9WDS IK GTQLIPQFXVKRKJ-UNSMHXHVSA-N
DMO9WDS IU methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
DMO9WDS CA CAS 180468-34-2
DMO9WDS CB CHEBI:135696
DMO9WDS DE Attention deficit hyperactivity disorder
DM6ECN9 ID DM6ECN9
DM6ECN9 DN Aluminium
DM6ECN9 HS Approved
DM6ECN9 SN ALUMINUM; Adom; Aluminio; Metana; AO Al; Al alloy; Alaun [German]; Allbri aluminum paste and powder; Alumina fibre; Aluminium bronze; Aluminium flake; Aluminum alloy; Aluminum dehydrated; Aluminum dust; Aluminum metal; Aluminum powder; Aluminum production; Aluminum pyro powders; Aluminum soluble salts; Aluminum welding fumes; Emanay atomized aluminum powder; Metana aluminum paste; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminum; Noral aluminium; Noral aluminum; Noral ink grade aluminium; A 00; A 95; A 99; A 995; A 999; AA 1099; AA1199; AD 1; AD1M; AO A1; AV00; AV000; Aa1193; Aluminum 27; Aluminum A00; Aluminum hydride [UN2463] [Dangerous when wet]; JISC 3108; JISC 3110; L16; NA9260; Pigment metal 1; ALUMINUM, ATOMIZED; Al(0); Aluminium(0); Aluminium, elementar; Aluminum (dust or fume); Aluminum (fume or dust); Aluminum (metal); Aluminum metal, alkyls; Aluminum metal, pyro powders; Aluminum metal, respirable fraction; Aluminum metal, soluble salts; Aluminum metal, total dust; Aluminum metal, welding fumes; Aluminum powder, coated [UN1309] [Flammable solid]; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum, elemental; Aluminum, molten [NA9260] [Class 9]; Aluminum, pyro powders; Aluminum, soluble salts; Aluminum, welding fumes; C-Pigment 1; C-Pigment 1 [German]; Noral non-leafing grade; Aluminum, pyro powders/welding fumes; C.I. 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); ALUMINUM, 99.999%; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11008_ALDRICH; 11008_RIEDEL; 11009_ALDRICH; 11009_RIEDEL; 11010_ALDRICH; 11010_RIEDEL; 13Al
DM6ECN9 TC Antiinflammatory Agents
DM6ECN9 DT Small molecular drug
DM6ECN9 PC 5359268
DM6ECN9 MW 26.981
DM6ECN9 FM Al
DM6ECN9 IC InChI=1S/Al
DM6ECN9 CS [Al]
DM6ECN9 IK XAGFODPZIPBFFR-UHFFFAOYSA-N
DM6ECN9 IU aluminum
DM6ECN9 CA CAS 7429-90-5
DM6ECN9 CB CHEBI:28984
DM6ECN9 DE Hyperhidrosis
DMHR8KW ID DMHR8KW
DMHR8KW DN Alvimopan
DMHR8KW HS Approved
DMHR8KW SN Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CP GSK
DMHR8KW TC Analgesics
DMHR8KW DT Small molecular drug
DMHR8KW PC 5488548
DMHR8KW MW 424.5
DMHR8KW FM C25H32N2O4
DMHR8KW IC InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
DMHR8KW CS C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O
DMHR8KW IK UPNUIXSCZBYVBB-JVFUWBCBSA-N
DMHR8KW IU 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CA CAS 156053-89-3
DMHR8KW CB CHEBI:135686
DMHR8KW DE Gastrointestinal disease
DMS3YE9 ID DMS3YE9
DMS3YE9 DN Amantadine
DMS3YE9 HS Approved
DMS3YE9 SN Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane
DMS3YE9 TC Antiviral Agents
DMS3YE9 DT Small molecular drug
DMS3YE9 PC 2130
DMS3YE9 MW 151.25
DMS3YE9 FM C10H17N
DMS3YE9 IC InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
DMS3YE9 CS C1C2CC3CC1CC(C2)(C3)N
DMS3YE9 IK DKNWSYNQZKUICI-UHFFFAOYSA-N
DMS3YE9 IU adamantan-1-amine
DMS3YE9 CA CAS 768-94-5
DMS3YE9 CB CHEBI:2618
DMS3YE9 DE Influenza A virus infection
DMOP0BL ID DMOP0BL
DMOP0BL DN Ambenonium
DMOP0BL HS Approved
DMOP0BL SN Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
DMOP0BL CP Sanofi Aventis Us Llc
DMOP0BL TC Antiarrhythmic Agents
DMOP0BL DT Small molecular drug
DMOP0BL PC 2131
DMOP0BL MW 537.6
DMOP0BL FM C28H42Cl2N4O2+2
DMOP0BL IC InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
DMOP0BL CS CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl
DMOP0BL IK OMHBPUNFVFNHJK-UHFFFAOYSA-P
DMOP0BL IU (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium
DMOP0BL CA CAS 7648-98-8
DMOP0BL CB CHEBI:2627
DMOP0BL DE Myasthenia gravis
DMD1QXW ID DMD1QXW
DMD1QXW DN Ambrisentan
DMD1QXW HS Approved
DMD1QXW SN Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CP GSK
DMD1QXW DT Small molecular drug
DMD1QXW PC 6918493
DMD1QXW MW 378.4
DMD1QXW FM C22H22N2O4
DMD1QXW IC InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMD1QXW CS CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
DMD1QXW IK OUJTZYPIHDYQMC-LJQANCHMSA-N
DMD1QXW IU (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CA CAS 177036-94-1
DMD1QXW CB CHEBI:135949
DMD1QXW DE Pulmonary arterial hypertension
DMWJE9D ID DMWJE9D
DMWJE9D DN Ambroxol
DMWJE9D HS Approved
DMWJE9D SN Ambroxol hydrochloride; 23828-92-4; Ambroxol HCl; Mucosolvan; Mucoangin; Ambroxolhydrochloride; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; UNII-CC995ZMV90; Ambroxol hydrochloride; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; Ambroxol Hydrochloride [JAN]; CC995ZMV90; 15942-05-9; Ambroxol hydrochloride (JAN); 2-Amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride
DMWJE9D CP Exsar
DMWJE9D DT Small molecular drug
DMWJE9D PC 2132
DMWJE9D MW 378.1
DMWJE9D FM C13H18Br2N2O
DMWJE9D IC InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2
DMWJE9D CS C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
DMWJE9D IK JBDGDEWWOUBZPM-UHFFFAOYSA-N
DMWJE9D IU 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
DMWJE9D CA CAS 18683-91-5
DMWJE9D CB CHEBI:92994
DMWJE9D DE Bronchitis
DMM1JL9 ID DMM1JL9
DMM1JL9 DN Amcinonide
DMM1JL9 HS Approved
DMM1JL9 SN Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate
DMM1JL9 TC Antiinflammatory Agents
DMM1JL9 DT Small molecular drug
DMM1JL9 PC 443958
DMM1JL9 MW 502.6
DMM1JL9 FM C28H35FO7
DMM1JL9 IC InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
DMM1JL9 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6
DMM1JL9 IK ILKJAFIWWBXGDU-MOGDOJJUSA-N
DMM1JL9 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate
DMM1JL9 CA CAS 51022-69-6
DMM1JL9 CB CHEBI:31199
DMM1JL9 DE Inflammation
DMIG6FY ID DMIG6FY
DMIG6FY DN Amdinocillin
DMIG6FY HS Approved
DMIG6FY SN Coactin; Hexacillin; Mecilinamo; Mecillinam; Mecillinamum; Selexidin; Amdinocillin Mecillinam; Amdinocillin [USAN]; Penicillin HX; FL 1060; Ro 109070; Amdinocillin (USAN); Coactin (TN); FL-1060; Mecilinamo [INN-Spanish]; Mecillinam (INN); Mecillinamum [INN-Latin]; Ro 10-9070; Ro-10-9070; Rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid
DMIG6FY CP Leo Pharmaceutical
DMIG6FY TC Antibiotics
DMIG6FY DT Small molecular drug
DMIG6FY PC 36273
DMIG6FY MW 325.4
DMIG6FY FM C15H23N3O3S
DMIG6FY IC InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1
DMIG6FY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C
DMIG6FY IK BWWVAEOLVKTZFQ-NTZNESFSSA-N
DMIG6FY IU (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIG6FY CA CAS 32887-01-7
DMIG6FY DE Bacterial infection
DM6I2WQ ID DM6I2WQ
DM6I2WQ DN Amezinium
DM6I2WQ HS Approved
DM6I2WQ SN Amezinium methyl sulfate
DM6I2WQ DT Small molecular drug
DM6I2WQ PC 71927
DM6I2WQ MW 202.23
DM6I2WQ FM C11H12N3O+
DM6I2WQ IC InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
DM6I2WQ CS COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
DM6I2WQ IK VXROHTDSRBRJLN-UHFFFAOYSA-O
DM6I2WQ IU 6-methoxy-1-phenylpyridazin-1-ium-4-amine
DM6I2WQ CA CAS 41658-78-0
DM6I2WQ CB CHEBI:145698
DM6I2WQ DE Hypotension
DM9YSNQ ID DM9YSNQ
DM9YSNQ DN Amfepramone
DM9YSNQ HS Approved
DM9YSNQ SN Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone; Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone
DM9YSNQ DT Small molecular drug
DM9YSNQ PC 7029
DM9YSNQ MW 205.3
DM9YSNQ FM C13H19NO
DM9YSNQ IC InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
DM9YSNQ CS CCN(CC)C(C)C(=O)C1=CC=CC=C1
DM9YSNQ IK XXEPPPIWZFICOJ-UHFFFAOYSA-N
DM9YSNQ IU 2-(diethylamino)-1-phenylpropan-1-one
DM9YSNQ CA CAS 90-84-6
DM9YSNQ CB CHEBI:4530
DM9YSNQ DE Obesity; Migraine
DMK08L3 ID DMK08L3
DMK08L3 DN Amifampridine
DMK08L3 HS Approved
DMK08L3 SN 3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913
DMK08L3 CP Catalyst Pharmaceuticals
DMK08L3 PC 5918
DMK08L3 MW 109.13
DMK08L3 FM C5H7N3
DMK08L3 IC InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
DMK08L3 CS C1=CN=CC(=C1N)N
DMK08L3 IK OYTKINVCDFNREN-UHFFFAOYSA-N
DMK08L3 IU pyridine-3,4-diamine
DMK08L3 CA CAS 54-96-6
DMK08L3 CB CHEBI:135948
DMK08L3 DE LambertEaton myasthenic syndrome
DM5FL14 ID DM5FL14
DM5FL14 DN Amifostine
DM5FL14 HS Approved
DM5FL14 SN Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310
DM5FL14 CP Medimmune Oncology Inc
DM5FL14 DT Small molecular drug
DM5FL14 PC 2141
DM5FL14 MW 214.23
DM5FL14 FM C5H15N2O3PS
DM5FL14 IC InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
DM5FL14 CS C(CN)CNCCSP(=O)(O)O
DM5FL14 IK JKOQGQFVAUAYPM-UHFFFAOYSA-N
DM5FL14 IU 2-(3-aminopropylamino)ethylsulfanylphosphonic acid
DM5FL14 CA CAS 20537-88-6
DM5FL14 CB CHEBI:2636
DM5FL14 DE Mucositis
DM5PDRB ID DM5PDRB
DM5PDRB DN Amikacin
DM5PDRB HS Approved
DM5PDRB SN Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
DM5PDRB CP Abbott Laboratories
DM5PDRB TC Antibiotics
DM5PDRB DT Small molecular drug
DM5PDRB PC 37768
DM5PDRB MW 585.6
DM5PDRB FM C22H43N5O13
DM5PDRB IC InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
DM5PDRB CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DM5PDRB IK LKCWBDHBTVXHDL-RMDFUYIESA-N
DM5PDRB IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DM5PDRB CA CAS 37517-28-5
DM5PDRB CB CHEBI:2637
DM5PDRB DE Bacterial infection; Tuberculosis
DMRTSGP ID DMRTSGP
DMRTSGP DN Amiloride
DMRTSGP HS Approved
DMRTSGP SN Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)
DMRTSGP CP Tornett pharmaceutical
DMRTSGP TC Diuretics
DMRTSGP DT Small molecular drug
DMRTSGP PC 16231
DMRTSGP MW 229.63
DMRTSGP FM C6H8ClN7O
DMRTSGP IC InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
DMRTSGP CS C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
DMRTSGP IK XSDQTOBWRPYKKA-UHFFFAOYSA-N
DMRTSGP IU 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMRTSGP CA CAS 2609-46-3
DMRTSGP CB CHEBI:2639
DMRTSGP DE Congestive heart failure
DMFGND4 ID DMFGND4
DMFGND4 DN Aminocaproic acid
DMFGND4 HS Approved
DMFGND4 SN 6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
DMFGND4 CP Intelfarm Co.
DMFGND4 TC Antifibrinolytic Agents
DMFGND4 DT Small molecular drug
DMFGND4 PC 564
DMFGND4 MW 131.17
DMFGND4 FM C6H13NO2
DMFGND4 IC InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
DMFGND4 CS C(CCC(=O)O)CCN
DMFGND4 IK SLXKOJJOQWFEFD-UHFFFAOYSA-N
DMFGND4 IU 6-aminohexanoic acid
DMFGND4 CA CAS 60-32-2
DMFGND4 CB CHEBI:16586
DMFGND4 DE Bleeding disorder; Postoperative hemorrhage
DMWFHMZ ID DMWFHMZ
DMWFHMZ DN Aminoglutethimide
DMWFHMZ HS Approved
DMWFHMZ SN Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
DMWFHMZ CP Norvatis Phamaceuticals Corporation
DMWFHMZ TC Anticancer Agents
DMWFHMZ DT Small molecular drug
DMWFHMZ PC 2145
DMWFHMZ MW 232.28
DMWFHMZ FM C13H16N2O2
DMWFHMZ IC InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
DMWFHMZ CS CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMWFHMZ IK ROBVIMPUHSLWNV-UHFFFAOYSA-N
DMWFHMZ IU 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
DMWFHMZ CA CAS 125-84-8
DMWFHMZ CB CHEBI:2654
DMWFHMZ DE Cushing disease
DMS4BLQ ID DMS4BLQ
DMS4BLQ DN Aminolevulinic acid hci
DMS4BLQ HS Approved
DMS4BLQ SN Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)
DMS4BLQ DT Small molecular drug
DMS4BLQ PC 137
DMS4BLQ MW 131.13
DMS4BLQ FM C5H9NO3
DMS4BLQ IC InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
DMS4BLQ CS C(CC(=O)O)C(=O)CN
DMS4BLQ IK ZGXJTSGNIOSYLO-UHFFFAOYSA-N
DMS4BLQ IU 5-amino-4-oxopentanoic acid
DMS4BLQ CA CAS 106-60-5
DMS4BLQ CB CHEBI:17549
DMS4BLQ DE Acne vulgaris; Actinic keratosis
DMWNHPC ID DMWNHPC
DMWNHPC DN Aminolevulinic Acid Hydrochloride
DMWNHPC HS Approved
DMWNHPC SN Levulan; Levulan Kerastick
DMWNHPC CP Dusa Pharmaceuticals Inc
DMWNHPC DT Small molecular drug
DMWNHPC PC 123608
DMWNHPC MW 167.59
DMWNHPC FM C5H10ClNO3
DMWNHPC IC InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
DMWNHPC CS C(CC(=O)O)C(=O)CN.Cl
DMWNHPC IK ZLHFONARZHCSET-UHFFFAOYSA-N
DMWNHPC IU 5-amino-4-oxopentanoic acid;hydrochloride
DMWNHPC CA CAS 5451-09-2
DMWNHPC CB CHEBI:132969
DMWNHPC DE Actinic keratosis
DML2NIB ID DML2NIB
DML2NIB DN Aminophylline
DML2NIB HS Approved
DML2NIB SN Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
DML2NIB TC Bronchodilator Agents
DML2NIB DT Small molecular drug
DML2NIB PC 9433
DML2NIB MW 420.43
DML2NIB FM C16H24N10O4
DML2NIB IC InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
DML2NIB CS CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
DML2NIB IK FQPFAHBPWDRTLU-UHFFFAOYSA-N
DML2NIB IU 1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine
DML2NIB CA CAS 317-34-0
DML2NIB CB CHEBI:2659
DML2NIB DE Bronchial asthma; Asthma
DMENSL5 ID DMENSL5
DMENSL5 DN Aminosalicylic acid
DMENSL5 HS Approved
DMENSL5 SN 4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium
DMENSL5 CP Panray Corp Sub Ormont Drug And Chemical Co Inc
DMENSL5 DT Small molecular drug
DMENSL5 PC 4649
DMENSL5 MW 153.14
DMENSL5 FM C7H7NO3
DMENSL5 IC InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
DMENSL5 CS C1=CC(=C(C=C1N)O)C(=O)O
DMENSL5 IK WUBBRNOQWQTFEX-UHFFFAOYSA-N
DMENSL5 IU 4-amino-2-hydroxybenzoic acid
DMENSL5 CA CAS 65-49-6
DMENSL5 CB CHEBI:27565
DMENSL5 DE Pulmonary and extrapulmonary tuberculosis; Inflammatory bowel disease
DMUTEX3 ID DMUTEX3
DMUTEX3 DN Amiodarone
DMUTEX3 HS Approved
DMUTEX3 SN Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
DMUTEX3 CP Wyeth-Ayerst Laboratories
DMUTEX3 TC Antiarrhythmic Agents
DMUTEX3 DT Small molecular drug
DMUTEX3 PC 2157
DMUTEX3 MW 645.3
DMUTEX3 FM C25H29I2NO3
DMUTEX3 IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMUTEX3 CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMUTEX3 IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMUTEX3 IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMUTEX3 CA CAS 1951-25-3
DMUTEX3 CB CHEBI:2663
DMUTEX3 DE Tachyarrhythmias
DMSJVAM ID DMSJVAM
DMSJVAM DN Amisulpride
DMSJVAM HS Approved
DMSJVAM SN Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CP Sanofi-Aventis
DMSJVAM TC Antipsychotic Agents
DMSJVAM DT Small molecular drug
DMSJVAM PC 2159
DMSJVAM MW 369.5
DMSJVAM FM C17H27N3O4S
DMSJVAM IC InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
DMSJVAM CS CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMSJVAM IK NTJOBXMMWNYJFB-UHFFFAOYSA-N
DMSJVAM IU 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CA CAS 71675-85-9
DMSJVAM CB CHEBI:64045
DMSJVAM DE Schizophrenia
DMK7F9S ID DMK7F9S
DMK7F9S DN Amitriptyline
DMK7F9S HS Approved
DMK7F9S SN Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
DMK7F9S CP Hoffmann La Roche Inc
DMK7F9S TC Analgesics
DMK7F9S DT Small molecular drug
DMK7F9S PC 2160
DMK7F9S MW 277.4
DMK7F9S FM C20H23N
DMK7F9S IC InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
DMK7F9S CS CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DMK7F9S IK KRMDCWKBEZIMAB-UHFFFAOYSA-N
DMK7F9S IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DMK7F9S CA CAS 50-48-6
DMK7F9S CB CHEBI:2666
DMK7F9S DE Depression
DM0DQM5 ID DM0DQM5
DM0DQM5 DN Amlexanox
DM0DQM5 HS Approved
DM0DQM5 SN ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid
DM0DQM5 CP Access Pharmaceuticals
DM0DQM5 TC Antiulcer Agents
DM0DQM5 DT Small molecular drug
DM0DQM5 PC 2161
DM0DQM5 MW 298.29
DM0DQM5 FM C16H14N2O4
DM0DQM5 IC InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
DM0DQM5 CS CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
DM0DQM5 IK SGRYPYWGNKJSDL-UHFFFAOYSA-N
DM0DQM5 IU 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
DM0DQM5 CA CAS 68302-57-8
DM0DQM5 CB CHEBI:31205
DM0DQM5 DE Respiratory tract inflammation
DMBDAZV ID DMBDAZV
DMBDAZV DN Amlodipine
DMBDAZV HS Approved
DMBDAZV SN Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CP Dainippon Sumitomo
DMBDAZV TC Antihypertensive Agents
DMBDAZV DT Small molecular drug
DMBDAZV PC 2162
DMBDAZV MW 408.9
DMBDAZV FM C20H25ClN2O5
DMBDAZV IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
DMBDAZV CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DMBDAZV IK HTIQEAQVCYTUBX-UHFFFAOYSA-N
DMBDAZV IU 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CA CAS 88150-42-9
DMBDAZV CB CHEBI:2668
DMBDAZV DE Hypertension
DMOEVK6 ID DMOEVK6
DMOEVK6 DN Ammonia
DMOEVK6 HS Approved
DMOEVK6 SN Ammonia N13
DMOEVK6 CP Feinstein
DMOEVK6 DT Small molecular drug
DMOEVK6 PC 222
DMOEVK6 MW 17.031
DMOEVK6 FM H3N
DMOEVK6 IC InChI=1S/H3N/h1H3
DMOEVK6 CS N
DMOEVK6 IK QGZKDVFQNNGYKY-UHFFFAOYSA-N
DMOEVK6 IU azane
DMOEVK6 CA CAS 7664-41-7
DMOEVK6 CB CHEBI:16134
DMOEVK6 DE Coronary artery disease
DM0GQ8N ID DM0GQ8N
DM0GQ8N DN Amobarbital
DM0GQ8N HS Approved
DM0GQ8N SN AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
DM0GQ8N TC Hypnotics and Sedatives
DM0GQ8N DT Small molecular drug
DM0GQ8N PC 2164
DM0GQ8N MW 226.27
DM0GQ8N FM C11H18N2O3
DM0GQ8N IC InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DM0GQ8N CS CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
DM0GQ8N IK VIROVYVQCGLCII-UHFFFAOYSA-N
DM0GQ8N IU 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
DM0GQ8N CA CAS 57-43-2
DM0GQ8N CB CHEBI:2673
DM0GQ8N DE Insomnia
DME4RA8 ID DME4RA8
DME4RA8 DN Amodiaquine
DME4RA8 HS Approved
DME4RA8 SN Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751
DME4RA8 TC Antimalarials
DME4RA8 DT Small molecular drug
DME4RA8 PC 2165
DME4RA8 MW 355.9
DME4RA8 FM C20H22ClN3O
DME4RA8 IC InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DME4RA8 CS CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DME4RA8 IK OVCDSSHSILBFBN-UHFFFAOYSA-N
DME4RA8 IU 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DME4RA8 CA CAS 86-42-0
DME4RA8 CB CHEBI:2674
DME4RA8 DE Malaria
DML8QSZ ID DML8QSZ
DML8QSZ DN Amosulalol
DML8QSZ HS Approved
DML8QSZ SN Lowgan; LY-137224; YM-09538
DML8QSZ CP Yamanouchi Pharmaceutical Co Ltd
DML8QSZ DT Small molecular drug
DML8QSZ PC 2169
DML8QSZ MW 380.5
DML8QSZ FM C18H24N2O5S
DML8QSZ IC InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
DML8QSZ CS CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
DML8QSZ IK LVEXHFZHOIWIIP-UHFFFAOYSA-N
DML8QSZ IU 5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
DML8QSZ CA CAS 85320-68-9
DML8QSZ CB CHEBI:135592
DML8QSZ DE Hypertension
DMKITQE ID DMKITQE
DMKITQE DN Amoxapine
DMKITQE HS Approved
DMKITQE SN Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE TC Antidepressants
DMKITQE DT Small molecular drug
DMKITQE PC 2170
DMKITQE MW 313.8
DMKITQE FM C17H16ClN3O
DMKITQE IC InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
DMKITQE CS C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DMKITQE IK QWGDMFLQWFTERH-UHFFFAOYSA-N
DMKITQE IU 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE CA CAS 14028-44-5
DMKITQE CB CHEBI:2675
DMKITQE DE Major depressive disorder
DMUYNEI ID DMUYNEI
DMUYNEI DN Amoxicillin
DMUYNEI HS Approved
DMUYNEI SN AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMUYNEI CP AstraZeneca
DMUYNEI TC Antibiotics
DMUYNEI DT Small molecular drug
DMUYNEI PC 33613
DMUYNEI MW 365.4
DMUYNEI FM C16H19N3O5S
DMUYNEI IC InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
DMUYNEI CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
DMUYNEI IK LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DMUYNEI IU (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUYNEI CA CAS 26787-78-0
DMUYNEI CB CHEBI:2676
DMUYNEI DE Bacterial infection
DMSZQAK ID DMSZQAK
DMSZQAK DN Amphetamine
DMSZQAK HS Approved
DMSZQAK SN Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
DMSZQAK CP PharmacoFore Inc
DMSZQAK DT Small molecular drug
DMSZQAK PC 3007
DMSZQAK MW 135.21
DMSZQAK FM C9H13N
DMSZQAK IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
DMSZQAK CS CC(CC1=CC=CC=C1)N
DMSZQAK IK KWTSXDURSIMDCE-UHFFFAOYSA-N
DMSZQAK IU 1-phenylpropan-2-amine
DMSZQAK CA CAS 300-62-9
DMSZQAK CB CHEBI:2679
DMSZQAK DE Attention deficit hyperactivity disorder
DMTAJQE ID DMTAJQE
DMTAJQE DN Amphotericin B
DMTAJQE HS Approved
DMTAJQE SN ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)
DMTAJQE TC Antifungal Agents
DMTAJQE DT Small molecular drug
DMTAJQE PC 5280965
DMTAJQE MW 924.1
DMTAJQE FM C47H73NO17
DMTAJQE IC InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
DMTAJQE CS C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DMTAJQE IK APKFDSVGJQXUKY-INPOYWNPSA-N
DMTAJQE IU (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
DMTAJQE CA CAS 1397-89-3
DMTAJQE DE Fungal infection; Mycoses
DMHWE7P ID DMHWE7P
DMHWE7P DN Ampicillin
DMHWE7P HS Approved
DMHWE7P SN ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMHWE7P CP Stadapharm GmbH
DMHWE7P TC Antibiotics
DMHWE7P DT Small molecular drug
DMHWE7P PC 6249
DMHWE7P MW 349.4
DMHWE7P FM C16H19N3O4S
DMHWE7P IC InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
DMHWE7P CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
DMHWE7P IK AVKUERGKIZMTKX-NJBDSQKTSA-N
DMHWE7P IU (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHWE7P CA CAS 69-53-4
DMHWE7P CB CHEBI:28971
DMHWE7P DE Bacterial infection
DM5BS98 ID DM5BS98
DM5BS98 DN Ampiroxicam
DM5BS98 HS Approved
DM5BS98 SN Flucam; Nacyl; Nasil; CP-65703
DM5BS98 CP Pfizer Inc
DM5BS98 DT Small molecular drug
DM5BS98 PC 2176
DM5BS98 MW 447.5
DM5BS98 FM C20H21N3O7S
DM5BS98 IC InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
DM5BS98 CS CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
DM5BS98 IK LSNWBKACGXCGAJ-UHFFFAOYSA-N
DM5BS98 IU ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate
DM5BS98 CA CAS 99464-64-9
DM5BS98 CB CHEBI:31210
DM5BS98 DE Inflammation
DMLMXE0 ID DMLMXE0
DMLMXE0 DN Amprenavir
DMLMXE0 HS Approved
DMLMXE0 SN AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
DMLMXE0 CP GlaxoSmithKline
DMLMXE0 TC Anti-HIV Agents
DMLMXE0 DT Small molecular drug
DMLMXE0 PC 65016
DMLMXE0 MW 505.6
DMLMXE0 FM C25H35N3O6S
DMLMXE0 IC InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
DMLMXE0 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
DMLMXE0 IK YMARZQAQMVYCKC-OEMFJLHTSA-N
DMLMXE0 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMLMXE0 CA CAS 161814-49-9
DMLMXE0 CB CHEBI:40050
DMLMXE0 DE Human immunodeficiency virus infection
DMZKYIV ID DMZKYIV
DMZKYIV DN Amsacrine
DMZKYIV HS Approved
DMZKYIV SN Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
DMZKYIV CP Travenol Laboratories Inc
DMZKYIV TC Anticancer Agents
DMZKYIV DT Small molecular drug
DMZKYIV PC 2179
DMZKYIV MW 393.5
DMZKYIV FM C21H19N3O3S
DMZKYIV IC InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
DMZKYIV CS COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
DMZKYIV IK XCPGHVQEEXUHNC-UHFFFAOYSA-N
DMZKYIV IU N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
DMZKYIV CA CAS 51264-14-3
DMZKYIV CB CHEBI:2687
DMZKYIV DE Acute lymphoblastic leukaemia
DMAWU35 ID DMAWU35
DMAWU35 DN Amtolmetin guacil
DMAWU35 HS Approved
DMAWU35 SN Artromed; Atromed; Eufans; Amtolmetin guacyl; MED-15; ST-679
DMAWU35 CP Sigma-Tau Ind Farm Riunite SpA
DMAWU35 DT Small molecular drug
DMAWU35 PC 65655
DMAWU35 MW 420.5
DMAWU35 FM C24H24N2O5
DMAWU35 IC InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27)
DMAWU35 CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC
DMAWU35 IK CWJNMKKMGIAGDK-UHFFFAOYSA-N
DMAWU35 IU (2-methoxyphenyl) 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetate
DMAWU35 CA CAS 87344-06-7
DMAWU35 CB CHEBI:135678
DMAWU35 DE Inflammation
DMJKO05 ID DMJKO05
DMJKO05 DN Amyl nitrite
DMJKO05 HS Approved
DMJKO05 SN Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644
DMJKO05 DT Small molecular drug
DMJKO05 PC 10026
DMJKO05 MW 117.15
DMJKO05 FM C5H11NO2
DMJKO05 IC InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3
DMJKO05 CS CCCCCON=O
DMJKO05 IK CSDTZUBPSYWZDX-UHFFFAOYSA-N
DMJKO05 IU pentyl nitrite
DMJKO05 CA CAS 463-04-7
DMJKO05 CB CHEBI:55344
DMJKO05 DE Angina pectoris
DMJXIC9 ID DMJXIC9
DMJXIC9 DN Anagliptin
DMJXIC9 HS Approved
DMJXIC9 SN Anagliptin; 739366-20-2; UNII-K726J96838; suiny; CHEMBL1929396; (S)-N-(2-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; K726J96838; CHEMBL1929387; N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; Anagliptin [INN]; N-[2-({2-[(2s)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-A]pyrimidine-6-Carboxamide; Anagliptin (JAN/INN); SCHEMBL905393; sk-0403
DMJXIC9 CP Kowa Research Institute
DMJXIC9 DT Small molecular drug
DMJXIC9 PC 44513473
DMJXIC9 MW 383.4
DMJXIC9 FM C19H25N7O2
DMJXIC9 IC InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
DMJXIC9 CS CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
DMJXIC9 IK LDXYBEHACFJIEL-HNNXBMFYSA-N
DMJXIC9 IU N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
DMJXIC9 CA CAS 739366-20-2
DMJXIC9 CB CHEBI:136043
DMJXIC9 DE Type-2 diabetes
DMSQ8MD ID DMSQ8MD
DMSQ8MD DN Anagrelide
DMSQ8MD HS Approved
DMSQ8MD SN Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CP Shire Phamaceuticals
DMSQ8MD TC Antithrombotic Agents
DMSQ8MD DT Small molecular drug
DMSQ8MD PC 135409400
DMSQ8MD MW 256.079
DMSQ8MD FM C10H7Cl2N3O
DMSQ8MD IC InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
DMSQ8MD CS C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
DMSQ8MD IK OTBXOEAOVRKTNQ-UHFFFAOYSA-N
DMSQ8MD IU 6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CA CAS 68475-42-3
DMSQ8MD CB CHEBI:142290
DMSQ8MD DE Thrombocythemia; Essential thrombocythemia
DMU8KOD ID DMU8KOD
DMU8KOD DN Anakinra
DMU8KOD HS Approved
DMU8KOD SN Kineret; Kineret (TN); Anakinra (USAN/INN)
DMU8KOD CP Amgen Inc
DMU8KOD TC Antiinflammatory Agents
DMU8KOD SQ DB00026 sequence: MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
DMU8KOD DE Rheumatoid arthritis
DMV96ZH ID DMV96ZH
DMV96ZH DN Anapsos
DMV96ZH HS Approved
DMV96ZH SN Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
DMV96ZH CP ASAC Pharmaceutical International AIE
DMV96ZH DE Atopic dermatitis
DMNP60F ID DMNP60F
DMNP60F DN Anastrozole
DMNP60F HS Approved
DMNP60F SN Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CP AstraZeneca
DMNP60F TC Anticancer Agents
DMNP60F DT Small molecular drug
DMNP60F PC 2187
DMNP60F MW 293.4
DMNP60F FM C17H19N5
DMNP60F IC InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
DMNP60F CS CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
DMNP60F IK YBBLVLTVTVSKRW-UHFFFAOYSA-N
DMNP60F IU 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CA CAS 120511-73-1
DMNP60F CB CHEBI:2704
DMNP60F DE Breast cancer
DMLWQ27 ID DMLWQ27
DMLWQ27 DN Angiotensin Ii
DMLWQ27 HS Approved
DMLWQ27 SN Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]
DMLWQ27 CP La Jolla Pharmaceutical Company
DMLWQ27 DT Small molecular drug
DMLWQ27 PC 172198
DMLWQ27 MW 1046.2
DMLWQ27 FM C50H71N13O12
DMLWQ27 IC InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMLWQ27 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMLWQ27 IK CZGUSIXMZVURDU-JZXHSEFVSA-N
DMLWQ27 IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMLWQ27 CA CAS 4474-91-3
DMLWQ27 CB CHEBI:2719
DMLWQ27 DE Increase blood pressure
DM8QM5U ID DM8QM5U
DM8QM5U DN Anidulafungin
DM8QM5U HS Approved
DM8QM5U SN Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DM8QM5U CP Pfizer Pharmaceuticals
DM8QM5U TC Antifungal Agents
DM8QM5U DT Small molecular drug
DM8QM5U PC 166548
DM8QM5U MW 1140.2
DM8QM5U FM C58H73N7O17
DM8QM5U IC InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DM8QM5U CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DM8QM5U IK JHVAMHSQVVQIOT-MFAJLEFUSA-N
DM8QM5U IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DM8QM5U CA CAS 166663-25-8
DM8QM5U CB CHEBI:55346
DM8QM5U DE Convulsion
DMBAUED ID DMBAUED
DMBAUED DN Anileridine
DMBAUED HS Approved
DMBAUED SN Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester
DMBAUED TC Analgesics
DMBAUED DT Small molecular drug
DMBAUED PC 8944
DMBAUED MW 352.5
DMBAUED FM C22H28N2O2
DMBAUED IC InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
DMBAUED CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3
DMBAUED IK LKYQLAWMNBFNJT-UHFFFAOYSA-N
DMBAUED IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
DMBAUED CA CAS 144-14-9
DMBAUED CB CHEBI:61203
DMBAUED DE Pain
DMC128O ID DMC128O
DMC128O DN Anileridine Hydrochloride
DMC128O HS Approved
DMC128O SN Anileridine Phosphate; Leritine
DMC128O CP Merck And Co Inc
DMC128O TC Neurology Agents
DMC128O DT Small molecular drug
DMC128O PC 31338
DMC128O MW 425.4
DMC128O FM C22H30Cl2N2O2
DMC128O IC InChI=1S/C22H28N2O2.2ClH/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;;/h3-11H,2,12-17,23H2,1H3;2*1H
DMC128O CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3.Cl.Cl
DMC128O IK ZYTHLJLPPSSDIP-UHFFFAOYSA-N
DMC128O IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate;dihydrochloride
DMC128O CA CAS 126-12-5
DMC128O CB CHEBI:61208
DMC128O DE Pain
DMOIFW0 ID DMOIFW0
DMOIFW0 DN Aniracetam
DMOIFW0 HS Approved
DMOIFW0 SN aniracetam; 72432-10-1; Draganon; Sarpul; 1-(4-Methoxybenzoyl)-2-pyrrolidinone; Ampamet; 1-(4-methoxybenzoyl)pyrrolidin-2-one; 1-p-Anisoyl-2-pyrrolidinone; Ro 13-5057; Aniracetamun [INN-Latin]; Aniracetam [USAN:INN:JAN]; UNII-5L16LKN964; Ro 135057; BRN 4807205; Ro-13-5057; 1-p-anisoylpyrrolidin-2-one; 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-; CHEMBL36994; MLS000079240; CHEBI:47943; 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]; ZXNRTKGTQJPIJK-UHFFFAOYSA-N; 5L16LKN964; NCGC00015116-10; SMR000038438
DMOIFW0 DT Small molecular drug
DMOIFW0 PC 2196
DMOIFW0 MW 219.24
DMOIFW0 FM C12H13NO3
DMOIFW0 IC InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
DMOIFW0 CS COC1=CC=C(C=C1)C(=O)N2CCCC2=O
DMOIFW0 IK ZXNRTKGTQJPIJK-UHFFFAOYSA-N
DMOIFW0 IU 1-(4-methoxybenzoyl)pyrrolidin-2-one
DMOIFW0 CA CAS 72432-10-1
DMOIFW0 CB CHEBI:47943
DMOIFW0 DE Cerebrovascular ischaemia
DM2C48U ID DM2C48U
DM2C48U DN Anisindione
DM2C48U HS Approved
DM2C48U SN Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione
DM2C48U TC Anticoagulants
DM2C48U DT Small molecular drug
DM2C48U PC 2197
DM2C48U MW 252.26
DM2C48U FM C16H12O3
DM2C48U IC InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
DM2C48U CS COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2C48U IK XRCFXMGQEVUZFC-UHFFFAOYSA-N
DM2C48U IU 2-(4-methoxyphenyl)indene-1,3-dione
DM2C48U CA CAS 117-37-3
DM2C48U CB CHEBI:133809
DM2C48U DE Coagulation defect
DMW51AX ID DMW51AX
DMW51AX DN Anisodamine
DMW51AX HS Approved
DMW51AX SN anisodamine; racanisodamine; 55869-99-3; (6S)-6-Hydroxyhyoscyamine; (-)-Anisodamine; AC1O6SQS; AC1L4C7W; SCHEMBL620576; ZINC2112569; 8053AH; API0000388; 869A993; Q-100648; [(1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; (S)-((1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; [(1R,3S,5R,6R)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate
DMW51AX DT Small molecular drug
DMW51AX PC 6918612
DMW51AX MW 305.4
DMW51AX FM C17H23NO4
DMW51AX IC InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
DMW51AX CS CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3
DMW51AX IK WTQYWNWRJNXDEG-RBZJEDDUSA-N
DMW51AX IU [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMW51AX CA CAS 55869-99-3
DMW51AX DE Central and peripheral nervous disease
DMNOSWU ID DMNOSWU
DMNOSWU DN Anisodine
DMNOSWU HS Approved
DMNOSWU SN anisodine; 52646-92-1; SCHEMBL474045; AC1N31M8; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester
DMNOSWU DT Small molecular drug
DMNOSWU PC 11616712
DMNOSWU MW 319.4
DMNOSWU FM C17H21NO5
DMNOSWU IC InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1
DMNOSWU CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O
DMNOSWU IK JEJREKXHLFEVHN-QDXGGTILSA-N
DMNOSWU IU [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate
DMNOSWU CA CAS 52646-92-1
DMNOSWU DE Central and peripheral nervous disease
DMIJRF0 ID DMIJRF0
DMIJRF0 DN Anisotropine Methylbromide
DMIJRF0 HS Approved
DMIJRF0 SN Anisotropine; Endovalpin; Lytispasm; Valpin; Anisotropine methobromide; Anisotropine methyl bromide;Methyloctatropine bromide; Metilbromuro de octatropina; Octatropine methylbromide; Octatropini methylbromidum; Octatropone Bromide; Valpin 50; Anisotropine methylbromide (USAN); Anisotropine methylbromide [USAN:JAN]; Endovalpin (TN); Lytispasm (TN); Methylbromure d'octatropine; Methyloctatropine bromide (JAN); Metilbromuro de octatropina [INN-Spanish]; Octatropine methylbromide (INN); Octatropinimethylbromidum [INN-Latin]; Valpin (TN); Valpin 50 (TN); Methylbromure d'octatropine [INN-French]; Anisotropine methylbromide, (endo)-isomer; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 1-alpha-H,5-alpha-H-Tropanium,3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 2-Propylpentanoyltropinium methylbromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; 8-Methyltropinium bromide 2-propylpentanoate; 8-Methyltropinium bromide 2-propylvalerate
DMIJRF0 TC Anticholinergic Agents
DMIJRF0 DT Small molecular drug
DMIJRF0 PC 657201
DMIJRF0 MW 362.3
DMIJRF0 FM C17H32BrNO2
DMIJRF0 IC InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15+,16?;
DMIJRF0 CS CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-]
DMIJRF0 IK QSFKGMJOKUZAJM-JXMYBXCISA-M
DMIJRF0 IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide
DMIJRF0 CA CAS 80-50-2
DMIJRF0 DE Peptic ulcer
DM6Q4B0 ID DM6Q4B0
DM6Q4B0 DN Anistreplase
DM6Q4B0 HS Approved
DM6Q4B0 TC Thrombolytic Agents
DM6Q4B0 SQ DB00029 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DM6Q4B0 DE Acute coronary syndrome
DMUMOEV ID DMUMOEV
DMUMOEV DN Ansuvimab
DMUMOEV HS Approved
DMUMOEV DT Antibody
DMUMOEV DE Ebola virus infection
DMA04JS ID DMA04JS
DMA04JS DN Antazoline
DMA04JS HS Approved
DMA04JS SN Analergine; Antastan; Antasten; Antazolin; Antazolina; Antazolinum; Antihistal; Antistin; Antistine; Azalone; Histostab;Imidamin; Imidamine; Phenazolin; Phenazoline; Antazolina [Spanish]; Antazolinum [Latin]; Antazolina [INN-Spanish]; Antazoline (INN); Antazoline [INN:BAN]; Antazolinum [INN-Latin]; Ben-A-hist; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; 2-(N-Benzylanilinomethyl)-2-imidazoline; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 2-Phenyl-benzyl-amino-methylimidazolin; 2-Phenyl-benzyl-amino-methylimidazolin [German]; 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; 5512-M
DMA04JS DT Small molecular drug
DMA04JS PC 2200
DMA04JS MW 265.35
DMA04JS FM C17H19N3
DMA04JS IC InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
DMA04JS CS C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3
DMA04JS IK REYFJDPCWQRWAA-UHFFFAOYSA-N
DMA04JS IU N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
DMA04JS CA CAS 91-75-8
DMA04JS CB CHEBI:84115
DMA04JS DE Nasal congestion
DMNC64R ID DMNC64R
DMNC64R DN Antegren
DMNC64R HS Approved
DMNC64R DT Antibody
DMNC64R DE Multiple sclerosis
DMH4CFE ID DMH4CFE
DMH4CFE DN Antithymocyte globulin
DMH4CFE HS Approved
DMH4CFE SN Atgam (TN); Thymoglobulin (TN)
DMH4CFE CP Pfizer Pharmaceuticals
DMH4CFE TC Immunomodulatory Agents
DMH4CFE DE Aplastic anemia
DM89JLN ID DM89JLN
DM89JLN DN Apixaban
DM89JLN HS Approved
DM89JLN SN GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
DM89JLN CP Pfizer
DM89JLN DT Small molecular drug
DM89JLN PC 10182969
DM89JLN MW 459.5
DM89JLN FM C25H25N5O4
DM89JLN IC InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
DM89JLN CS COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
DM89JLN IK QNZCBYKSOIHPEH-UHFFFAOYSA-N
DM89JLN IU 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
DM89JLN CA CAS 503612-47-3
DM89JLN CB CHEBI:72296
DM89JLN DE Thrombosis
DMX38HQ ID DMX38HQ
DMX38HQ DN Apomorphine
DMX38HQ HS Approved
DMX38HQ SN Apomorphine (intranasal, Parkinson's disease)
DMX38HQ CP Archimedes Pharma Ltd
DMX38HQ DT Small molecular drug
DMX38HQ PC 6005
DMX38HQ MW 267.32
DMX38HQ FM C17H17NO2
DMX38HQ IC InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
DMX38HQ CS CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMX38HQ IK VMWNQDUVQKEIOC-CYBMUJFWSA-N
DMX38HQ IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMX38HQ CA CAS 58-00-4
DMX38HQ CB CHEBI:48538
DMX38HQ DE Parkinson disease; Sexual dysfunction; Idiopathic parkinson disease
DMO4PVE ID DMO4PVE
DMO4PVE DN Apraclonidine
DMO4PVE HS Approved
DMO4PVE SN Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine
DMO4PVE CP Alcon Canada Inc
DMO4PVE TC Antiglaucomic Agents
DMO4PVE DT Small molecular drug
DMO4PVE PC 2216
DMO4PVE MW 245.11
DMO4PVE FM C9H10Cl2N4
DMO4PVE IC InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
DMO4PVE CS C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl
DMO4PVE IK IEJXVRYNEISIKR-UHFFFAOYSA-N
DMO4PVE IU 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
DMO4PVE CA CAS 66711-21-5
DMO4PVE CB CHEBI:2788
DMO4PVE DE Intra ocular pressure reduction
DMTWS9E ID DMTWS9E
DMTWS9E DN Apremilast
DMTWS9E HS Approved
DMTWS9E SN Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
DMTWS9E CP Celgene
DMTWS9E DT Small molecular drug
DMTWS9E PC 11561674
DMTWS9E MW 460.5
DMTWS9E FM C22H24N2O7S
DMTWS9E IC InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
DMTWS9E CS CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
DMTWS9E IK IMOZEMNVLZVGJZ-QGZVFWFLSA-N
DMTWS9E IU N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
DMTWS9E CA CAS 608141-41-9
DMTWS9E CB CHEBI:78540
DMTWS9E DE Psoriasis vulgaris
DM053KT ID DM053KT
DM053KT DN Aprepitant
DM053KT HS Approved
DM053KT SN Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
DM053KT CP Merck & Co
DM053KT TC Antiemetics
DM053KT DT Small molecular drug
DM053KT PC 135413536
DM053KT MW 534.4
DM053KT FM C23H21F7N4O3
DM053KT IC InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1
DM053KT CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F
DM053KT IK ATALOFNDEOCMKK-OITMNORJSA-N
DM053KT IU 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DM053KT CA CAS 170729-80-3
DM053KT CB CHEBI:499361
DM053KT DE Depression; Nausea; Solid tumour/cancer
DMBXWU8 ID DMBXWU8
DMBXWU8 DN Aprindine
DMBXWU8 HS Approved
DMBXWU8 SN Aprindin; Aprindina; Aprindinum; Aprinidine; Fibocil; AC 1802; Aprindina [INN-Spanish]; Aprindinum [INN-Latin]; Aprindine (USAN/INN); Aprindine [USAN:BAN:INN]; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediaminemonohydrochloride; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine
DMBXWU8 TC Antiarrhythmic Agents
DMBXWU8 DT Small molecular drug
DMBXWU8 PC 2218
DMBXWU8 MW 322.5
DMBXWU8 FM C22H30N2
DMBXWU8 IC InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
DMBXWU8 CS CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3
DMBXWU8 IK NZLBHDRPUJLHCE-UHFFFAOYSA-N
DMBXWU8 IU N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine
DMBXWU8 CA CAS 37640-71-4
DMBXWU8 CB CHEBI:135370
DMBXWU8 DE Cardiac arrhythmias
DMOWK6B ID DMOWK6B
DMOWK6B DN Aprobarbital
DMOWK6B HS Approved
DMOWK6B SN Allional; Allonal; Allylisopropylmalonylurea; Allylpropymal; Allypropymal; Allypropymalum; Alurate; Aprobarbita; Aprobarbitale; Aprobarbitalum; Aprobarbitone; Aprozal; Numal; Allylisopropylbarbituric acid; Alurate elixir verdum; Aprobarbitale [DCIT]; Isopropylallylbarbituric acid; Alurate (TN); Aprobarbital (INN); Aprobarbital [INN:DCF]; Aprobarbitalum [INN-Latin]; Isonal (swedish); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-(9CI); 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-isopropylbarbiturate; 5-Allyl-5-isopropylbarbituricacid; 5-Isopropyl-5-allylbarbituric acid; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B TC Anticonvulsants
DMOWK6B DT Small molecular drug
DMOWK6B PC 6464
DMOWK6B MW 210.23
DMOWK6B FM C10H14N2O3
DMOWK6B IC InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)
DMOWK6B CS CC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DMOWK6B IK UORJNBVJVRLXMQ-UHFFFAOYSA-N
DMOWK6B IU 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B CA CAS 77-02-1
DMOWK6B CB CHEBI:2791
DMOWK6B DE Anaesthesia; Insomnia
DM0QD4W ID DM0QD4W
DM0QD4W DN Aprotinin
DM0QD4W HS Approved
DM0QD4W SN Trasylol; Zymofren; Trazinin; Iniprol; Riker 52G; Bayer A 128; UNII-04XPW8C0FL; 04XPW8C0FL; APROTININ; RP-9921; Aprotininum; Aprotinina; Aprotinine; Antilysine; Repulson; Antagosan; Pantinol; Onquinin; Trascolan; Protimbin; Inhibin; Contrykal; Antilysin; Antikrein; Fosten; Tzalol; Gordox; Kir richter; Trypsin inhibitor; Aprotinin solution; 9087-70-1; BPTI; APROTININ BOVINE; Basic protease inhibitor; Aprotininum [INN-Latin]; Aprotinine [INN-French]; Aprotinina [INN-Spanish]; Pancreatic trypsin inhibitor; Kunitz and Northrop inhibitor
DM0QD4W CP Novo Nordisk A/S
DM0QD4W DT Small molecular drug
DM0QD4W SQ Aprotinin (bovine pancreatic trypsin inhibitor): RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
DM0QD4W PC 146027575
DM0QD4W MW 6511
DM0QD4W FM C284H432N84O79S7
DM0QD4W IC InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147+,148-,149-,150+,151-,152-,153+,154+,167+,168-,169+,170+,171+,172+,173+,174-,175-,176+,177-,178+,179-,180+,181-,182+,183-,184+,185+,186+,187+,188+,189+,190-,191+,192+,193+,194+,195-,196+,197+,198+,199-,200+,201+,202-,203-,204+,205+,206+,221-,222+,223+,224-,225-,226-/m1/s1
DM0QD4W CS CC[C@@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N6CCC[C@@H]6C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CCC(=O)N)[C@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)[C@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@H](C)CC
DM0QD4W IK ZPNFWUPYTFPOJU-VKTQZXOTSA-N
DM0QD4W IU (3R)-4-[[(2S)-1-[[(1S,2aR,4R,5aR,8aR,11aR,13R,14aR,16S,17aS,19S,20aR,25S,26aR,29aR,31S,32aR,34S,35aS,37R,38aS,41aS,42R,44aS,45R,47aR,48S,50aS,51R,53aS,54R,56aR,57S,59aR,60S,62aS,63S,66S,69S,72S,75S,78S,81S,84S,87S,90S,93R)-29a,62a,69,84-tetrakis(4-aminobutyl)-35a,75,78-tris(2-amino-2-oxoethyl)-14a-(3-amino-3-oxopropyl)-8a,41a,72-tribenzyl-50a,53a-bis[(2R)-butan-2-yl]-47a,48,56a,81,90-pentakis(3-carbamimidamidopropyl)-31,60-bis(2-carboxyethyl)-42-[[2-[[2-[[(1R)-1-carboxyethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamoyl]-57-(carboxymethyl)-11a,45-bis[(1S)-1-hydroxyethyl]-13-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-2a,16,38a,44a-tetrakis[(4-hydroxyphenyl)methyl]-26a,32a,59a,63,87-pentamethyl-20a,34-bis(2-methylpropyl)-51-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,22a,24,25a,28a,30,31a,33,34a,36,37a,40a,43a,44,46a,47,49a,50,52a,53,55a,56,58a,59,61a,62,64a,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-5a-propan-2-yl-39,40,66a,67a,70a,71a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,21a,23,24a,27a,29,30a,32,33a,35,36a,39a,42a,43,45a,46,48a,49,51a,52,54a,55,57a,58,60a,61,63a,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazahexacyclo[91.71.4.454,117.04,8.019,23.025,29]doheptacontahectan-37-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid
DM0QD4W CA CAS 9087-70-1
DM0QD4W DE Bleeding disorder
DMHTXSL ID DMHTXSL
DMHTXSL DN Arbekacin
DMHTXSL HS Approved
DMHTXSL SN Habekacin (TN)
DMHTXSL CP Meiji Seika
DMHTXSL DT Small molecular drug
DMHTXSL PC 68682
DMHTXSL MW 552.6
DMHTXSL FM C22H44N6O10
DMHTXSL IC InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
DMHTXSL CS C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N
DMHTXSL IK MKKYBZZTJQGVCD-XTCKQBCOSA-N
DMHTXSL IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMHTXSL CA CAS 51025-85-5
DMHTXSL CB CHEBI:37922
DMHTXSL DE Bacterial infection
DMOQK8Z ID DMOQK8Z
DMOQK8Z DN Arbidol
DMOQK8Z HS Approved
DMOQK8Z SN Umifenovir; Arbidole; MC-101
DMOQK8Z CP Good Earth Medicine
DMOQK8Z DT Small molecular drug
DMOQK8Z PC 131411
DMOQK8Z MW 477.4
DMOQK8Z FM C22H25BrN2O3S
DMOQK8Z IC InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
DMOQK8Z CS CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3
DMOQK8Z IK KCFYEAOKVJSACF-UHFFFAOYSA-N
DMOQK8Z IU ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
DMOQK8Z CA CAS 131707-25-0
DMOQK8Z CB CHEBI:134730
DMOQK8Z DE Virus infection
DMCY8AF ID DMCY8AF
DMCY8AF DN Arbutamine
DMCY8AF HS Approved
DMCY8AF SN Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF TC Cardiotonic Agents
DMCY8AF DT Small molecular drug
DMCY8AF PC 60789
DMCY8AF MW 317.4
DMCY8AF FM C18H23NO4
DMCY8AF IC InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1
DMCY8AF CS C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O
DMCY8AF IK IIRWWTKISYTTBL-SFHVURJKSA-N
DMCY8AF IU 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF CA CAS 128470-16-6
DMCY8AF CB CHEBI:50580
DMCY8AF DE Coronary artery disease
DM9GH25 ID DM9GH25
DM9GH25 DN Arcitumomab
DM9GH25 HS Approved
DM9GH25 SN CEA-Scan; Arcitumomab (USAN/INN); Cea-Scan (TN)
DM9GH25 TC Diagnostic Agents
DM9GH25 DT Antibody
DM9GH25 DE Breast cancer
DMYRX8B ID DMYRX8B
DMYRX8B DN Ardeparin
DMYRX8B HS Approved
DMYRX8B SN Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
DMYRX8B CP Celcius Laboratories
DMYRX8B TC Anticoagulants
DMYRX8B DT Small molecular drug
DMYRX8B PC 772
DMYRX8B MW 1134.9
DMYRX8B FM C26H42N2O37S5
DMYRX8B IC InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
DMYRX8B CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
DMYRX8B IK HTTJABKRGRZYRN-UHFFFAOYSA-N
DMYRX8B IU 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DMYRX8B CA CAS 9005-49-6
DMYRX8B DE Venous thrombosis; Thrombosis; Deep vein thrombosis; Venous thromboembolism
DMVMY7K ID DMVMY7K
DMVMY7K DN Arepanrix
DMVMY7K HS Approved
DMVMY7K SN H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK
DMVMY7K CP GlaxoSmithKline plc
DMVMY7K DT Vaccine
DMVMY7K DE Influenza virus infection
DMYM974 ID DMYM974
DMYM974 DN Arformoterol
DMYM974 HS Approved
DMYM974 SN 67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate
DMYM974 CP Sepracor phamaceuticals
DMYM974 TC Bronchodilator Agents
DMYM974 DT Small molecular drug
DMYM974 PC 3083544
DMYM974 MW 344.4
DMYM974 FM C19H24N2O4
DMYM974 IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
DMYM974 CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O
DMYM974 IK BPZSYCZIITTYBL-YJYMSZOUSA-N
DMYM974 IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
DMYM974 CA CAS 67346-49-0
DMYM974 CB CHEBI:408174
DMYM974 DE Chronic obstructive pulmonary disease; Asthma
DMFI46A ID DMFI46A
DMFI46A DN Argatroban
DMFI46A HS Approved
DMFI46A SN Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
DMFI46A TC Anticoagulants
DMFI46A DT Small molecular drug
DMFI46A PC 92722
DMFI46A MW 508.6
DMFI46A FM C23H36N6O5S
DMFI46A IC InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
DMFI46A CS C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
DMFI46A IK KXNPVXPOPUZYGB-IOVMHBDKSA-N
DMFI46A IU (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
DMFI46A CA CAS 74863-84-6
DMFI46A CB CHEBI:94385
DMFI46A DE Thrombosis
DMRE4FC ID DMRE4FC
DMRE4FC DN Arginine
DMRE4FC HS Approved
DMRE4FC SN DL-Arginine hydrochloride; 32042-43-6; 2-Amino-5-guanidinopentanoic acid hydrochloride; argininhydrochlorid; DL-Arginine HCl; 220144-84-3; H-DL-Arg-OH.xHCl; DL-(+/-)-Arginine Hydrochloride; 1-Hydrochloride arginine; NSC7914; Arginine monochloride; 2-Amino-5-guanidinovaleric acid monohydrochloride; WLN: MUYZM3YZVQ & DL-Arginine hydrochloride, 98%, anhydrous; Arginine monohydrochloride, L-(+)-; ARGININE, (L); L(+)-Arginine hydrochloride; D-Arginine, hydrochloride (1:1); EINECS 250-903-0; EINECS 239-674-8
DMRE4FC DT Small molecular drug
DMRE4FC PC 6322
DMRE4FC MW 174.2
DMRE4FC FM C6H14N4O2
DMRE4FC IC InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
DMRE4FC CS C(C[C@@H](C(=O)O)N)CN=C(N)N
DMRE4FC IK ODKSFYDXXFIFQN-BYPYZUCNSA-N
DMRE4FC IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMRE4FC CA CAS 74-79-3
DMRE4FC CB CHEBI:16467
DMRE4FC DE Growth hormone deficiency
DM3NUMH ID DM3NUMH
DM3NUMH DN Aripiprazole
DM3NUMH HS Approved
DM3NUMH SN 129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
DM3NUMH CP Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
DM3NUMH TC Antipsychotic Agents
DM3NUMH DT Small molecular drug
DM3NUMH PC 60795
DM3NUMH MW 448.4
DM3NUMH FM C23H27Cl2N3O2
DM3NUMH IC InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
DM3NUMH CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
DM3NUMH IK CEUORZQYGODEFX-UHFFFAOYSA-N
DM3NUMH IU 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DM3NUMH CA CAS 129722-12-9
DM3NUMH CB CHEBI:31236
DM3NUMH DE Major depressive disorder; Schizophrenia; Bipolar disorder; Erythropoietic porphyrias
DMGB035 ID DMGB035
DMGB035 DN Armodafinil
DMGB035 HS Approved
DMGB035 SN Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 CP Cephalon
DMGB035 DT Small molecular drug
DMGB035 PC 9690109
DMGB035 MW 273.4
DMGB035 FM C15H15NO2S
DMGB035 IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
DMGB035 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
DMGB035 IK YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 IU 2-[(R)-benzhydrylsulfinyl]acetamide
DMGB035 CA CAS 112111-43-0
DMGB035 CB CHEBI:77590
DMGB035 DE Pediatric cancer
DMT81LZ ID DMT81LZ
DMT81LZ DN Arn-509
DMT81LZ HS Approved
DMT81LZ SN Arn-509 (AR inhibitor)
DMT81LZ CP Johnson & Johnson
DMT81LZ DT Small molecular drug
DMT81LZ PC 24872560
DMT81LZ MW 477.4
DMT81LZ FM C21H15F4N5O2S
DMT81LZ IC InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
DMT81LZ CS CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
DMT81LZ IK HJBWBFZLDZWPHF-UHFFFAOYSA-N
DMT81LZ IU 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide
DMT81LZ CA CAS 956104-40-8
DMT81LZ DE Acute myeloid leukaemia; Prostate cancer
DM1P6FR ID DM1P6FR
DM1P6FR DN Arry-162
DM1P6FR HS Approved
DM1P6FR SN 606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
DM1P6FR CP Array BioPharma
DM1P6FR DT Small molecular drug
DM1P6FR PC 10288191
DM1P6FR MW 441.2
DM1P6FR FM C17H15BrF2N4O3
DM1P6FR IC InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DM1P6FR CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
DM1P6FR IK ACWZRVQXLIRSDF-UHFFFAOYSA-N
DM1P6FR IU 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DM1P6FR CA CAS 606143-89-9
DM1P6FR CB CHEBI:145371
DM1P6FR DE Melanoma
DMTL2Y1 ID DMTL2Y1
DMTL2Y1 DN Arsenic
DMTL2Y1 HS Approved
DMTL2Y1 SN Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ
DMTL2Y1 PC 5359596
DMTL2Y1 MW 74.921
DMTL2Y1 FM As
DMTL2Y1 IC RQNWIZPPADIBDY-UHFFFAOYSA-N
DMTL2Y1 CS [As]
DMTL2Y1 IK 1S/As
DMTL2Y1 IU arsenic
DMTL2Y1 CA CAS 7440-38-2
DMTL2Y1 CB CHEBI:27563
DMTL2Y1 DE Acute myeloid leukaemia
DM61TA4 ID DM61TA4
DM61TA4 DN Arsenic trioxide
DM61TA4 HS Approved
DM61TA4 SN Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
DM61TA4 TC Anticancer Agents
DM61TA4 DT Small molecular drug
DM61TA4 PC 14888
DM61TA4 MW 197.841
DM61TA4 FM As2O3
DM61TA4 IC InChI=1S/2As.3O/q2*+3;3*-2
DM61TA4 CS [O-2].[O-2].[O-2].[As+3].[As+3]
DM61TA4 IK QTLQKAJBUDWPIB-UHFFFAOYSA-N
DM61TA4 IU arsenic(3+);oxygen(2-)
DM61TA4 CA CAS 1327-53-3
DM61TA4 DE Acute lymphoblastic leukaemia
DMQLX7O ID DMQLX7O
DMQLX7O DN Arteether
DMQLX7O HS Approved
DMQLX7O SN Beta arteether; Artecef (TN); Artemotil (TN)
DMQLX7O CP Artecef BV
DMQLX7O DT Small molecular drug
DMQLX7O PC 3000469
DMQLX7O MW 312.4
DMQLX7O FM C17H28O5
DMQLX7O IC InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
DMQLX7O CS CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](CC3)(OO4)C)C)C
DMQLX7O IK NLYNIRQVMRLPIQ-XQLAAWPRSA-N
DMQLX7O IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DMQLX7O CA CAS 75887-54-6
DMQLX7O CB CHEBI:135335
DMQLX7O DE Malaria
DM48QOT ID DM48QOT
DM48QOT DN Artemether
DM48QOT HS Approved
DM48QOT SN Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
DM48QOT DT Small molecular drug
DM48QOT PC 68911
DM48QOT MW 298.37
DM48QOT FM C16H26O5
DM48QOT IC InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
DM48QOT CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
DM48QOT IK SXYIRMFQILZOAM-HVNFFKDJSA-N
DM48QOT IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DM48QOT CA CAS 71963-77-4
DM48QOT CB CHEBI:195280
DM48QOT DE Malaria
DMOY7W3 ID DMOY7W3
DMOY7W3 DN Artemisinin
DMOY7W3 HS Approved
DMOY7W3 SN Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
DMOY7W3 DT Small molecular drug
DMOY7W3 PC 68827
DMOY7W3 MW 282.33
DMOY7W3 FM C15H22O5
DMOY7W3 IC InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
DMOY7W3 CS C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C
DMOY7W3 IK BLUAFEHZUWYNDE-NNWCWBAJSA-N
DMOY7W3 IU (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
DMOY7W3 CA CAS 63968-64-9
DMOY7W3 CB CHEBI:223316
DMOY7W3 DE Malaria
DMFETDK ID DMFETDK
DMFETDK DN Artemisinin SP
DMFETDK HS Approved
DMFETDK SN Isoguvacine; isoguvacine; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; 64603-90-3; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; UNII-YTF580771Y; CHEMBL39071; CHEBI:34799; YTF580771Y; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; AC1OEMUS; 1,2,3,6-tetrahydropyridinium-4-carboxylate; 1,2,3,6-tetrahydropyridin-1-ium-4-carboxylate; Tocris-0235; Spectrum_001974; Lopac-G-002; AC1L1GNT; Spectrum3_001869; Biomol-NT_000254; AC1Q5QG1; Lopac0_000561; KBioSS_002540; BSPBio_003318; DivK1c_000115
DMFETDK DT Small molecular drug
DMFETDK PC 3765
DMFETDK MW 127.14
DMFETDK FM C6H9NO2
DMFETDK IC InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h1,7H,2-4H2,(H,8,9)
DMFETDK CS C1CNCC=C1C(=O)O
DMFETDK IK KRVDMABBKYMBHG-UHFFFAOYSA-N
DMFETDK IU 1,2,3,6-tetrahydropyridine-4-carboxylic acid
DMFETDK CA CAS 64603-90-3
DMFETDK CB CHEBI:34799
DMFETDK DE Malaria
DMR27C8 ID DMR27C8
DMR27C8 DN Artesunate
DMR27C8 HS Approved
DMR27C8 SN Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
DMR27C8 DT Small molecular drug
DMR27C8 PC 6917864
DMR27C8 MW 384.4
DMR27C8 FM C19H28O8
DMR27C8 IC InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
DMR27C8 CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C
DMR27C8 IK FIHJKUPKCHIPAT-AHIGJZGOSA-N
DMR27C8 IU 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
DMR27C8 CA CAS 88495-63-0
DMR27C8 CB CHEBI:63918
DMR27C8 DE Malaria
DMOKCVI ID DMOKCVI
DMOKCVI DN ARZOXIFENE
DMOKCVI HS Approved
DMOKCVI SN Arzoxifene; 182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)
DMOKCVI DT Small molecular drug
DMOKCVI PC 179337
DMOKCVI MW 475.6
DMOKCVI FM C28H29NO4S
DMOKCVI IC InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
DMOKCVI CS COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5
DMOKCVI IK MCGDSOGUHLTADD-UHFFFAOYSA-N
DMOKCVI IU 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol
DMOKCVI CA CAS 182133-25-1
DMOKCVI DE Breast cancer
DMV05SW ID DMV05SW
DMV05SW DN As-1670542
DMV05SW HS Approved
DMV05SW SN AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542
DMV05SW CP Dova Pharmaceuticals
DMV05SW DT Small molecular drug
DMV05SW PC 9852519
DMV05SW MW 649.7
DMV05SW FM C29H34Cl2N6O3S2
DMV05SW IC InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)
DMV05SW CS C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
DMV05SW IK OFZJKCQENFPZBH-UHFFFAOYSA-N
DMV05SW IU 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
DMV05SW CA CAS 570406-98-3
DMV05SW DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMCZIHT ID DMCZIHT
DMCZIHT DN Asasantin
DMCZIHT HS Approved
DMCZIHT SN Aggrenox; Aspirin mixture with Dipyridamole; 87653-67-6; Asasantin Retard; Aspirin / Dipyridamole; aspirin, dipyridamole drug combination; TX-3301; TX 3301; C24H40N8O4.C9H8O4; Aspirin/extended-release dipyridamole; AC1L3AE0; SCHEMBL456521; DTXSID40236543; LS-178622; Benzoic acid, 2-(acetyloxy)-, mixt. with 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis(ethanol)
DMCZIHT CP Boehringer Ingelheim Corp
DMCZIHT DT Small molecular drug
DMCZIHT PC 137329
DMCZIHT MW 684.8
DMCZIHT FM C33H48N8O8
DMCZIHT IC InChI=1S/C24H40N8O4.C9H8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30;1-6(10)13-8-5-3-2-4-7(8)9(11)12/h33-36H,1-18H2;2-5H,1H3,(H,11,12)
DMCZIHT CS CC(=O)OC1=CC=CC=C1C(=O)O.C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMCZIHT IK NOHUXXDTQJPXSB-UHFFFAOYSA-N
DMCZIHT IU 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMCZIHT CA CAS 87653-67-6
DMCZIHT DE Cerebrovascular ischaemia
DMSQZE2 ID DMSQZE2
DMSQZE2 DN Asenapine
DMSQZE2 HS Approved
DMSQZE2 SN Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
DMSQZE2 CP Organon BioSciences
DMSQZE2 DT Small molecular drug
DMSQZE2 PC 3036780
DMSQZE2 MW 285.8
DMSQZE2 FM C17H16ClNO
DMSQZE2 IC InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
DMSQZE2 CS CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
DMSQZE2 IK VSWBSWWIRNCQIJ-GJZGRUSLSA-N
DMSQZE2 IU (2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DMSQZE2 CA CAS 65576-45-6
DMSQZE2 CB CHEBI:71246
DMSQZE2 DE Schizophrenia
DMM4FXA ID DMM4FXA
DMM4FXA DN Asfotase alfa
DMM4FXA HS Approved
DMM4FXA SN SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia
DMM4FXA CP Enobia Pharma Inc
DMM4FXA SQ Asfotase Alfa Sequence: LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD
DMM4FXA DE Genetic disease
DM672AH ID DM672AH
DM672AH DN Aspirin
DM672AH HS Approved
DM672AH SN ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
DM672AH CP Bayer Pharmaceuticals Corporation
DM672AH TC Analgesics
DM672AH DT Small molecular drug
DM672AH PC 2244
DM672AH MW 180.16
DM672AH FM C9H8O4
DM672AH IC InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
DM672AH CS CC(=O)OC1=CC=CC=C1C(=O)O
DM672AH IK BSYNRYMUTXBXSQ-UHFFFAOYSA-N
DM672AH IU 2-acetyloxybenzoic acid
DM672AH CA CAS 50-78-2
DM672AH CB CHEBI:15365
DM672AH DE Pain; Myocardial infarction; Cardiovascular disease
DMSYRBX ID DMSYRBX
DMSYRBX DN Atazanavir
DMSYRBX HS Approved
DMSYRBX SN 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
DMSYRBX CP Bristol-Myers Squibb
DMSYRBX TC Anti-HIV Agents
DMSYRBX DT Small molecular drug
DMSYRBX PC 148192
DMSYRBX MW 704.9
DMSYRBX FM C38H52N6O7
DMSYRBX IC InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
DMSYRBX CS CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMSYRBX IK AXRYRYVKAWYZBR-GASGPIRDSA-N
DMSYRBX IU methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMSYRBX CA CAS 198904-31-3
DMSYRBX CB CHEBI:37924
DMSYRBX DE Human immunodeficiency virus infection
DMNKG1Z ID DMNKG1Z
DMNKG1Z DN Atenolol
DMNKG1Z HS Approved
DMNKG1Z SN Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide
DMNKG1Z TC Antihypertensive Agents
DMNKG1Z DT Small molecular drug
DMNKG1Z PC 2249
DMNKG1Z MW 266.34
DMNKG1Z FM C14H22N2O3
DMNKG1Z IC InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
DMNKG1Z CS CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
DMNKG1Z IK METKIMKYRPQLGS-UHFFFAOYSA-N
DMNKG1Z IU 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMNKG1Z CA CAS 29122-68-7
DMNKG1Z CB CHEBI:2904
DMNKG1Z DE Hypertension
DMMF8U0 ID DMMF8U0
DMMF8U0 DN Atezolizumab
DMMF8U0 HS Approved
DMMF8U0 CP Genentech South San Francisco, CA
DMMF8U0 DT Monoclonal antibody
DMMF8U0 DE Melanoma; Breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancy; Myelodysplastic syndrome; Renal cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Acute myeloid leukaemia; Follicular lymphoma; Gastric adenocarcinoma; Multiple myeloma; Pancreatic cancer; Small-cell lung cancer; Solid tumour/cancer; Bronchioalveolar carcinoma; Ulcer; Non-small cell lung cancer
DM5L6HI ID DM5L6HI
DM5L6HI DN Atomoxetine
DM5L6HI HS Approved
DM5L6HI SN Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CP Eli Lilly
DM5L6HI DT Small molecular drug
DM5L6HI PC 54841
DM5L6HI MW 255.35
DM5L6HI FM C17H21NO
DM5L6HI IC InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
DM5L6HI CS CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
DM5L6HI IK VHGCDTVCOLNTBX-QGZVFWFLSA-N
DM5L6HI IU (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CA CAS 83015-26-3
DM5L6HI CB CHEBI:127342
DM5L6HI DE Attention deficit hyperactivity disorder
DMF28YC ID DMF28YC
DMF28YC DN Atorvastatin
DMF28YC HS Approved
DMF28YC SN Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
DMF28YC CP Pfizer Pharmaceuticals
DMF28YC TC Anticholesteremic Agents
DMF28YC DT Small molecular drug
DMF28YC PC 60823
DMF28YC MW 558.6
DMF28YC FM C33H35FN2O5
DMF28YC IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMF28YC CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMF28YC IK XUKUURHRXDUEBC-KAYWLYCHSA-N
DMF28YC IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMF28YC CA CAS 134523-00-5
DMF28YC CB CHEBI:39548
DMF28YC DE Cardiovascular disease
DMY4UMW ID DMY4UMW
DMY4UMW DN Atovaquone
DMY4UMW HS Approved
DMY4UMW SN Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
DMY4UMW CP GlaxoSmithKline
DMY4UMW TC Antifungal Agents
DMY4UMW DT Small molecular drug
DMY4UMW PC 74989
DMY4UMW MW 366.8
DMY4UMW FM C22H19ClO3
DMY4UMW IC InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2
DMY4UMW CS C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
DMY4UMW IK BSJMWHQBCZFXBR-UHFFFAOYSA-N
DMY4UMW IU 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
DMY4UMW CA CAS 94015-53-9
DMY4UMW CB CHEBI:575568
DMY4UMW DE Fungal infection
DM42HXN ID DM42HXN
DM42HXN DN Atracurium
DM42HXN HS Approved
DM42HXN SN Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CP Burroughs Wellcome Co
DM42HXN TC Neuromuscular Nondepolarizing Agents
DM42HXN DT Small molecular drug
DM42HXN PC 47319
DM42HXN MW 929.1
DM42HXN FM C53H72N2O12+2
DM42HXN IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
DM42HXN CS C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DM42HXN IK YXSLJKQTIDHPOT-UHFFFAOYSA-N
DM42HXN IU 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CA CAS 64228-79-1
DM42HXN CB CHEBI:2914
DM42HXN DE Anaesthesia
DMEN6X7 ID DMEN6X7
DMEN6X7 DN Atropine
DMEN6X7 HS Approved
DMEN6X7 SN dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
DMEN6X7 CP Pfizer Pharmaceuticals
DMEN6X7 TC Antiarrhythmic Agents
DMEN6X7 DT Small molecular drug
DMEN6X7 PC 174174
DMEN6X7 MW 289.4
DMEN6X7 FM C17H23NO3
DMEN6X7 IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
DMEN6X7 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
DMEN6X7 IK RKUNBYITZUJHSG-PJPHBNEVSA-N
DMEN6X7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMEN6X7 CA CAS 51-55-8
DMEN6X7 CB CHEBI:16684
DMEN6X7 DE Organophosphate poisoning; Poison intoxication
DM79Y2T ID DM79Y2T
DM79Y2T DN ATryn antithrombin
DM79Y2T HS Approved
DM79Y2T CP Revo biologics
DM79Y2T DE Multiple sclerosis
DMWE2N4 ID DMWE2N4
DMWE2N4 DN Auranofin
DMWE2N4 HS Approved
DMWE2N4 SN Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
DMWE2N4 TC Antirheumatic Agents
DMWE2N4 DT Small molecular drug
DMWE2N4 PC 24199313
DMWE2N4 MW 678.5
DMWE2N4 FM C20H34AuO9PS
DMWE2N4 IC InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
DMWE2N4 CS CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DMWE2N4 IK AUJRCFUBUPVWSZ-UHFFFAOYSA-M
DMWE2N4 IU gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
DMWE2N4 CA CAS 34031-32-8
DMWE2N4 DE Inflammatory arthritis
DM75CXN ID DM75CXN
DM75CXN DN Avanafil
DM75CXN HS Approved
DM75CXN SN Stendra (TN)
DM75CXN CP Vivus
DM75CXN DT Small molecular drug
DM75CXN PC 9869929
DM75CXN MW 483.9
DM75CXN FM C23H26ClN7O3
DM75CXN IC InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
DM75CXN CS COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
DM75CXN IK WEAJZXNPAWBCOA-INIZCTEOSA-N
DM75CXN IU 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
DM75CXN CA CAS 330784-47-9
DM75CXN CB CHEBI:66876
DM75CXN DE Erectile dysfunction
DMK2GZX ID DMK2GZX
DMK2GZX DN Avapritinib
DMK2GZX HS Approved
DMK2GZX SN 1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
DMK2GZX CP Blueprint Medicines Cambridge, MA
DMK2GZX PC 118023034
DMK2GZX MW 498.6
DMK2GZX FM C26H27FN10
DMK2GZX IC InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
DMK2GZX CS C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N
DMK2GZX IK DWYRIWUZIJHQKQ-SANMLTNESA-N
DMK2GZX IU (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine
DMK2GZX CA CAS 1703793-34-3
DMK2GZX DE Mast cell leukaemia; Systemic mastocytosis; Gastrointestinal stromal tumour
DMSZLJR ID DMSZLJR
DMSZLJR DN Avelumab
DMSZLJR HS Approved
DMSZLJR CP Merck KGaA/Pfizer
DMSZLJR DT Monoclonal antibody
DMSZLJR SQ Heavy chain: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMSZLJR DE Melanoma; Ovarian cancer; Solid tumour/cancer; Renal cell carcinoma; Merkel cell carcinoma
DM1AEH4 ID DM1AEH4
DM1AEH4 DN Avibactam
DM1AEH4 HS Approved
DM1AEH4 SN Avibactam; Avibactam (free acid); Avibactam [USAN:INN]; Avibactam free acid; AVE-1330A free acid; NXL 104; NXL104; Q15410251; SCHEMBL1666807; ZINC9302239; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; 1192500-31-4; 396731-14-9; BDBM50339145; CHEBI:85984; CHEMBL1689063; CS-0593; DB09060; HY-14879; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; UNII-7352665165
DM1AEH4 PC 9835049
DM1AEH4 MW 265.25
DM1AEH4 FM C7H11N3O6S
DM1AEH4 IC NDCUAPJVLWFHHB-UHNVWZDZSA-N
DM1AEH4 CS C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N
DM1AEH4 IK 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
DM1AEH4 IU [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DM1AEH4 CA CAS 396731-14-9
DM1AEH4 CB CHEBI:85984
DM1AEH4 DE Infectious cystitis
DMYHN59 ID DMYHN59
DMYHN59 DN Axicabtagene ciloleucel
DMYHN59 HS Approved
DMYHN59 CP Masonic Cancer Center, University of Minnesota
DMYHN59 DT CAR T Cell Therapy
DMYHN59 DE Acute lymphoblastic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; Large B-cell lymphoma
DMGVH6N ID DMGVH6N
DMGVH6N DN Axitinib
DMGVH6N HS Approved
DMGVH6N SN AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
DMGVH6N CP Pfizer
DMGVH6N TC Anticancer Agents
DMGVH6N DT Small molecular drug
DMGVH6N PC 6450551
DMGVH6N MW 386.5
DMGVH6N FM C22H18N4OS
DMGVH6N IC InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMGVH6N CS CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMGVH6N IK RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMGVH6N IU N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMGVH6N CA CAS 319460-85-0
DMGVH6N CB CHEBI:66910
DMGVH6N DE Renal cell carcinoma
DMTA5OE ID DMTA5OE
DMTA5OE DN Azacitidine
DMTA5OE HS Approved
DMTA5OE SN Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
DMTA5OE CP Celgene
DMTA5OE TC Anticancer Agents
DMTA5OE DT Small molecular drug
DMTA5OE PC 9444
DMTA5OE MW 244.2
DMTA5OE FM C8H12N4O5
DMTA5OE IC InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
DMTA5OE CS C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
DMTA5OE IK NMUSYJAQQFHJEW-KVTDHHQDSA-N
DMTA5OE IU 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMTA5OE CA CAS 320-67-2
DMTA5OE CB CHEBI:2038
DMTA5OE DE Myelodysplastic syndrome
DMZ80SB ID DMZ80SB
DMZ80SB DN Azatadine
DMZ80SB HS Approved
DMZ80SB SN Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
DMZ80SB TC Antihistamines
DMZ80SB DT Small molecular drug
DMZ80SB PC 19861
DMZ80SB MW 290.4
DMZ80SB FM C20H22N2
DMZ80SB IC InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3
DMZ80SB CS CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1
DMZ80SB IK SEBMTIQKRHYNIT-UHFFFAOYSA-N
DMZ80SB IU 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene
DMZ80SB CA CAS 3964-81-6
DMZ80SB CB CHEBI:2946
DMZ80SB DE Allergic rhinitis
DMMZSXQ ID DMMZSXQ
DMMZSXQ DN Azathioprine
DMMZSXQ HS Approved
DMMZSXQ SN Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
DMMZSXQ CP GlaxoSmithKline
DMMZSXQ TC Immunosuppressive Agents
DMMZSXQ DT Small molecular drug
DMMZSXQ PC 2265
DMMZSXQ MW 277.27
DMMZSXQ FM C9H7N7O2S
DMMZSXQ IC InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
DMMZSXQ CS CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
DMMZSXQ IK LMEKQMALGUDUQG-UHFFFAOYSA-N
DMMZSXQ IU 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
DMMZSXQ CA CAS 446-86-6
DMMZSXQ CB CHEBI:2948
DMMZSXQ DE Organ transplant rejection
DMHVL0J ID DMHVL0J
DMHVL0J DN Azelaic Acid
DMHVL0J HS Approved
DMHVL0J SN AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid
DMHVL0J TC Dermatologic Agents
DMHVL0J DT Small molecular drug
DMHVL0J PC 2266
DMHVL0J MW 188.22
DMHVL0J FM C9H16O4
DMHVL0J IC InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
DMHVL0J CS C(CCCC(=O)O)CCCC(=O)O
DMHVL0J IK BDJRBEYXGGNYIS-UHFFFAOYSA-N
DMHVL0J IU nonanedioic acid
DMHVL0J CA CAS 123-99-9
DMHVL0J CB CHEBI:48131
DMHVL0J DE Acne vulgaris
DMXTMBJ ID DMXTMBJ
DMXTMBJ DN Azelastine
DMXTMBJ HS Approved
DMXTMBJ SN Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CP Meda Pharmaceuticals Inc
DMXTMBJ TC Antiallergic Agents
DMXTMBJ DT Small molecular drug
DMXTMBJ PC 2267
DMXTMBJ MW 381.9
DMXTMBJ FM C22H24ClN3O
DMXTMBJ IC InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
DMXTMBJ CS CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
DMXTMBJ IK MBUVEWMHONZEQD-UHFFFAOYSA-N
DMXTMBJ IU 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CA CAS 58581-89-8
DMXTMBJ CB CHEBI:2950
DMXTMBJ DE Allergic conjunctivitis
DMOIX5S ID DMOIX5S
DMOIX5S DN Azilsartan
DMOIX5S HS Approved
DMOIX5S SN TAK 536; TAK-536; Azilsartan (INN/USAN)
DMOIX5S CP Takeda
DMOIX5S DT Small molecular drug
DMOIX5S PC 135415867
DMOIX5S MW 456.4
DMOIX5S FM C25H20N4O5
DMOIX5S IC InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
DMOIX5S CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
DMOIX5S IK KGSXMPPBFPAXLY-UHFFFAOYSA-N
DMOIX5S IU 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMOIX5S CA CAS 147403-03-0
DMOIX5S CB CHEBI:68850
DMOIX5S DE Hypertension
DMIR5QP ID DMIR5QP
DMIR5QP DN Azlocillin
DMIR5QP HS Approved
DMIR5QP SN Azlocilina; Azlocilline; Azlocillinum; Securopen; Bayer Brand of Azlocillin; Azlocilina [INN-Spanish]; Azlocillin Sodium (Sterile); Azlocilline [INN-French]; Azlocillinum [INN-Latin]; Bay-e 6905; Azlocillin (USAN/INN); Azlocillin [USAN:BAN:INN]; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
DMIR5QP CP Bayer Pharmaceuticals Corp
DMIR5QP TC Antibiotics
DMIR5QP DT Small molecular drug
DMIR5QP PC 6479523
DMIR5QP MW 461.5
DMIR5QP FM C20H23N5O6S
DMIR5QP IC InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1
DMIR5QP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
DMIR5QP IK JTWOMNBEOCYFNV-NFFDBFGFSA-N
DMIR5QP IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIR5QP CA CAS 37091-66-0
DMIR5QP CB CHEBI:2956
DMIR5QP DE Pseudomonas infection
DMDNJHG ID DMDNJHG
DMDNJHG DN Aztreonam
DMDNJHG HS Approved
DMDNJHG SN Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CP Bristol-Myers Squibb Company
DMDNJHG TC Antibiotics
DMDNJHG DT Small molecular drug
DMDNJHG PC 5742832
DMDNJHG MW 435.4
DMDNJHG FM C13H17N5O8S2
DMDNJHG IC InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
DMDNJHG CS C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
DMDNJHG IK WZPBZJONDBGPKJ-VEHQQRBSSA-N
DMDNJHG IU 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CA CAS 78110-38-0
DMDNJHG CB CHEBI:161680
DMDNJHG DE Bacterial infection
DMP54C7 ID DMP54C7
DMP54C7 DN Bacampicillin
DMP54C7 HS Approved
DMP54C7 SN Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester
DMP54C7 CP Pfizer Pharmaceuticals
DMP54C7 TC Antibiotics
DMP54C7 DT Small molecular drug
DMP54C7 PC 441397
DMP54C7 MW 465.5
DMP54C7 FM C21H27N3O7S
DMP54C7 IC InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1
DMP54C7 CS CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C
DMP54C7 IK PFOLLRNADZZWEX-FFGRCDKISA-N
DMP54C7 IU 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMP54C7 CA CAS 50972-17-3
DMP54C7 CB CHEBI:2968
DMP54C7 DE Bacterial infection
DM5OHYE ID DM5OHYE
DM5OHYE DN Bacitracin
DM5OHYE HS Approved
DM5OHYE SN Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA
DM5OHYE TC Antibiotics
DM5OHYE DT Small molecular drug
DM5OHYE PC 10909430
DM5OHYE MW 1422.7
DM5OHYE FM C66H103N17O16S
DM5OHYE IC InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
DM5OHYE CS CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
DM5OHYE IK CLKOFPXJLQSYAH-ABRJDSQDSA-N
DM5OHYE IU (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5OHYE CA CAS 1405-87-4
DM5OHYE CB CHEBI:35862
DM5OHYE DE Skin infection
DMD2871 ID DMD2871
DMD2871 DN Bacitracin
DMD2871 HS Approved
DMD2871 SN Bacillus subtilis; Bacitracin Zinc free sample; Bacitracin zinc [USP]; Bacitracins zinc complex; Bacitracins, zinc complex; EPA Pesticide Chemical Code 006309; SC-18930; SCHEMBL543112; Ziba-RX; Zinc bacitracin; 5-((1-((9-((4H-imidazol-4-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopent; AKOS015896384; Albac; Caswell No. 909A; EINECS 215-787-8; FT-0622546; FT-0654564
DMD2871 PC 3083711
DMD2871 MW 1488.1
DMD2871 FM C66H103N17O16SZn
DMD2871 IC QSNOBVJFKSQBBD-UHFFFAOYSA-N
DMD2871 CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3C=NC=N3)CC4=CC=CC=C4.[Zn]
DMD2871 IK 1S/C66H103N17O16S.Zn/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90;/h12-14,18-19,31,33-37,39-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88);
DMD2871 IU 4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(4H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid;zinc
DMD2871 CA CAS 1405-89-6
DMD2871 DE Pyothorax
DM0QV1J ID DM0QV1J
DM0QV1J DN Baclofen
DM0QV1J HS Approved
DM0QV1J SN Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA; ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid
DM0QV1J CP Norvatis Phamaceuticals Corporation
DM0QV1J TC Muscle Relaxants
DM0QV1J DT Small molecular drug
DM0QV1J PC 2284
DM0QV1J MW 213.66
DM0QV1J FM C10H12ClNO2
DM0QV1J IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DM0QV1J CS C1=CC(=CC=C1C(CC(=O)O)CN)Cl
DM0QV1J IK KPYSYYIEGFHWSV-UHFFFAOYSA-N
DM0QV1J IU 4-amino-3-(4-chlorophenyl)butanoic acid
DM0QV1J CA CAS 1134-47-0
DM0QV1J CB CHEBI:2972
DM0QV1J DE Multiple sclerosis; Fragile X syndrome
DMPWNDB ID DMPWNDB
DMPWNDB DN Balofloxacin
DMPWNDB HS Approved
DMPWNDB SN Baloxin; Balofloxacin [INN]; Q 35; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CP Chugai
DMPWNDB DT Small molecular drug
DMPWNDB PC 65958
DMPWNDB MW 389.4
DMPWNDB FM C20H24FN3O4
DMPWNDB IC InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)
DMPWNDB CS CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPWNDB IK MGQLHRYJBWGORO-UHFFFAOYSA-N
DMPWNDB IU 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CA CAS 127294-70-6
DMPWNDB DE Gram-positive bacterial infection
DM1UV7F ID DM1UV7F
DM1UV7F DN Baloxavir marboxil
DM1UV7F HS Approved
DM1UV7F SN UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527
DM1UV7F CP Shionogi/Roche
DM1UV7F PC 124081896
DM1UV7F MW 571.6
DM1UV7F FM C27H23F2N3O7S
DM1UV7F IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DM1UV7F CS COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DM1UV7F IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DM1UV7F IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DM1UV7F CA CAS 1985606-14-1
DM1UV7F DE Influenza virus infection
DMRJ9EN ID DMRJ9EN
DMRJ9EN DN Baloxavir marboxil
DMRJ9EN HS Approved
DMRJ9EN SN (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)
DMRJ9EN TC Antiviral Agents
DMRJ9EN DT Small molecular drug
DMRJ9EN PC 124081896
DMRJ9EN MW 571.552
DMRJ9EN FM C27H23F2N3O7S
DMRJ9EN IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DMRJ9EN CS COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DMRJ9EN IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DMRJ9EN IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DMRJ9EN CA CAS 1985606-14-1
DMRJ9EN DE Influenza A infection
DM7I1T9 ID DM7I1T9
DM7I1T9 DN Balsalazide
DM7I1T9 HS Approved
DM7I1T9 SN Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP
DM7I1T9 PC 54585
DM7I1T9 MW 357.32
DM7I1T9 FM C17H15N3O6
DM7I1T9 IC IPOKCKJONYRRHP-UHFFFAOYSA-N
DM7I1T9 CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DM7I1T9 IK 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DM7I1T9 IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DM7I1T9 CA CAS 80573-04-2
DM7I1T9 CB CHEBI:267413
DM7I1T9 DE Ulcerative colitis
DMO091F ID DMO091F
DMO091F DN Balsalazide
DMO091F HS Approved
DMO091F SN Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
DMO091F TC Antiinflammatory Agents
DMO091F DT Small molecular drug
DMO091F PC 54585
DMO091F MW 357.32
DMO091F FM C17H15N3O6
DMO091F IC InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DMO091F CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMO091F IK IPOKCKJONYRRHP-UHFFFAOYSA-N
DMO091F IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMO091F CA CAS 80573-04-2
DMO091F CB CHEBI:267413
DMO091F DE Inflammatory bowel disease
DMKLSHF ID DMKLSHF
DMKLSHF DN Bambuterol
DMKLSHF HS Approved
DMKLSHF SN Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
DMKLSHF CP AstraZeneca
DMKLSHF TC Bronchodilator Agents
DMKLSHF DT Small molecular drug
DMKLSHF PC 54766
DMKLSHF MW 367.4
DMKLSHF FM C18H29N3O5
DMKLSHF IC InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
DMKLSHF CS CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
DMKLSHF IK ANZXOIAKUNOVQU-UHFFFAOYSA-N
DMKLSHF IU [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate
DMKLSHF CA CAS 81732-65-2
DMKLSHF CB CHEBI:553827
DMKLSHF DE Asthma
DMXLHYN ID DMXLHYN
DMXLHYN DN Bamifylline
DMXLHYN HS Approved
DMXLHYN SN Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride
DMXLHYN DT Small molecular drug
DMXLHYN PC 16229
DMXLHYN MW 385.5
DMXLHYN FM C20H27N5O3
DMXLHYN IC InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3
DMXLHYN CS CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO
DMXLHYN IK VVUYEFBRTFASAH-UHFFFAOYSA-N
DMXLHYN IU 8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
DMXLHYN CA CAS 2016-63-9
DMXLHYN CB CHEBI:135605
DMXLHYN DE Chronic obstructive pulmonary disease
DME1DJX ID DME1DJX
DME1DJX DN Baquting
DME1DJX HS Approved
DME1DJX CP China Nuokang Bio-Pharmaceutical Inc
DME1DJX DE Bleeding disorder
DMJ8NMC ID DMJ8NMC
DMJ8NMC DN Barbital
DMJ8NMC HS Approved
DMJ8NMC SN Barbitale; Barbitalum; Barbitone; Barbitonum; DEBA; Diemal; Diemalum; Diethylbarbitone; Diethylmalonylurea; Dormileno; Dormonal; Ethylbarbital; Hypnogene; Malonal; Medinal; Sedeval; Uronal; Veroletten; Verolettin; Veronal; Vesperal; Barbital Faes Brand; Barbitale [DCIT]; Diethylbarbituric acid; Faes Brand of Barbital; Barbital (TN); Barbital (VAN); Barbital [INN:JAN]; Barbitalum [INN-Latin]; Veronal (TN); Barbital (JP15/INN); Kyselina 5,5-diethylbarbiturova; Kyselina 5,5-diethylbarbiturova [Czech]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-(9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethylbarbituric acid; 5,5-diethyl-1,3-diazinane-2,4,6-trione; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; 7979P
DMJ8NMC CP Schering-Plough
DMJ8NMC TC Hypnotics and Sedatives
DMJ8NMC DT Small molecular drug
DMJ8NMC PC 2294
DMJ8NMC MW 184.19
DMJ8NMC FM C8H12N2O3
DMJ8NMC IC InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
DMJ8NMC CS CCC1(C(=O)NC(=O)NC1=O)CC
DMJ8NMC IK FTOAOBMCPZCFFF-UHFFFAOYSA-N
DMJ8NMC IU 5,5-diethyl-1,3-diazinane-2,4,6-trione
DMJ8NMC CA CAS 57-44-3
DMJ8NMC CB CHEBI:31252
DMJ8NMC DE Insomnia
DMJIA6T ID DMJIA6T
DMJIA6T DN Barbiturate
DMJIA6T HS Approved
DMJIA6T SN Barbituric acid; BARBITURIC ACID; 67-52-7; Malonylurea; 6-Hydroxyuracil; 2,4,6(1H,3H,5H)-Pyrimidinetrione; Pyrimidinetrione; pyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6-Pyrimidinetrione; Malonylharnstoff; 2,4,6-Trioxohexahydropyrimidine; 1,3-diazinane-2,4,6-trione; Barbitursaeure; Hexahydropyrimidine-2,4,6-trione; Hydrouracil, 6-hydroxy-; Barbituric acid (VAN); Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; NSC 7889; UNII-WQ92Y2793G; 2,4,6-Pyrimidinetrione(1H,3H,5H); Barbituric acid (VAN) (8CI); CHEBI:16294; EINECS 200-658-0; Barbitursaeure; Pyrimidinetriol; Barbiturate anion; Sodiumbarbiturate; AG-670/31547005; Hexahydro-pyrimidine-2,4,6-trione; Pyrimidine-2,4,6(1H,3H,5H)-trione; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 11709_FLUKA; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Pyrimidinetriol; 2,4,6-Trihydroxypyrimidine; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; 4,6-dioxo-1H-pyrimidin-2-olate
DMJIA6T DT Small molecular drug
DMJIA6T PC 6211
DMJIA6T MW 128.09
DMJIA6T FM C4H4N2O3
DMJIA6T IC InChI=1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9)
DMJIA6T CS C1C(=O)NC(=O)NC1=O
DMJIA6T IK HNYOPLTXPVRDBG-UHFFFAOYSA-N
DMJIA6T IU 1,3-diazinane-2,4,6-trione
DMJIA6T CA CAS 67-52-7
DMJIA6T CB CHEBI:16294
DMJIA6T DE Depression; Anaesthesia
DM4ONW5 ID DM4ONW5
DM4ONW5 DN Baricitinib
DM4ONW5 HS Approved
DM4ONW5 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DM4ONW5 CP Incyte/Eli Lilly
DM4ONW5 DT Small molecular drug
DM4ONW5 PC 44205240
DM4ONW5 MW 371.4
DM4ONW5 FM C16H17N7O2S
DM4ONW5 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DM4ONW5 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM4ONW5 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N
DM4ONW5 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DM4ONW5 CA CAS 1187594-09-7
DM4ONW5 CB CHEBI:95341
DM4ONW5 DE Rheumatoid arthritis
DMWNRZT ID DMWNRZT
DMWNRZT DN Basiliximab
DMWNRZT HS Approved
DMWNRZT SN Simulect (TN)
DMWNRZT CP Norvatis Phamaceuticals Corporation
DMWNRZT TC Immunomodulatory Agents
DMWNRZT DT Monoclonal antibody
DMWNRZT SQ Basiliximab heavy chain: QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Basiliximab light chainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
DMWNRZT DE Organ transplant rejection
DMU9C8F ID DMU9C8F
DMU9C8F DN Bavencio
DMU9C8F HS Approved
DMU9C8F CP EMD Serono Rockland, MA Pfizer New York, NY
DMU9C8F DT Monoclonal antibody
DMU9C8F DE Melanoma; Merkel cell carcinoma; Breast cancer; Gastric adenocarcinoma; Haematological malignancy; Head and neck cancer; Squamous cell carcinoma; Urothelial carcinoma; Colon cancer; Testicular cancer
DMLOS5R ID DMLOS5R
DMLOS5R DN Bay 80-6946
DMLOS5R HS Approved
DMLOS5R SN Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS
DMLOS5R CP Bayer HealthCare Pharmaceuticals
DMLOS5R DT Small molecular drug
DMLOS5R PC 135565596
DMLOS5R MW 480.5
DMLOS5R FM C23H28N8O4
DMLOS5R IC InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
DMLOS5R CS COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
DMLOS5R IK MWYDSXOGIBMAET-UHFFFAOYSA-N
DMLOS5R IU 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide
DMLOS5R CA CAS 1032568-63-0
DMLOS5R DE Follicular lymphoma; Non-hodgkin lymphoma
DMY85QW ID DMY85QW
DMY85QW DN Bazedoxifene
DMY85QW HS Approved
DMY85QW SN Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424
DMY85QW CP Ligand Pharmaceuticals Inc
DMY85QW DT Small molecular drug
DMY85QW PC 154257
DMY85QW MW 470.6
DMY85QW FM C30H34N2O3
DMY85QW IC InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
DMY85QW CS CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
DMY85QW IK UCJGJABZCDBEDK-UHFFFAOYSA-N
DMY85QW IU 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
DMY85QW CA CAS 198481-32-2
DMY85QW CB CHEBI:135947
DMY85QW DE Osteopetrosis
DM1R5X4 ID DM1R5X4
DM1R5X4 DN Becaplermin
DM1R5X4 HS Approved
DM1R5X4 SN Regranex; Regranex (TN); Becaplermin (USAN/INN)
DM1R5X4 CP Ortho-McNeil Pharmaceutical
DM1R5X4 TC Antiulcer Agents
DM1R5X4 SQ DB00102 sequence: SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT
DM1R5X4 DE Diabetic complication
DMZPHIK ID DMZPHIK
DMZPHIK DN Beclomethasone
DMZPHIK HS Approved
DMZPHIK SN Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone
DMZPHIK CP Shire Pharmaceuticals
DMZPHIK TC Antiasthmatic Agents
DMZPHIK DT Small molecular drug
DMZPHIK PC 20469
DMZPHIK MW 408.9
DMZPHIK FM C22H29ClO5
DMZPHIK IC InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMZPHIK CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
DMZPHIK IK NBMKJKDGKREAPL-DVTGEIKXSA-N
DMZPHIK IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZPHIK CA CAS 4419-39-0
DMZPHIK CB CHEBI:3001
DMZPHIK DE Allergic rhinitis; Asthma
DM3906J ID DM3906J
DM3906J DN Bedaquiline
DM3906J HS Approved
DM3906J SN SIRTURO (TN)
DM3906J CP Johnson & Johnson
DM3906J DT Small molecular drug
DM3906J PC 5388906
DM3906J MW 555.5
DM3906J FM C32H31BrN2O2
DM3906J IC InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
DM3906J CS CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
DM3906J IK QUIJNHUBAXPXFS-XLJNKUFUSA-N
DM3906J IU (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol
DM3906J CA CAS 843663-66-1
DM3906J CB CHEBI:72292
DM3906J DE Multi-drug resistant tuberculosis
DM8WCXM ID DM8WCXM
DM8WCXM DN Befunolol hci
DM8WCXM HS Approved
DM8WCXM SN Bentox (TN)
DM8WCXM DT Small molecular drug
DM8WCXM PC 38286
DM8WCXM MW 327.8
DM8WCXM FM C16H22ClNO4
DM8WCXM IC InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
DM8WCXM CS CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-]
DM8WCXM IK TVVTWOGRPVJKDJ-UHFFFAOYSA-N
DM8WCXM IU [3-[(2-acetyl-1-benzofuran-7-yl)oxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride
DM8WCXM CA CAS 39543-79-8
DM8WCXM CB CHEBI:31254
DM8WCXM DE Glaucoma/ocular hypertension
DMBT3AI ID DMBT3AI
DMBT3AI DN Belantamab mafodotin
DMBT3AI HS Approved
DMBT3AI DT Antibody drug conjugate
DMBT3AI DE Multiple myeloma
DMXLYQF ID DMXLYQF
DMXLYQF DN Belatacept
DMXLYQF HS Approved
DMXLYQF SN Nulojix (TN); Belatacept (USAN/INN)
DMXLYQF CP Bristol-Myers Squibb
DMXLYQF SQ sequence for belatacept: MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMXLYQF DE Kidney transplant rejection; Heart transplant rejection
DM3OBQF ID DM3OBQF
DM3OBQF DN Belimumab
DM3OBQF HS Approved
DM3OBQF SN Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)
DM3OBQF CP GSK
DM3OBQF DT Antibody
DM3OBQF DE Systemic lupus erythematosus
DM2RBWK ID DM2RBWK
DM2RBWK DN Belladonna
DM2RBWK HS Approved
DM2RBWK DE Colitis
DM3SRJZ ID DM3SRJZ
DM3SRJZ DN Belotecan hydrocholoride
DM3SRJZ HS Approved
DM3SRJZ DE Small-cell lung cancer
DM1CI9R ID DM1CI9R
DM1CI9R DN Bempedoic acid
DM1CI9R HS Approved
DM1CI9R SN ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
DM1CI9R CP Esperion Therapeutics
DM1CI9R DT Small molecular drug
DM1CI9R PC 10472693
DM1CI9R MW 344.5
DM1CI9R FM C19H36O5
DM1CI9R IC InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
DM1CI9R CS CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
DM1CI9R IK HYHMLYSLQUKXKP-UHFFFAOYSA-N
DM1CI9R IU 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
DM1CI9R CA CAS 738606-46-7
DM1CI9R CB CHEBI:149601
DM1CI9R DE Cardiovascular disease; Familial hypercholesterolemia
DMH1M9B ID DMH1M9B
DMH1M9B DN Benazepril
DMH1M9B HS Approved
DMH1M9B SN Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CP Norvatis Phamaceuticals Corporation
DMH1M9B TC Antihypertensive Agents
DMH1M9B DT Small molecular drug
DMH1M9B PC 5362124
DMH1M9B MW 424.5
DMH1M9B FM C24H28N2O5
DMH1M9B IC InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
DMH1M9B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
DMH1M9B IK XPCFTKFZXHTYIP-PMACEKPBSA-N
DMH1M9B IU 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CA CAS 86541-75-5
DMH1M9B CB CHEBI:3011
DMH1M9B DE Hypertension
DMFH15Z ID DMFH15Z
DMFH15Z DN Bendamustine hydrochloride
DMFH15Z HS Approved
DMFH15Z SN Treanda (TN)
DMFH15Z CP Cephalon
DMFH15Z DT Small molecular drug
DMFH15Z PC 77082
DMFH15Z MW 394.7
DMFH15Z FM C16H22Cl3N3O2
DMFH15Z IC InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
DMFH15Z CS CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl
DMFH15Z IK ZHSKUOZOLHMKEA-UHFFFAOYSA-N
DMFH15Z IU 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
DMFH15Z CA CAS 3543-75-7
DMFH15Z DE leukaemia
DM7EVLC ID DM7EVLC
DM7EVLC DN Bendroflumethiazide
DM7EVLC HS Approved
DM7EVLC SN Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DM7EVLC CP Crescent Pharmaceuticals
DM7EVLC TC Antihypertensive Agents
DM7EVLC DT Small molecular drug
DM7EVLC PC 2315
DM7EVLC MW 421.4
DM7EVLC FM C15H14F3N3O4S2
DM7EVLC IC InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
DM7EVLC CS C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2
DM7EVLC IK HDWIHXWEUNVBIY-UHFFFAOYSA-N
DM7EVLC IU 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DM7EVLC CA CAS 73-48-3
DM7EVLC CB CHEBI:3013
DM7EVLC DE High blood pressure
DM7P1J4 ID DM7P1J4
DM7P1J4 DN Benralizumab
DM7P1J4 HS Approved
DM7P1J4 CP AstraZeneca
DM7P1J4 DT Monoclonal antibody
DM7P1J4 DE Asthma; Chronic obstructive pulmonary disease
DMRVBWU ID DMRVBWU
DMRVBWU DN Bentazepam
DMRVBWU HS Approved
DMRVBWU DT Small molecular drug
DMRVBWU PC 135412795
DMRVBWU MW 296.4
DMRVBWU FM C17H16N2OS
DMRVBWU IC InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)
DMRVBWU CS C1CCC2=C(C1)C3=C(S2)NC(=O)CN=C3C4=CC=CC=C4
DMRVBWU IK AIZFEOPQVZBNGH-UHFFFAOYSA-N
DMRVBWU IU 5-phenyl-1,3,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
DMRVBWU CA CAS 29462-18-8
DMRVBWU CB CHEBI:135252
DMRVBWU DE Anxiety disorder
DMF7EXL ID DMF7EXL
DMF7EXL DN Benzatropine
DMF7EXL HS Approved
DMF7EXL SN Benzatropina; Benzatropina [INN-Spanish]; Benzatropine; Benzatropinum; Benzatropinum [INN-Latin]; Benztropinum; Cobrentin; Cogentin; Cogentine; Akitan; Cogentinol; Tropine benzohydryl ether; benztropine; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 1NHL2J4X8K; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 86-13-5; CHEBI:3048; HSDB 3014; NCGC00159471-02; NK 02; UNII-1NHL2J4X8K
DMF7EXL PC 1201549
DMF7EXL MW 307.4
DMF7EXL FM C21H25NO
DMF7EXL IC GIJXKZJWITVLHI-YOFSQIOKSA-N
DMF7EXL CS CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMF7EXL IK 1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMF7EXL IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMF7EXL CA CAS 86-13-5
DMF7EXL CB CHEBI:3048
DMF7EXL DE Agitation/aggression
DMC3YUA ID DMC3YUA
DMC3YUA DN Benzbromarone
DMC3YUA HS Approved
DMC3YUA SN Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
DMC3YUA CP Labaz Laboratories
DMC3YUA DT Small molecular drug
DMC3YUA PC 2333
DMC3YUA MW 424.1
DMC3YUA FM C17H12Br2O3
DMC3YUA IC InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMC3YUA CS CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMC3YUA IK WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMC3YUA IU (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMC3YUA CA CAS 3562-84-3
DMC3YUA CB CHEBI:3023
DMC3YUA DE Gout
DMI18HW ID DMI18HW
DMI18HW DN Benzocaine
DMI18HW HS Approved
DMI18HW SN Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester
DMI18HW CP Wyeth Pharmaceuticals
DMI18HW TC Anesthetics
DMI18HW DT Small molecular drug
DMI18HW PC 2337
DMI18HW MW 165.19
DMI18HW FM C9H11NO2
DMI18HW IC InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
DMI18HW CS CCOC(=O)C1=CC=C(C=C1)N
DMI18HW IK BLFLLBZGZJTVJG-UHFFFAOYSA-N
DMI18HW IU ethyl 4-aminobenzoate
DMI18HW CA CAS 94-09-7
DMI18HW CB CHEBI:116735
DMI18HW DE Anaesthesia
DMKB9FI ID DMKB9FI
DMKB9FI DN Benzoic acid
DMKB9FI HS Approved
DMKB9FI SN Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1
DMKB9FI DT Small molecular drug
DMKB9FI PC 243
DMKB9FI MW 122.12
DMKB9FI FM C7H6O2
DMKB9FI IC InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)
DMKB9FI CS C1=CC=C(C=C1)C(=O)O
DMKB9FI IK WPYMKLBDIGXBTP-UHFFFAOYSA-N
DMKB9FI IU benzoic acid
DMKB9FI CA CAS 65-85-0
DMKB9FI CB CHEBI:30746
DMKB9FI DE Fungal infection
DM9U4FO ID DM9U4FO
DM9U4FO DN Benzonatate
DM9U4FO HS Approved
DM9U4FO SN Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
DM9U4FO TC Antitussives
DM9U4FO DT Small molecular drug
DM9U4FO PC 7699
DM9U4FO MW 603.7
DM9U4FO FM C30H53NO11
DM9U4FO IC InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3
DM9U4FO CS CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DM9U4FO IK MAFMQEKGGFWBAB-UHFFFAOYSA-N
DM9U4FO IU 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
DM9U4FO CA CAS 104-31-4
DM9U4FO CB CHEBI:3032
DM9U4FO DE Cough
DMIJATC ID DMIJATC
DMIJATC DN Benzphetamine
DMIJATC HS Approved
DMIJATC SN Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
DMIJATC CP Pharmacia
DMIJATC DT Small molecular drug
DMIJATC PC 5311017
DMIJATC MW 239.35
DMIJATC FM C17H21N
DMIJATC IC InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
DMIJATC CS C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
DMIJATC IK YXKTVDFXDRQTKV-HNNXBMFYSA-N
DMIJATC IU (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine
DMIJATC CA CAS 156-08-1
DMIJATC CB CHEBI:3044
DMIJATC DE Obesity
DMU4D5Y ID DMU4D5Y
DMU4D5Y DN Benzquinamide
DMU4D5Y HS Approved
DMU4D5Y SN Benzchinamid; Benzchinamide; Benzchinamidum; Benzochinamide; Benzoquinamida; Benzoquinamide; Benzquinamid; Benzquinamida; Benzquinamidum; Emeticon; Promecon; Quantril; Quantryl; P 2647; Benzoquinamida [INN-Spanish]; Benzquinamide (USAN); Benzquinamidum [INN-Latin]; Emete-con; P-2647; Benzquinamide [USAN:INN:BAN]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamideacetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-(9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate
DMU4D5Y TC Antiemetics
DMU4D5Y DT Small molecular drug
DMU4D5Y PC 2342
DMU4D5Y MW 404.5
DMU4D5Y FM C22H32N2O5
DMU4D5Y IC InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3
DMU4D5Y CS CCN(CC)C(=O)C1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C)OC)OC
DMU4D5Y IK JSZILQVIPPROJI-UHFFFAOYSA-N
DMU4D5Y IU [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate
DMU4D5Y CA CAS 63-12-7
DMU4D5Y CB CHEBI:27662
DMU4D5Y DE Nausea
DMQWZ0H ID DMQWZ0H
DMQWZ0H DN Benzthiazide
DMQWZ0H HS Approved
DMQWZ0H SN Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMQWZ0H TC Antihypertensive Agents
DMQWZ0H DT Small molecular drug
DMQWZ0H PC 2343
DMQWZ0H MW 431.9
DMQWZ0H FM C15H14ClN3O4S3
DMQWZ0H IC InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
DMQWZ0H CS C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N
DMQWZ0H IK NDTSRXAMMQDVSW-UHFFFAOYSA-N
DMQWZ0H IU 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMQWZ0H CA CAS 91-33-8
DMQWZ0H CB CHEBI:3047
DMQWZ0H DE High blood pressure
DMGZOVN ID DMGZOVN
DMGZOVN DN Benztropine
DMGZOVN HS Approved
DMGZOVN SN Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI)
DMGZOVN CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMGZOVN TC Antiparkinson Agents
DMGZOVN DT Small molecular drug
DMGZOVN PC 1201549
DMGZOVN MW 307.4
DMGZOVN FM C21H25NO
DMGZOVN IC InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMGZOVN CS CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMGZOVN IK GIJXKZJWITVLHI-YOFSQIOKSA-N
DMGZOVN IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMGZOVN CA CAS 86-13-5
DMGZOVN CB CHEBI:3048
DMGZOVN DE Parkinson disease
DMBVYDI ID DMBVYDI
DMBVYDI DN Benzyl alcohol
DMBVYDI HS Approved
DMBVYDI SN Ulesfia (TN)
DMBVYDI CP Sciele Pharma
DMBVYDI DT Small molecular drug
DMBVYDI PC 244
DMBVYDI MW 108.14
DMBVYDI FM C7H8O
DMBVYDI IC InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMBVYDI CS C1=CC=C(C=C1)CO
DMBVYDI IK WVDDGKGOMKODPV-UHFFFAOYSA-N
DMBVYDI IU phenylmethanol
DMBVYDI CA CAS 100-51-6
DMBVYDI CB CHEBI:17987
DMBVYDI DE Head and body lice
DMDPYI5 ID DMDPYI5
DMDPYI5 DN Benzyl benzoate
DMDPYI5 HS Approved
DMDPYI5 SN BENZYL BENZOATE; 120-51-4; Benylate; Ascabiol; Novoscabin; Benzoic acid, phenylmethyl ester; Benzoic acid benzyl ester; Scobenol; Scabitox; Ascabin; Benzyl phenylformate; Phenylmethyl benzoate; Scabiozon; Scabagen; Peruscabin; Colebenz; Scabanca; Benzylets; Benzoic acid, benzyl ester; Vanzoate; Scabide; Benzyl benzenecarboxylate; benzylbenzoate; Antiscabiosum; Benzylis benzoas; Benzyl alcohol benzoic ester; Peruscabina; Venzonate; Spasmodin; Benzylum benzoicum; Benzylester kyseliny benzoove; Benzoesaeurebenzylester; Caswell No. 082
DMDPYI5 DT Small molecular drug
DMDPYI5 PC 2345
DMDPYI5 MW 212.24
DMDPYI5 FM C14H12O2
DMDPYI5 IC InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2
DMDPYI5 CS C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2
DMDPYI5 IK SESFRYSPDFLNCH-UHFFFAOYSA-N
DMDPYI5 IU benzyl benzoate
DMDPYI5 CA CAS 120-51-4
DMDPYI5 CB CHEBI:41237
DMDPYI5 DE Infestations of lice and scabies
DMQHM2D ID DMQHM2D
DMQHM2D DN Benzylpenicilloyl Polylysine
DMQHM2D HS Approved
DMQHM2D SN Benzylpenicilloyl; Benzylpenicilloyl G; Benzylpenicilloyl G polylysine; Benzylpenicilloyl-polylysine; Penicilloyl-polylysine; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
DMQHM2D TC Analgesics
DMQHM2D DT Small molecular drug
DMQHM2D PC 45266800
DMQHM2D MW 626.8
DMQHM2D FM C28H46N6O8S
DMQHM2D IC InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
DMQHM2D CS CC1([C@@H](N[C@H](S1)C(C(=O)NCCCC[C@H](C(=O)O)N)NC(=O)CC2=CC=CC=C2)C(=O)O)C.C(CCN)C[C@H](C(=O)O)N
DMQHM2D IK IMPVZRLKKKXMKQ-SGDOCVTFSA-N
DMQHM2D IU (2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid;(2R)-2,6-diaminohexanoic acid
DMQHM2D CA CAS 31855-75-1
DMQHM2D CB CHEBI:59297
DMQHM2D DE Bacterial infection
DMXDZAQ ID DMXDZAQ
DMXDZAQ DN Bepotastine
DMXDZAQ HS Approved
DMXDZAQ SN Betotastine; Tau 284; TAU-284DS; Talion (TN); (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CP Tanabe Seiyaku Co
DMXDZAQ TC Antiallergic Agents
DMXDZAQ DT Small molecular drug
DMXDZAQ PC 164522
DMXDZAQ MW 388.9
DMXDZAQ FM C21H25ClN2O3
DMXDZAQ IC InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1
DMXDZAQ CS C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O
DMXDZAQ IK YWGDOWXRIALTES-NRFANRHFSA-N
DMXDZAQ IU 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CA CAS 125602-71-3
DMXDZAQ CB CHEBI:71204
DMXDZAQ DE Allergic rhinitis
DM0RKS4 ID DM0RKS4
DM0RKS4 DN Bepridil
DM0RKS4 HS Approved
DM0RKS4 SN Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline
DM0RKS4 TC Antiarrhythmic Agents
DM0RKS4 DT Small molecular drug
DM0RKS4 PC 2351
DM0RKS4 MW 366.5
DM0RKS4 FM C24H34N2O
DM0RKS4 IC InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
DM0RKS4 CS CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
DM0RKS4 IK UIEATEWHFDRYRU-UHFFFAOYSA-N
DM0RKS4 IU N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline
DM0RKS4 CA CAS 64706-54-3
DM0RKS4 CB CHEBI:3061
DM0RKS4 DE Chronic/stable angina
DMEBY2D ID DMEBY2D
DMEBY2D DN Beriplast-P
DMEBY2D HS Approved
DMEBY2D SN Fibrin sealant, Aventis Behring
DMEBY2D CP Aventis Behring LLC
DMEBY2D DE Wound healing
DMWA2DZ ID DMWA2DZ
DMWA2DZ DN Berotralstat
DMWA2DZ HS Approved
DMWA2DZ SN UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CP BioCryst Pharmaceuticals
DMWA2DZ DT Small molecular drug
DMWA2DZ PC 137528262
DMWA2DZ MW 562.6
DMWA2DZ FM C30H26F4N6O
DMWA2DZ IC InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
DMWA2DZ CS C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
DMWA2DZ IK UXNXMBYCBRBRFD-MUUNZHRXSA-N
DMWA2DZ IU 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CA CAS 1809010-50-1
DMWA2DZ DE Hereditary angioedema
DMPHXMI ID DMPHXMI
DMPHXMI DN Besifloxacin
DMPHXMI HS Approved
DMPHXMI SN Besivance (TN)
DMPHXMI CP Bausch & Lomb
DMPHXMI DT Small molecular drug
DMPHXMI PC 10178705
DMPHXMI MW 393.8
DMPHXMI FM C19H21ClFN3O3
DMPHXMI IC InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1
DMPHXMI CS C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPHXMI IK QFFGVLORLPOAEC-SNVBAGLBSA-N
DMPHXMI IU 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMPHXMI CA CAS 141388-76-3
DMPHXMI CB CHEBI:135622
DMPHXMI DE Ocular inflammation
DM8L9D4 ID DM8L9D4
DM8L9D4 DN Bestatin
DM8L9D4 HS Approved
DM8L9D4 SN Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
DM8L9D4 DT Small molecular drug
DM8L9D4 PC 72172
DM8L9D4 MW 308.37
DM8L9D4 FM C16H24N2O4
DM8L9D4 IC InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
DM8L9D4 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
DM8L9D4 IK VGGGPCQERPFHOB-RDBSUJKOSA-N
DM8L9D4 IU (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
DM8L9D4 CA CAS 58970-76-6
DM8L9D4 DE Acute myeloid leukaemia
DMI6GKT ID DMI6GKT
DMI6GKT DN Beta-acetyldigoxin
DMI6GKT HS Approved
DMI6GKT SN Novodigal (TN)
DMI6GKT DT Small molecular drug
DMI6GKT PC 10350481
DMI6GKT MW 823
DMI6GKT FM C43H66O15
DMI6GKT IC InChI=1S/C43H66O15/c1-20-38(55-23(4)44)30(45)17-36(53-20)57-40-22(3)54-37(18-32(40)47)58-39-21(2)52-35(16-31(39)46)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(48)42(6)27(10-12-43(28,42)50)24-13-34(49)51-19-24/h13,20-22,25-33,35-40,45-48,50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMI6GKT CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)O)O
DMI6GKT IK NREAGDHHMSOWKZ-DXJNJSHLSA-N
DMI6GKT IU [(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate
DMI6GKT CA CAS 5355-48-6
DMI6GKT CB CHEBI:135892
DMI6GKT DE Cardiovascular disease
DM0RXBT ID DM0RXBT
DM0RXBT DN Beta-carotene
DM0RXBT HS Approved
DM0RXBT SN beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]
DM0RXBT DT Small molecular drug
DM0RXBT PC 5280489
DM0RXBT MW 536.9
DM0RXBT FM C40H56
DM0RXBT IC InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+
DM0RXBT CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\\C)\\C)/C)/C
DM0RXBT IK OENHQHLEOONYIE-JLTXGRSLSA-N
DM0RXBT IU 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene
DM0RXBT CA CAS 7235-40-7
DM0RXBT CB CHEBI:17579
DM0RXBT DE Vitamin deficiency
DMGRZW2 ID DMGRZW2
DMGRZW2 DN Betaine
DMGRZW2 HS Approved
DMGRZW2 SN Cystadane
DMGRZW2 CP Rare Disease Therapeutics Inc
DMGRZW2 DT Small molecular drug
DMGRZW2 PC 247
DMGRZW2 MW 117.15
DMGRZW2 FM C5H11NO2
DMGRZW2 IC InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
DMGRZW2 CS C[N+](C)(C)CC(=O)[O-]
DMGRZW2 IK KWIUHFFTVRNATP-UHFFFAOYSA-N
DMGRZW2 IU 2-(trimethylazaniumyl)acetate
DMGRZW2 CA CAS 107-43-7
DMGRZW2 CB CHEBI:17750
DMGRZW2 DE Inborn error of metabolism
DMAHJEF ID DMAHJEF
DMAHJEF DN Betamethasone
DMAHJEF HS Approved
DMAHJEF SN betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
DMAHJEF TC Antiinflammatory Agents
DMAHJEF DT Small molecular drug
DMAHJEF PC 9782
DMAHJEF MW 392.5
DMAHJEF FM C22H29FO5
DMAHJEF IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMAHJEF CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMAHJEF IK UREBDLICKHMUKA-DVTGEIKXSA-N
DMAHJEF IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMAHJEF CA CAS 378-44-9
DMAHJEF CB CHEBI:3077
DMAHJEF DE Inflammation
DMRMS1A ID DMRMS1A
DMRMS1A DN Betamethasone Benzoate
DMRMS1A HS Approved
DMRMS1A SN Uticort
DMRMS1A CP Parke Davis Div Warner Lambert Co
DMRMS1A DT Small molecular drug
DMRMS1A PC 5282492
DMRMS1A MW 496.6
DMRMS1A FM C29H33FO6
DMRMS1A IC InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1
DMRMS1A CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C
DMRMS1A IK SOQJPQZCPBDOMF-YCUXZELOSA-N
DMRMS1A IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate
DMRMS1A CA CAS 22298-29-9
DMRMS1A CB CHEBI:135798
DMRMS1A DE Inflammation
DMMIAXO ID DMMIAXO
DMMIAXO DN Betamethasone valerate
DMMIAXO HS Approved
DMMIAXO SN Beta-val; Betaderm; Betatrex; Dermabet; Valnac
DMMIAXO CP Schering Corp Sub Schering Plough Corp
DMMIAXO DT Small molecular drug
DMMIAXO PC 16533
DMMIAXO MW 476.6
DMMIAXO FM C27H37FO6
DMMIAXO IC InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1
DMMIAXO CS CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO
DMMIAXO IK SNHRLVCMMWUAJD-SUYDQAKGSA-N
DMMIAXO IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DMMIAXO CA CAS 2152-44-5
DMMIAXO CB CHEBI:31277
DMMIAXO DE Dermatological disease
DM6EUL5 ID DM6EUL5
DM6EUL5 DN Betaxolol
DM6EUL5 HS Approved
DM6EUL5 SN Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CP Lorex Pharmaceuticals
DM6EUL5 TC Antihypertensive Agents
DM6EUL5 DT Small molecular drug
DM6EUL5 PC 2369
DM6EUL5 MW 307.4
DM6EUL5 FM C18H29NO3
DM6EUL5 IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
DM6EUL5 CS CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
DM6EUL5 IK NWIUTZDMDHAVTP-UHFFFAOYSA-N
DM6EUL5 IU 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CA CAS 63659-18-7
DM6EUL5 CB CHEBI:3082
DM6EUL5 DE Hypertension
DMUFGAY ID DMUFGAY
DMUFGAY DN Betazole
DMUFGAY HS Approved
DMUFGAY SN Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole
DMUFGAY CP Eli Lilly And Co
DMUFGAY TC Antihistamines
DMUFGAY DT Small molecular drug
DMUFGAY PC 7741
DMUFGAY MW 111.15
DMUFGAY FM C5H9N3
DMUFGAY IC InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)
DMUFGAY CS C1=C(NN=C1)CCN
DMUFGAY IK JXDFEQONERDKSS-UHFFFAOYSA-N
DMUFGAY IU 2-(1H-pyrazol-5-yl)ethanamine
DMUFGAY CA CAS 105-20-4
DMUFGAY CB CHEBI:59170
DMUFGAY DE Gastric secretory disorder
DMCLHO0 ID DMCLHO0
DMCLHO0 DN Bethanechol
DMCLHO0 HS Approved
DMCLHO0 SN Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium
DMCLHO0 CP Merck & Co
DMCLHO0 TC Parasympathomimetics
DMCLHO0 DT Small molecular drug
DMCLHO0 PC 2370
DMCLHO0 MW 161.22
DMCLHO0 FM C7H17N2O2+
DMCLHO0 IC InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
DMCLHO0 CS CC(C[N+](C)(C)C)OC(=O)N
DMCLHO0 IK NZUPCNDJBJXXRF-UHFFFAOYSA-O
DMCLHO0 IU 2-carbamoyloxypropyl(trimethyl)azanium
DMCLHO0 CA CAS 674-38-4
DMCLHO0 CB CHEBI:3084
DMCLHO0 DE Urinary retention
DM2C4RF ID DM2C4RF
DM2C4RF DN Betrixaban
DM2C4RF HS Approved
DM2C4RF SN Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3
DM2C4RF CP Portola Pharmaceuticals
DM2C4RF DT Small molecular drug
DM2C4RF PC 10275777
DM2C4RF MW 451.9
DM2C4RF FM C23H22ClN5O3
DM2C4RF IC InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
DM2C4RF CS CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
DM2C4RF IK XHOLNRLADUSQLD-UHFFFAOYSA-N
DM2C4RF IU N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
DM2C4RF CA CAS 330942-05-7
DM2C4RF CB CHEBI:140421
DM2C4RF DE Venous thromboembolism; Cerebrovascular ischaemia
DMSD1UN ID DMSD1UN
DMSD1UN DN Bevacizumab
DMSD1UN HS Approved
DMSD1UN SN Bevacizumab (ophthalmic slow-release tissue tablet)
DMSD1UN CP University of London
DMSD1UN DT Monoclonal antibody
DMSD1UN SQ Bevacizumab light chain: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >"Bevacizumab heavy chain"EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSD1UN DE Solid tumour/cancer; Colorectal cancer; Lung cancer; Metastatic colorectal cancer; Brain metastases; Ovarian cancer
DMZFICR ID DMZFICR
DMZFICR DN Bevantolol
DMZFICR HS Approved
DMZFICR SN Bevantololum; Bevantolol [INN:BAN]; Bevantololum [INN-Latin]; (+-)-bevantolol; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
DMZFICR TC Antihypertensive Agents
DMZFICR DT Small molecular drug
DMZFICR PC 2372
DMZFICR MW 345.4
DMZFICR FM C20H27NO4
DMZFICR IC InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
DMZFICR CS CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O
DMZFICR IK HXLAFSUPPDYFEO-UHFFFAOYSA-N
DMZFICR IU 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol
DMZFICR CA CAS 59170-23-9
DMZFICR CB CHEBI:238698
DMZFICR DE Hypertension
DMOBIKY ID DMOBIKY
DMOBIKY DN Bexarotene
DMOBIKY HS Approved
DMOBIKY SN Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
DMOBIKY CP Eisai Inc
DMOBIKY TC Anticancer Agents
DMOBIKY DT Small molecular drug
DMOBIKY PC 82146
DMOBIKY MW 348.5
DMOBIKY FM C24H28O2
DMOBIKY IC InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
DMOBIKY CS CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
DMOBIKY IK NAVMQTYZDKMPEU-UHFFFAOYSA-N
DMOBIKY IU 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
DMOBIKY CA CAS 153559-49-0
DMOBIKY CB CHEBI:50859
DMOBIKY DE Cutaneous T-cell lymphoma
DMZDCS0 ID DMZDCS0
DMZDCS0 DN Bezafibrate
DMZDCS0 HS Approved
DMZDCS0 SN Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 TC Antilipemic Agents
DMZDCS0 DT Small molecular drug
DMZDCS0 PC 39042
DMZDCS0 MW 361.8
DMZDCS0 FM C19H20ClNO4
DMZDCS0 IC InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
DMZDCS0 CS CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
DMZDCS0 IK IIBYAHWJQTYFKB-UHFFFAOYSA-N
DMZDCS0 IU 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 CA CAS 41859-67-0
DMZDCS0 CB CHEBI:47612
DMZDCS0 DE Hyperlipidaemia
DMTZC5G ID DMTZC5G
DMTZC5G DN Bezlotoxumab
DMTZC5G HS Approved
DMTZC5G SN CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava
DMTZC5G CP Merck & Co.
DMTZC5G DT Monoclonal antibody
DMTZC5G DE C. difficile infection
DMTKD7Q ID DMTKD7Q
DMTKD7Q DN BIBW 2992
DMTKD7Q HS Approved
DMTKD7Q SN Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens
DMTKD7Q CP Boehringer Ingelheim
DMTKD7Q DT Small molecular drug
DMTKD7Q PC 10184653
DMTKD7Q MW 485.9
DMTKD7Q FM C24H25ClFN5O3
DMTKD7Q IC InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
DMTKD7Q CS CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
DMTKD7Q IK ULXXDDBFHOBEHA-CWDCEQMOSA-N
DMTKD7Q IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
DMTKD7Q CA CAS 850140-72-6
DMTKD7Q CB CHEBI:61390
DMTKD7Q DE Non-small-cell lung cancer
DMZMSPF ID DMZMSPF
DMZMSPF DN Bicalutamide
DMZMSPF HS Approved
DMZMSPF SN Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
DMZMSPF CP AstraZeneca plc
DMZMSPF TC Anticancer Agents
DMZMSPF DT Small molecular drug
DMZMSPF PC 2375
DMZMSPF MW 430.4
DMZMSPF FM C18H14F4N2O4S
DMZMSPF IC InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
DMZMSPF CS CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
DMZMSPF IK LKJPYSCBVHEWIU-UHFFFAOYSA-N
DMZMSPF IU N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
DMZMSPF CA CAS 90357-06-5
DMZMSPF CB CHEBI:91617
DMZMSPF DE Prostate cancer
DMG0H8K ID DMG0H8K
DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K HS Approved
DMG0H8K SN S900007760; Bictegravir mixture with emtricitabine and tenofovir alafenamide
DMG0H8K CP Gilead Sciences
DMG0H8K PC 129626368
DMG0H8K MW 1173.1
DMG0H8K FM C50H57F4N12O13PS
DMG0H8K IC InChI=1S/C21H18F3N3O5.C21H29N6O5P.C8H10FN3O3S/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28;1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30);5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1,5-6,13H,2-3H2,(H2,10,11,14)/t10-,11+,16+;15-,16+,33+;5-,6+/m010/s1
DMG0H8K CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F.C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMG0H8K IK GMIGIKGMWTUBHA-UKQLQXPXSA-N
DMG0H8K IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMG0H8K DE Human immunodeficiency virus infection
DM3KN7V ID DM3KN7V
DM3KN7V DN Bifonazole
DM3KN7V HS Approved
DM3KN7V SN Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CP Bayer Pharmaceuticals Corporation
DM3KN7V TC Antifungal Agents
DM3KN7V DT Small molecular drug
DM3KN7V PC 2378
DM3KN7V MW 310.4
DM3KN7V FM C22H18N2
DM3KN7V IC InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
DM3KN7V CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4
DM3KN7V IK OCAPBUJLXMYKEJ-UHFFFAOYSA-N
DM3KN7V IU 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CA CAS 60628-96-8
DM3KN7V CB CHEBI:78692
DM3KN7V DE Fungal infection
DMX0E5B ID DMX0E5B
DMX0E5B DN Bimatoprost
DMX0E5B HS Approved
DMX0E5B SN Bimatoprost (topical, alopecia)
DMX0E5B CP Allergan Inc
DMX0E5B DT Small molecular drug
DMX0E5B PC 5311027
DMX0E5B MW 415.6
DMX0E5B FM C25H37NO4
DMX0E5B IC InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
DMX0E5B CS CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
DMX0E5B IK AQOKCDNYWBIDND-FTOWTWDKSA-N
DMX0E5B IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
DMX0E5B CA CAS 155206-00-1
DMX0E5B CB CHEBI:51230
DMX0E5B DE Alopecia; Glaucoma/ocular hypertension
DME78OA ID DME78OA
DME78OA DN Biperiden
DME78OA HS Approved
DME78OA SN Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol
DME78OA CP Knoll Pharma
DME78OA TC Antiparkinson Agents
DME78OA DT Small molecular drug
DME78OA PC 2381
DME78OA MW 311.5
DME78OA FM C21H29NO
DME78OA IC InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
DME78OA CS C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
DME78OA IK YSXKPIUOCJLQIE-UHFFFAOYSA-N
DME78OA IU 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
DME78OA CA CAS 514-65-8
DME78OA CB CHEBI:3112
DME78OA DE Parkinson disease
DMTKU46 ID DMTKU46
DMTKU46 DN Bismuth
DMTKU46 HS Approved
DMTKU46 SN Bismut; Bismuto; Wismut; Bismuth standard for AAS; Bismuth standard for ICP; LTBB002773; Bismuth(III) nitrate solution; Bismuth, elemental; Bismuth-209; BISMUTH, 99.95%; BISMUTH, 99.999%; 83Bi
DMTKU46 TC Antidiarrheals
DMTKU46 DT Small molecular drug
DMTKU46 PC 5359367
DMTKU46 MW 208.98
DMTKU46 FM Bi
DMTKU46 IC InChI=1S/Bi
DMTKU46 CS [Bi]
DMTKU46 IK JCXGWMGPZLAOME-UHFFFAOYSA-N
DMTKU46 IU bismuth
DMTKU46 CA CAS 7440-69-9
DMTKU46 CB CHEBI:33301
DMTKU46 DE Diarrhea
DM3UZ95 ID DM3UZ95
DM3UZ95 DN Bisoprolol
DM3UZ95 HS Approved
DM3UZ95 SN Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
DM3UZ95 TC Antihypertensive Agents
DM3UZ95 DT Small molecular drug
DM3UZ95 PC 2405
DM3UZ95 MW 325.4
DM3UZ95 FM C18H31NO4
DM3UZ95 IC InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
DM3UZ95 CS CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O
DM3UZ95 IK VHYCDWMUTMEGQY-UHFFFAOYSA-N
DM3UZ95 IU 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
DM3UZ95 CA CAS 66722-44-9
DM3UZ95 CB CHEBI:3127
DM3UZ95 DE Hypertension
DMK6XAV ID DMK6XAV
DMK6XAV DN Bitolterol
DMK6XAV HS Approved
DMK6XAV SN Tornalate
DMK6XAV CP Sanofi Aventis Us Llc
DMK6XAV DT Small molecular drug
DMK6XAV PC 35330
DMK6XAV MW 461.5
DMK6XAV FM C28H31NO5
DMK6XAV IC InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
DMK6XAV CS CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C
DMK6XAV IK FZGVEKPRDOIXJY-UHFFFAOYSA-N
DMK6XAV IU [4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate
DMK6XAV CA CAS 30392-40-6
DMK6XAV CB CHEBI:3133
DMK6XAV DE Chronic obstructive pulmonary disease; Asthma
DMECRX1 ID DMECRX1
DMECRX1 DN Bivalirudin
DMECRX1 HS Approved
DMECRX1 SN 128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
DMECRX1 TC Antithrombotic Agents
DMECRX1 DT Small molecular drug
DMECRX1 PC 16129704
DMECRX1 MW 2180.3
DMECRX1 FM C98H138N24O33
DMECRX1 IC InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1
DMECRX1 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N
DMECRX1 IK OIRCOABEOLEUMC-GEJPAHFPSA-N
DMECRX1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMECRX1 CA CAS 128270-60-0
DMECRX1 CB CHEBI:59173
DMECRX1 DE Thrombocytopenia
DMR8YD6 ID DMR8YD6
DMR8YD6 DN B-Lactams
DMR8YD6 HS Approved
DMR8YD6 SN Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 DT Small molecular drug
DMR8YD6 PC 5280445
DMR8YD6 MW 286.24
DMR8YD6 FM C15H10O6
DMR8YD6 IC InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMR8YD6 CS C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMR8YD6 IK IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMR8YD6 IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 CA CAS 491-70-3
DMR8YD6 CB CHEBI:15864
DMR8YD6 DE Bacterial infection
DMNER5S ID DMNER5S
DMNER5S DN Bleomycin
DMNER5S HS Approved
DMNER5S SN BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
DMNER5S CP Bristol-Myers Squibb
DMNER5S TC Anticancer Agents
DMNER5S DT Small molecular drug
DMNER5S PC 5360373
DMNER5S MW 1415.6
DMNER5S FM C55H84N17O21S3+
DMNER5S IC InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
DMNER5S CS CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
DMNER5S IK OYVAGSVQBOHSSS-WXFSZRTFSA-O
DMNER5S IU 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
DMNER5S CA CAS 11056-06-7
DMNER5S DE Hodgkin lymphoma
DMGECIJ ID DMGECIJ
DMGECIJ DN Blinatumomab
DMGECIJ HS Approved
DMGECIJ SN AMG 103; Blincyto
DMGECIJ CP Amgen
DMGECIJ DT Monoclonal antibody
DMGECIJ SQ single chain variable fragment fusion protein : DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH
DMGECIJ DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma
DMQTAGO ID DMQTAGO
DMQTAGO DN BMS-201038
DMQTAGO HS Approved
DMQTAGO SN AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01
DMQTAGO CP Bristol-Myers Squibb
DMQTAGO DT Small molecular drug
DMQTAGO PC 9853053
DMQTAGO MW 693.7
DMQTAGO FM C39H37F6N3O2
DMQTAGO IC InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
DMQTAGO CS C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMQTAGO IK MBBCVAKAJPKAKM-UHFFFAOYSA-N
DMQTAGO IU N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMQTAGO CA CAS 182431-12-5
DMQTAGO CB CHEBI:72297
DMQTAGO DE Familial hypercholesterolemia
DMBSHMF ID DMBSHMF
DMBSHMF DN Boceprevir
DMBSHMF HS Approved
DMBSHMF SN Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
DMBSHMF DT Small molecular drug
DMBSHMF PC 10324367
DMBSHMF MW 519.7
DMBSHMF FM C27H45N5O5
DMBSHMF IC InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMBSHMF CS CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMBSHMF IK LHHCSNFAOIFYRV-DOVBMPENSA-N
DMBSHMF IU (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMBSHMF CA CAS 394730-60-0
DMBSHMF CB CHEBI:68621
DMBSHMF DE Hepatitis C virus infection
DM2EXC5 ID DM2EXC5
DM2EXC5 DN BOL-303259-X
DM2EXC5 HS Approved
DM2EXC5 SN Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
DM2EXC5 CP Bausch and Lomb/Valeant Pharmaceuticals
DM2EXC5 DT Small molecular drug
DM2EXC5 PC 11156438
DM2EXC5 MW 507.6
DM2EXC5 FM C27H41NO8
DM2EXC5 IC InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
DM2EXC5 CS C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
DM2EXC5 IK LOVMMUBRQUFEAH-UIEAZXIASA-N
DM2EXC5 IU 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DM2EXC5 CA CAS 860005-21-6
DM2EXC5 DE Open-angle glaucoma; Renal cell carcinoma
DMIFYLX ID DMIFYLX
DMIFYLX DN Bopindolol
DMIFYLX HS Approved
DMIFYLX SN BOPINDOLOL; 62658-63-3; Sandonorm; (+-)-Bopindolol; 1-(tert-Butylamino)-3-((2-methyl-1H-indol-4-yl)oxy)propan-2-yl benzoate; Bopindololum [INN-Latin]; Bopindolol [INN]; UUOJIACWOAYWEZ-UHFFFAOYSA-N; Bopindolol (INN); Wandonorm; 69010-88-4; NCGC00163155-01; Sandonorm (TN); (+-)-4-(2-Benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole; DSSTox_CID_2684; DSSTox_RID_76690; (+-)-1-(tert-Butylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol benzoate (ester); DSSTox_GSID_22684
DMIFYLX DT Small molecular drug
DMIFYLX PC 44112
DMIFYLX MW 380.5
DMIFYLX FM C23H28N2O3
DMIFYLX IC InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
DMIFYLX CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
DMIFYLX IK UUOJIACWOAYWEZ-UHFFFAOYSA-N
DMIFYLX IU [1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate
DMIFYLX CA CAS 62658-63-3
DMIFYLX CB CHEBI:143782
DMIFYLX DE Hypertension
DMNO38U ID DMNO38U
DMNO38U DN Bortezomib
DMNO38U HS Approved
DMNO38U SN 179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
DMNO38U CP Takeda
DMNO38U TC Anticancer Agents
DMNO38U DT Small molecular drug
DMNO38U PC 387447
DMNO38U MW 384.2
DMNO38U FM C19H25BN4O4
DMNO38U IC InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
DMNO38U CS B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
DMNO38U IK GXJABQQUPOEUTA-RDJZCZTQSA-N
DMNO38U IU [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
DMNO38U CA CAS 179324-69-7
DMNO38U CB CHEBI:52717
DMNO38U DE Multiple myeloma; Non-hodgkin lymphoma; Mantle cell lymphoma
DMIOGBU ID DMIOGBU
DMIOGBU DN Bosentan
DMIOGBU HS Approved
DMIOGBU SN Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CP Actelion Pharmaceuticals
DMIOGBU TC Antihypertensive Agents
DMIOGBU DT Small molecular drug
DMIOGBU PC 104865
DMIOGBU MW 551.6
DMIOGBU FM C27H29N5O6S
DMIOGBU IC InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
DMIOGBU CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
DMIOGBU IK GJPICJJJRGTNOD-UHFFFAOYSA-N
DMIOGBU IU 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CA CAS 147536-97-8
DMIOGBU CB CHEBI:51450
DMIOGBU DE Pulmonary arterial hypertension
DMTI8YE ID DMTI8YE
DMTI8YE DN Bosutinib
DMTI8YE HS Approved
DMTI8YE SN SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)
DMTI8YE CP Wyeth Research
DMTI8YE TC Anticancer Agents
DMTI8YE DT Small molecular drug
DMTI8YE PC 5328940
DMTI8YE MW 530.4
DMTI8YE FM C26H29Cl2N5O3
DMTI8YE IC InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
DMTI8YE CS CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
DMTI8YE IK UBPYILGKFZZVDX-UHFFFAOYSA-N
DMTI8YE IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
DMTI8YE CA CAS 380843-75-4
DMTI8YE CB CHEBI:39112
DMTI8YE DE Breast cancer
DMW67MU ID DMW67MU
DMW67MU DN Botulinum Toxin Type A
DMW67MU HS Approved
DMW67MU SN Botox; Botulinum toxin type A (JAN)
DMW67MU SQ Botulinum Toxin Type A Sequence: MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
DMW67MU DE Blepharospasm
DM58QS1 ID DM58QS1
DM58QS1 DN Botulinum Toxin Type B
DM58QS1 HS Approved
DM58QS1 SN BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN)
DM58QS1 CP Allergan Inc
DM58QS1 TC Antidystonic Agents
DM58QS1 SQ Botulinum neurotoxin type B - Clostridium botulinum: MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE
DM58QS1 DE Parkinson disease
DM20LIM ID DM20LIM
DM20LIM DN Bremelanotide
DM20LIM HS Approved
DM20LIM SN Bremelanotide (USAN/INN); PT-141; Rekynda
DM20LIM CP Palatin Technol
DM20LIM DT Small molecular drug
DM20LIM PC 9941379
DM20LIM MW 1025.2
DM20LIM FM C50H68N14O10
DM20LIM IC InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DM20LIM CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
DM20LIM IK FFHBJDQSGDNCIV-MFVUMRCOSA-N
DM20LIM IU (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
DM20LIM CA CAS 189691-06-3
DM20LIM DE Erectile dysfunction; Hypoactive sexual desire dysfunction
DMWLC57 ID DMWLC57
DMWLC57 DN Brentuximab vedotin
DMWLC57 HS Approved
DMWLC57 SN Adcetris (TN)
DMWLC57 CP Millennium Pharmaceuticals; Seattle Genetics
DMWLC57 DT Monoclonal antibody
DMWLC57 DE Hodgkin lymphoma
DM1FX74 ID DM1FX74
DM1FX74 DN Bretylium
DM1FX74 HS Approved
DM1FX74 SN Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
DM1FX74 CP Hospira Inc
DM1FX74 TC Antiarrhythmic Agents
DM1FX74 DT Small molecular drug
DM1FX74 PC 2431
DM1FX74 MW 243.16
DM1FX74 FM C11H17BrN+
DM1FX74 IC InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
DM1FX74 CS CC[N+](C)(C)CC1=CC=CC=C1Br
DM1FX74 IK AAQOQKQBGPPFNS-UHFFFAOYSA-N
DM1FX74 IU (2-bromophenyl)methyl-ethyl-dimethylazanium
DM1FX74 CA CAS 59-41-6
DM1FX74 CB CHEBI:3172
DM1FX74 DE Ventricular fibrillation
DM7W94S ID DM7W94S
DM7W94S DN Brigatinib
DM7W94S HS Approved
DM7W94S SN 1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958
DM7W94S CP Ariad Pharmaceuticals/Takeda
DM7W94S DT Small molecular drug
DM7W94S PC 68165256
DM7W94S MW 584.1
DM7W94S FM C29H39ClN7O2P
DM7W94S IC InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
DM7W94S CS CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
DM7W94S IK AILRADAXUVEEIR-UHFFFAOYSA-N
DM7W94S IU 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine
DM7W94S CA CAS 1197953-54-0
DM7W94S DE Non-small-cell lung cancer; Anaplastic large cell lymphoma
DMBR01X ID DMBR01X
DMBR01X DN Brilinta
DMBR01X HS Approved
DMBR01X SN Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique
DMBR01X CP AstraZeneca
DMBR01X DT Small molecular drug
DMBR01X PC 9871419
DMBR01X MW 522.6
DMBR01X FM C23H28F2N6O4S
DMBR01X IC InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
DMBR01X CS CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
DMBR01X IK OEKWJQXRCDYSHL-FNOIDJSQSA-N
DMBR01X IU (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
DMBR01X CA CAS 274693-27-5
DMBR01X CB CHEBI:68558
DMBR01X DE Myocardial infarction; Arterial thrombosis; Thrombosis
DMQLT4N ID DMQLT4N
DMQLT4N DN Brimonidine
DMQLT4N HS Approved
DMQLT4N SN brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine
DMQLT4N CP PSivida Corp
DMQLT4N DT Small molecular drug
DMQLT4N PC 2435
DMQLT4N MW 292.13
DMQLT4N FM C11H10BrN5
DMQLT4N IC InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
DMQLT4N CS C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
DMQLT4N IK XYLJNLCSTIOKRM-UHFFFAOYSA-N
DMQLT4N IU 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMQLT4N CA CAS 59803-98-4
DMQLT4N CB CHEBI:3175
DMQLT4N DE Ocular hypertension; Glaucoma/ocular hypertension
DMBAPFG ID DMBAPFG
DMBAPFG DN Brinzolamide
DMBAPFG HS Approved
DMBAPFG SN Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
DMBAPFG CP Alcon Laboratories
DMBAPFG TC Antiglaucomic Agents
DMBAPFG DT Small molecular drug
DMBAPFG PC 68844
DMBAPFG MW 383.5
DMBAPFG FM C12H21N3O5S3
DMBAPFG IC InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
DMBAPFG CS CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMBAPFG IK HCRKCZRJWPKOAR-JTQLQIEISA-N
DMBAPFG IU (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMBAPFG CA CAS 138890-62-7
DMBAPFG CB CHEBI:3176
DMBAPFG DE Open-angle glaucoma
DMSEPK8 ID DMSEPK8
DMSEPK8 DN Brivaracetam
DMSEPK8 HS Approved
DMSEPK8 SN Rikelta; UCB-34714; Brivaracetam (USAN/INN)
DMSEPK8 CP UCB
DMSEPK8 DT Small molecular drug
DMSEPK8 PC 9837243
DMSEPK8 MW 212.29
DMSEPK8 FM C11H20N2O2
DMSEPK8 IC InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
DMSEPK8 CS CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
DMSEPK8 IK MSYKRHVOOPPJKU-BDAKNGLRSA-N
DMSEPK8 IU (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
DMSEPK8 CA CAS 357336-20-0
DMSEPK8 CB CHEBI:133013
DMSEPK8 DE Epilepsy; Pain; Complex partial seizure
DMASDQ6 ID DMASDQ6
DMASDQ6 DN Brodalumab
DMASDQ6 HS Approved
DMASDQ6 SN AMG 827
DMASDQ6 CP Valeant Pharmaceuticals
DMASDQ6 DT Monoclonal antibody
DMASDQ6 DE Plaque psoriasis; Asthma; Psoriasis vulgaris
DMW8QNG ID DMW8QNG
DMW8QNG DN Brolucizumab
DMW8QNG HS Approved
DMW8QNG CP Alcon
DMW8QNG DT Antibody
DMW8QNG DE Wet age-related macular degeneration; Diabetic macular edema
DMY9TCW ID DMY9TCW
DMY9TCW DN Bromazepam
DMY9TCW HS Approved
DMY9TCW SN Bromazepamum; Calmepam; Compedium; Compendium; Creosedin; Durazanil; Lectopam; Lekotam; Lexaurin; Lexilium; Lexomil; Lexotan; Lexotanil; Normoc; Somalium; Ultramidol; Bromazepamum [Latin]; LA Xvii; KL 001; Ro 53350; Apo-Bromazepam; Brazepam (TN); Bromaze (TN); Bromazepam(USAN; Bromazepamum [INN-Latin]; Gen-Bromazepam; KL-001; Lectopam (TN); Lexotan (TN); Novo-bromazepam; Nu-Bromazepam; Ro 4-9253; Ro 5-3350; Bromazepam (JP15/USAN/INN); Bromazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CP Hoffmann-La Roche pharmaceutical company
DMY9TCW TC Hypnotics and Sedatives
DMY9TCW DT Small molecular drug
DMY9TCW PC 2441
DMY9TCW MW 316.15
DMY9TCW FM C14H10BrN3O
DMY9TCW IC InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
DMY9TCW CS C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3
DMY9TCW IK VMIYHDSEFNYJSL-UHFFFAOYSA-N
DMY9TCW IU 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CA CAS 1812-30-2
DMY9TCW CB CHEBI:31302
DMY9TCW DE Panic attacks; Anxiety disorder
DMKB79O ID DMKB79O
DMKB79O DN Bromfenac
DMKB79O HS Approved
DMKB79O SN Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O TC Antiinflammatory Agents
DMKB79O DT Small molecular drug
DMKB79O PC 60726
DMKB79O MW 334.16
DMKB79O FM C15H12BrNO3
DMKB79O IC InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
DMKB79O CS C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
DMKB79O IK ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
DMKB79O IU 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O CA CAS 91714-94-2
DMKB79O CB CHEBI:240107
DMKB79O DE Postoperative inflammation; Inflammation
DMVE3TK ID DMVE3TK
DMVE3TK DN Bromocriptine
DMVE3TK HS Approved
DMVE3TK SN Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
DMVE3TK CP Norvatis Phamaceuticals Corporation
DMVE3TK TC Antiparkinson Agents
DMVE3TK DT Small molecular drug
DMVE3TK PC 31101
DMVE3TK MW 654.6
DMVE3TK FM C32H40BrN5O5
DMVE3TK IC InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
DMVE3TK CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
DMVE3TK IK OZVBMTJYIDMWIL-AYFBDAFISA-N
DMVE3TK IU (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMVE3TK CA CAS 25614-03-3
DMVE3TK CB CHEBI:3181
DMVE3TK DE Parkinson disease
DMNDJT5 ID DMNDJT5
DMNDJT5 DN Bromodiphenhydramine
DMNDJT5 HS Approved
DMNDJT5 SN Amodryl; Bromanautine; Bromazin; Bromazina; Bromazine; Bromazinum; Bromdiphenhydramine; Bromdiphenhydraminum; Deserol; Histabromamine; Ambodryl hydrochloride; Bromdiphenhydramine hydrochloride; Bromdiphenylhydramine hydrochloride; Bromodiphenhydramine hydrochloride; Ambrodyl (TN); Bromazina [INN-Spanish]; Bromazine [INN:BAN]; Bromazinum [INN-Latin]; Bromo-Benadryl; Bromo-Benzdryl; Neo-Benadryl; Beta-dimethylaminoethyl p-bromobenzhydryl ether; Beta-(p-Bromobenzhydryloxy)ethyldimethylamine; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine
DMNDJT5 TC Antihistamines
DMNDJT5 DT Small molecular drug
DMNDJT5 PC 2444
DMNDJT5 MW 334.2
DMNDJT5 FM C17H20BrNO
DMNDJT5 IC InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3
DMNDJT5 CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br
DMNDJT5 IK NUNIWXHYABYXKF-UHFFFAOYSA-N
DMNDJT5 IU 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine
DMNDJT5 CA CAS 118-23-0
DMNDJT5 CB CHEBI:59177
DMNDJT5 DE Hay fever
DM24XYQ ID DM24XYQ
DM24XYQ DN Bromperidol
DM24XYQ HS Approved
DM24XYQ SN bromperidol; 10457-90-6; Impromen; Bromoperidol; Tesoprel; Azurene; 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; UNII-LYH6F7I22E; Bromperidolum [INN-Latin]; R 11333; EINECS 233-943-3; 4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; CC 2489; BRN 1552256; LYH6F7I22E; 4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; RKLNONIVDFXQRX-UHFFFAOYSA-N; 4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; NCGC00016692-01; CAS-10457-90-6
DM24XYQ DT Small molecular drug
DM24XYQ PC 2448
DM24XYQ MW 420.3
DM24XYQ FM C21H23BrFNO2
DM24XYQ IC InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM24XYQ CS C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F
DM24XYQ IK RKLNONIVDFXQRX-UHFFFAOYSA-N
DM24XYQ IU 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM24XYQ CA CAS 10457-90-6
DM24XYQ CB CHEBI:31305
DM24XYQ DE Schizophrenia
DMFOVSD ID DMFOVSD
DMFOVSD DN Brompheniramine
DMFOVSD HS Approved
DMFOVSD SN Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
DMFOVSD CP Alpharma Us Pharmaceuticals Division
DMFOVSD TC Antiallergic Agents
DMFOVSD DT Small molecular drug
DMFOVSD PC 6834
DMFOVSD MW 319.24
DMFOVSD FM C16H19BrN2
DMFOVSD IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DMFOVSD CS CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMFOVSD IK ZDIGNSYAACHWNL-UHFFFAOYSA-N
DMFOVSD IU 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMFOVSD CA CAS 86-22-6
DMFOVSD CB CHEBI:3183
DMFOVSD DE Allergic rhinitis
DMXKZT3 ID DMXKZT3
DMXKZT3 DN Buclizine
DMXKZT3 HS Approved
DMXKZT3 SN Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CP McNeil Laboratories
DMXKZT3 TC Antihistamines
DMXKZT3 DT Small molecular drug
DMXKZT3 PC 6729
DMXKZT3 MW 433
DMXKZT3 FM C28H33ClN2
DMXKZT3 IC InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
DMXKZT3 CS CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMXKZT3 IK MOYGZHXDRJNJEP-UHFFFAOYSA-N
DMXKZT3 IU 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CA CAS 82-95-1
DMXKZT3 CB CHEBI:3205
DMXKZT3 DE Nausea
DMJIBAW ID DMJIBAW
DMJIBAW DN Budesonide
DMJIBAW HS Approved
DMJIBAW SN Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
DMJIBAW CP AstraZeneca
DMJIBAW TC Antiinflammatory Agents
DMJIBAW DT Small molecular drug
DMJIBAW PC 5281004
DMJIBAW MW 430.5
DMJIBAW FM C25H34O6
DMJIBAW IC InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
DMJIBAW CS CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
DMJIBAW IK VOVIALXJUBGFJZ-KWVAZRHASA-N
DMJIBAW IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMJIBAW CA CAS 51333-22-3
DMJIBAW CB CHEBI:3207
DMJIBAW DE Asthma
DMODHQI ID DMODHQI
DMODHQI DN Budipine
DMODHQI HS Approved
DMODHQI SN Parkinsan; BY-701
DMODHQI CP ALTANA Pharma AG
DMODHQI DT Small molecular drug
DMODHQI PC 68778
DMODHQI MW 293.4
DMODHQI FM C21H27N
DMODHQI IC InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
DMODHQI CS CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMODHQI IK QIHLUZAFSSMXHQ-UHFFFAOYSA-N
DMODHQI IU 1-tert-butyl-4,4-diphenylpiperidine
DMODHQI CA CAS 57982-78-2
DMODHQI CB CHEBI:135228
DMODHQI DE Migraine
DMG1OPF ID DMG1OPF
DMG1OPF DN Buflomedil
DMG1OPF HS Approved
DMG1OPF SN Loftyl; Buflomedil hydrochloride
DMG1OPF CP Laboratoire L Lafon SA
DMG1OPF DT Small molecular drug
DMG1OPF PC 2467
DMG1OPF MW 307.4
DMG1OPF FM C17H25NO4
DMG1OPF IC InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
DMG1OPF CS COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
DMG1OPF IK OWYLAEYXIQKAOL-UHFFFAOYSA-N
DMG1OPF IU 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one
DMG1OPF CA CAS 55837-25-7
DMG1OPF CB CHEBI:94538
DMG1OPF DE Peripheral vascular disease
DMX82DO ID DMX82DO
DMX82DO DN Buformin
DMX82DO HS Approved
DMX82DO SN Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224
DMX82DO PC 2468
DMX82DO MW 157.22
DMX82DO FM C6H15N5
DMX82DO IC InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
DMX82DO CS CCCCN=C(N)N=C(N)N
DMX82DO IK XSEUMFJMFFMCIU-UHFFFAOYSA-N
DMX82DO IU 2-butyl-1-(diaminomethylidene)guanidine
DMX82DO CA CAS 692-13-7
DMX82DO CB CHEBI:3209
DMX82DO DE Type 2 diabetes
DMJUVE6 ID DMJUVE6
DMJUVE6 DN Bulevirtide
DMJUVE6 HS Approved
DMJUVE6 SN Lipopeptide
DMJUVE6 CP MYR Pharma
DMJUVE6 DT Peptide
DMJUVE6 DE Hepatitis D virus infection
DMRV7H0 ID DMRV7H0
DMRV7H0 DN Bumetanide
DMRV7H0 HS Approved
DMRV7H0 SN Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
DMRV7H0 CP Hoffmann-La Roche pharmaceutical company
DMRV7H0 TC Diuretics
DMRV7H0 DT Small molecular drug
DMRV7H0 PC 2471
DMRV7H0 MW 364.4
DMRV7H0 FM C17H20N2O5S
DMRV7H0 IC InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
DMRV7H0 CS CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
DMRV7H0 IK MAEIEVLCKWDQJH-UHFFFAOYSA-N
DMRV7H0 IU 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
DMRV7H0 CA CAS 28395-03-1
DMRV7H0 CB CHEBI:3213
DMRV7H0 DE Congestive heart failure
DM4I8O7 ID DM4I8O7
DM4I8O7 DN Bunazosin
DM4I8O7 HS Approved
DM4I8O7 SN Andante; E 015; DE-070; Detantol-R; E-1015; E-643
DM4I8O7 CP Eisai Co Ltd
DM4I8O7 DT Small molecular drug
DM4I8O7 PC 2472
DM4I8O7 MW 373.4
DM4I8O7 FM C19H27N5O3
DM4I8O7 IC InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
DM4I8O7 CS CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DM4I8O7 IK RHLJLALHBZGAFM-UHFFFAOYSA-N
DM4I8O7 IU 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
DM4I8O7 CA CAS 80755-51-7
DM4I8O7 CB CHEBI:135576
DM4I8O7 DE Glaucoma/ocular hypertension
DM4PRFC ID DM4PRFC
DM4PRFC DN Bupivacaine
DM4PRFC HS Approved
DM4PRFC SN Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CP AstraZeneca
DM4PRFC TC Anesthetics
DM4PRFC DT Small molecular drug
DM4PRFC PC 2474
DM4PRFC MW 288.4
DM4PRFC FM C18H28N2O
DM4PRFC IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
DM4PRFC CS CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
DM4PRFC IK LEBVLXFERQHONN-UHFFFAOYSA-N
DM4PRFC IU 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CA CAS 38396-39-3
DM4PRFC CB CHEBI:77431
DM4PRFC DE Anaesthesia; Pain
DMPRI8G ID DMPRI8G
DMPRI8G DN Buprenorphine
DMPRI8G HS Approved
DMPRI8G SN Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M
DMPRI8G CP Reckitt; Colman
DMPRI8G TC Analgesics
DMPRI8G DT Small molecular drug
DMPRI8G PC 644073
DMPRI8G MW 467.6
DMPRI8G FM C29H41NO4
DMPRI8G IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
DMPRI8G CS C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMPRI8G IK RMRJXGBAOAMLHD-IHFGGWKQSA-N
DMPRI8G IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMPRI8G CA CAS 52485-79-7
DMPRI8G CB CHEBI:3216
DMPRI8G DE Pain; Migraine; Psychiatric disorder
DMBQEGT ID DMBQEGT
DMBQEGT DN Buprenorphine + naloxone
DMBQEGT HS Approved
DMBQEGT SN Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461
DMBQEGT CP Orexo
DMBQEGT DT Small molecular drug
DMBQEGT PC 6321408
DMBQEGT MW 467.6
DMBQEGT FM C29H41NO4
DMBQEGT IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1
DMBQEGT CS C[C@]([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMBQEGT IK RMRJXGBAOAMLHD-MLLHIGKASA-N
DMBQEGT IU (1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBQEGT CA CAS 52485-79-7
DMBQEGT DE Opioid dependence; Major depressive disorder
DM5PCS7 ID DM5PCS7
DM5PCS7 DN Bupropion
DM5PCS7 HS Approved
DM5PCS7 SN bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone
DM5PCS7 CP GlaxoSmithKline plc
DM5PCS7 DT Small molecular drug
DM5PCS7 PC 444
DM5PCS7 MW 239.74
DM5PCS7 FM C13H18ClNO
DM5PCS7 IC InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5PCS7 CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DM5PCS7 IK SNPPWIUOZRMYNY-UHFFFAOYSA-N
DM5PCS7 IU 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DM5PCS7 CA CAS 34911-55-2
DM5PCS7 CB CHEBI:3219
DM5PCS7 DE Smoking dependence
DMKUOQV ID DMKUOQV
DMKUOQV DN Burosumab
DMKUOQV HS Approved
DMKUOQV SN Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29
DMKUOQV CP Ultragenyx Pharmaceutical/Kyowa Hakko Kirin
DMKUOQV DT Antibody
DMKUOQV DE X-linked hypophosphataemia
DMBS632 ID DMBS632
DMBS632 DN Buspirone
DMBS632 HS Approved
DMBS632 SN Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CP Bristol-Myers Squibb
DMBS632 TC Antianxiety Agents
DMBS632 DT Small molecular drug
DMBS632 PC 2477
DMBS632 MW 385.5
DMBS632 FM C21H31N5O2
DMBS632 IC InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
DMBS632 CS C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
DMBS632 IK QWCRAEMEVRGPNT-UHFFFAOYSA-N
DMBS632 IU 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CA CAS 36505-84-7
DMBS632 CB CHEBI:3223
DMBS632 DE Anxiety disorder
DMXYJ9C ID DMXYJ9C
DMXYJ9C DN Busulfan
DMXYJ9C HS Approved
DMXYJ9C SN Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CP GlaxoSmithKline
DMXYJ9C TC Anticancer Agents
DMXYJ9C DT Small molecular drug
DMXYJ9C PC 2478
DMXYJ9C MW 246.3
DMXYJ9C FM C6H14O6S2
DMXYJ9C IC InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
DMXYJ9C CS CS(=O)(=O)OCCCCOS(=O)(=O)C
DMXYJ9C IK COVZYZSDYWQREU-UHFFFAOYSA-N
DMXYJ9C IU 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CA CAS 55-98-1
DMXYJ9C CB CHEBI:28901
DMXYJ9C DE Myeloproliferative syndrome
DMC5AST ID DMC5AST
DMC5AST DN Butabarbital
DMC5AST HS Approved
DMC5AST SN Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
DMC5AST TC Antianxiety Agents
DMC5AST DT Small molecular drug
DMC5AST PC 2479
DMC5AST MW 212.25
DMC5AST FM C10H16N2O3
DMC5AST IC InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
DMC5AST CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMC5AST IK ZRIHAIZYIMGOAB-UHFFFAOYSA-N
DMC5AST IU 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione
DMC5AST CA CAS 125-40-6
DMC5AST CB CHEBI:3228
DMC5AST DE Insomnia
DM584TM ID DM584TM
DM584TM DN Butacaine
DM584TM HS Approved
DM584TM SN Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1)
DM584TM DT Small molecular drug
DM584TM PC 2480
DM584TM MW 306.4
DM584TM FM C18H30N2O2
DM584TM IC InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
DM584TM CS CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N
DM584TM IK HQFWVSGBVLEQGA-UHFFFAOYSA-N
DM584TM IU 3-(dibutylamino)propyl 4-aminobenzoate
DM584TM CA CAS 149-16-6
DM584TM CB CHEBI:94820
DM584TM DE Pain
DM9J04X ID DM9J04X
DM9J04X DN Butalbital
DM9J04X HS Approved
DM9J04X SN Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
DM9J04X TC Analgesics
DM9J04X DT Small molecular drug
DM9J04X PC 2481
DM9J04X MW 224.26
DM9J04X FM C11H16N2O3
DM9J04X IC InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM9J04X CS CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
DM9J04X IK UZVHFVZFNXBMQJ-UHFFFAOYSA-N
DM9J04X IU 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM9J04X CA CAS 77-26-9
DM9J04X CB CHEBI:102524
DM9J04X DE Anxiety disorder; Headache
DMOJ4ZI ID DMOJ4ZI
DMOJ4ZI DN Butenafine
DMOJ4ZI HS Approved
DMOJ4ZI SN Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
DMOJ4ZI CP Schering-Plough
DMOJ4ZI TC Antifungal Agents
DMOJ4ZI DT Small molecular drug
DMOJ4ZI PC 2484
DMOJ4ZI MW 317.5
DMOJ4ZI FM C23H27N
DMOJ4ZI IC InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
DMOJ4ZI CS CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
DMOJ4ZI IK ABJKWBDEJIDSJZ-UHFFFAOYSA-N
DMOJ4ZI IU 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
DMOJ4ZI CA CAS 101828-21-1
DMOJ4ZI CB CHEBI:3238
DMOJ4ZI DE Dermatologic infection
DM7JHX0 ID DM7JHX0
DM7JHX0 DN Butethal
DM7JHX0 HS Approved
DM7JHX0 SN Aethylbutylbarbitursaeure; Budorm; Butabarbitol; Butobarbital; Butobarbitalum; Butobarbitone; Butobarbitural; Etoval; Hyperbutal; Longanoct; Meonal; Monodorm; Neonal; Sonerile; Soneryl; Butobarbital [BAN]; Butobarbital (BAN); Neonal (TN); Butyl,5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-(9CI); 5-BUTYL-5-ETHYLBARBITURIC ACID; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-butylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 TC Hypnotics and Sedatives
DM7JHX0 DT Small molecular drug
DM7JHX0 PC 6473
DM7JHX0 MW 212.25
DM7JHX0 FM C10H16N2O3
DM7JHX0 IC InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)
DM7JHX0 CS CCCCC1(C(=O)NC(=O)NC1=O)CC
DM7JHX0 IK STDBAQMTJLUMFW-UHFFFAOYSA-N
DM7JHX0 IU 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 CA CAS 77-28-1
DM7JHX0 CB CHEBI:134884
DM7JHX0 DE Insomnia
DM8SY60 ID DM8SY60
DM8SY60 DN Butoconazole
DM8SY60 HS Approved
DM8SY60 SN Butaconazole; Butoconazol; Butoconazolum; Femstat; Gynofort; Duplicate RN for parent cpd; RS 35887; Butoconazol [INN-Spanish]; Butoconazole (INN); Butoconazole [INN:BAN]; Butoconazolum [INN-Latin]; Gynofort (TN); RS 35887-10-3; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; (+/-)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; (-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; 1H-Imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate
DM8SY60 CP Roche Palo Alto Llc
DM8SY60 TC Antifungal Agents
DM8SY60 DT Small molecular drug
DM8SY60 PC 47472
DM8SY60 MW 411.8
DM8SY60 FM C19H17Cl3N2S
DM8SY60 IC InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2
DM8SY60 CS C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl
DM8SY60 IK SWLMUYACZKCSHZ-UHFFFAOYSA-N
DM8SY60 IU 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole
DM8SY60 CA CAS 64872-76-0
DM8SY60 CB CHEBI:3240
DM8SY60 DE Candidiasis
DM5KYPJ ID DM5KYPJ
DM5KYPJ DN Butorphanol
DM5KYPJ HS Approved
DM5KYPJ SN Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
DM5KYPJ CP Apotex Inc
DM5KYPJ TC Analgesics
DM5KYPJ DT Small molecular drug
DM5KYPJ PC 5361092
DM5KYPJ MW 327.5
DM5KYPJ FM C21H29NO2
DM5KYPJ IC InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
DM5KYPJ CS C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
DM5KYPJ IK IFKLAQQSCNILHL-QHAWAJNXSA-N
DM5KYPJ IU (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DM5KYPJ CA CAS 42408-82-2
DM5KYPJ CB CHEBI:3242
DM5KYPJ DE Pain
DMZKXB7 ID DMZKXB7
DMZKXB7 DN Butylscopolamine
DMZKXB7 HS Approved
DMZKXB7 SN AC1LCV8Y
DMZKXB7 DT Small molecular drug
DMZKXB7 PC 160883
DMZKXB7 MW 360.5
DMZKXB7 FM C21H30NO4+
DMZKXB7 IC InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1
DMZKXB7 CS CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DMZKXB7 IK YBCNXCRZPWQOBR-MWGADRMYSA-N
DMZKXB7 IU [(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMZKXB7 CA CAS 7182-53-8
DMZKXB7 CB CHEBI:145701
DMZKXB7 DE Dysmenorrhea
DMPAZHC ID DMPAZHC
DMPAZHC DN Cabazitaxel
DMPAZHC HS Approved
DMPAZHC SN Jevtana; Taxoid XRP6258; Jevtana (TN)
DMPAZHC CP Sanofi-Aventis
DMPAZHC DT Small molecular drug
DMPAZHC PC 9854073
DMPAZHC MW 835.9
DMPAZHC FM C45H57NO14
DMPAZHC IC InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
DMPAZHC CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
DMPAZHC IK BMQGVNUXMIRLCK-OAGWZNDDSA-N
DMPAZHC IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMPAZHC CA CAS 183133-96-2
DMPAZHC CB CHEBI:63584
DMPAZHC DE Breast cancer; Solid tumour/cancer
DMQ4HIN ID DMQ4HIN
DMQ4HIN DN Cabergoline
DMQ4HIN HS Approved
DMQ4HIN SN Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
DMQ4HIN CP Pfizer Pharmaceuticals
DMQ4HIN TC Anticancer Agents
DMQ4HIN DT Small molecular drug
DMQ4HIN PC 54746
DMQ4HIN MW 451.6
DMQ4HIN FM C26H37N5O2
DMQ4HIN IC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
DMQ4HIN CS CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
DMQ4HIN IK KORNTPPJEAJQIU-KJXAQDMKSA-N
DMQ4HIN IU (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMQ4HIN CA CAS 81409-90-7
DMQ4HIN CB CHEBI:3286
DMQ4HIN DE Hyperprolactinaemia
DMIYDT4 ID DMIYDT4
DMIYDT4 DN Cabozantinib
DMIYDT4 HS Approved
DMIYDT4 SN Cabometyx; Cometriq
DMIYDT4 CP Exelixis
DMIYDT4 DT Small molecular drug
DMIYDT4 PC 25102847
DMIYDT4 MW 501.5
DMIYDT4 FM C28H24FN3O5
DMIYDT4 IC InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
DMIYDT4 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DMIYDT4 IK ONIQOQHATWINJY-UHFFFAOYSA-N
DMIYDT4 IU 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMIYDT4 CA CAS 849217-68-1
DMIYDT4 CB CHEBI:72317
DMIYDT4 DE Thyroid cancer; Ovarian cancer
DMKBJWP ID DMKBJWP
DMKBJWP DN Caffeine
DMKBJWP HS Approved
DMKBJWP SN CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline
DMKBJWP CP Ben Venue Laboratories
DMKBJWP TC Antihypertensive Agents
DMKBJWP DT Small molecular drug
DMKBJWP PC 2519
DMKBJWP MW 194.19
DMKBJWP FM C8H10N4O2
DMKBJWP IC InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMKBJWP CS CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMKBJWP IK RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMKBJWP IU 1,3,7-trimethylpurine-2,6-dione
DMKBJWP CA CAS 58-08-2
DMKBJWP CB CHEBI:27732
DMKBJWP DE Orthostatic hypotension
DMQZBXI ID DMQZBXI
DMQZBXI DN Calaspargase pegol
DMQZBXI HS Approved
DMQZBXI SN UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
DMQZBXI CP Servier
DMQZBXI DT Antibody
DMQZBXI DE Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia
DMN4CV5 ID DMN4CV5
DMN4CV5 DN Calcidiol
DMN4CV5 HS Approved
DMN4CV5 SN Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
DMN4CV5 CP United Research Laboratories
DMN4CV5 TC Vitamins
DMN4CV5 DT Small molecular drug
DMN4CV5 PC 5283731
DMN4CV5 MW 400.6
DMN4CV5 FM C27H44O2
DMN4CV5 IC InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
DMN4CV5 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMN4CV5 IK JWUBBDSIWDLEOM-DTOXIADCSA-N
DMN4CV5 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMN4CV5 CA CAS 19356-17-3
DMN4CV5 CB CHEBI:17933
DMN4CV5 DE Vitamin D deficiency
DM03CP7 ID DM03CP7
DM03CP7 DN Calcipotriol
DM03CP7 HS Approved
DM03CP7 SN Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
DM03CP7 CP LEO Pharma Inc
DM03CP7 TC Antipsoriatic Agents
DM03CP7 DT Small molecular drug
DM03CP7 PC 5288783
DM03CP7 MW 412.6
DM03CP7 FM C27H40O3
DM03CP7 IC InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
DM03CP7 CS C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM03CP7 IK LWQQLNNNIPYSNX-UROSTWAQSA-N
DM03CP7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM03CP7 CA CAS 112965-21-6
DM03CP7 CB CHEBI:50749
DM03CP7 DE Psoriasis vulgaris
DM0N9WA ID DM0N9WA
DM0N9WA DN Calcitonin Human
DM0N9WA HS Approved
DM0N9WA CP Novartis Pharmaceuticals Corp
DM0N9WA TC Anticancer Agents
DM0N9WA PC 45055432
DM0N9WA MW 3417.9
DM0N9WA FM C151H226N40O45S3
DM0N9WA IC InChI=1S/C151H226N40O45S3/c1-17-75(8)118(144(229)163-67-114(205)183-117(74(6)7)143(228)162-64-112(203)165-77(10)150(235)190-50-29-38-106(190)124(158)209)185-125(210)76(9)166-145(230)120(79(12)194)186-131(216)92(45-47-109(155)200)170-142(227)107-39-30-51-191(107)151(236)103(58-85-35-25-20-26-36-85)180-148(233)122(81(14)196)188-139(224)99(59-87-63-159-71-164-87)176-133(218)96(55-83-31-21-18-22-32-83)174-128(213)90(37-27-28-49-152)168-136(221)101(61-111(157)202)177-134(219)97(56-84-33-23-19-24-34-84)175-137(222)102(62-116(207)208)178-129(214)91(44-46-108(154)199)171-147(232)121(80(13)195)187-138(223)98(57-86-40-42-88(198)43-41-86)179-146(231)119(78(11)193)184-115(206)66-161-127(212)94(53-72(2)3)172-130(215)93(48-52-237-16)169-141(226)105-70-239-238-69-89(153)126(211)160-65-113(204)167-100(60-110(156)201)135(220)173-95(54-73(4)5)132(217)181-104(68-192)140(225)189-123(82(15)197)149(234)182-105/h18-26,31-36,40-43,63,71-82,89-107,117-123,192-198H,17,27-30,37-39,44-62,64-70,152-153H2,1-16H3,(H2,154,199)(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,209)(H,159,164)(H,160,211)(H,161,212)(H,162,228)(H,163,229)(H,165,203)(H,166,230)(H,167,204)(H,168,221)(H,169,226)(H,170,227)(H,171,232)(H,172,215)(H,173,220)(H,174,213)(H,175,222)(H,176,218)(H,177,219)(H,178,214)(H,179,231)(H,180,233)(H,181,217)(H,182,234)(H,183,205)(H,184,206)(H,185,210)(H,186,216)(H,187,223)(H,188,224)(H,189,225)(H,207,208)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-,122-,123-/m0/s1
DM0N9WA CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N
DM0N9WA IK LDVRMNJZLWXJPL-JKQNMTHDSA-N
DM0N9WA IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM0N9WA CB CHEBI:135973
DM0N9WA DE Postmenopausal osteoporosis; Pain; Paget's disease
DM8ZVJ7 ID DM8ZVJ7
DM8ZVJ7 DN Calcitriol
DM8ZVJ7 HS Approved
DM8ZVJ7 SN calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
DM8ZVJ7 CP Cytotech Labs LLC
DM8ZVJ7 DT Small molecular drug
DM8ZVJ7 PC 5280453
DM8ZVJ7 MW 416.6
DM8ZVJ7 FM C27H44O3
DM8ZVJ7 IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
DM8ZVJ7 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM8ZVJ7 IK GMRQFYUYWCNGIN-NKMMMXOESA-N
DM8ZVJ7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM8ZVJ7 CA CAS 32222-06-3
DM8ZVJ7 CB CHEBI:17823
DM8ZVJ7 DE Congenital alopecia
DM3W15N ID DM3W15N
DM3W15N DN Calcium carbimide
DM3W15N HS Approved
DM3W15N SN Nitrolime; Alzodef; Aero cyanamid granular; USAF CY-2; Aero cyanamid special grade; Nitrolim; Cyanamid; Calcium cyanamid; Lime Nitroget; Cyanamid granular; NCI-C02937; CY-L 500; Cyanamid special grade; UN 1403, Nitrolime; WLN: CA NCN; NSC7078; NSC-7078
DM3W15N DT Small molecular drug
DM3W15N PC 56955933
DM3W15N MW 80.1
DM3W15N FM CCaN2
DM3W15N IC InChI=1S/CN2.Ca/c2-1-3;/q-2;+2
DM3W15N CS C(=[N-])=[N-].[Ca+2]
DM3W15N IK MYFXBBAEXORJNB-UHFFFAOYSA-N
DM3W15N IU calcium;azanidylidenemethylideneazanide
DM3W15N CA CAS 156-62-7
DM3W15N CB CHEBI:64301
DM3W15N DE Alcohol dependence
DMJ3CFY ID DMJ3CFY
DMJ3CFY DN Calcium phosphate dihydrate
DMJ3CFY HS Approved
DMJ3CFY SN Calcium phosphate dihydrate
DMJ3CFY DT Small molecular drug
DMJ3CFY PC 22340838
DMJ3CFY MW 346.204
DMJ3CFY FM Ca3H4O10P2
DMJ3CFY IC InChI=1S/3Ca.2H3O4P.2H2O/c;;;2*1-5(2,3)4;;/h;;;2*(H3,1,2,3,4);2*1H2/q3*+2;;;;/p-6
DMJ3CFY CS O.O.[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMJ3CFY IK WKMXOPXIVBEXRR-UHFFFAOYSA-H
DMJ3CFY IU tricalcium;diphosphate;dihydrate
DMJ3CFY DE Dental Caries
DMWIO46 ID DMWIO46
DMWIO46 DN Camphor
DMWIO46 HS Approved
DMWIO46 SN camphor; 76-22-2; 2-Camphanone; 2-Bornanone; DL-Camphor; (+)-Camphor; l-(-)-Camphor; (+/-)-Camphor; Root bark oil; 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one; Bornan-2-one; Alphanon; Kampfer; Gum camphor; Spirit of camphor; Formosa camphor; Laurel camphor; 2-Camphonone; Matricaria camphor; Camphor, synthetic; Bornane, 2-oxo-; 1,7,7-Trimethylnorcamphor; Root bark spirit; 2-Keto-1,7,7-trimethylnorcamphane; DL-Bornan-2-one; D-(+)-Camphor; Norcamphor, 1,7,7-trimethyl-; 21368-68-3; Camphor, (1R,4R)-(+)-; Bicyclo[2.2.1]heptan-2-one, 1,7,7-tri
DMWIO46 DT Small molecular drug
DMWIO46 PC 2537
DMWIO46 MW 152.23
DMWIO46 FM C10H16O
DMWIO46 IC InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3
DMWIO46 CS CC1(C2CCC1(C(=O)C2)C)C
DMWIO46 IK DSSYKIVIOFKYAU-UHFFFAOYSA-N
DMWIO46 IU 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
DMWIO46 CA CAS 76-22-2
DMWIO46 CB CHEBI:36773
DMWIO46 DE Acute or chronic pain
DMFRM1I ID DMFRM1I
DMFRM1I DN Canagliflozin
DMFRM1I HS Approved
DMFRM1I SN 842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0
DMFRM1I CP Johnson & Johnson
DMFRM1I DT Small molecular drug
DMFRM1I PC 24812758
DMFRM1I MW 444.5
DMFRM1I FM C24H25FO5S
DMFRM1I IC InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
DMFRM1I CS CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
DMFRM1I IK XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DMFRM1I IU (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMFRM1I CA CAS 842133-18-0
DMFRM1I CB CHEBI:73274
DMFRM1I DE Type-2 diabetes; Diabetic nephropathy; Type-1 diabetes
DM8HLO5 ID DM8HLO5
DM8HLO5 DN Canakinumab
DM8HLO5 HS Approved
DM8HLO5 SN Ilaris (TN)
DM8HLO5 CP Novartis
DM8HLO5 DT Antibody
DM8HLO5 SQ 8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|: QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HLO5 DE Vasculitis; Urticaria; Rheumatoid arthritis; Cryopyrin-associated periodic syndromes
DMRK8OT ID DMRK8OT
DMRK8OT DN Candesartan
DMRK8OT HS Approved
DMRK8OT SN candesartan; 139481-59-7; Blopress; Ratacand; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; UNII-S8Q36MD2XX; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEMBL1016; S8Q36MD2XX; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; CHEBI:3347; C24H20N6O3; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; NCGC00167474-01; AK-57139; Blopress; Candesartan [BAN]; CV11974; Amias (TN); Atacand (TN); Blopress (TN); Candesartan [USAN:INN]; KS-5003; Ratacand (TN); Candesartan (USAN/INN); Atacand, Blopress, Amias, Ratacand,Candesartan; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; [3H]candesartan
DMRK8OT CP AstraZeneca
DMRK8OT TC Antihypertensive Agents
DMRK8OT DT Small molecular drug
DMRK8OT PC 2541
DMRK8OT MW 440.5
DMRK8OT FM C24H20N6O3
DMRK8OT IC InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMRK8OT CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMRK8OT IK HTQMVQVXFRQIKW-UHFFFAOYSA-N
DMRK8OT IU 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMRK8OT CA CAS 139481-59-7
DMRK8OT CB CHEBI:3347
DMRK8OT DE Hypertension
DMNZSC1 ID DMNZSC1
DMNZSC1 DN Candicidin
DMNZSC1 HS Approved
DMNZSC1 SN (23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 TC Antibiotics
DMNZSC1 DT Small molecular drug
DMNZSC1 PC 10079874
DMNZSC1 MW 1109.3
DMNZSC1 FM C59H84N2O18
DMNZSC1 IC InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1
DMNZSC1 CS C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O
DMNZSC1 IK OPGSFDUODIJJGF-JBUZINEHSA-N
DMNZSC1 IU (23E,25E,27E,29E,31E,33E,35E)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-38-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 CA CAS 1403-17-4
DMNZSC1 CB CHEBI:3349
DMNZSC1 DE Bacterial infection
DM8JRH0 ID DM8JRH0
DM8JRH0 DN Cangrelor
DM8JRH0 HS Approved
DM8JRH0 SN Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
DM8JRH0 CP The Medicines Company
DM8JRH0 DT Small molecular drug
DM8JRH0 PC 9854012
DM8JRH0 MW 776.4
DM8JRH0 FM C17H25Cl2F3N5O12P3S2
DM8JRH0 IC InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
DM8JRH0 CS CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
DM8JRH0 IK PAEBIVWUMLRPSK-IDTAVKCVSA-N
DM8JRH0 IU [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
DM8JRH0 CA CAS 163706-06-7
DM8JRH0 CB CHEBI:90841
DM8JRH0 DE Thrombosis
DM0659E ID DM0659E
DM0659E DN Cannabidiol
DM0659E HS Approved
DM0659E SN cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E CP GW Pharmaceuticals
DM0659E DT Small molecular drug
DM0659E PC 644019
DM0659E MW 314.5
DM0659E FM C21H30O2
DM0659E IC InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
DM0659E CS CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
DM0659E IK QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E IU 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DM0659E CA CAS 13956-29-1
DM0659E CB CHEBI:69478
DM0659E DE LennoxGastaut syndrome; Dravet syndrome; Epilepsy; Infantile spasm
DMBP5N3 ID DMBP5N3
DMBP5N3 DN Cantharidin
DMBP5N3 HS Approved
DMBP5N3 SN DSSTox_CID_21752; DSSTox_RID_79835; DSSTox_GSID_41752; CAS-56-25-7; NCGC00016247-01; Spectrum_001114; SpecPlus_000537; Spectrum4_000920; Spectrum2_000630; Prestwick0_000885; Spectrum3_000621; Prestwick1_000885; Spectrum5_001618; Prestwick2_000885; KBioSS_001594; KBioGR_001420; BSPBio_002182; MLS002153505; SCHEMBL152261; DivK1c_006633; SPBio_002889; SPBio_000600; CHEMBL299846; DTXSID7041752; KBio2_006730; KBio3_001682; KBio2_004162; KBio2_001594; KBio1_001577; MolPort-003-665-556; HMS1570B12; Tox21_110326; CCG-39927; Tox21_110326_1
DMBP5N3 DT Small molecular drug
DMBP5N3 PC 5944
DMBP5N3 MW 196.2
DMBP5N3 FM C10H12O4
DMBP5N3 IC InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-
DMBP5N3 CS C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
DMBP5N3 IK DHZBEENLJMYSHQ-XCVPVQRUSA-N
DMBP5N3 IU (1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DMBP5N3 CA CAS 56-25-7
DMBP5N3 CB CHEBI:64213
DMBP5N3 DE Molluscum contagiosum infection
DMTS85L ID DMTS85L
DMTS85L DN Capecitabine
DMTS85L HS Approved
DMTS85L SN Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)
DMTS85L CP Roche
DMTS85L TC Anticancer Agents
DMTS85L DT Small molecular drug
DMTS85L PC 60953
DMTS85L MW 359.35
DMTS85L FM C15H22FN3O6
DMTS85L IC InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
DMTS85L CS CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O
DMTS85L IK GAGWJHPBXLXJQN-UORFTKCHSA-N
DMTS85L IU pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
DMTS85L CA CAS 154361-50-9
DMTS85L CB CHEBI:31348
DMTS85L DE Colorectal cancer; Breast cancer
DMPUKA7 ID DMPUKA7
DMPUKA7 DN Caplacizumab
DMPUKA7 HS Approved
DMPUKA7 DT Antibody
DMPUKA7 DE Thrombotic thrombocytopenic purpura
DMYCXKL ID DMYCXKL
DMYCXKL DN Capmatinib
DMYCXKL HS Approved
DMYCXKL SN 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O
DMYCXKL CP Incyte
DMYCXKL DT Small molecular drug
DMYCXKL PC 25145656
DMYCXKL MW 412.4
DMYCXKL FM C23H17FN6O
DMYCXKL IC InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
DMYCXKL CS CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
DMYCXKL IK LIOLIMKSCNQPLV-UHFFFAOYSA-N
DMYCXKL IU 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
DMYCXKL CA CAS 1029712-80-8
DMYCXKL DE Hepatocellular carcinoma; Recurrent glioblastoma; Non-small-cell lung cancer
DMNZBRY ID DMNZBRY
DMNZBRY DN Capreomycin
DMNZBRY HS Approved
DMNZBRY SN Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY TC Antibiotics
DMNZBRY DT Small molecular drug
DMNZBRY PC 3000502
DMNZBRY MW 1321.4
DMNZBRY FM C50H88N28O15
DMNZBRY IC InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1
DMNZBRY CS C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N
DMNZBRY IK VCOPTHOUUNAYKQ-WBTCAYNUSA-N
DMNZBRY IU (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY CA CAS 11003-38-6
DMNZBRY DE Bacterial infection; Mycobacterium infection
DM346QI ID DM346QI
DM346QI DN Capreomycin Sulfate
DM346QI HS Approved
DM346QI SN Capastat Sulfate
DM346QI CP Akorn Inc
DM346QI DE Tuberculosis
DMHERIJ ID DMHERIJ
DMHERIJ DN Capromab
DMHERIJ HS Approved
DMHERIJ SN Prostascint (TN)
DMHERIJ TC Imaging Agents
DMHERIJ DT Antibody
DMHERIJ DE Prostate cancer
DMGMF6V ID DMGMF6V
DMGMF6V DN Capsaicin
DMGMF6V HS Approved
DMGMF6V SN Capsaicin (transdermal patch formulation, neuropathic pain)
DMGMF6V CP Samyang Corp
DMGMF6V DT Small molecular drug
DMGMF6V PC 1548943
DMGMF6V MW 305.4
DMGMF6V FM C18H27NO3
DMGMF6V IC InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
DMGMF6V CS CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMGMF6V IK YKPUWZUDDOIDPM-SOFGYWHQSA-N
DMGMF6V IU (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
DMGMF6V CA CAS 404-86-4
DMGMF6V CB CHEBI:3374
DMGMF6V DE Neuropathic pain
DM458UM ID DM458UM
DM458UM DN Captopril
DM458UM HS Approved
DM458UM SN Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline
DM458UM CP Bristol-Myers Squibb
DM458UM TC Antihypertensive Agents
DM458UM DT Small molecular drug
DM458UM PC 44093
DM458UM MW 217.29
DM458UM FM C9H15NO3S
DM458UM IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DM458UM CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DM458UM IK FAKRSMQSSFJEIM-RQJHMYQMSA-N
DM458UM IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DM458UM CA CAS 62571-86-2
DM458UM CB CHEBI:3380
DM458UM DE Hypertension
DMX9K8F ID DMX9K8F
DMX9K8F DN Carbachol
DMX9K8F HS Approved
DMX9K8F SN Carbach; Carbacholin; Carbacholine; Carbacholinum; Carbacholum; Carbacol; Carbacolina; Carbacolo; Carbamiotin; Carbamoylcholine; Carbastat; Carbochol; Carbocholin; Carbocholine; Carbyl; Carcholin; Coletyl; Doryl; Jestryl; Karbachol; Lentin; Lentine; Miostat; Moryl; Rilentol; Vasoperif; CARBACHOL CHLORIDE; Carbachol hydrochloride; Carbacholine chloride; Carbacholini chloridum; Carbacholinium chloratum; Carbacholum chloratum; Carbacolo [DCIT]; Carbaminocholine chloride; Carbaminoylcholine chloride; Carbamoylcholine chloride; Carbamylcholine chloride; Choline carbamate chloride; Choline chloride carbamate; Choline chlorine carbamate; Isopto Carbachol; Karbachol [Czech]; Karbamoylcholin chlorid; Karbamoylcholin chlorid [Czech]; Lentine [French]; Mistura C; C 4382; TL 457; C-1770; Carbacholum [INN-Latin]; Carbacol [INN-Spanish]; Carbamic acid, ester with choline chloride; Carbamoylcholine-hydrochloride; Carbastat (TN); Carboptic (TN); Choline chloride, carbamate; Doryl (VAN); Doryl (pharmaceutical); Gamma-Carbamoyl choline chloride; Isopto Carbachol (TN); Miostat (TN); Carbachol [INN:BAN:JAN]; Choline, chloride carbamate(ester); Choline, chloride, carbamate; P. V. Carbachol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); (2-Carbamoyloxyethyl)trimethylammonium chloride; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; (2-Hydroxyethyl)trimethylammonium chloride carbamate; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride
DMX9K8F CP Norvatis Phamaceuticals Corporation
DMX9K8F TC Cardiotonic Agents
DMX9K8F DT Small molecular drug
DMX9K8F PC 5831
DMX9K8F MW 182.65
DMX9K8F FM C6H15ClN2O2
DMX9K8F IC InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
DMX9K8F CS C[N+](C)(C)CCOC(=O)N.[Cl-]
DMX9K8F IK AIXAANGOTKPUOY-UHFFFAOYSA-N
DMX9K8F IU 2-carbamoyloxyethyl(trimethyl)azanium;chloride
DMX9K8F CA CAS 51-83-2
DMX9K8F CB CHEBI:3385
DMX9K8F DE Glaucoma/ocular hypertension
DMZOLBI ID DMZOLBI
DMZOLBI DN Carbamazepine
DMZOLBI HS Approved
DMZOLBI SN Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
DMZOLBI CP Lundbeck Inc
DMZOLBI DT Small molecular drug
DMZOLBI PC 2554
DMZOLBI MW 236.27
DMZOLBI FM C15H12N2O
DMZOLBI IC InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
DMZOLBI CS C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
DMZOLBI IK FFGPTBGBLSHEPO-UHFFFAOYSA-N
DMZOLBI IU benzo[b][1]benzazepine-11-carboxamide
DMZOLBI CA CAS 298-46-4
DMZOLBI CB CHEBI:3387
DMZOLBI DE Gastric adenocarcinoma; Epilepsy; Type-1 diabetes
DMLEDNK ID DMLEDNK
DMLEDNK DN Carbenicillin
DMLEDNK HS Approved
DMLEDNK SN CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMLEDNK CP Roerig Div Pfizer Inc
DMLEDNK TC Antibiotics
DMLEDNK DT Small molecular drug
DMLEDNK PC 20824
DMLEDNK MW 378.4
DMLEDNK FM C17H18N2O6S
DMLEDNK IC InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1
DMLEDNK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C
DMLEDNK IK FPPNZSSZRUTDAP-UWFZAAFLSA-N
DMLEDNK IU (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMLEDNK CA CAS 4697-36-3
DMLEDNK CB CHEBI:3393
DMLEDNK DE Infection of the upper and lower urinary tract
DME2XG3 ID DME2XG3
DME2XG3 DN Carbenicillin Indanyl Sodium
DME2XG3 HS Approved
DME2XG3 SN Geocillin
DME2XG3 CP Pfizer Laboratories Div Pfizer Inc
DME2XG3 TC Antiinfective Agents
DME2XG3 DT Small molecular drug
DME2XG3 PC 23676503
DME2XG3 MW 516.5
DME2XG3 FM C26H25N2NaO6S
DME2XG3 IC InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
DME2XG3 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+]
DME2XG3 IK QFWPXOXWAUAYAB-XZVIDJSISA-M
DME2XG3 IU sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DME2XG3 CA CAS 26605-69-6
DME2XG3 CB CHEBI:31358
DME2XG3 DE Bacterial infection
DMUSLW3 ID DMUSLW3
DMUSLW3 DN Carbetocin
DMUSLW3 HS Approved
DMUSLW3 SN Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
DMUSLW3 CP Pfizer Pharmaceuticals
DMUSLW3 TC Antitocolytic Agents
DMUSLW3 DT Small molecular drug
DMUSLW3 PC 16681432
DMUSLW3 MW 988.2
DMUSLW3 FM C45H69N11O12S
DMUSLW3 IC InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
DMUSLW3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUSLW3 IK NSTRIRCPWQHTIA-DTRKZRJBSA-N
DMUSLW3 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
DMUSLW3 CA CAS 37025-55-1
DMUSLW3 CB CHEBI:59204
DMUSLW3 DE Postpartum haemorrhage
DMHRG8Q ID DMHRG8Q
DMHRG8Q DN Carbidopa
DMHRG8Q HS Approved
DMHRG8Q SN Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
DMHRG8Q TC Antiparkinson Agents
DMHRG8Q DT Small molecular drug
DMHRG8Q PC 34359
DMHRG8Q MW 226.23
DMHRG8Q FM C10H14N2O4
DMHRG8Q IC InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
DMHRG8Q CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
DMHRG8Q IK TZFNLOMSOLWIDK-JTQLQIEISA-N
DMHRG8Q IU (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
DMHRG8Q CA CAS 28860-95-9
DMHRG8Q CB CHEBI:39585
DMHRG8Q DE Parkinson disease
DMULAI4 ID DMULAI4
DMULAI4 DN Carbimazole
DMULAI4 HS Approved
DMULAI4 SN Athyromazole; Atirozidina; Basolest; Carbethoxymethimazole; Carbimazol; Carbimazolum; Carbinazole; Carbotiroid; Mertiran; Neomercazole; TYRAZOL; Thyrostat; Carbimazol henning; Carbimazol spofa; CG1; Cg 1; Carbimazol henning (TN); Carbimazole (INN); Carbimazolum [INN-Latin]; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Carbimazol [INN-Spanish, French]; Carbimazole [INN:BAN:DCF]; Ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester
DMULAI4 TC Antithyroid Agents
DMULAI4 DT Small molecular drug
DMULAI4 PC 31072
DMULAI4 MW 186.23
DMULAI4 FM C7H10N2O2S
DMULAI4 IC InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3
DMULAI4 CS CCOC(=O)N1C=CN(C1=S)C
DMULAI4 IK CFOYWRHIYXMDOT-UHFFFAOYSA-N
DMULAI4 IU ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate
DMULAI4 CA CAS 22232-54-8
DMULAI4 CB CHEBI:617099
DMULAI4 DE Hyperthyroidism
DMCT31R ID DMCT31R
DMCT31R DN Carbinoxamine
DMCT31R HS Approved
DMCT31R SN Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
DMCT31R CP McNeil Laboratories
DMCT31R TC Antihistamines
DMCT31R DT Small molecular drug
DMCT31R PC 2564
DMCT31R MW 290.79
DMCT31R FM C16H19ClN2O
DMCT31R IC InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
DMCT31R CS CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DMCT31R IK OJFSXZCBGQGRNV-UHFFFAOYSA-N
DMCT31R IU 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
DMCT31R CA CAS 486-16-8
DMCT31R CB CHEBI:3398
DMCT31R DE Vasomotor/allergic rhinitis
DMG281S ID DMG281S
DMG281S DN Carboplatin
DMG281S HS Approved
DMG281S SN Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
DMG281S CP Bristol-Myers Squibb
DMG281S TC Anticancer Agents
DMG281S DT Small molecular drug
DMG281S PC 426756
DMG281S MW 371.25
DMG281S FM C6H12N2O4Pt
DMG281S IC InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
DMG281S CS C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
DMG281S IK VSRXQHXAPYXROS-UHFFFAOYSA-N
DMG281S IU azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMG281S CA CAS 41575-94-4
DMG281S CB CHEBI:31355
DMG281S DE Ovarian cancer
DMS3508 ID DMS3508
DMS3508 DN Carboprost tromethamine
DMS3508 HS Approved
DMS3508 SN Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine
DMS3508 TC Abortifacient Agents
DMS3508 DT Small molecular drug
DMS3508 PC 5281074
DMS3508 MW 489.6
DMS3508 FM C25H47NO8
DMS3508 IC InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1
DMS3508 CS CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMS3508 IK UMMADZJLZAPZAW-XOWPVRJPSA-N
DMS3508 IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
DMS3508 CA CAS 58551-69-2
DMS3508 DE Abortion
DM48K0X ID DM48K0X
DM48K0X DN Carfilzomib
DM48K0X HS Approved
DM48K0X SN Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
DM48K0X CP Onyx Pharmaceuticals
DM48K0X DT Small molecular drug
DM48K0X PC 11556711
DM48K0X MW 719.9
DM48K0X FM C40H57N5O7
DM48K0X IC InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
DM48K0X CS CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
DM48K0X IK BLMPQMFVWMYDKT-NZTKNTHTSA-N
DM48K0X IU (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
DM48K0X CA CAS 868540-17-4
DM48K0X CB CHEBI:65347
DM48K0X DE Multiple myeloma; Small-cell lung cancer
DMCY0TI ID DMCY0TI
DMCY0TI DN Carglumic acid
DMCY0TI HS Approved
DMCY0TI SN Carbaglu (TN)
DMCY0TI CP Orphan Europe
DMCY0TI DT Small molecular drug
DMCY0TI PC 121396
DMCY0TI MW 190.15
DMCY0TI FM C6H10N2O5
DMCY0TI IC InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
DMCY0TI CS C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
DMCY0TI IK LCQLHJZYVOQKHU-VKHMYHEASA-N
DMCY0TI IU (2S)-2-(carbamoylamino)pentanedioic acid
DMCY0TI CA CAS 1188-38-1
DMCY0TI CB CHEBI:71028
DMCY0TI DE Acute hyperammonaemia
DMJYDVK ID DMJYDVK
DMJYDVK DN Cariprazine
DMJYDVK HS Approved
DMJYDVK SN Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH
DMJYDVK CP Forest Laboratories; Gedeon Richter
DMJYDVK DT Small molecular drug
DMJYDVK PC 11154555
DMJYDVK MW 427.4
DMJYDVK FM C21H32Cl2N4O
DMJYDVK IC InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)
DMJYDVK CS CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
DMJYDVK IK KPWSJANDNDDRMB-UHFFFAOYSA-N
DMJYDVK IU 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
DMJYDVK CA CAS 839712-12-8
DMJYDVK CB CHEBI:90933
DMJYDVK DE Bipolar disorder
DMWR1JC ID DMWR1JC
DMWR1JC DN Carisoprodol
DMWR1JC HS Approved
DMWR1JC SN carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol
DMWR1JC DT Small molecular drug
DMWR1JC PC 2576
DMWR1JC MW 260.329
DMWR1JC FM C12H24N2O4
DMWR1JC IC InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
DMWR1JC CS CCCC(C)(COC(=O)N)COC(=O)NC(C)C
DMWR1JC IK OFZCIYFFPZCNJE-UHFFFAOYSA-N
DMWR1JC IU [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
DMWR1JC CA CAS 78-44-4
DMWR1JC CB CHEBI:3419
DMWR1JC DE Musculoskeletal disorder
DMHTB31 ID DMHTB31
DMHTB31 DN Carphenazine
DMHTB31 HS Approved
DMHTB31 SN Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CP Wyeth Ayerst Laboratories
DMHTB31 TC Antipsychotic Agents
DMHTB31 DT Small molecular drug
DMHTB31 PC 18104
DMHTB31 MW 425.6
DMHTB31 FM C24H31N3O2S
DMHTB31 IC InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DMHTB31 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMHTB31 IK XZSMZRXAEFNJCU-UHFFFAOYSA-N
DMHTB31 IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CA CAS 2622-30-2
DMHTB31 DE Insomnia; Schizophrenia
DMHMP05 ID DMHMP05
DMHMP05 DN Carprofen
DMHMP05 HS Approved
DMHMP05 SN Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al
DMHMP05 CP Pfizer Pharmaceuticals
DMHMP05 TC Analgesics
DMHMP05 DT Small molecular drug
DMHMP05 PC 2581
DMHMP05 MW 273.71
DMHMP05 FM C15H12ClNO2
DMHMP05 IC InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
DMHMP05 CS CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O
DMHMP05 IK PUXBGTOOZJQSKH-UHFFFAOYSA-N
DMHMP05 IU 2-(6-chloro-9H-carbazol-2-yl)propanoic acid
DMHMP05 CA CAS 53716-49-7
DMHMP05 CB CHEBI:364453
DMHMP05 DE Pain
DMFMDOB ID DMFMDOB
DMFMDOB DN Carteolol
DMFMDOB HS Approved
DMFMDOB SN Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
DMFMDOB CP CIBA Vision Sterile Mfg
DMFMDOB TC Antihypertensive Agents
DMFMDOB DT Small molecular drug
DMFMDOB PC 2583
DMFMDOB MW 292.37
DMFMDOB FM C16H24N2O3
DMFMDOB IC InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
DMFMDOB CS CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O
DMFMDOB IK LWAFSWPYPHEXKX-UHFFFAOYSA-N
DMFMDOB IU 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
DMFMDOB CA CAS 51781-06-7
DMFMDOB CB CHEBI:3437
DMFMDOB DE Glaucoma/ocular hypertension
DMHTEAO ID DMHTEAO
DMHTEAO DN Carvedilol
DMHTEAO HS Approved
DMHTEAO SN Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
DMHTEAO CP GlaxoSmithKline plc
DMHTEAO TC Vasodilator Agents
DMHTEAO DT Small molecular drug
DMHTEAO PC 2585
DMHTEAO MW 406.5
DMHTEAO FM C24H26N2O4
DMHTEAO IC InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMHTEAO CS COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMHTEAO IK OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMHTEAO IU 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMHTEAO CA CAS 72956-09-3
DMHTEAO CB CHEBI:3441
DMHTEAO DE Congestive heart failure
DMZPXRC ID DMZPXRC
DMZPXRC DN Carzinophilin
DMZPXRC HS Approved
DMZPXRC SN CARZINOPHILIN; Cardinophyllin; Cardinophillin; Azinomycin; CARZINOPHILIN A; Carzinophyllin; NSC 20088; Antibiotic from Streptomyces Sahachiroi; BRN 5721373; C31H33N3O11; 1403-28-7; Carzinophilin (8CI); AC1MHU1X; Carzinophilin (8CI)(9CI); LS-52587; LS-52588; 11002-20-3; [(1S)-2-[[(1E)-1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[[(E)-1-hydroxy-3-oxobut-1-en-2-yl]amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate
DMZPXRC DT Small molecular drug
DMZPXRC PC 227922
DMZPXRC MW 639.6
DMZPXRC FM C31H33N3O12
DMZPXRC IC InChI=1S/C31H33N3O12/c1-14-7-6-8-18-19(14)9-17(43-5)10-20(18)26(40)32-13-30(4)24(39)28(41)45-31(46-30)25(23(38)22-11-34(22)16(3)37)44-27(33-29(31)42)21(12-35)15(2)36/h6-10,12,22-25,38-39H,11,13H2,1-5H3,(H,32,40)(H,33,42)
DMZPXRC CS CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C(C(=O)OC4(O3)C(OC(=C(C=O)C(=O)C)NC4=O)C(C5CN5C(=O)C)O)O)C)OC
DMZPXRC IK GNGRYODSYNVRFD-UHFFFAOYSA-N
DMZPXRC IU N-[[7-[(1-acetylaziridin-2-yl)-hydroxymethyl]-9-(1,3-dioxobutan-2-ylidene)-3-hydroxy-4-methyl-2,11-dioxo-1,5,8-trioxa-10-azaspiro[5.5]undecan-4-yl]methyl]-3-methoxy-5-methylnaphthalene-1-carboxamide
DMZPXRC DE Solid tumour/cancer
DMGQIPT ID DMGQIPT
DMGQIPT DN Caspofungin
DMGQIPT HS Approved
DMGQIPT SN CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
DMGQIPT CP Merck & Co
DMGQIPT TC Antifungal Agents
DMGQIPT DT Small molecular drug
DMGQIPT PC 2826718
DMGQIPT MW 1093.3
DMGQIPT FM C52H88N10O15
DMGQIPT IC InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
DMGQIPT CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O
DMGQIPT IK JYIKNQVWKBUSNH-OGZDCFRISA-N
DMGQIPT IU N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMGQIPT CA CAS 162808-62-0
DMGQIPT CB CHEBI:474180
DMGQIPT DE Fungal infection
DMRSZA5 ID DMRSZA5
DMRSZA5 DN Cefacetrile
DMRSZA5 HS Approved
DMRSZA5 SN Cefacetril; Cefacetrilo; Cefacetrilum; Celospor; Cephacetrile; Vetrimast [veterinary]; Cefacetrile (INN); Cefacetrilo [INN-Spanish]; Cefacetrilum [INN-Latin]; Celospor (TN); Celtol (TN); Cristacef (TN); Vetrimast [veterinary] (TN); C-36278-Ba; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); 7-Cyanacetylamino-cephalosporansaeure
DMRSZA5 TC Antibiotics
DMRSZA5 DT Small molecular drug
DMRSZA5 PC 91562
DMRSZA5 MW 339.33
DMRSZA5 FM C13H13N3O6S
DMRSZA5 IC InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
DMRSZA5 CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O
DMRSZA5 IK RRYMAQUWDLIUPV-BXKDBHETSA-N
DMRSZA5 IU (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMRSZA5 CA CAS 10206-21-0
DMRSZA5 CB CHEBI:135437
DMRSZA5 DE Bacterial infection
DMJXDGC ID DMJXDGC
DMJXDGC DN Cefaclor
DMJXDGC HS Approved
DMJXDGC SN Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
DMJXDGC CP Eli Lilly
DMJXDGC TC Antibiotics
DMJXDGC DT Small molecular drug
DMJXDGC PC 51039
DMJXDGC MW 367.8
DMJXDGC FM C15H14ClN3O4S
DMJXDGC IC InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
DMJXDGC CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DMJXDGC IK QYIYFLOTGYLRGG-GPCCPHFNSA-N
DMJXDGC IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJXDGC CA CAS 53994-73-3
DMJXDGC CB CHEBI:3478
DMJXDGC DE Bacterial infection
DMMC345 ID DMMC345
DMMC345 DN Cefadroxil
DMMC345 HS Approved
DMMC345 SN CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMMC345 CP Pharco B international
DMMC345 TC Antibiotics
DMMC345 DT Small molecular drug
DMMC345 PC 47965
DMMC345 MW 363.4
DMMC345 FM C16H17N3O5S
DMMC345 IC InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
DMMC345 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DMMC345 IK BOEGTKLJZSQCCD-UEKVPHQBSA-N
DMMC345 IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMC345 CA CAS 50370-12-2
DMMC345 CB CHEBI:3479
DMMC345 DE Bacterial infection
DMVYSLE ID DMVYSLE
DMVYSLE DN Cefalotin
DMVYSLE HS Approved
DMVYSLE SN Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid
DMVYSLE CP Eli Lilly
DMVYSLE TC Antibiotics
DMVYSLE DT Small molecular drug
DMVYSLE PC 6024
DMVYSLE MW 396.4
DMVYSLE FM C16H16N2O6S2
DMVYSLE IC InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1
DMVYSLE CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O
DMVYSLE IK XIURVHNZVLADCM-IUODEOHRSA-N
DMVYSLE IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVYSLE CA CAS 153-61-7
DMVYSLE CB CHEBI:124991
DMVYSLE DE Bacterial infection
DMNEXZF ID DMNEXZF
DMNEXZF DN Cefamandole
DMNEXZF HS Approved
DMNEXZF SN Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DMNEXZF CP Eli Lilly
DMNEXZF TC Antibiotics
DMNEXZF DT Small molecular drug
DMNEXZF PC 456255
DMNEXZF MW 462.5
DMNEXZF FM C18H18N6O5S2
DMNEXZF IC InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1
DMNEXZF CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O
DMNEXZF IK OLVCFLKTBJRLHI-AXAPSJFSSA-N
DMNEXZF IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMNEXZF CA CAS 34444-01-4
DMNEXZF CB CHEBI:3480
DMNEXZF DE Microorganisms infection
DMPDYFR ID DMPDYFR
DMPDYFR DN Cefazolin
DMPDYFR HS Approved
DMPDYFR SN CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
DMPDYFR CP Fujisawa Pharmaceutical Co
DMPDYFR TC Antibiotics
DMPDYFR DT Small molecular drug
DMPDYFR PC 33255
DMPDYFR MW 454.5
DMPDYFR FM C14H14N8O4S3
DMPDYFR IC InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
DMPDYFR CS CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O
DMPDYFR IK MLYYVTUWGNIJIB-BXKDBHETSA-N
DMPDYFR IU (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPDYFR CA CAS 25953-19-9
DMPDYFR CB CHEBI:474053
DMPDYFR DE Bacterial infection
DMJ7A0H ID DMJ7A0H
DMJ7A0H DN Cefdinir
DMJ7A0H HS Approved
DMJ7A0H SN CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMJ7A0H CP Abbott Laboratories
DMJ7A0H TC Antibiotics
DMJ7A0H DT Small molecular drug
DMJ7A0H PC 6915944
DMJ7A0H MW 395.4
DMJ7A0H FM C14H13N5O5S2
DMJ7A0H IC InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
DMJ7A0H CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O
DMJ7A0H IK RTXOFQZKPXMALH-GHXIOONMSA-N
DMJ7A0H IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJ7A0H CA CAS 91832-40-5
DMJ7A0H CB CHEBI:3485
DMJ7A0H DE Bacterial infection
DMSUVM1 ID DMSUVM1
DMSUVM1 DN Cefditoren
DMSUVM1 HS Approved
DMSUVM1 SN Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMSUVM1 CP Cornerstone BioPharma
DMSUVM1 TC Antibiotics
DMSUVM1 DT Small molecular drug
DMSUVM1 PC 9870843
DMSUVM1 MW 506.6
DMSUVM1 FM C19H18N6O5S3
DMSUVM1 IC InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
DMSUVM1 CS CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMSUVM1 IK KMIPKYQIOVAHOP-YLGJWRNMSA-N
DMSUVM1 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSUVM1 CA CAS 104145-95-1
DMSUVM1 CB CHEBI:59343
DMSUVM1 DE Bacterial infection
DMHVWIK ID DMHVWIK
DMHVWIK DN Cefepime
DMHVWIK HS Approved
DMHVWIK SN Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
DMHVWIK CP Bristol-Myers Squibb
DMHVWIK TC Antibiotics
DMHVWIK DT Small molecular drug
DMHVWIK PC 5479537
DMHVWIK MW 480.6
DMHVWIK FM C19H24N6O5S2
DMHVWIK IC InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
DMHVWIK CS C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
DMHVWIK IK HVFLCNVBZFFHBT-ZKDACBOMSA-N
DMHVWIK IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMHVWIK CA CAS 88040-23-7
DMHVWIK CB CHEBI:478164
DMHVWIK DE Bacterial infection
DMY60I8 ID DMY60I8
DMY60I8 DN Cefixime
DMY60I8 HS Approved
DMY60I8 SN CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMY60I8 CP Wyeth Pharmaceuticals
DMY60I8 TC Antibiotics
DMY60I8 DT Small molecular drug
DMY60I8 PC 5362065
DMY60I8 MW 453.5
DMY60I8 FM C16H15N5O7S2
DMY60I8 IC InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
DMY60I8 CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
DMY60I8 IK OKBVVJOGVLARMR-QSWIMTSFSA-N
DMY60I8 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY60I8 CA CAS 79350-37-1
DMY60I8 CB CHEBI:472657
DMY60I8 DE Bacterial infection
DMPLY7B ID DMPLY7B
DMPLY7B DN Cefmenoxime
DMPLY7B HS Approved
DMPLY7B SN Cefmax; Cefmenoxima; Cefmenoximum; Tacef; Cefmenoxime [INN]; A 50912; AB 50912; SCE 1365; Abbott-50192; Cefmenoxima [INN-Spanish]; Cefmenoxime (INN); Cefmenoximum [INN-Latin]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMPLY7B TC Antibiotics
DMPLY7B DT Small molecular drug
DMPLY7B PC 9570757
DMPLY7B MW 511.6
DMPLY7B FM C16H17N9O5S3
DMPLY7B IC InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
DMPLY7B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMPLY7B IK HJJDBAOLQAWBMH-YCRCPZNHSA-N
DMPLY7B IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPLY7B CA CAS 65085-01-0
DMPLY7B CB CHEBI:55490
DMPLY7B DE Bacterial infection
DM42W1B ID DM42W1B
DM42W1B DN Cefmetazole
DM42W1B HS Approved
DM42W1B SN CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DM42W1B CP Pharmacia And Upjohn Co
DM42W1B TC Antibiotics
DM42W1B DT Small molecular drug
DM42W1B PC 42008
DM42W1B MW 471.5
DM42W1B FM C15H17N7O5S3
DM42W1B IC InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1
DM42W1B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
DM42W1B IK SNBUBQHDYVFSQF-HIFRSBDPSA-N
DM42W1B IU (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM42W1B CA CAS 56796-20-4
DM42W1B CB CHEBI:3489
DM42W1B DE Bacterial infection
DMORSGU ID DMORSGU
DMORSGU DN Cefodizime
DMORSGU HS Approved
DMORSGU SN AC1NSFIB; CDZM; CHEBI:63214; CHEMBL2303613; Cefodizima; Cefodizima [INN-Spanish]; Cefodizime; Cefodizime (INN); Cefodizime Acid; Cefodizime [INN:BAN]; Cefodizimum; Cefodizimum [INN-Latin]; Cefodizme; DTXSID2022757; Diezime; EC 700-301-3; EX-A1379; HR 221 [AS SODIUM]; HR-221; HR-221 [As Sodium]; J-700161; Modivid; Neucef; S-771221B [As Sodium]; SCHEMBL151101; THR 221 [AS SODIUM]; THR-221; THR-221 [As Sodium]; Timecef; UNII-Z31298J4HQ; Z31298J4HQ
DMORSGU TC Anti-Bacterial Agents
DMORSGU DT Small molecular drug
DMORSGU PC 5361871
DMORSGU MW 584.655
DMORSGU FM C20H20N6O7S4
DMORSGU IC InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
DMORSGU CS CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O
DMORSGU IK XDZKBRJLTGRPSS-BGZQYGJUSA-N
DMORSGU IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMORSGU CA CAS 69739-16-8
DMORSGU CB CHEBI:63214
DMORSGU DE Bacterial infections
DMTX2BH ID DMTX2BH
DMTX2BH DN Cefonicid
DMTX2BH HS Approved
DMTX2BH SN Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CP Glaxosmithkline
DMTX2BH TC Antibiotics
DMTX2BH DT Small molecular drug
DMTX2BH PC 43594
DMTX2BH MW 542.6
DMTX2BH FM C18H18N6O8S3
DMTX2BH IC InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
DMTX2BH CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O
DMTX2BH IK DYAIAHUQIPBDIP-AXAPSJFSSA-N
DMTX2BH IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CA CAS 61270-58-4
DMTX2BH CB CHEBI:3491
DMTX2BH DE Bacterial infection
DM53PV8 ID DM53PV8
DM53PV8 DN Cefoperazone
DM53PV8 HS Approved
DM53PV8 SN Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
DM53PV8 CP Pfizer Pharmaceuticals
DM53PV8 TC Antibiotics
DM53PV8 DT Small molecular drug
DM53PV8 PC 44187
DM53PV8 MW 645.7
DM53PV8 FM C25H27N9O8S2
DM53PV8 IC InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
DM53PV8 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DM53PV8 IK GCFBRXLSHGKWDP-XCGNWRKASA-N
DM53PV8 IU (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM53PV8 CA CAS 62893-19-0
DM53PV8 CB CHEBI:3493
DM53PV8 DE Bacterial infection
DMSQVD6 ID DMSQVD6
DMSQVD6 DN Ceforanide
DMSQVD6 HS Approved
DMSQVD6 SN Ceforanido; Ceforanidum; Precef; Radacef; Bl s786; BL-S 786; BL-S786; Ceforanido [INN-Spanish]; Ceforanidum [INN-Latin]; Precef (TN); Ceforanide (USP/INN); Ceforanide [USAN:INN:BAN]; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
DMSQVD6 TC Antibiotics
DMSQVD6 DT Small molecular drug
DMSQVD6 PC 43507
DMSQVD6 MW 519.6
DMSQVD6 FM C20H21N7O6S2
DMSQVD6 IC InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
DMSQVD6 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O
DMSQVD6 IK SLAYUXIURFNXPG-CRAIPNDOSA-N
DMSQVD6 IU (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSQVD6 CA CAS 60925-61-3
DMSQVD6 CB CHEBI:3495
DMSQVD6 DE Bacterial infection
DMEB837 ID DMEB837
DMEB837 DN Cefotaxime
DMEB837 HS Approved
DMEB837 SN Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7
DMEB837 PC 5742673
DMEB837 MW 455.5
DMEB837 FM C16H17N5O7S2
DMEB837 IC GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMEB837 CS CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
DMEB837 IK 1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMEB837 IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEB837 CA CAS 60846-21-1
DMEB837 CB CHEBI:204928
DMEB837 DE Meningitis
DMMKHBJ ID DMMKHBJ
DMMKHBJ DN Cefotaxime
DMMKHBJ HS Approved
DMMKHBJ SN Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*)
DMMKHBJ CP Roussel Uclaf
DMMKHBJ TC Antibiotics
DMMKHBJ DT Small molecular drug
DMMKHBJ PC 5742673
DMMKHBJ MW 455.5
DMMKHBJ FM C16H17N5O7S2
DMMKHBJ IC InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMMKHBJ CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMMKHBJ IK GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMMKHBJ IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMKHBJ CA CAS 63527-52-6
DMMKHBJ CB CHEBI:204928
DMMKHBJ DE Bacterial infection
DM07TX3 ID DM07TX3
DM07TX3 DN Cefotetan
DM07TX3 HS Approved
DM07TX3 SN Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DM07TX3 CP AstraZeneca
DM07TX3 TC Antibiotics
DM07TX3 DT Small molecular drug
DM07TX3 PC 53025
DM07TX3 MW 575.6
DM07TX3 FM C17H17N7O8S4
DM07TX3 IC InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
DM07TX3 CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O
DM07TX3 IK SRZNHPXWXCNNDU-RHBCBLIFSA-N
DM07TX3 IU (6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07TX3 CA CAS 69712-56-7
DM07TX3 CB CHEBI:3499
DM07TX3 DE Bacterial infection
DMF5HU6 ID DMF5HU6
DMF5HU6 DN Cefotiam
DMF5HU6 HS Approved
DMF5HU6 SN Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
DMF5HU6 CP Takeda
DMF5HU6 TC Antibiotics
DMF5HU6 DT Small molecular drug
DMF5HU6 PC 43708
DMF5HU6 MW 525.6
DMF5HU6 FM C18H23N9O4S3
DMF5HU6 IC InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1
DMF5HU6 CS CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O
DMF5HU6 IK QYQDKDWGWDOFFU-IUODEOHRSA-N
DMF5HU6 IU (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMF5HU6 CA CAS 61622-34-2
DMF5HU6 CB CHEBI:355510
DMF5HU6 DE Respiratory tract infection
DMY8NC4 ID DMY8NC4
DMY8NC4 DN Cefoxitin
DMY8NC4 HS Approved
DMY8NC4 SN Cefoxitina; Cefoxitine; Cefoxitinum; Cefoxotin; Cenomycin; Mefoxin; Mefoxitin; Rephoxitin; cefoxitin; ceftoxitin; 35607-66-0; CEPHOXITIN; 4kow; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; 6OEV9DX57Y; AK118716; CAS-35607-66-0; CFX; CHEBI:209807; CHEMBL996; DSSTox_CID_2764; DSSTox_GSID_22764; DSSTox_RID_76721; NCGC00183034-01; UNII-6OEV9DX57Y
DMY8NC4 PC 441199
DMY8NC4 MW 427.5
DMY8NC4 FM C16H17N3O7S2
DMY8NC4 IC WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMY8NC4 CS COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMY8NC4 IK 1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMY8NC4 IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY8NC4 CA CAS 35607-66-0
DMY8NC4 CB CHEBI:209807
DMY8NC4 DE Peritonitis
DMYTXVR ID DMYTXVR
DMYTXVR DN Cefoxitin
DMYTXVR HS Approved
DMYTXVR SN Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMYTXVR CP Merck & Co
DMYTXVR TC Antibiotics
DMYTXVR DT Small molecular drug
DMYTXVR PC 441199
DMYTXVR MW 427.5
DMYTXVR FM C16H17N3O7S2
DMYTXVR IC InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMYTXVR CS CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMYTXVR IK WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMYTXVR IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYTXVR CA CAS 35607-66-0
DMYTXVR CB CHEBI:209807
DMYTXVR DE Bacterial infection
DMKBTFG ID DMKBTFG
DMKBTFG DN Cefozopran
DMKBTFG HS Approved
DMKBTFG SN CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
DMKBTFG CP Takeda
DMKBTFG DT Small molecular drug
DMKBTFG PC 9571080
DMKBTFG MW 515.5
DMKBTFG FM C19H17N9O5S2
DMKBTFG IC InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
DMKBTFG CS CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]
DMKBTFG IK QDUIJCOKQCCXQY-WHJQOFBOSA-N
DMKBTFG IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMKBTFG CA CAS 113359-04-9
DMKBTFG CB CHEBI:3502
DMKBTFG DE Gram-positive bacterial infection
DMZ2WL4 ID DMZ2WL4
DMZ2WL4 DN Cefpiramide
DMZ2WL4 HS Approved
DMZ2WL4 SN Cefpiramido; Cefpiramidum; WY 44635; Cefpiramide [USAN:INN]; Cefpiramido [INN-Spanish]; Cefpiramidum [INN-Latin]; WY44,635; Cefpiramide (USP/INN); (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe-nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMZ2WL4 CP Wyeth Ayerst Laboratories
DMZ2WL4 TC Antibiotics
DMZ2WL4 DT Small molecular drug
DMZ2WL4 PC 636405
DMZ2WL4 MW 612.6
DMZ2WL4 FM C25H24N8O7S2
DMZ2WL4 IC InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
DMZ2WL4 CS CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DMZ2WL4 IK PWAUCHMQEXVFJR-PMAPCBKXSA-N
DMZ2WL4 IU (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMZ2WL4 CA CAS 70797-11-4
DMZ2WL4 CB CHEBI:59213
DMZ2WL4 DE Bacterial infection
DMJUNY5 ID DMJUNY5
DMJUNY5 DN Cefpodoxime
DMJUNY5 HS Approved
DMJUNY5 SN CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CP Pfizer Pharmaceuticals
DMJUNY5 TC Antibiotics
DMJUNY5 DT Small molecular drug
DMJUNY5 PC 6335986
DMJUNY5 MW 427.5
DMJUNY5 FM C15H17N5O6S2
DMJUNY5 IC InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
DMJUNY5 CS COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMJUNY5 IK WYUSVOMTXWRGEK-HBWVYFAYSA-N
DMJUNY5 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CA CAS 80210-62-4
DMJUNY5 CB CHEBI:3504
DMJUNY5 DE Bacterial infection
DM7DSYP ID DM7DSYP
DM7DSYP DN Cefprozil
DM7DSYP HS Approved
DM7DSYP SN Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CP Bristol-Myers Squibb
DM7DSYP TC Antibiotics
DM7DSYP DT Small molecular drug
DM7DSYP PC 5281006
DM7DSYP MW 389.4
DM7DSYP FM C18H19N3O5S
DM7DSYP IC InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1
DM7DSYP CS C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DM7DSYP IK WDLWHQDACQUCJR-ZAMMOSSLSA-N
DM7DSYP IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CA CAS 92676-86-3
DM7DSYP CB CHEBI:3506
DM7DSYP DE Bacterial infection
DMUNSWV ID DMUNSWV
DMUNSWV DN Cefradine
DMUNSWV HS Approved
DMUNSWV SN Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
DMUNSWV CP Kent Pharms
DMUNSWV TC Antibiotics
DMUNSWV DT Small molecular drug
DMUNSWV PC 38103
DMUNSWV MW 349.4
DMUNSWV FM C16H19N3O4S
DMUNSWV IC InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMUNSWV CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O
DMUNSWV IK RDLPVSKMFDYCOR-UEKVPHQBSA-N
DMUNSWV IU (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMUNSWV CA CAS 38821-53-3
DMUNSWV CB CHEBI:3547
DMUNSWV DE Bacterial infection
DMQXLF3 ID DMQXLF3
DMQXLF3 DN Cefsulodin
DMQXLF3 HS Approved
DMQXLF3 SN cefsulodin; (6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1NR4MP; SCHEMBL65524; DTXSID6022769; Cefsulodin free acid (SCE-129), Antibiotic for Culture Media Use Only
DMQXLF3 DT Small molecular drug
DMQXLF3 PC 656575
DMQXLF3 MW 532.6
DMQXLF3 FM C22H20N4O8S2
DMQXLF3 IC InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
DMQXLF3 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N
DMQXLF3 IK SYLKGLMBLAAGSC-QLVMHMETSA-N
DMQXLF3 IU (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMQXLF3 CA CAS 62587-73-9
DMQXLF3 CB CHEBI:3507
DMQXLF3 DE Pseudomonas infection
DM41GRA ID DM41GRA
DM41GRA DN Ceftazidime
DM41GRA HS Approved
DM41GRA SN Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
DM41GRA CP GlaxoSmithKline
DM41GRA TC Antibiotics
DM41GRA DT Small molecular drug
DM41GRA PC 5481173
DM41GRA MW 546.6
DM41GRA FM C22H22N6O7S2
DM41GRA IC InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
DM41GRA CS CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
DM41GRA IK ORFOPKXBNMVMKC-DWVKKRMSSA-N
DM41GRA IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM41GRA CA CAS 72558-82-8
DM41GRA CB CHEBI:3508
DM41GRA DE Bacterial infection
DMWV2AG ID DMWV2AG
DMWV2AG DN Ceftibuten
DMWV2AG HS Approved
DMWV2AG SN CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMWV2AG CP Shionogi USA
DMWV2AG TC Antibiotics
DMWV2AG DT Small molecular drug
DMWV2AG PC 5282242
DMWV2AG MW 410.4
DMWV2AG FM C15H14N4O6S2
DMWV2AG IC InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1
DMWV2AG CS C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O
DMWV2AG IK UNJFKXSSGBWRBZ-BJCIPQKHSA-N
DMWV2AG IU (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWV2AG CA CAS 97519-39-6
DMWV2AG CB CHEBI:3510
DMWV2AG DE Chronic bronchitis
DMR2SOZ ID DMR2SOZ
DMR2SOZ DN Ceftiofur
DMR2SOZ HS Approved
DMR2SOZ SN Excede (TN)
DMR2SOZ CP Pfizer
DMR2SOZ DT Small molecular drug
DMR2SOZ PC 6328657
DMR2SOZ MW 523.6
DMR2SOZ FM C19H17N5O7S3
DMR2SOZ IC InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
DMR2SOZ CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O
DMR2SOZ IK ZBHXIWJRIFEVQY-IHMPYVIRSA-N
DMR2SOZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMR2SOZ CA CAS 80370-57-6
DMR2SOZ DE Bacterial infection
DM3VOGS ID DM3VOGS
DM3VOGS DN Ceftizoxime
DM3VOGS HS Approved
DM3VOGS SN Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid
DM3VOGS CP Fujisawa Pharmaceutical Co
DM3VOGS TC Antibiotics
DM3VOGS DT Small molecular drug
DM3VOGS PC 6533629
DM3VOGS MW 383.4
DM3VOGS FM C13H13N5O5S2
DM3VOGS IC InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
DM3VOGS CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O
DM3VOGS IK NNULBSISHYWZJU-LLKWHZGFSA-N
DM3VOGS IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM3VOGS CA CAS 68401-81-0
DM3VOGS CB CHEBI:553473
DM3VOGS DE Bacterial infection
DM9QWAH ID DM9QWAH
DM9QWAH DN Ceftolozane/tazobactam
DM9QWAH HS Approved
DM9QWAH SN CXA-101/tazobactam; CXA-201; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa
DM9QWAH TC Antiinfective Agents
DM9QWAH DE Discovery agent
DMCEW64 ID DMCEW64
DMCEW64 DN Ceftriaxone
DMCEW64 HS Approved
DMCEW64 SN Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMCEW64 CP Hoffmann-La Roche pharmaceutical company
DMCEW64 TC Antibiotics
DMCEW64 DT Small molecular drug
DMCEW64 PC 5479530
DMCEW64 MW 554.6
DMCEW64 FM C18H18N8O7S3
DMCEW64 IC InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
DMCEW64 CS CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMCEW64 IK VAAUVRVFOQPIGI-SPQHTLEESA-N
DMCEW64 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMCEW64 CA CAS 73384-59-5
DMCEW64 CB CHEBI:29007
DMCEW64 DE Bacterial infection
DMSIMD8 ID DMSIMD8
DMSIMD8 DN Cefuroxime
DMSIMD8 HS Approved
DMSIMD8 SN Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMSIMD8 CP GlaxoSmithKline
DMSIMD8 TC Antibiotics
DMSIMD8 DT Small molecular drug
DMSIMD8 PC 5479529
DMSIMD8 MW 424.4
DMSIMD8 FM C16H16N4O8S
DMSIMD8 IC InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
DMSIMD8 CS CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
DMSIMD8 IK JFPVXVDWJQMJEE-IZRZKJBUSA-N
DMSIMD8 IU (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSIMD8 CA CAS 55268-75-2
DMSIMD8 CB CHEBI:3515
DMSIMD8 DE Acute bronchitis
DM4CHN0 ID DM4CHN0
DM4CHN0 DN Cefuroxime axetil
DM4CHN0 HS Approved
DM4CHN0 SN cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef
DM4CHN0 PC 6321416
DM4CHN0 MW 510.5
DM4CHN0 FM C20H22N4O10S
DM4CHN0 IC InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
DM4CHN0 CS CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N
DM4CHN0 IK KEJCWVGMRLCZQQ-YJBYXUATSA-N
DM4CHN0 IU 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4CHN0 CA CAS 64544-07-6
DM4CHN0 CB CHEBI:3516
DM4CHN0 DE Bacterial infections
DM6LOQU ID DM6LOQU
DM6LOQU DN Celecoxib
DM6LOQU HS Approved
DM6LOQU SN CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CP Pfizer
DM6LOQU TC Analgesics
DM6LOQU DT Small molecular drug
DM6LOQU PC 2662
DM6LOQU MW 381.4
DM6LOQU FM C17H14F3N3O2S
DM6LOQU IC InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM6LOQU CS CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM6LOQU IK RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM6LOQU IU 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CA CAS 169590-42-5
DM6LOQU CB CHEBI:41423
DM6LOQU DE Rheumatoid arthritis; Pain
DMD5LBX ID DMD5LBX
DMD5LBX DN Celiprolol HCL
DMD5LBX HS Approved
DMD5LBX SN Selectol (TN)
DMD5LBX DT Small molecular drug
DMD5LBX PC 42373
DMD5LBX MW 416
DMD5LBX FM C20H34ClN3O4
DMD5LBX IC InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
DMD5LBX CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl
DMD5LBX IK VKJHTUVLJYWAEY-UHFFFAOYSA-N
DMD5LBX IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea;hydrochloride
DMD5LBX CA CAS 57470-78-7
DMD5LBX CB CHEBI:31385
DMD5LBX DE Hypertension
DMYT2FP ID DMYT2FP
DMYT2FP DN Cellulose Sodium Phosphate
DMYT2FP HS Approved
DMYT2FP SN Calcibind
DMYT2FP CP Mission Pharmacal Co
DMYT2FP DE Hypercalciuria
DMTIUFA ID DMTIUFA
DMTIUFA DN Celtura
DMTIUFA HS Approved
DMTIUFA SN A/H1N1v; A/H1N1v vaccine (influenza virus infection), Novartis; H1N1 pandemic influenza A vaccine (MF59-adjuvanted, cell culture), Novartis
DMTIUFA CP Novartis AG
DMTIUFA DT Vaccine
DMTIUFA DE Influenza virus infection
DMKMJHE ID DMKMJHE
DMKMJHE DN Cemiplimab
DMKMJHE HS Approved
DMKMJHE SN REGN2810; REGN-2810; REGN 2810
DMKMJHE CP Regeneron/Sanofi
DMKMJHE DT Monoclonal antibody
DMKMJHE DE Cutaneous squamous cell carcinoma
DM8Y2RU ID DM8Y2RU
DM8Y2RU DN Cenegermin
DM8Y2RU HS Approved
DM8Y2RU SN cenegermin; Cenegermin [INN]; UNII-B6E7K36KT8; B6E7K36KT8; Human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli nerve growth factor
DM8Y2RU CP Domp
DM8Y2RU DT Antibody
DM8Y2RU DE Neurotrophic keratitis
DMXQS7K ID DMXQS7K
DMXQS7K DN Cenestin
DMXQS7K HS Approved
DMXQS7K SN Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo
DMXQS7K CP Duramed Pharmaceuticals Inc
DMXQS7K DT Small molecular drug
DMXQS7K PC 23676225
DMXQS7K MW 370.4
DMXQS7K FM C18H19NaO5S
DMXQS7K IC InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1
DMXQS7K CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+]
DMXQS7K IK QTTMOCOWZLSYSV-QWAPEVOJSA-M
DMXQS7K IU sodium;[(9S,13S,14S)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMXQS7K CA CAS 12126-59-9
DMXQS7K CB CHEBI:32143
DMXQS7K DE Menopause symptom; Osteoporosis
DM8KLU9 ID DM8KLU9
DM8KLU9 DN Cenobamate
DM8KLU9 HS Approved
DM8KLU9 SN Cenobamate; Cenobamate (USAN/INN); Cenobamate [INN]; Cenobamate [USAN:INN]; P85X70RZWS; SCHEMBL1682643; YKP3089; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 913088-80-9; CHEMBL3989949; CS-0014686; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; HY-17607; UNII-P85X70RZWS
DM8KLU9 PC 11962412
DM8KLU9 MW 267.67
DM8KLU9 FM C10H10ClN5O2
DM8KLU9 IC GFHAXPJGXSQLPT-VIFPVBQESA-N
DM8KLU9 CS C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
DM8KLU9 IK 1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DM8KLU9 IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DM8KLU9 CA CAS 913088-80-9
DM8KLU9 DE Focal seizure
DMGOVHA ID DMGOVHA
DMGOVHA DN Cenobamate
DMGOVHA HS Approved
DMGOVHA SN Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352
DMGOVHA DT Small molecular drug
DMGOVHA PC 11962412
DMGOVHA MW 267.67
DMGOVHA FM C10H10ClN5O2
DMGOVHA IC InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DMGOVHA CS C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
DMGOVHA IK GFHAXPJGXSQLPT-VIFPVBQESA-N
DMGOVHA IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DMGOVHA CA CAS 913088-80-9
DMGOVHA DE Complex partial seizure
DMD5JU8 ID DMD5JU8
DMD5JU8 DN Cephalexin
DMD5JU8 HS Approved
DMD5JU8 SN Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
DMD5JU8 CP Eli Lilly
DMD5JU8 TC Antibiotics
DMD5JU8 DT Small molecular drug
DMD5JU8 PC 27447
DMD5JU8 MW 347.4
DMD5JU8 FM C16H17N3O4S
DMD5JU8 IC InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMD5JU8 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMD5JU8 IK ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
DMD5JU8 IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMD5JU8 CA CAS 15686-71-2
DMD5JU8 CB CHEBI:3534
DMD5JU8 DE Bacterial infection
DMYZITL ID DMYZITL
DMYZITL DN Cephaloglycin
DMYZITL HS Approved
DMYZITL SN CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
DMYZITL TC Antibiotics
DMYZITL DT Small molecular drug
DMYZITL PC 19150
DMYZITL MW 405.4
DMYZITL FM C18H19N3O6S
DMYZITL IC InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1
DMYZITL CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMYZITL IK FUBBGQLTSCSAON-PBFPGSCMSA-N
DMYZITL IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYZITL CA CAS 3577-01-3
DMYZITL CB CHEBI:34613
DMYZITL DE Bacterial infection
DM79XDW ID DM79XDW
DM79XDW DN Cephalosporin
DM79XDW HS Approved
DM79XDW SN Cephalothin (TN)
DM79XDW CP Eli Lilly
DM79XDW TC Antibiotics
DM79XDW DT Small molecular drug
DM79XDW PC 25058126
DM79XDW MW 387.4
DM79XDW FM C15H21N3O7S
DM79XDW IC InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1
DM79XDW CS C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N
DM79XDW IK JGKXEMYIHDYWCZ-JFUSQASVSA-N
DM79XDW IU (2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DM79XDW DE Bacterial infection
DM51Z9E ID DM51Z9E
DM51Z9E DN Cephalothin sodium
DM51Z9E HS Approved
DM51Z9E SN Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin In Plastic Container
DM51Z9E CP Eli Lilly And Co
DM51Z9E TC Antiinfective Agents
DM51Z9E DT Small molecular drug
DM51Z9E PC 23675321
DM51Z9E MW 418.4
DM51Z9E FM C16H15N2NaO6S2
DM51Z9E IC InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1
DM51Z9E CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[Na+]
DM51Z9E IK VUFGUVLLDPOSBC-XRZFDKQNSA-M
DM51Z9E IU sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM51Z9E CA CAS 58-71-9
DM51Z9E CB CHEBI:3542
DM51Z9E DE Bacterial infection
DMV2JNY ID DMV2JNY
DMV2JNY DN Cephapirin
DMV2JNY HS Approved
DMV2JNY SN CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid
DMV2JNY TC Antibiotics
DMV2JNY DT Small molecular drug
DMV2JNY PC 30699
DMV2JNY MW 423.5
DMV2JNY FM C17H17N3O6S2
DMV2JNY IC InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
DMV2JNY CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O
DMV2JNY IK UQLLWWBDSUHNEB-CZUORRHYSA-N
DMV2JNY IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMV2JNY CA CAS 21593-23-7
DMV2JNY CB CHEBI:554446
DMV2JNY DE Sepsis
DM9Y5JB ID DM9Y5JB
DM9Y5JB DN Cepharanthine
DM9Y5JB HS Approved
DM9Y5JB SN CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)
DM9Y5JB PC 10206
DM9Y5JB MW 606.7
DM9Y5JB FM C37H38N2O6
DM9Y5JB IC InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
DM9Y5JB CS CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DM9Y5JB IK YVPXVXANRNDGTA-WDYNHAJCSA-N
DM9Y5JB IU (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DM9Y5JB CA CAS 481-49-2
DM9Y5JB CB CHEBI:3546
DM9Y5JB DE Thrombocytopenia
DMB920Z ID DMB920Z
DMB920Z DN Ceritinib
DMB920Z HS Approved
DMB920Z SN ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
DMB920Z DT Small molecular drug
DMB920Z PC 57379345
DMB920Z MW 558.1
DMB920Z FM C28H36ClN5O3S
DMB920Z IC InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
DMB920Z CS CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
DMB920Z IK VERWOWGGCGHDQE-UHFFFAOYSA-N
DMB920Z IU 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
DMB920Z CA CAS 1032900-25-6
DMB920Z CB CHEBI:78432
DMB920Z DE Non-small-cell lung cancer
DMXCM7H ID DMXCM7H
DMXCM7H DN Cerivastatin
DMXCM7H HS Approved
DMXCM7H SN cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
DMXCM7H DT Small molecular drug
DMXCM7H PC 446156
DMXCM7H MW 459.5
DMXCM7H FM C26H34FNO5
DMXCM7H IC InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
DMXCM7H CS CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
DMXCM7H IK SEERZIQQUAZTOL-ANMDKAQQSA-N
DMXCM7H IU (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMXCM7H CA CAS 145599-86-6
DMXCM7H CB CHEBI:3558
DMXCM7H DE Hyperlipidaemia; Multiple myeloma
DM0HAC8 ID DM0HAC8
DM0HAC8 DN Cerliponase Alfa
DM0HAC8 HS Approved
DM0HAC8 SN Brineura
DM0HAC8 CP BioMarin Pharmaceutical
DM0HAC8 DT Recombinant protein
DM0HAC8 SQ Cerliponase alfa Sequence: SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
DM0HAC8 DE Tripeptidyl peptidase 1 deficiency; Neuronal ceroid lipofuscinosis
DM5CL9Z ID DM5CL9Z
DM5CL9Z DN Certolizumab
DM5CL9Z HS Approved
DM5CL9Z SN CDP-870; Cimzia; PHA-738144; Simziya
DM5CL9Z CP UCB
DM5CL9Z DT Monoclonal antibody
DM5CL9Z DE Rheumatoid arthritis
DMUR94J ID DMUR94J
DMUR94J DN Certoparin sodium
DMUR94J HS Approved
DMUR94J SN Alphaparin (TN)
DMUR94J DE Deep vein thrombosis
DM6N4PR ID DM6N4PR
DM6N4PR DN Cerulenin
DM6N4PR HS Approved
DM6N4PR SN Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide
DM6N4PR TC Antiinfective Agents
DM6N4PR DT Small molecular drug
DM6N4PR PC 5282054
DM6N4PR MW 223.27
DM6N4PR FM C12H17NO3
DM6N4PR IC InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1
DM6N4PR CS C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N
DM6N4PR IK GVEZIHKRYBHEFX-NQQPLRFYSA-N
DM6N4PR IU (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide
DM6N4PR CA CAS 17397-89-6
DM6N4PR CB CHEBI:171741
DM6N4PR DE Weight loss
DM2WE5K ID DM2WE5K
DM2WE5K DN Ceruletide
DM2WE5K HS Approved
DM2WE5K SN Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
DM2WE5K CP Pharmacia And Upjohn Co
DM2WE5K TC Diagnostic Agents
DM2WE5K DT Small molecular drug
DM2WE5K PC 16129675
DM2WE5K MW 1352.4
DM2WE5K FM C58H73N13O21S2
DM2WE5K IC InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1
DM2WE5K CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O
DM2WE5K IK YRALAIOMGQZKOW-HYAOXDFASA-N
DM2WE5K IU (3S)-3-[[(2S)-5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DM2WE5K CA CAS 17650-98-5
DM2WE5K CB CHEBI:59219
DM2WE5K DE Caerulein stimulated gastric and pancreatic secretion; Solid tumour/cancer
DMOMP9U ID DMOMP9U
DMOMP9U DN Cetirizine
DMOMP9U HS Approved
DMOMP9U SN Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CP Pfizer Pharmaceuticals
DMOMP9U TC Antiallergic Agents
DMOMP9U DT Small molecular drug
DMOMP9U PC 2678
DMOMP9U MW 388.9
DMOMP9U FM C21H25ClN2O3
DMOMP9U IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
DMOMP9U CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMOMP9U IK ZKLPARSLTMPFCP-UHFFFAOYSA-N
DMOMP9U IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CA CAS 83881-51-0
DMOMP9U CB CHEBI:3561
DMOMP9U DE Allergic rhinitis
DMSP4JX ID DMSP4JX
DMSP4JX DN Cetraxate
DMSP4JX HS Approved
DMSP4JX SN Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006
DMSP4JX CP Daiichi Seiyaku Co Ltd
DMSP4JX DT Small molecular drug
DMSP4JX PC 2680
DMSP4JX MW 305.4
DMSP4JX FM C17H23NO4
DMSP4JX IC InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20)
DMSP4JX CS C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O
DMSP4JX IK FHRSHSOEWXUORL-UHFFFAOYSA-N
DMSP4JX IU 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
DMSP4JX CA CAS 34675-84-8
DMSP4JX CB CHEBI:17340
DMSP4JX DE Peptic ulcer
DMFD9Q6 ID DMFD9Q6
DMFD9Q6 DN Cetrorelix
DMFD9Q6 HS Approved
DMFD9Q6 SN Cetrorelixum; Cetrorelix (INN); Cetrotide (TN); HS-2008; Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
DMFD9Q6 CP Merck Serono
DMFD9Q6 TC Infertility Agents
DMFD9Q6 DT Small molecular drug
DMFD9Q6 PC 25074887
DMFD9Q6 MW 1431
DMFD9Q6 FM C70H92ClN17O14
DMFD9Q6 IC InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1
DMFD9Q6 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMFD9Q6 IK SBNPWPIBESPSIF-MHWMIDJBSA-N
DMFD9Q6 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFD9Q6 CA CAS 120287-85-6
DMFD9Q6 CB CHEBI:59224
DMFD9Q6 DE Ovarian stimulation
DMLNCE0 ID DMLNCE0
DMLNCE0 DN Cetuximab
DMLNCE0 HS Approved
DMLNCE0 SN Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
DMLNCE0 CP Bristol-Myers Squibb
DMLNCE0 TC Anticancer Agents
DMLNCE0 DT Antibody
DMLNCE0 SQ Cetuximab heavy chain: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Cetuximab light chainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMLNCE0 DE Colorectal cancer
DMWSMND ID DMWSMND
DMWSMND DN Cevimeline
DMWSMND HS Approved
DMWSMND SN Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
DMWSMND CP Daiichi Sankyo Pharma Development
DMWSMND TC Parasympathomimetics
DMWSMND DT Small molecular drug
DMWSMND PC 83898
DMWSMND MW 199.32
DMWSMND FM C10H17NOS
DMWSMND IC InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
DMWSMND CS C[C@@H]1O[C@]2(CN3CCC2CC3)CS1
DMWSMND IK WUTYZMFRCNBCHQ-PSASIEDQSA-N
DMWSMND IU (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
DMWSMND CA CAS 107233-08-9
DMWSMND DE Sjogren syndrome
DMKN345 ID DMKN345
DMKN345 DN Charybdotoxin
DMKN345 HS Approved
DMKN345 SN ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus
DMKN345 DT Small molecular drug
DMKN345 PC 56842037
DMKN345 MW 4296
DMKN345 FM C176H277N57O55S7
DMKN345 IC InChI=1S/C176H277N57O55S7/c1-81(2)58-106-149(263)213-110(62-91-67-191-80-197-91)152(266)215-112(64-127(183)246)156(270)231-135(85(8)240)170(284)219-114(69-234)157(271)200-95(36-25-54-192-174(185)186)138(252)196-68-130(249)199-96(32-17-21-50-177)139(253)222-120-75-291-295-79-124(226-159(273)116(71-236)218-167(281)132(82(3)4)228-155(269)113(65-128(184)247)216-169(283)134(84(7)239)230-154(268)108(59-88-28-13-12-14-29-88)210-145(259)102-44-47-129(248)198-102)166(280)232-137(87(10)242)172(286)233-136(86(9)241)171(285)220-115(70-235)158(272)204-98(34-19-23-52-179)141(255)206-104(45-48-131(250)251)147(261)225-122-77-292-290-74-119(223-143(257)99(35-20-24-53-180)201-140(254)97(33-18-22-51-178)203-153(267)111(63-126(182)245)214-148(262)105(49-57-289-11)208-162(120)276)161(275)205-101(38-27-56-194-176(189)190)144(258)224-121(164(278)211-107(60-89-39-41-92(243)42-40-89)150(264)221-118(73-238)173(287)288)76-293-294-78-123(163(277)207-103(43-46-125(181)244)146(260)202-100(142(256)209-106)37-26-55-193-175(187)188)227-168(282)133(83(5)6)229-160(274)117(72-237)217-151(265)109(212-165(122)279)61-90-66-195-94-31-16-15-30-93(90)94/h12-16,28-31,39-42,66-67,80-87,95-124,132-137,195,234-243H,17-27,32-38,43-65,68-79,177-180H2,1-11H3,(H2,181,244)(H2,182,245)(H2,183,246)(H2,184,247)(H,191,197)(H,196,252)(H,198,248)(H,199,249)(H,200,271)(H,201,254)(H,202,260)(H,203,267)(H,204,272)(H,205,275)(H,206,255)(H,207,277)(H,208,276)(H,209,256)(H,210,259)(H,211,278)(H,212,279)(H,213,263)(H,214,262)(H,215,266)(H,216,283)(H,217,265)(H,218,281)(H,219,284)(H,220,285)(H,221,264)(H,222,253)(H,223,257)(H,224,258)(H,225,261)(H,226,273)(H,227,282)(H,228,269)(H,229,274)(H,230,268)(H,231,270)(H,232,280)(H,233,286)(H,250,251)(H,287,288)(H4,185,186,192)(H4,187,188,193)(H4,189,190,194)/t84-,85-,86-,87-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+/m1/s1
DMKN345 CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCCN)CCCCN)CC(=O)N)CCSC)CCCCN)CCCNC(=N)N)CO)[C@@H](C)O)CC(=O)N)CC6=CN=CN6)CC(C)C)CCCNC(=N)N)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC7=CNC8=CC=CC=C87)CO)C(C)C)C(=O)N[C@@H](CC9=CC=C(C=C9)O)C(=O)N[C@@H](CO)C(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CO)[C@@H](C)O)O
DMKN345 IK CNVQLPPZGABUCM-LIGYZCPXSA-N
DMKN345 IU (2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(1R,4S,7R,12R,15S,18S,21S,24S,27S,30S,33S,36S,42S,45R,50R,53S,56S,59S,62S,65S,68R,75S,78S,81S,84S,89S,92S,95S)-42,62,75,78-tetrakis(4-aminobutyl)-50-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-27,81-bis(2-amino-2-oxoethyl)-15-(3-amino-3-oxopropyl)-4,18,36-tris(3-carbamimidamidopropyl)-65-(2-carboxyethyl)-30,53,56-tris[(1R)-1-hydroxyethyl]-33,59,92-tris(hydroxymethyl)-24-(1H-imidazol-5-ylmethyl)-89-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-84-(2-methylsulfanylethyl)-2,5,13,16,19,22,25,28,31,34,37,40,43,51,54,57,60,63,66,74,77,80,83,86,87,90,93,96-octacosaoxo-95-propan-2-yl-9,10,47,48,70,71-hexathia-3,6,14,17,20,23,26,29,32,35,38,41,44,52,55,58,61,64,67,73,76,79,82,85,88,91,94,97-octacosazatricyclo[43.27.14.1112,68]heptanonacontane-7-carbonyl]amino]propanoyl]amino]propanoic acid
DMKN345 CA CAS 95751-30-7
DMKN345 DE Scorpion envenoming syndrome
DMQ8JIK ID DMQ8JIK
DMQ8JIK DN Chenodiol
DMQ8JIK HS Approved
DMQ8JIK SN 474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum
DMQ8JIK CP Sigma Tau Pharmaceuticals Inc
DMQ8JIK DT Small molecular drug
DMQ8JIK PC 10133
DMQ8JIK MW 392.6
DMQ8JIK FM C24H40O4
DMQ8JIK IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
DMQ8JIK CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMQ8JIK IK RUDATBOHQWOJDD-BSWAIDMHSA-N
DMQ8JIK IU (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMQ8JIK CA CAS 474-25-9
DMQ8JIK CB CHEBI:16755
DMQ8JIK DE Cholelithiasis
DMXGJEI ID DMXGJEI
DMXGJEI DN Chlophedianol
DMXGJEI HS Approved
DMXGJEI SN Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]
DMXGJEI CP 3m Pharmaceuticals Inc
DMXGJEI TC Anesthetics
DMXGJEI DT Small molecular drug
DMXGJEI PC 2795
DMXGJEI MW 289.8
DMXGJEI FM C17H20ClNO
DMXGJEI IC InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
DMXGJEI CS CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O
DMXGJEI IK WRCHFMBCVFFYEQ-UHFFFAOYSA-N
DMXGJEI IU 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
DMXGJEI CA CAS 791-35-5
DMXGJEI CB CHEBI:135207
DMXGJEI DE Dry cough; Anaesthesia
DMRKE63 ID DMRKE63
DMRKE63 DN Chlorambucil
DMRKE63 HS Approved
DMRKE63 SN Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)
DMRKE63 CP GlaxoSmithKline
DMRKE63 TC Anticancer Agents
DMRKE63 DT Small molecular drug
DMRKE63 PC 2708
DMRKE63 MW 304.2
DMRKE63 FM C14H19Cl2NO2
DMRKE63 IC InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
DMRKE63 CS C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
DMRKE63 IK JCKYGMPEJWAADB-UHFFFAOYSA-N
DMRKE63 IU 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
DMRKE63 CA CAS 305-03-3
DMRKE63 CB CHEBI:28830
DMRKE63 DE Chronic lymphocytic leukaemia
DMFXEWT ID DMFXEWT
DMFXEWT DN Chloramphenicol
DMFXEWT HS Approved
DMFXEWT SN Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol
DMFXEWT CP Aventis Pharmaceuticals Inc.
DMFXEWT TC Antibiotics
DMFXEWT DT Small molecular drug
DMFXEWT PC 5959
DMFXEWT MW 323.13
DMFXEWT FM C11H12Cl2N2O5
DMFXEWT IC InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
DMFXEWT CS C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
DMFXEWT IK WIIZWVCIJKGZOK-RKDXNWHRSA-N
DMFXEWT IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
DMFXEWT CA CAS 56-75-7
DMFXEWT CB CHEBI:17698
DMFXEWT DE Bacterial infection
DMTN5XI ID DMTN5XI
DMTN5XI DN Chlordiazepoxide
DMTN5XI HS Approved
DMTN5XI SN Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CP Patheon Pharmaceuticals Inc
DMTN5XI TC Antianxiety Agents
DMTN5XI DT Small molecular drug
DMTN5XI PC 2712
DMTN5XI MW 299.75
DMTN5XI FM C16H14ClN3O
DMTN5XI IC InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3
DMTN5XI CS CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
DMTN5XI IK BUCORZSTKDOEKQ-UHFFFAOYSA-N
DMTN5XI IU 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CA CAS 58-25-3
DMTN5XI CB CHEBI:3611
DMTN5XI DE Anxiety disorder
DMQ9MVG ID DMQ9MVG
DMQ9MVG DN Chlorhexidine
DMQ9MVG HS Approved
DMQ9MVG SN AVAGARD; Chlorhexidin; Chlorhexidinum; Cloresidina; Clorhexidina; Fimeil; Hexadol; Hibiclens; Hibispray; Hibistat;Nolvasan; Novalsan; Peridex; Periogard; Rotersept; Savloclens; Soretol; Sterido; Sterilon; Superspray; Tubulicid; Chlorhexidin [Czech]; Chlorhexidine Base; Chlorhexidine gluconate; Cloresidina [DCIT]; Decanoylacetaldehyde Sodium Sulfide; Dentisept [veterinary]; Savlon babycare; Sebidin A; Sodium Houttuyfonamide; Avagard (TN); BIOPATCH (TN); ChloraPrep (TN); Chlorhexamed (TN); Chlorhexidine (INN);Chlorhexidine [INN:BAN]; Chlorhexidinum [INN-Latin]; Chlorohex (TN); Clohex (TN); Clorexil (TN); Clorhexidina [INN-Spanish]; Corsodyl (TN); Dentisept [veterinary] (TN); Dexidin (TN); Exidine (TN); Hibiclens (TN); Hibiscrub (TN); MK-412A; Merfen-incolore; Oro-Clense; Oronine (TN); Perichlor (TN); Peridex (TN); Peridont (TN); Periochip (TN); Periogard Oral Rinse (TN); Perioxidina (TN); Savacol (TN); Suthol (TN); Dejavu-MW (TN); Merfen-incolore (TN); Lisium (*Dihydrochloride*); Nolvasan (*Diacetate*); SOLU-I.V (TN); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca-nediimidamide; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; 1,6-Di(N-p-chlorophenyldiguanido)hexane
DMQ9MVG CP G. D. Pharmaceuticals
DMQ9MVG TC Antibiotics
DMQ9MVG DT Small molecular drug
DMQ9MVG PC 9552079
DMQ9MVG MW 505.4
DMQ9MVG FM C22H30Cl2N10
DMQ9MVG IC InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)
DMQ9MVG CS C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl
DMQ9MVG IK GHXZTYHSJHQHIJ-UHFFFAOYSA-N
DMQ9MVG IU (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
DMQ9MVG CA CAS 55-56-1
DMQ9MVG CB CHEBI:3614
DMQ9MVG DE Bacterial infection
DMSF4PR ID DMSF4PR
DMSF4PR DN Chlormerodrin
DMSF4PR HS Approved
DMSF4PR SN Chlormerodrina; Chloromeridin; Neogidrin; Chlormerodrin Hg 197; Chlormerodrin Hg 203; Chlormerodrin (197Hg); Chlormerodrin (203Hg); Chlormerodrin Hg 197 (TN); Chlormerodrin Hg 197 (USAN); Chlormerodrin Hg 197 [USAN:USP XX]; Chlormerodrin Hg 203 (USAN); Hg-203 chlormerodrin; Loro-}; Neohydrin-203; Chlormerodrin (197Hg) (INN); Neohydrin-203 (TN); Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Urea, (2-methoxypropyl)-, mercury complex; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203; Chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; (3-(Chloromercuri)-2-methoxypropyl)urea; 3-Chloromercuri-2-methoxypropylurea; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride
DMSF4PR TC Diagnostic Agents
DMSF4PR DT Small molecular drug
DMSF4PR PC 25210
DMSF4PR MW 367.2
DMSF4PR FM C5H11ClHgN2O2
DMSF4PR IC InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1
DMSF4PR CS COC(CNC(=O)N)C[Hg]Cl
DMSF4PR IK BJFGVYCULWBXKF-UHFFFAOYSA-M
DMSF4PR IU [3-(carbamoylamino)-2-methoxypropyl]-chloromercury
DMSF4PR CA CAS 10375-56-1
DMSF4PR CB CHEBI:59445
DMSF4PR DE Diagnostic imaging
DMTWUXR ID DMTWUXR
DMTWUXR DN Chlormezanone
DMTWUXR HS Approved
DMTWUXR SN Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide
DMTWUXR TC Analgesics
DMTWUXR DT Small molecular drug
DMTWUXR PC 2717
DMTWUXR MW 273.74
DMTWUXR FM C11H12ClNO3S
DMTWUXR IC InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
DMTWUXR CS CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl
DMTWUXR IK WEQAYVWKMWHEJO-UHFFFAOYSA-N
DMTWUXR IU 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
DMTWUXR CA CAS 80-77-3
DMTWUXR CB CHEBI:3619
DMTWUXR DE Anxiety disorder
DMSOQK1 ID DMSOQK1
DMSOQK1 DN Chloroprocaine
DMSOQK1 HS Approved
DMSOQK1 SN Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester
DMSOQK1 CP Abbott Laboratories
DMSOQK1 TC Anesthetics
DMSOQK1 DT Small molecular drug
DMSOQK1 PC 8612
DMSOQK1 MW 270.75
DMSOQK1 FM C13H19ClN2O2
DMSOQK1 IC InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
DMSOQK1 CS CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl
DMSOQK1 IK VDANGULDQQJODZ-UHFFFAOYSA-N
DMSOQK1 IU 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
DMSOQK1 CA CAS 133-16-4
DMSOQK1 CB CHEBI:3636
DMSOQK1 DE Anaesthesia
DMSI5CB ID DMSI5CB
DMSI5CB DN Chloroquine
DMSI5CB HS Approved
DMSI5CB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMSI5CB CP Medreich Sterilab Ltd
DMSI5CB TC Antimalarials
DMSI5CB DT Small molecular drug
DMSI5CB PC 2719
DMSI5CB MW 319.9
DMSI5CB FM C18H26ClN3
DMSI5CB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMSI5CB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMSI5CB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMSI5CB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMSI5CB CA CAS 54-05-7
DMSI5CB CB CHEBI:3638
DMSI5CB DE Malaria
DMLHESP ID DMLHESP
DMLHESP DN Chlorothiazide
DMLHESP HS Approved
DMLHESP SN Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMLHESP CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMLHESP TC Antihypertensive Agents
DMLHESP DT Small molecular drug
DMLHESP PC 2720
DMLHESP MW 295.7
DMLHESP FM C7H6ClN3O4S2
DMLHESP IC InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
DMLHESP CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
DMLHESP IK JBMKAUGHUNFTOL-UHFFFAOYSA-N
DMLHESP IU 6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMLHESP CA CAS 58-94-6
DMLHESP CB CHEBI:3640
DMLHESP DE Congestive heart failure
DMFZBMQ ID DMFZBMQ
DMFZBMQ DN Chloroxine
DMFZBMQ HS Approved
DMFZBMQ SN chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2
DMFZBMQ DT Small molecular drug
DMFZBMQ PC 2722
DMFZBMQ MW 214.04
DMFZBMQ FM C9H5Cl2NO
DMFZBMQ IC InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DMFZBMQ CS C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1
DMFZBMQ IK WDFKMLRRRCGAKS-UHFFFAOYSA-N
DMFZBMQ IU 5,7-dichloroquinolin-8-ol
DMFZBMQ CA CAS 773-76-2
DMFZBMQ CB CHEBI:59477
DMFZBMQ DE Erythema
DM5URA2 ID DM5URA2
DM5URA2 DN Chlorpheniramine
DM5URA2 HS Approved
DM5URA2 SN Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
DM5URA2 CP Schering-Plough Corporation
DM5URA2 TC Antiallergic Agents
DM5URA2 DT Small molecular drug
DM5URA2 PC 2725
DM5URA2 MW 274.79
DM5URA2 FM C16H19ClN2
DM5URA2 IC InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DM5URA2 CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM5URA2 IK SOYKEARSMXGVTM-UHFFFAOYSA-N
DM5URA2 IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM5URA2 CA CAS 113-92-8
DM5URA2 CB CHEBI:52010
DM5URA2 DE Allergic rhinitis
DMQRPOS ID DMQRPOS
DMQRPOS DN Chlorphentermine hydrochloride
DMQRPOS HS Approved
DMQRPOS SN Pre-sate
DMQRPOS CP Parke Davis Div Warner Lambert Co
DMQRPOS DT Small molecular drug
DMQRPOS PC 65477
DMQRPOS MW 220.14
DMQRPOS FM C10H15Cl2N
DMQRPOS IC InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H
DMQRPOS CS CC(C)(CC1=CC=C(C=C1)Cl)N.Cl
DMQRPOS IK WEJDYJKJPUPMLH-UHFFFAOYSA-N
DMQRPOS IU 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride
DMQRPOS CA CAS 151-06-4
DMQRPOS DE Appetite suppressant
DM1IFGT ID DM1IFGT
DM1IFGT DN Chlorproguanil
DM1IFGT HS Approved
DM1IFGT SN Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide
DM1IFGT DT Small molecular drug
DM1IFGT PC 9571037
DM1IFGT MW 288.17
DM1IFGT FM C11H15Cl2N5
DM1IFGT IC InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
DM1IFGT CS CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl
DM1IFGT IK ISZNZKHCRKXXAU-UHFFFAOYSA-N
DM1IFGT IU (1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine
DM1IFGT CA CAS 537-21-3
DM1IFGT CB CHEBI:135192
DM1IFGT DE Malaria
DMBGZI3 ID DMBGZI3
DMBGZI3 DN Chlorpromazine
DMBGZI3 HS Approved
DMBGZI3 SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DMBGZI3 CP GlaxoSmithKline
DMBGZI3 TC Antipsychotic Agents
DMBGZI3 DT Small molecular drug
DMBGZI3 PC 2726
DMBGZI3 MW 318.9
DMBGZI3 FM C17H19ClN2S
DMBGZI3 IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DMBGZI3 CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMBGZI3 IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DMBGZI3 IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DMBGZI3 CA CAS 34468-21-8
DMBGZI3 CB CHEBI:3647
DMBGZI3 DE Schizophrenia
DMPHZQE ID DMPHZQE
DMPHZQE DN Chlorpropamide
DMPHZQE HS Approved
DMPHZQE SN Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
DMPHZQE TC Hypoglycemic Agents
DMPHZQE DT Small molecular drug
DMPHZQE PC 2727
DMPHZQE MW 276.74
DMPHZQE FM C10H13ClN2O3S
DMPHZQE IC InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
DMPHZQE CS CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
DMPHZQE IK RKWGIWYCVPQPMF-UHFFFAOYSA-N
DMPHZQE IU 1-(4-chlorophenyl)sulfonyl-3-propylurea
DMPHZQE CA CAS 94-20-2
DMPHZQE CB CHEBI:3650
DMPHZQE DE Non-insulin dependent diabetes
DMY0KGJ ID DMY0KGJ
DMY0KGJ DN Chlorprothixene
DMY0KGJ HS Approved
DMY0KGJ SN Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ TC Antipsychotic Agents
DMY0KGJ DT Small molecular drug
DMY0KGJ PC 667467
DMY0KGJ MW 315.9
DMY0KGJ FM C18H18ClNS
DMY0KGJ IC InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
DMY0KGJ CS CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMY0KGJ IK WSPOMRSOLSGNFJ-AUWJEWJLSA-N
DMY0KGJ IU (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ CA CAS 113-59-7
DMY0KGJ CB CHEBI:50931
DMY0KGJ DE Psychotic disorder
DM4DMBT ID DM4DMBT
DM4DMBT DN Chlorthalidone
DM4DMBT HS Approved
DM4DMBT SN Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
DM4DMBT TC Antihypertensive Agents
DM4DMBT DT Small molecular drug
DM4DMBT PC 2732
DM4DMBT MW 338.8
DM4DMBT FM C14H11ClN2O4S
DM4DMBT IC InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
DM4DMBT CS C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
DM4DMBT IK JIVPVXMEBJLZRO-UHFFFAOYSA-N
DM4DMBT IU 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
DM4DMBT CA CAS 77-36-1
DM4DMBT CB CHEBI:3654
DM4DMBT DE Edema; Hypertension
DMCYVDT ID DMCYVDT
DMCYVDT DN Chlorzoxazone
DMCYVDT HS Approved
DMCYVDT SN Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one
DMCYVDT TC Analgesics
DMCYVDT DT Small molecular drug
DMCYVDT PC 2733
DMCYVDT MW 169.56
DMCYVDT FM C7H4ClNO2
DMCYVDT IC InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
DMCYVDT CS C1=CC2=C(C=C1Cl)NC(=O)O2
DMCYVDT IK TZFWDZFKRBELIQ-UHFFFAOYSA-N
DMCYVDT IU 5-chloro-3H-1,3-benzoxazol-2-one
DMCYVDT CA CAS 95-25-0
DMCYVDT CB CHEBI:3655
DMCYVDT DE Acute pain
DMGU74E ID DMGU74E
DMGU74E DN Cholecalciferol
DMGU74E HS Approved
DMGU74E SN Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
DMGU74E TC Vitamins
DMGU74E DT Small molecular drug
DMGU74E PC 5280795
DMGU74E MW 384.6
DMGU74E FM C27H44O
DMGU74E IC InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMGU74E CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMGU74E IK QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMGU74E IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMGU74E CA CAS 67-97-0
DMGU74E CB CHEBI:28940
DMGU74E DE Vitamin D deficiency
DM7OKQV ID DM7OKQV
DM7OKQV DN Cholic acid
DM7OKQV HS Approved
DM7OKQV SN cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV DT Small molecular drug
DM7OKQV PC 221493
DM7OKQV MW 408.6
DM7OKQV FM C24H40O5
DM7OKQV IC InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
DM7OKQV CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM7OKQV IK BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV IU (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM7OKQV CA CAS 81-25-4
DM7OKQV CB CHEBI:16359
DM7OKQV DE Synthesis disorder; Peroxisomal disorder
DMOI1ZF ID DMOI1ZF
DMOI1ZF DN Choline alfoscerate
DMOI1ZF HS Approved
DMOI1ZF SN Delecit (TN)
DMOI1ZF DT Small molecular drug
DMOI1ZF PC 657272
DMOI1ZF MW 257.22
DMOI1ZF FM C8H20NO6P
DMOI1ZF IC InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMOI1ZF CS C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
DMOI1ZF IK SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMOI1ZF IU [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOI1ZF CA CAS 28319-77-9
DMOI1ZF CB CHEBI:16870
DMOI1ZF DE Amnesia
DM8P137 ID DM8P137
DM8P137 DN Choline salicylate
DM8P137 HS Approved
DM8P137 SN 2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1)
DM8P137 DT Small molecular drug
DM8P137 PC 54686350
DM8P137 MW 241.28
DM8P137 FM C12H19NO4
DM8P137 IC InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1
DM8P137 CS C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-]
DM8P137 IK UDKCHVLMFQVBAA-UHFFFAOYSA-M
DM8P137 IU 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium
DM8P137 CA CAS 2016-36-6
DM8P137 CB CHEBI:3668
DM8P137 DE Inflammation
DMFMZ3G ID DMFMZ3G
DMFMZ3G DN Choriogonadotropin alfa
DMFMZ3G HS Approved
DMFMZ3G TC Fertility Agents
DMFMZ3G SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMFMZ3G DE Female infertility
DMFT73E ID DMFT73E
DMFT73E DN Chorionic Gonadotropin
DMFT73E HS Approved
DMFT73E SN A.P.L.; Chorionic Gonadotropin; Follutein; Pregnyl
DMFT73E CP Ferring Pharmaceuticals Inc
DMFT73E DE Fertility problem
DM2NA4K ID DM2NA4K
DM2NA4K DN Ciclesonide
DM2NA4K HS Approved
DM2NA4K SN Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
DM2NA4K CP Altana Pharma
DM2NA4K TC Antiallergic Agents
DM2NA4K DT Small molecular drug
DM2NA4K PC 6918155
DM2NA4K MW 540.7
DM2NA4K FM C32H44O7
DM2NA4K IC InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
DM2NA4K CS CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6
DM2NA4K IK LUKZNWIVRBCLON-GXOBDPJESA-N
DM2NA4K IU [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
DM2NA4K CA CAS 126544-47-6
DM2NA4K CB CHEBI:31397
DM2NA4K DE Obstructive airway disease; Asthma
DMN5T2A ID DMN5T2A
DMN5T2A DN Ciclopirox
DMN5T2A HS Approved
DMN5T2A SN Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A TC Antifungal Agents
DMN5T2A DT Small molecular drug
DMN5T2A PC 2749
DMN5T2A MW 207.27
DMN5T2A FM C12H17NO2
DMN5T2A IC InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
DMN5T2A CS CC1=CC(=O)N(C(=C1)C2CCCCC2)O
DMN5T2A IK SCKYRAXSEDYPSA-UHFFFAOYSA-N
DMN5T2A IU 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A CA CAS 29342-05-0
DMN5T2A CB CHEBI:453011
DMN5T2A DE Fungal infection
DMAZJFX ID DMAZJFX
DMAZJFX DN Ciclosporin
DMAZJFX HS Approved
DMAZJFX SN Ciclosporin; Ciclosporin (Ciclosporin A); Ciclosporina; Ciclosporina [INN-Spanish]; Ciclosporine; Ciclosporine [INN-French]; Ciclosporinum; Ciclosporinum [INN-Latin]; Cipol N; Consupren; Cyclosporin; Cyclosporine A; Equoral; Antibiotic S 7481F1; Gengraf; Neoplanta; Neoral; Ramihyphin A; Restasis; S-Neoral; Sandimmun; Sandimmun Neoral; Sandimmune; Sang 35; Sang-35; SangCyA; Sigmasporin Microoral; cyclosporin A; cyclosporine; 59865-13-3; 83HN0GTJ6D; CHEBI:4031; CSA; DSSTox_CID_365; DSSTox_RID_75541; MFCD00274558; MLS001333756; UNII-83HN0GTJ6D
DMAZJFX PC 5284373
DMAZJFX MW 1202.6
DMAZJFX FM C62H111N11O12
DMAZJFX IC PMATZTZNYRCHOR-CGLBZJNRSA-N
DMAZJFX CS CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMAZJFX IK 1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
DMAZJFX IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMAZJFX CA CAS 59865-13-3
DMAZJFX CB CHEBI:4031
DMAZJFX DE Viral hepatitis
DMT2KRV ID DMT2KRV
DMT2KRV DN Ciclosporin
DMT2KRV HS Approved
DMT2KRV SN Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMT2KRV CP Sandoz
DMT2KRV TC Immunosuppressive Agents
DMT2KRV DT Protein/peptide drug
DMT2KRV PC 24883466
DMT2KRV MW 1202.6
DMT2KRV FM C62H111N11O12
DMT2KRV IC InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMT2KRV CS CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMT2KRV IK PMATZTZNYRCHOR-VJRYSDSKSA-N
DMT2KRV IU (3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMT2KRV CA CAS 59865-13-3
DMT2KRV DE Psoriasis vulgaris; Xerophthalmia; Brain injury
DMA13GD ID DMA13GD
DMA13GD DN Cidofovir
DMA13GD HS Approved
DMA13GD SN CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
DMA13GD CP Pfizer Pharmaceuticals
DMA13GD TC Anti-HIV Agents
DMA13GD DT Small molecular drug
DMA13GD PC 60613
DMA13GD MW 279.19
DMA13GD FM C8H14N3O6P
DMA13GD IC InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
DMA13GD CS C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
DMA13GD IK VWFCHDSQECPREK-LURJTMIESA-N
DMA13GD IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
DMA13GD CA CAS 113852-37-2
DMA13GD CB CHEBI:3696
DMA13GD DE Cytomegalovirus infection
DME2H5T ID DME2H5T
DME2H5T DN Cilastatin
DME2H5T HS Approved
DME2H5T SN Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CP Merck
DME2H5T TC Antibiotics
DME2H5T DT Small molecular drug
DME2H5T PC 6435415
DME2H5T MW 358.5
DME2H5T FM C16H26N2O5S
DME2H5T IC InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1
DME2H5T CS CC1(C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@@H](C(=O)O)N)/C(=O)O)C
DME2H5T IK DHSUYTOATWAVLW-WFVMDLQDSA-N
DME2H5T IU (Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CA CAS 82009-34-5
DME2H5T CB CHEBI:3697
DME2H5T DE Bacterial infection
DM4V6JA ID DM4V6JA
DM4V6JA DN Cilazapril
DM4V6JA HS Approved
DM4V6JA SN Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate
DM4V6JA TC Antihypertensive Agents
DM4V6JA DT Small molecular drug
DM4V6JA PC 56330
DM4V6JA MW 417.5
DM4V6JA FM C22H31N3O5
DM4V6JA IC InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
DM4V6JA CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O
DM4V6JA IK HHHKFGXWKKUNCY-FHWLQOOXSA-N
DM4V6JA IU (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
DM4V6JA CA CAS 88768-40-5
DM4V6JA CB CHEBI:3698
DM4V6JA DE Congestive heart failure
DMZMSCT ID DMZMSCT
DMZMSCT DN Cilostazol
DMZMSCT HS Approved
DMZMSCT SN cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
DMZMSCT CP Otsuka Pharmaceutical Co
DMZMSCT TC Vasodilator Agents
DMZMSCT DT Small molecular drug
DMZMSCT PC 2754
DMZMSCT MW 369.5
DMZMSCT FM C20H27N5O2
DMZMSCT IC InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
DMZMSCT CS C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
DMZMSCT IK RRGUKTPIGVIEKM-UHFFFAOYSA-N
DMZMSCT IU 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
DMZMSCT CA CAS 73963-72-1
DMZMSCT CB CHEBI:31401
DMZMSCT DE Intermittent claudication
DMH61ZB ID DMH61ZB
DMH61ZB DN Cimetidine
DMH61ZB HS Approved
DMH61ZB SN Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
DMH61ZB CP GlaxoSmithKline
DMH61ZB TC Antiulcer Agents
DMH61ZB DT Small molecular drug
DMH61ZB PC 2756
DMH61ZB MW 252.34
DMH61ZB FM C10H16N6S
DMH61ZB IC InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
DMH61ZB CS CC1=C(N=CN1)CSCCNC(=NC)NC#N
DMH61ZB IK AQIXAKUUQRKLND-UHFFFAOYSA-N
DMH61ZB IU 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMH61ZB CA CAS 51481-61-9
DMH61ZB CB CHEBI:3699
DMH61ZB DE Acid-reflux disorder
DMZHPNE ID DMZHPNE
DMZHPNE DN Cimetropium bromide
DMZHPNE HS Approved
DMZHPNE SN Alginor (TN)
DMZHPNE CP DeAngelini
DMZHPNE DT Small molecular drug
DMZHPNE PC 20054870
DMZHPNE MW 438.4
DMZHPNE FM C21H28BrNO4
DMZHPNE IC InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1
DMZHPNE CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5.[Br-]
DMZHPNE IK WDURTRGFUGAJHA-HNHWXVNLSA-M
DMZHPNE IU [(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMZHPNE CA CAS 51598-60-8
DMZHPNE DE Spasm; Gastric motility disorder
DMCX0K3 ID DMCX0K3
DMCX0K3 DN Cinacalcet
DMCX0K3 HS Approved
DMCX0K3 SN Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
DMCX0K3 CP Amgen
DMCX0K3 TC Calcimimetics
DMCX0K3 DT Small molecular drug
DMCX0K3 PC 156419
DMCX0K3 MW 357.4
DMCX0K3 FM C22H22F3N
DMCX0K3 IC InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
DMCX0K3 CS C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
DMCX0K3 IK VDHAWDNDOKGFTD-MRXNPFEDSA-N
DMCX0K3 IU N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
DMCX0K3 CA CAS 226256-56-0
DMCX0K3 CB CHEBI:48390
DMCX0K3 DE Hyperparathyroidism; Kidney disease
DMFIC0M ID DMFIC0M
DMFIC0M DN Cinalukast
DMFIC0M HS Approved
DMFIC0M SN Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M TC Antiarrhythmic Agents
DMFIC0M DT Small molecular drug
DMFIC0M PC 6436135
DMFIC0M MW 412.5
DMFIC0M FM C23H28N2O3S
DMFIC0M IC InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
DMFIC0M CS CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C3CCC3)C(=O)O
DMFIC0M IK BZMKNPGKXJAIDV-VAWYXSNFSA-N
DMFIC0M IU 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M CA CAS 128312-51-6
DMFIC0M CB CHEBI:126598
DMFIC0M DE Asthma
DM7U5QJ ID DM7U5QJ
DM7U5QJ DN Cinnarizine
DM7U5QJ HS Approved
DM7U5QJ SN Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine
DM7U5QJ CP Janssen Pharmaceutica
DM7U5QJ TC Antiallergic Agents
DM7U5QJ DT Small molecular drug
DM7U5QJ PC 1547484
DM7U5QJ MW 368.5
DM7U5QJ FM C26H28N2
DM7U5QJ IC InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
DM7U5QJ CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7U5QJ IK DERZBLKQOCDDDZ-JLHYYAGUSA-N
DM7U5QJ IU 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine
DM7U5QJ CA CAS 16699-20-0
DM7U5QJ CB CHEBI:31403
DM7U5QJ DE Vertigo meniere disease
DMDX1ZC ID DMDX1ZC
DMDX1ZC DN Cinolazepam
DMDX1ZC HS Approved
DMDX1ZC SN Cinolazepamum; Gerodorm; Cinolazepam [INN]; OX 373; Cinolazepam (INN); Cinolazepamum [INN-Latin]; Gerodorm (TN); OX-373;1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile
DMDX1ZC TC Anticonvulsants
DMDX1ZC DT Small molecular drug
DMDX1ZC PC 3033621
DMDX1ZC MW 357.8
DMDX1ZC FM C18H13ClFN3O2
DMDX1ZC IC InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
DMDX1ZC CS C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F
DMDX1ZC IK XAXMYHMKTCNRRZ-UHFFFAOYSA-N
DMDX1ZC IU 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile
DMDX1ZC CA CAS 75696-02-5
DMDX1ZC CB CHEBI:59514
DMDX1ZC DE Muscle spasm
DM4EWNS ID DM4EWNS
DM4EWNS DN Cinoxacin
DM4EWNS HS Approved
DM4EWNS SN Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS TC Antiinfective Agents
DM4EWNS DT Small molecular drug
DM4EWNS PC 2762
DM4EWNS MW 262.22
DM4EWNS FM C12H10N2O5
DM4EWNS IC InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
DM4EWNS CS CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
DM4EWNS IK VDUWPHTZYNWKRN-UHFFFAOYSA-N
DM4EWNS IU 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS CA CAS 28657-80-9
DM4EWNS CB CHEBI:3716
DM4EWNS DE Urinary tract infection
DMVIKJZ ID DMVIKJZ
DMVIKJZ DN Cinryze
DMVIKJZ HS Approved
DMVIKJZ DE Hereditary angioedema
DMGC5DB ID DMGC5DB
DMGC5DB DN Ciprofibrate
DMGC5DB HS Approved
DMGC5DB SN Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid
DMGC5DB TC Anticancer Agents
DMGC5DB DT Small molecular drug
DMGC5DB PC 2763
DMGC5DB MW 289.15
DMGC5DB FM C13H14Cl2O3
DMGC5DB IC InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
DMGC5DB CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
DMGC5DB IK KPSRODZRAIWAKH-UHFFFAOYSA-N
DMGC5DB IU 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
DMGC5DB CA CAS 52214-84-3
DMGC5DB CB CHEBI:50867
DMGC5DB DE Hyperlipoproteinemia
DM2NLS9 ID DM2NLS9
DM2NLS9 DN Ciprofloxacin XR
DM2NLS9 HS Approved
DM2NLS9 SN ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
DM2NLS9 CP Depomed Bayer
DM2NLS9 DT Small molecular drug
DM2NLS9 PC 2764
DM2NLS9 MW 331.34
DM2NLS9 FM C17H18FN3O3
DM2NLS9 IC InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
DM2NLS9 CS C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DM2NLS9 IK MYSWGUAQZAJSOK-UHFFFAOYSA-N
DM2NLS9 IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DM2NLS9 CA CAS 85721-33-1
DM2NLS9 CB CHEBI:100241
DM2NLS9 DE Bacterial infection; Gram-positive bacterial infection; Biliary cancer; Cystic fibrosis
DMZR26N ID DMZR26N
DMZR26N DN Ciprofloxacin+dexamethasone
DMZR26N HS Approved
DMZR26N SN CIPRODEX; Ciprofloxacin mixture with dexamethasone; 130244-48-3; Ciprodex Otic; Ciprofloxacin / dexamethasone; Ciprofloxacin and dexamethasone; Ciprofloxacin-dexamethasone Mixt.; SCHEMBL2523572; DTXSID50156420; NTRHYMXQWWPZDD-WKSAPEMMSA-N; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
DMZR26N CP Alcon
DMZR26N DT Small molecular drug
DMZR26N PC 9961920
DMZR26N MW 723.8
DMZR26N FM C39H47F2N3O8
DMZR26N IC InChI=1S/C22H29FO5.C17H18FN3O3/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;7-10,19H,1-6H2,(H,23,24)/t12-,15+,16+,17+,19+,20+,21+,22+;/m1./s1
DMZR26N CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DMZR26N IK NTRHYMXQWWPZDD-WKSAPEMMSA-N
DMZR26N IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZR26N CA CAS 130244-48-3
DMZR26N DE Otitis externa; Acute otitis media
DMY7PED ID DMY7PED
DMY7PED DN Cisapride
DMY7PED HS Approved
DMY7PED SN cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825; Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454
DMY7PED CP Janssen Pharmaceutica
DMY7PED TC Gastrointestinal Agents
DMY7PED DT Small molecular drug
DMY7PED PC 6917698
DMY7PED MW 465.9
DMY7PED FM C23H29ClFN3O4
DMY7PED IC InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
DMY7PED CS CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
DMY7PED IK DCSUBABJRXZOMT-IRLDBZIGSA-N
DMY7PED IU 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
DMY7PED CA CAS 81098-60-4
DMY7PED CB CHEBI:3720
DMY7PED DE Gastroesophageal reflux disease; Gastrointestinal disease
DMUZPJ5 ID DMUZPJ5
DMUZPJ5 DN Cisatracurium
DMUZPJ5 HS Approved
DMUZPJ5 SN Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free
DMUZPJ5 CP Abbvie Inc
DMUZPJ5 DT Small molecular drug
DMUZPJ5 PC 62887
DMUZPJ5 MW 929.1
DMUZPJ5 FM C53H72N2O12+2
DMUZPJ5 IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
DMUZPJ5 CS C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DMUZPJ5 IK YXSLJKQTIDHPOT-LJCJQEJUSA-N
DMUZPJ5 IU 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DMUZPJ5 CA CAS 96946-41-7
DMUZPJ5 CB CHEBI:140621
DMUZPJ5 DE Muscle spasm
DMRHGI9 ID DMRHGI9
DMRHGI9 DN Cisplatin
DMRHGI9 HS Approved
DMRHGI9 SN Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
DMRHGI9 CP Bristol-Myers Squibb
DMRHGI9 TC Anticancer Agents
DMRHGI9 DT Small molecular drug
DMRHGI9 PC 5702198
DMRHGI9 MW 300.05
DMRHGI9 FM Cl2H6N2Pt
DMRHGI9 IC InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
DMRHGI9 CS N.N.Cl[Pt]Cl
DMRHGI9 IK LXZZYRPGZAFOLE-UHFFFAOYSA-L
DMRHGI9 IU azane;dichloroplatinum
DMRHGI9 CA CAS 15663-27-1
DMRHGI9 DE Solid tumour/cancer; Osteosarcoma
DM2G9AE ID DM2G9AE
DM2G9AE DN Citalopram
DM2G9AE HS Approved
DM2G9AE SN Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CP Forest Laboratories, Inc
DM2G9AE TC Antidepressants
DM2G9AE DT Small molecular drug
DM2G9AE PC 2771
DM2G9AE MW 324.4
DM2G9AE FM C20H21FN2O
DM2G9AE IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DM2G9AE CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DM2G9AE IK WSEQXVZVJXJVFP-UHFFFAOYSA-N
DM2G9AE IU 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CA CAS 59729-33-8
DM2G9AE CB CHEBI:77397
DM2G9AE DE Depression
DMI4XBM ID DMI4XBM
DMI4XBM DN Citicoline
DMI4XBM HS Approved
DMI4XBM SN Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine
DMI4XBM CP Ferrer Internacional SA
DMI4XBM DT Small molecular drug
DMI4XBM PC 13804
DMI4XBM MW 488.32
DMI4XBM FM C14H26N4O11P2
DMI4XBM IC InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1
DMI4XBM CS C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O
DMI4XBM IK RZZPDXZPRHQOCG-OJAKKHQRSA-N
DMI4XBM IU [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
DMI4XBM CA CAS 987-78-0
DMI4XBM CB CHEBI:16436
DMI4XBM DE Cerebrovascular ischaemia
DMMEBWR ID DMMEBWR
DMMEBWR DN Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR HS Approved
DMMEBWR SN Prepopik (TN)
DMMEBWR CP Ferring Pharmaceuticals
DMMEBWR DT Small molecular drug
DMMEBWR PC 68654
DMMEBWR MW 481.4
DMMEBWR FM C18H13NNa2O8S2
DMMEBWR IC InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMMEBWR CS C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+]
DMMEBWR IK GOZDTZWAMGHLDY-UHFFFAOYSA-L
DMMEBWR IU disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate
DMMEBWR CA CAS 10040-45-6
DMMEBWR CB CHEBI:32147
DMMEBWR DE Crohn disease
DM3JDRP ID DM3JDRP
DM3JDRP DN Cladribine
DM3JDRP HS Approved
DM3JDRP SN Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
DM3JDRP CP EMD Serono Rockland, MA
DM3JDRP TC Anticancer Agents
DM3JDRP DT Small molecular drug
DM3JDRP PC 20279
DM3JDRP MW 285.69
DM3JDRP FM C10H12ClN5O3
DM3JDRP IC InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
DM3JDRP CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
DM3JDRP IK PTOAARAWEBMLNO-KVQBGUIXSA-N
DM3JDRP IU (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DM3JDRP CA CAS 4291-63-8
DM3JDRP CB CHEBI:567361
DM3JDRP DE Multiple sclerosis; Relapsing-remitting multiple sclerosis; Hairy cell leukaemia
DM4M1SG ID DM4M1SG
DM4M1SG DN Clarithromycin
DM4M1SG HS Approved
DM4M1SG SN Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
DM4M1SG CP Abbott Laboratories
DM4M1SG TC Antibiotics
DM4M1SG DT Small molecular drug
DM4M1SG PC 84029
DM4M1SG MW 748
DM4M1SG FM C38H69NO13
DM4M1SG IC InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DM4M1SG CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
DM4M1SG IK AGOYDEPGAOXOCK-KCBOHYOISA-N
DM4M1SG IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4M1SG CA CAS 81103-11-9
DM4M1SG CB CHEBI:3732
DM4M1SG DE Bacterial infection
DMPGR1E ID DMPGR1E
DMPGR1E DN Clascoterone
DMPGR1E HS Approved
DMPGR1E SN CB-03-01
DMPGR1E CP Cosmo Pharmaceuticals SpA
DMPGR1E DT Small molecular drug
DMPGR1E PC 11750009
DMPGR1E MW 402.5
DMPGR1E FM C24H34O5
DMPGR1E IC InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1
DMPGR1E CS CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
DMPGR1E IK GPNHMOZDMYNCPO-PDUMRIMRSA-N
DMPGR1E IU [(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate
DMPGR1E CA CAS 19608-29-8
DMPGR1E DE Acne vulgaris
DM2FGRT ID DM2FGRT
DM2FGRT DN Clavulanate
DM2FGRT HS Approved
DM2FGRT SN Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))
DM2FGRT CP GlaxoSmithKline
DM2FGRT TC Antibiotics
DM2FGRT DT Small molecular drug
DM2FGRT PC 5280980
DM2FGRT MW 199.16
DM2FGRT FM C8H9NO5
DM2FGRT IC InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
DM2FGRT CS C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O
DM2FGRT IK HZZVJAQRINQKSD-PBFISZAISA-N
DM2FGRT IU (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM2FGRT CA CAS 58001-44-8
DM2FGRT CB CHEBI:48947
DM2FGRT DE Bacterial infection
DMBZWQL ID DMBZWQL
DMBZWQL DN Clemastine
DMBZWQL HS Approved
DMBZWQL SN Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
DMBZWQL CP Norvatis Phamaceuticals Corporation
DMBZWQL TC Antiallergic Agents
DMBZWQL DT Small molecular drug
DMBZWQL PC 26987
DMBZWQL MW 343.9
DMBZWQL FM C21H26ClNO
DMBZWQL IC InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
DMBZWQL CS C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
DMBZWQL IK YNNUSGIPVFPVBX-NHCUHLMSSA-N
DMBZWQL IU (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
DMBZWQL CA CAS 15686-51-8
DMBZWQL CB CHEBI:3738
DMBZWQL DE Allergic rhinitis
DMCKYZ5 ID DMCKYZ5
DMCKYZ5 DN Clenbuterol
DMCKYZ5 HS Approved
DMCKYZ5 SN Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
DMCKYZ5 TC Bronchodilator Agents
DMCKYZ5 DT Small molecular drug
DMCKYZ5 PC 2783
DMCKYZ5 MW 277.19
DMCKYZ5 FM C12H18Cl2N2O
DMCKYZ5 IC InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
DMCKYZ5 CS CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
DMCKYZ5 IK STJMRWALKKWQGH-UHFFFAOYSA-N
DMCKYZ5 IU 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
DMCKYZ5 CA CAS 37148-27-9
DMCKYZ5 CB CHEBI:174690
DMCKYZ5 DE Chronic breathing disorder
DMW4M97 ID DMW4M97
DMW4M97 DN Clevidipine butyrate
DMW4M97 HS Approved
DMW4M97 SN Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3
DMW4M97 CP The Medicines Company
DMW4M97 DT Small molecular drug
DMW4M97 PC 153994
DMW4M97 MW 456.3
DMW4M97 FM C21H23Cl2NO6
DMW4M97 IC InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
DMW4M97 CS CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMW4M97 IK KPBZROQVTHLCDU-UHFFFAOYSA-N
DMW4M97 IU 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMW4M97 CA CAS 167221-71-8
DMW4M97 CB CHEBI:135738
DMW4M97 DE Hypertension
DMUMQZ0 ID DMUMQZ0
DMUMQZ0 DN Clidinium
DMUMQZ0 HS Approved
DMUMQZ0 SN clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,; Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CP Hoffmann La Roche Inc
DMUMQZ0 TC Analgesics
DMUMQZ0 DT Small molecular drug
DMUMQZ0 PC 2784
DMUMQZ0 MW 352.4
DMUMQZ0 FM C22H26NO3+
DMUMQZ0 IC InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1
DMUMQZ0 CS C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMUMQZ0 IK HOOSGZJRQIVJSZ-UHFFFAOYSA-N
DMUMQZ0 IU (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CA CAS 7020-55-5
DMUMQZ0 CB CHEBI:3743
DMUMQZ0 DE Irritable bowel syndrome; Abdominal stomach pain
DM15HL8 ID DM15HL8
DM15HL8 DN Clindamycin
DM15HL8 HS Approved
DM15HL8 SN Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
DM15HL8 CP Pharmacia And Upjohn Co
DM15HL8 TC Antibiotics
DM15HL8 DT Small molecular drug
DM15HL8 PC 446598
DM15HL8 MW 425
DM15HL8 FM C18H33ClN2O5S
DM15HL8 IC InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
DM15HL8 CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
DM15HL8 IK KDLRVYVGXIQJDK-AWPVFWJPSA-N
DM15HL8 IU (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DM15HL8 CA CAS 18323-44-9
DM15HL8 DE Acne vulgaris
DMW1OQ0 ID DMW1OQ0
DMW1OQ0 DN Clobazam - Lundbeck
DMW1OQ0 HS Approved
DMW1OQ0 SN Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410; Onfi
DMW1OQ0 TC Neurology Agents
DMW1OQ0 DT Small molecular drug
DMW1OQ0 PC 2789
DMW1OQ0 MW 300.74
DMW1OQ0 FM C16H13ClN2O2
DMW1OQ0 IC InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMW1OQ0 CS CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMW1OQ0 IK CXOXHMZGEKVPMT-UHFFFAOYSA-N
DMW1OQ0 IU 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
DMW1OQ0 CA CAS 22316-47-8
DMW1OQ0 CB CHEBI:31413
DMW1OQ0 DE Anxiety disorder; Epilepsy
DMUXP52 ID DMUXP52
DMUXP52 DN Clobetasol
DMUXP52 HS Approved
DMUXP52 SN Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
DMUXP52 CP Fougera Pharmaceuticals Inc
DMUXP52 TC Antiinflammatory Agents
DMUXP52 DT Small molecular drug
DMUXP52 PC 5311051
DMUXP52 MW 410.9
DMUXP52 FM C22H28ClFO4
DMUXP52 IC InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMUXP52 CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C
DMUXP52 IK FCSHDIVRCWTZOX-DVTGEIKXSA-N
DMUXP52 IU (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUXP52 CA CAS 25122-41-2
DMUXP52 CB CHEBI:205919
DMUXP52 DE Rosacea; Oral lichen planus
DM9ZMQH ID DM9ZMQH
DM9ZMQH DN Clocortolone
DM9ZMQH HS Approved
DM9ZMQH SN Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
DM9ZMQH CP Promius Pharma Llc
DM9ZMQH DT Small molecular drug
DM9ZMQH PC 5311052
DM9ZMQH MW 410.9
DM9ZMQH FM C22H28ClFO4
DM9ZMQH IC InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
DM9ZMQH CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)Cl)C)F
DM9ZMQH IK YMTMADLUXIRMGX-RFPWEZLHSA-N
DM9ZMQH IU (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM9ZMQH CA CAS 4828-27-7
DM9ZMQH CB CHEBI:59582
DM9ZMQH DE Rosacea
DM9Y6X7 ID DM9Y6X7
DM9Y6X7 DN Clodronate
DM9Y6X7 HS Approved
DM9Y6X7 SN Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)
DM9Y6X7 TC Antihypocalcemic Agents
DM9Y6X7 DT Small molecular drug
DM9Y6X7 PC 25419
DM9Y6X7 MW 244.89
DM9Y6X7 FM CH4Cl2O6P2
DM9Y6X7 IC InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
DM9Y6X7 CS C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
DM9Y6X7 IK ACSIXWWBWUQEHA-UHFFFAOYSA-N
DM9Y6X7 IU [dichloro(phosphono)methyl]phosphonic acid
DM9Y6X7 CA CAS 10596-23-3
DM9Y6X7 CB CHEBI:110423
DM9Y6X7 DE Hypercalcaemia
DMCVJ86 ID DMCVJ86
DMCVJ86 DN Clofarabine
DMCVJ86 HS Approved
DMCVJ86 SN CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
DMCVJ86 TC Anticancer Agents
DMCVJ86 DT Small molecular drug
DMCVJ86 PC 119182
DMCVJ86 MW 303.68
DMCVJ86 FM C10H11ClFN5O3
DMCVJ86 IC InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
DMCVJ86 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
DMCVJ86 IK WDDPHFBMKLOVOX-AYQXTPAHSA-N
DMCVJ86 IU (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
DMCVJ86 CA CAS 123318-82-1
DMCVJ86 CB CHEBI:681569
DMCVJ86 DE Acute lymphoblastic leukaemia; Myelodysplastic syndrome
DMEBOFW ID DMEBOFW
DMEBOFW DN Clofazimine
DMEBOFW HS Approved
DMEBOFW SN clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
DMEBOFW CP Norvatis Phamaceuticals Corporation
DMEBOFW TC Antiinflammatory Agents
DMEBOFW DT Small molecular drug
DMEBOFW PC 2794
DMEBOFW MW 473.4
DMEBOFW FM C27H22Cl2N4
DMEBOFW IC InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
DMEBOFW CS CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
DMEBOFW IK WDQPAMHFFCXSNU-UHFFFAOYSA-N
DMEBOFW IU N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
DMEBOFW CA CAS 2030-63-9
DMEBOFW CB CHEBI:3749
DMEBOFW DE Crohn disease; Mycobacterium infection
DMPC1J7 ID DMPC1J7
DMPC1J7 DN Clofibrate
DMPC1J7 HS Approved
DMPC1J7 SN Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate
DMPC1J7 CP Ayerst Laboratories Inc
DMPC1J7 TC Antilipemic Agents
DMPC1J7 DT Small molecular drug
DMPC1J7 PC 2796
DMPC1J7 MW 242.7
DMPC1J7 FM C12H15ClO3
DMPC1J7 IC InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
DMPC1J7 CS CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
DMPC1J7 IK KNHUKKLJHYUCFP-UHFFFAOYSA-N
DMPC1J7 IU ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
DMPC1J7 CA CAS 637-07-0
DMPC1J7 CB CHEBI:3750
DMPC1J7 DE Dysbetalipoproteinemia
DMKI7RB ID DMKI7RB
DMKI7RB DN Clomifene
DMKI7RB HS Approved
DMKI7RB SN Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine
DMKI7RB TC Fertility Agents
DMKI7RB DT Small molecular drug
DMKI7RB PC 1548953
DMKI7RB MW 406
DMKI7RB FM C26H28ClNO
DMKI7RB IC InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
DMKI7RB CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
DMKI7RB IK GKIRPKYJQBWNGO-OCEACIFDSA-N
DMKI7RB IU 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
DMKI7RB CA CAS 15690-57-0
DMKI7RB CB CHEBI:3752
DMKI7RB DE Female infertility
DMS51VC ID DMS51VC
DMS51VC DN Clomiphene citrate
DMS51VC HS Approved
DMS51VC SN Clomid; Milophene; Serophene
DMS51VC CP Sanofi Aventis Us Llc
DMS51VC DT Small molecular drug
DMS51VC PC 3033832
DMS51VC MW 598.1
DMS51VC FM C32H36ClNO8
DMS51VC IC InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
DMS51VC CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMS51VC IK PYTMYKVIJXPNBD-OQKDUQJOSA-N
DMS51VC IU 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMS51VC CA CAS 7619-53-6
DMS51VC DE Female infertility
DMINRKW ID DMINRKW
DMINRKW DN Clomipramine
DMINRKW HS Approved
DMINRKW SN Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)
DMINRKW CP Norvatis Phamaceuticals Corporation
DMINRKW TC Antidepressants
DMINRKW DT Small molecular drug
DMINRKW PC 2801
DMINRKW MW 314.9
DMINRKW FM C19H23ClN2
DMINRKW IC InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
DMINRKW CS CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMINRKW IK GDLIGKIOYRNHDA-UHFFFAOYSA-N
DMINRKW IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DMINRKW CA CAS 303-49-1
DMINRKW CB CHEBI:47780
DMINRKW DE Depression
DM0ZRMQ ID DM0ZRMQ
DM0ZRMQ DN Clomocycline
DM0ZRMQ HS Approved
DM0ZRMQ SN Chlormethylenecycline; Clomociclina; Clomocyclina; Clomocyclinum; Clomociclina [INN-Spanish]; Clomocycline (INN); Clomocycline [INN:BAN]; Clomocyclinum [INN-Latin]; N-2-Hydroxymethylchlortetracycline; N'-Methylolo-chlortetracycline; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
DM0ZRMQ TC Antibiotics
DM0ZRMQ DT Small molecular drug
DM0ZRMQ PC 54680675
DM0ZRMQ MW 508.9
DM0ZRMQ FM C23H25ClN2O9
DM0ZRMQ IC InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-29,32,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1
DM0ZRMQ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)NCO)N(C)C)O
DM0ZRMQ IK BXTHDFJCJQJHKD-KMVLDZISSA-N
DM0ZRMQ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DM0ZRMQ CA CAS 1181-54-0
DM0ZRMQ CB CHEBI:59589
DM0ZRMQ DE Bacterial infection
DMTO13J ID DMTO13J
DMTO13J DN Clonazepam
DMTO13J HS Approved
DMTO13J SN Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
DMTO13J CP Roche Pharmaceuticals
DMTO13J TC Anticonvulsants
DMTO13J DT Small molecular drug
DMTO13J PC 2802
DMTO13J MW 315.71
DMTO13J FM C15H10ClN3O3
DMTO13J IC InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
DMTO13J CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
DMTO13J IK DGBIGWXXNGSACT-UHFFFAOYSA-N
DMTO13J IU 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
DMTO13J CA CAS 1622-61-3
DMTO13J CB CHEBI:3756
DMTO13J DE Epilepsy; Seizure disorder
DM6RZ9Q ID DM6RZ9Q
DM6RZ9Q DN Clonidine
DM6RZ9Q HS Approved
DM6RZ9Q SN clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
DM6RZ9Q CP Intas Pharmaceuticals
DM6RZ9Q TC Antihypertensive Agents
DM6RZ9Q DT Small molecular drug
DM6RZ9Q PC 2803
DM6RZ9Q MW 230.09
DM6RZ9Q FM C9H9Cl2N3
DM6RZ9Q IC InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
DM6RZ9Q CS C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
DM6RZ9Q IK GJSURZIOUXUGAL-UHFFFAOYSA-N
DM6RZ9Q IU N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
DM6RZ9Q CA CAS 4205-90-7
DM6RZ9Q CB CHEBI:3757
DM6RZ9Q DE Hypertension; Diabetic neuropathy
DMOL54H ID DMOL54H
DMOL54H DN Clopidogrel
DMOL54H HS Approved
DMOL54H SN clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
DMOL54H CP Prism Pharmaceuticals Inc
DMOL54H DT Small molecular drug
DMOL54H PC 60606
DMOL54H MW 321.8
DMOL54H FM C16H16ClNO2S
DMOL54H IC InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
DMOL54H CS COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
DMOL54H IK GKTWGGQPFAXNFI-HNNXBMFYSA-N
DMOL54H IU methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
DMOL54H CA CAS 113665-84-2
DMOL54H CB CHEBI:37941
DMOL54H DE Thrombosis
DMC3JST ID DMC3JST
DMC3JST DN Clorazepate
DMC3JST HS Approved
DMC3JST SN Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CP Taro Pharmaceutical Industries Ltd
DMC3JST TC Hypnotics and Sedatives
DMC3JST DT Small molecular drug
DMC3JST PC 2809
DMC3JST MW 314.72
DMC3JST FM C16H11ClN2O3
DMC3JST IC InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
DMC3JST CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
DMC3JST IK XDDJGVMJFWAHJX-UHFFFAOYSA-N
DMC3JST IU 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CA CAS 23887-31-2
DMC3JST CB CHEBI:3761
DMC3JST DE Anxiety disorder
DMCEUJD ID DMCEUJD
DMCEUJD DN Clorgyline
DMCEUJD HS Approved
DMCEUJD SN Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD TC Antiparkinson Agents
DMCEUJD DT Small molecular drug
DMCEUJD PC 4380
DMCEUJD MW 272.17
DMCEUJD FM C13H15Cl2NO
DMCEUJD IC InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3
DMCEUJD CS CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C
DMCEUJD IK BTFHLQRNAMSNLC-UHFFFAOYSA-N
DMCEUJD IU 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD CA CAS 17780-72-2
DMCEUJD CB CHEBI:3763
DMCEUJD DE Skin imperfections; Parkinson disease
DM6K1OA ID DM6K1OA
DM6K1OA DN Clothiapine
DM6K1OA HS Approved
DM6K1OA SN Clothiapine; Clotiapine; 2058-52-8; Entumine; Entumin; Etumine; HF 2159; Clotiapinum [INN-Latin]; Clotiapina [INN-Spanish]; UNII-Z05HCY0X1T; S-805C; Clothiapine [USAN]; EINECS 218-162-8; LW 2159; C18H18ClN3S; BRN 0568276; Z05HCY0X1T; CHEMBL304902; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine; KAAZGXDPUNNEFN-UHFFFAOYSA-N; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; Clothiapine (USAN); HF-2159; NCGC00160387-01
DM6K1OA DT Small molecular drug
DM6K1OA PC 16351
DM6K1OA MW 343.9
DM6K1OA FM C18H18ClN3S
DM6K1OA IC InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM6K1OA CS CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM6K1OA IK KAAZGXDPUNNEFN-UHFFFAOYSA-N
DM6K1OA IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine
DM6K1OA CA CAS 2058-52-8
DM6K1OA CB CHEBI:31424
DM6K1OA DE Schizophrenia
DM59AZT ID DM59AZT
DM59AZT DN Clotiazepam
DM59AZT HS Approved
DM59AZT SN Clotiazepamum; Clozan; Distensan; Rise; Rize; Rizen; Tienor; Trecalmo; Veratran; Y 6047; Clotiazepam [INN:JAN]; Clotiazepamum [INN-Latin]; Clozan (TN); Distensan (TN); Rize (TN); Rizen (TN); Trecalmo (TN); Veratran (TN); Y-6047; Clotiazepam (JP15/INN); 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-(8CI); 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one
DM59AZT TC Hypnotics and Sedatives
DM59AZT DT Small molecular drug
DM59AZT PC 2811
DM59AZT MW 318.8
DM59AZT FM C16H15ClN2OS
DM59AZT IC InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3
DM59AZT CS CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C
DM59AZT IK CHBRHODLKOZEPZ-UHFFFAOYSA-N
DM59AZT IU 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one
DM59AZT CA CAS 33671-46-4
DM59AZT CB CHEBI:31425
DM59AZT DE Anxiety disorder
DMMFCIH ID DMMFCIH
DMMFCIH DN Clotrimazole
DMMFCIH HS Approved
DMMFCIH SN Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole
DMMFCIH CP Bayer Pharmaceuticals Corporation
DMMFCIH TC Antifungal Agents
DMMFCIH DT Small molecular drug
DMMFCIH PC 2812
DMMFCIH MW 344.8
DMMFCIH FM C22H17ClN2
DMMFCIH IC InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
DMMFCIH CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
DMMFCIH IK VNFPBHJOKIVQEB-UHFFFAOYSA-N
DMMFCIH IU 1-[(2-chlorophenyl)-diphenylmethyl]imidazole
DMMFCIH CA CAS 23593-75-1
DMMFCIH CB CHEBI:3764
DMMFCIH DE Fungal infection
DMUTL7O ID DMUTL7O
DMUTL7O DN Cloxacillin
DMUTL7O HS Approved
DMUTL7O SN Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
DMUTL7O CP Beecham phamaceuticals
DMUTL7O TC Antibiotics
DMUTL7O DT Small molecular drug
DMUTL7O PC 6098
DMUTL7O MW 435.9
DMUTL7O FM C19H18ClN3O5S
DMUTL7O IC InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1
DMUTL7O CS CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMUTL7O IK LQOLIRLGBULYKD-JKIFEVAISA-N
DMUTL7O IU (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUTL7O CA CAS 61-72-3
DMUTL7O CB CHEBI:49566
DMUTL7O DE Bacterial infection
DMFC71L ID DMFC71L
DMFC71L DN Clozapine
DMFC71L HS Approved
DMFC71L SN Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
DMFC71L CP Sandoz
DMFC71L TC Antipsychotic Agents
DMFC71L DT Small molecular drug
DMFC71L PC 135398737
DMFC71L MW 326.8
DMFC71L FM C18H19ClN4
DMFC71L IC InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DMFC71L CS CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMFC71L IK QZUDBNBUXVUHMW-UHFFFAOYSA-N
DMFC71L IU 3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DMFC71L CA CAS 5786-21-0
DMFC71L CB CHEBI:3766
DMFC71L DE Schizophrenia
DMPC2QY ID DMPC2QY
DMPC2QY DN CNTO-1959
DMPC2QY HS Approved
DMPC2QY SN Guselkumab
DMPC2QY CP Janssen/Johnson & Johnson
DMPC2QY DT Antibody
DMPC2QY SQ Heavy chain: EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMPC2QY DE Plaque psoriasis; Asthma
DM8HBJI ID DM8HBJI
DM8HBJI DN Coagulation Factor IX
DM8HBJI HS Approved
DM8HBJI TC Anticoagulants
DM8HBJI DE Haemophilia B
DM6L4H2 ID DM6L4H2
DM6L4H2 DN Cobicistat
DM6L4H2 HS Approved
DM6L4H2 SN 1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl
DM6L4H2 CP GILEAD
DM6L4H2 DT Small molecular drug
DM6L4H2 PC 25151504
DM6L4H2 MW 776
DM6L4H2 FM C40H53N7O5S2
DM6L4H2 IC InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
DM6L4H2 CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DM6L4H2 IK ZCIGNRJZKPOIKD-CQXVEOKZSA-N
DM6L4H2 IU 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DM6L4H2 CA CAS 1004316-88-4
DM6L4H2 CB CHEBI:72291
DM6L4H2 DE Human immunodeficiency virus infection
DMDKXTO ID DMDKXTO
DMDKXTO DN Cobicistat/darunavir
DMDKXTO HS Approved
DMDKXTO SN Prezcobix; Cobicistat / darunavir; Darunavir / Cobicistat; Cobicistat and darunavir; Cobicistat mixture with darunavir; Darunavir and cobicistat
DMDKXTO CP Gilead Sciences
DMDKXTO DT Small molecular drug
DMDKXTO PC 57327017
DMDKXTO MW 1323.7
DMDKXTO FM C67H90N10O12S3
DMDKXTO IC InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1
DMDKXTO CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DMDKXTO IK CXORHDVSJFELCV-HWDLLDTBSA-N
DMDKXTO IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMDKXTO DE Human immunodeficiency virus infection
DMSOX7I ID DMSOX7I
DMSOX7I DN Cocaine
DMSOX7I HS Approved
DMSOX7I SN Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
DMSOX7I TC Anesthetics
DMSOX7I DT Small molecular drug
DMSOX7I PC 446220
DMSOX7I MW 303.35
DMSOX7I FM C17H21NO4
DMSOX7I IC InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
DMSOX7I CS CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC
DMSOX7I IK ZPUCINDJVBIVPJ-LJISPDSOSA-N
DMSOX7I IU methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMSOX7I CA CAS 50-36-2
DMSOX7I CB CHEBI:27958
DMSOX7I DE Anaesthesia
DMJX6ZG ID DMJX6ZG
DMJX6ZG DN Codeine
DMJX6ZG HS Approved
DMJX6ZG SN codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate
DMJX6ZG CP Forest Pharmaceuticals
DMJX6ZG TC Analgesics
DMJX6ZG DT Small molecular drug
DMJX6ZG PC 5284371
DMJX6ZG MW 299.4
DMJX6ZG FM C18H21NO3
DMJX6ZG IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMJX6ZG CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
DMJX6ZG IK OROGSEYTTFOCAN-DNJOTXNNSA-N
DMJX6ZG IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMJX6ZG CA CAS 76-57-3
DMJX6ZG CB CHEBI:16714
DMJX6ZG DE Pain; Cough
DM2POTE ID DM2POTE
DM2POTE DN Colchicine
DM2POTE HS Approved
DM2POTE SN Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine
DM2POTE TC Gout Suppressants
DM2POTE DT Small molecular drug
DM2POTE PC 6167
DM2POTE MW 399.4
DM2POTE FM C22H25NO6
DM2POTE IC InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DM2POTE CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DM2POTE IK IAKHMKGGTNLKSZ-INIZCTEOSA-N
DM2POTE IU N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM2POTE CA CAS 64-86-8
DM2POTE CB CHEBI:27882
DM2POTE DE Acute gouty arthritis
DMJ01D8 ID DMJ01D8
DMJ01D8 DN Colforsin daropate hci
DMJ01D8 HS Approved
DMJ01D8 SN Adehl (TN); Adele (TN)
DMJ01D8 CP Nippon Kayaku
DMJ01D8 DT Small molecular drug
DMJ01D8 PC 444028
DMJ01D8 MW 546.1
DMJ01D8 FM C27H44ClNO8
DMJ01D8 IC InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1
DMJ01D8 CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl
DMJ01D8 IK VIRRLEDAYYYTOD-YHEOSNBFSA-N
DMJ01D8 IU [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 3-(dimethylamino)propanoate;hydrochloride
DMJ01D8 CA CAS 138605-00-2
DMJ01D8 CB CHEBI:31429
DMJ01D8 DE Asthma
DMZ9BMU ID DMZ9BMU
DMZ9BMU DN Colistimethate
DMZ9BMU HS Approved
DMZ9BMU SN Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable
DMZ9BMU TC Antibiotics
DMZ9BMU DT Small molecular drug
DMZ9BMU PC 216258
DMZ9BMU MW 1749.8
DMZ9BMU FM C58H105N16Na5O28S5
DMZ9BMU IC InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
DMZ9BMU CS CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
DMZ9BMU IK IQWHCHZFYPIVRV-UHFFFAOYSA-I
DMZ9BMU IU pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
DMZ9BMU CA CAS 8068-28-8
DMZ9BMU DE Respiratory tract infection
DMMD9QE ID DMMD9QE
DMMD9QE DN Colistin
DMMD9QE HS Approved
DMMD9QE SN Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)
DMMD9QE CP Parkdale Pharmaceuticals
DMMD9QE TC Antibiotics
DMMD9QE DT Small molecular drug
DMMD9QE PC 5311054
DMMD9QE MW 1155.4
DMMD9QE FM C52H98N16O13
DMMD9QE IC InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1
DMMD9QE CS CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O
DMMD9QE IK YKQOSKADJPQZHB-QNPLFGSASA-N
DMMD9QE IU N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
DMMD9QE CA CAS 1066-17-7
DMMD9QE DE Pseudomonas infection
DMFJ2OG ID DMFJ2OG
DMFJ2OG DN Collagenase
DMFJ2OG HS Approved
DMFJ2OG TC Antiulcer Agents
DMFJ2OG DE Skin burns; Dermal ulcers
DM1V329 ID DM1V329
DM1V329 DN Conivaptan
DM1V329 HS Approved
DM1V329 SN Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
DM1V329 CP Astellas Pharma Inc
DM1V329 DT Small molecular drug
DM1V329 PC 151171
DM1V329 MW 498.6
DM1V329 FM C32H26N4O2
DM1V329 IC InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
DM1V329 CS CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM1V329 IK IKENVDNFQMCRTR-UHFFFAOYSA-N
DM1V329 IU N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
DM1V329 CA CAS 210101-16-9
DM1V329 CB CHEBI:681850
DM1V329 DE Euvolemic hyponatremia
DMLT0E1 ID DMLT0E1
DMLT0E1 DN Conjugated estrogens
DMLT0E1 HS Approved
DMLT0E1 SN Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMLT0E1 CP Wyeth Pharmaceuticals
DMLT0E1 TC Estrogens
DMLT0E1 DT Small molecular drug
DMLT0E1 PC 45357473
DMLT0E1 MW 372.4
DMLT0E1 FM C18H21NaO5S
DMLT0E1 IC InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1
DMLT0E1 CS C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
DMLT0E1 IK VUCAHVBMSFIGAI-TWCWWGPMSA-M
DMLT0E1 IU sodium;[(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMLT0E1 DE Menopause symptom; Vasomotor symptom
DMTPIZC ID DMTPIZC
DMTPIZC DN Conjugated estrogens a
DMTPIZC HS Approved
DMTPIZC SN Conestin (TN)
DMTPIZC DE Hormone replacement therapy
DMU7SF8 ID DMU7SF8
DMU7SF8 DN Conjugated estrogens b
DMU7SF8 HS Approved
DMU7SF8 SN Enjuvia (TN)
DMU7SF8 DE Hormone replacement therapy
DMF29Q5 ID DMF29Q5
DMF29Q5 DN Connexyn
DMF29Q5 HS Approved
DMF29Q5 SN Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
DMF29Q5 DT Small molecular drug
DMF29Q5 PC 71401
DMF29Q5 MW 282.5
DMF29Q5 FM C9H10Cl3N3O
DMF29Q5 IC InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
DMF29Q5 CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl
DMF29Q5 IK DGFYECXYGUIODH-UHFFFAOYSA-N
DMF29Q5 IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
DMF29Q5 CA CAS 29110-48-3
DMF29Q5 CB CHEBI:5559
DMF29Q5 DE Attention deficit hyperactivity disorder
DM26KR1 ID DM26KR1
DM26KR1 DN Copper dotatate Cu-64
DM26KR1 HS Approved
DM26KR1 SN UNII-N3858377KC; N3858377KC; Copper 64-DOTA-tate; Copper Cu-64 dotatate; 1426155-87-4; Cuprate(2-)-64Cu, (N-(2-(4,10-bis((carboxy-kappaO)methyl)-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN7,kappaN10)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoni
DM26KR1 DT Radioactive diagnostic agent
DM26KR1 PC 124220636
DM26KR1 MW 1497.5
DM26KR1 FM C65H88CuN14O19S2
DM26KR1 IC InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0
DM26KR1 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2]
DM26KR1 IK IJRLLVFQGCCPPI-NVGRTJHCSA-L
DM26KR1 IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)
DM26KR1 CA CAS 1426155-87-4
DM26KR1 DE Diagnostic imaging
DMP9TWZ ID DMP9TWZ
DMP9TWZ DN Corticotropin
DMP9TWZ HS Approved
DMP9TWZ SN corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine
DMP9TWZ CP Questcor pharmaceuticals
DMP9TWZ SQ ACTH(1-39): SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF
DMP9TWZ PC 16132265
DMP9TWZ MW 4541
DMP9TWZ FM C207H308N56O58S
DMP9TWZ IC InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1
DMP9TWZ CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N
DMP9TWZ IK IDLFZVILOHSSID-OVLDLUHVSA-N
DMP9TWZ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMP9TWZ CA CAS 12427-33-7
DMP9TWZ CB CHEBI:3892
DMP9TWZ DE Diabetic nephropathy; Cushing disease
DMU5QZX ID DMU5QZX
DMU5QZX DN Cortisone
DMU5QZX HS Approved
DMU5QZX SN 11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone
DMU5QZX DT Small molecular drug
DMU5QZX PC 222786
DMU5QZX MW 360.4
DMU5QZX FM C21H28O5
DMU5QZX IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DMU5QZX CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C
DMU5QZX IK MFYSYFVPBJMHGN-ZPOLXVRWSA-N
DMU5QZX IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
DMU5QZX CA CAS 53-06-5
DMU5QZX CB CHEBI:16962
DMU5QZX DE Atopic dermatitis
DMG8K57 ID DMG8K57
DMG8K57 DN Cortisone acetate
DMG8K57 HS Approved
DMG8K57 SN Cortone
DMG8K57 CP Pharmacia And Upjohn Co
DMG8K57 TC Anticancer Agents
DMG8K57 DT Small molecular drug
DMG8K57 PC 5745
DMG8K57 MW 402.5
DMG8K57 FM C23H30O6
DMG8K57 IC InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
DMG8K57 CS CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMG8K57 IK ITRJWOMZKQRYTA-RFZYENFJSA-N
DMG8K57 IU [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMG8K57 CA CAS 50-04-4
DMG8K57 CB CHEBI:3897
DMG8K57 DE Solid tumour/cancer
DMUIASK ID DMUIASK
DMUIASK DN Cosyntropin
DMUIASK HS Approved
DMUIASK SN Cortrosyn; Tetracosactide; Cortrosyn (TN); Cosyntropin (USAN); Tetracosactide (INN)
DMUIASK CP Sandoz
DMUIASK TC Diagnostic Agents
DMUIASK PC 16129617
DMUIASK MW 2933.4
DMUIASK FM C136H210N40O31S
DMUIASK IC InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1
DMUIASK CS CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N
DMUIASK IK ZOEFCCMDUURGSE-CQVUSSRSSA-N
DMUIASK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
DMUIASK CA CAS 16960-16-0
DMUIASK DE Adrenocortical insufficiency
DMCEZ1B ID DMCEZ1B
DMCEZ1B DN Cotinine
DMCEZ1B HS Approved
DMCEZ1B SN cotinine; (-)-Cotinine; 486-56-6; Cotinina; Cotininum; (S)-(-)-Cotinine; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; Cotinine (-); (S)-Cotinine; UNII-K5161X06LL; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; CHEBI:68641; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; UIKROCXWUNQSPJ-VIFPVBQESA-N; K5161X06LL; Cotinine [INN]; MFCD00077696; Cotininum [INN-Latin]; Cotinina [INN-Spanish]; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B DT Small molecular drug
DMCEZ1B PC 854019
DMCEZ1B MW 176.21
DMCEZ1B FM C10H12N2O
DMCEZ1B IC InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1
DMCEZ1B CS CN1[C@@H](CCC1=O)C2=CN=CC=C2
DMCEZ1B IK UIKROCXWUNQSPJ-VIFPVBQESA-N
DMCEZ1B IU (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B CA CAS 486-56-6
DMCEZ1B CB CHEBI:68641
DMCEZ1B DE Insecticide
DMJ7IQX ID DMJ7IQX
DMJ7IQX DN Crestor/TriLipix
DMJ7IQX HS Approved
DMJ7IQX CP AstraZeneca
DMJ7IQX DE Dyslipidemia
DMNVKU6 ID DMNVKU6
DMNVKU6 DN Crisaborole
DMNVKU6 HS Approved
DMNVKU6 SN Crisaborole ointment 2%; PF-06930164
DMNVKU6 CP Pfizer/Anacor Pharmaceuticals
DMNVKU6 DT Small molecular drug
DMNVKU6 PC 44591583
DMNVKU6 MW 251.05
DMNVKU6 FM C14H10BNO3
DMNVKU6 IC InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
DMNVKU6 CS B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
DMNVKU6 IK USZAGAREISWJDP-UHFFFAOYSA-N
DMNVKU6 IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
DMNVKU6 CA CAS 906673-24-3
DMNVKU6 CB CHEBI:134677
DMNVKU6 DE Atopic dermatitis
DMAHOVJ ID DMAHOVJ
DMAHOVJ DN Crizanlizumab
DMAHOVJ HS Approved
DMAHOVJ SN SEG101
DMAHOVJ CP Novartis
DMAHOVJ DT Antibody
DMAHOVJ DE Vaso-occlusive crisis; Sickle-cell disorder
DM4F29C ID DM4F29C
DM4F29C DN Crizotinib
DM4F29C HS Approved
DM4F29C SN Xalkori (TN); novel ALK inhibitors
DM4F29C CP Pfizer New York, NY
DM4F29C DT Small molecular drug
DM4F29C PC 11626560
DM4F29C MW 450.3
DM4F29C FM C21H22Cl2FN5O
DM4F29C IC InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
DM4F29C CS C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
DM4F29C IK KTEIFNKAUNYNJU-GFCCVEGCSA-N
DM4F29C IU 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
DM4F29C CA CAS 877399-52-5
DM4F29C CB CHEBI:64310
DM4F29C DE Non-small-cell lung cancer
DM4AMQZ ID DM4AMQZ
DM4AMQZ DN Crofelemer
DM4AMQZ HS Approved
DM4AMQZ SN Fulyzaq (TN)
DM4AMQZ CP Salix
DM4AMQZ DT Small molecular drug
DM4AMQZ PC 17397714
DM4AMQZ MW 308.3
DM4AMQZ FM C18H16N2O3
DM4AMQZ IC InChI=1S/C18H16N2O3/c1-22-16-10-6-5-9-14(16)12-19-18(21)15-11-17(23-20-15)13-7-3-2-4-8-13/h2-11H,12H2,1H3,(H,19,21)
DM4AMQZ CS COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3
DM4AMQZ IK JDNAIBCYTQGWFC-UHFFFAOYSA-N
DM4AMQZ IU N-[(2-methoxyphenyl)methyl]-5-phenyl-1,2-oxazole-3-carboxamide
DM4AMQZ DE HIV-associated diarrhoea
DM74LZK ID DM74LZK
DM74LZK DN Cromoglicate
DM74LZK HS Approved
DM74LZK SN Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)
DM74LZK CP Zambon Group
DM74LZK TC Antiasthmatic Agents
DM74LZK DT Small molecular drug
DM74LZK PC 2882
DM74LZK MW 468.4
DM74LZK FM C23H16O11
DM74LZK IC InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
DM74LZK CS C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
DM74LZK IK IMZMKUWMOSJXDT-UHFFFAOYSA-N
DM74LZK IU 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
DM74LZK CA CAS 16110-51-3
DM74LZK CB CHEBI:59773
DM74LZK DE Asthma; Allergic rhinitis
DMHCTAL ID DMHCTAL
DMHCTAL DN Cryptenamine Acetates
DMHCTAL HS Approved
DMHCTAL SN Unitensen; Cryptenamine Tannates
DMHCTAL CP Medpointe Pharmaceuticals Medpointe Healthcare Inc
DMHCTAL TC Cardiovascular Agents
DMHCTAL DE Hypertension
DMB8PF3 ID DMB8PF3
DMB8PF3 DN CT-102
DMB8PF3 HS Approved
DMB8PF3 CP Curative Health Services
DMB8PF3 DE Diabetic foot ulcer
DMP0NFQ ID DMP0NFQ
DMP0NFQ DN Cupric Sulfate
DMP0NFQ HS Approved
DMP0NFQ SN Copper sulfate; 7758-98-7; CUPRIC SULFATE; Copper(II) sulfate; Cupric sulfate anhydrous; Copper sulphate; Copper(2+) sulfate; Cupricsulfate; Blue stone; Copper monosulfate; Copper II sulfate; Trinagle; Hylinec; Delcup; Cupric sulphate; Copper(ii) sulfate, anhydrous; Monocopper sulfate; Copper sulfate (1:1); Incracide 10A; Incracide E 51; Sulfuric acid copper(2+) salt (1:1); BCS copper fungicide; Blue copper (VAN); Copper Sulfate Powder; Bonide Root Destroyer; CuSO4; Kupfersulfat [German]; All Clear Root Destroyer; Copper sulfate (CuSO
DMP0NFQ CP Abraxis Pharmaceutical Products
DMP0NFQ TC Antiinfective Agents
DMP0NFQ DT Small molecular drug
DMP0NFQ PC 24462
DMP0NFQ MW 159.61
DMP0NFQ FM CuO4S
DMP0NFQ IC InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMP0NFQ CS [O-]S(=O)(=O)[O-].[Cu+2]
DMP0NFQ IK ARUVKPQLZAKDPS-UHFFFAOYSA-L
DMP0NFQ IU copper;sulfate
DMP0NFQ CA CAS 7758-98-7
DMP0NFQ CB CHEBI:23414
DMP0NFQ DE Pest attack; Fungal infection; Herbicide
DMHSJB4 ID DMHSJB4
DMHSJB4 DN Cyclacillin
DMHSJB4 HS Approved
DMHSJB4 SN Aminocyclohexylpenicillin; Bastcillin; Calthor; Ciclacilina; Ciclacillin; Ciclacilline; Ciclacillinum; Ciclacillum; Citosarin; Cyclapen; Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vipicil; Wyvital; Aminocyclohexyl penicillin; Cyclacillin [USAN]; AC 98; WY 4508; WY4508; C-12104; Ciclacilina [INN-Spanish]; Ciclacilline [INN-French]; Ciclacillinum [INN-Latin]; Cyclacillin (USAN); Cyclapen (TN); Cyclapen-W; Vastcillin (TN); Wy-4508; Ciclacillin (JP15/INN); Cyclapen-W (TN); (1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMHSJB4 TC Antibiotics
DMHSJB4 DT Small molecular drug
DMHSJB4 PC 19003
DMHSJB4 MW 341.4
DMHSJB4 FM C15H23N3O4S
DMHSJB4 IC InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1
DMHSJB4 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C
DMHSJB4 IK HGBLNBBNRORJKI-WCABBAIRSA-N
DMHSJB4 IU (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHSJB4 CA CAS 3485-14-1
DMHSJB4 CB CHEBI:31444
DMHSJB4 DE Bacterial infection
DMO0R76 ID DMO0R76
DMO0R76 DN Cyclandelate
DMO0R76 HS Approved
DMO0R76 SN cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207
DMO0R76 DT Small molecular drug
DMO0R76 PC 2893
DMO0R76 MW 276.4
DMO0R76 FM C17H24O3
DMO0R76 IC InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
DMO0R76 CS CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
DMO0R76 IK WZHCOOQXZCIUNC-UHFFFAOYSA-N
DMO0R76 IU (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate
DMO0R76 CA CAS 456-59-7
DMO0R76 CB CHEBI:3988
DMO0R76 DE Dementia
DM9G7BS ID DM9G7BS
DM9G7BS DN Cyclizine
DM9G7BS HS Approved
DM9G7BS SN Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine
DM9G7BS CP Seatrace Pharmaceuticals
DM9G7BS TC Antiemetics
DM9G7BS DT Small molecular drug
DM9G7BS PC 6726
DM9G7BS MW 266.4
DM9G7BS FM C18H22N2
DM9G7BS IC InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
DM9G7BS CS CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9G7BS IK UVKZSORBKUEBAZ-UHFFFAOYSA-N
DM9G7BS IU 1-benzhydryl-4-methylpiperazine
DM9G7BS CA CAS 82-92-8
DM9G7BS CB CHEBI:3994
DM9G7BS DE Nausea
DM1YBRM ID DM1YBRM
DM1YBRM DN Cyclobenzaprine
DM1YBRM HS Approved
DM1YBRM SN Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.
DM1YBRM CP Janssen Research And Development Llc
DM1YBRM TC Antidepressants
DM1YBRM DT Small molecular drug
DM1YBRM PC 2895
DM1YBRM MW 275.4
DM1YBRM FM C20H21N
DM1YBRM IC InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
DM1YBRM CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
DM1YBRM IK JURKNVYFZMSNLP-UHFFFAOYSA-N
DM1YBRM IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine
DM1YBRM CA CAS 303-53-7
DM1YBRM CB CHEBI:3996
DM1YBRM DE Depression
DMT5RMB ID DMT5RMB
DMT5RMB DN Cyclofenil
DMT5RMB HS Approved
DMT5RMB SN cyclofenil; 2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066
DMT5RMB DT Small molecular drug
DMT5RMB PC 2898
DMT5RMB MW 364.4
DMT5RMB FM C23H24O4
DMT5RMB IC InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3
DMT5RMB CS CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C
DMT5RMB IK GVOUFPWUYJWQSK-UHFFFAOYSA-N
DMT5RMB IU [4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate
DMT5RMB CA CAS 2624-43-3
DMT5RMB CB CHEBI:31446
DMT5RMB DE Infertility
DMA8LM5 ID DMA8LM5
DMA8LM5 DN Cyclopentolate
DMA8LM5 HS Approved
DMA8LM5 SN Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
DMA8LM5 CP Akorn Inc
DMA8LM5 TC Parasympatholytics
DMA8LM5 DT Small molecular drug
DMA8LM5 PC 2905
DMA8LM5 MW 291.4
DMA8LM5 FM C17H25NO3
DMA8LM5 IC InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
DMA8LM5 CS CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
DMA8LM5 IK SKYSRIRYMSLOIN-UHFFFAOYSA-N
DMA8LM5 IU 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
DMA8LM5 CA CAS 512-15-2
DMA8LM5 CB CHEBI:4024
DMA8LM5 DE Examination of eyes or vision
DM4O2Z7 ID DM4O2Z7
DM4O2Z7 DN Cyclophosphamide
DM4O2Z7 HS Approved
DM4O2Z7 SN ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
DM4O2Z7 CP Baxter International Inc
DM4O2Z7 TC Anticancer Agents
DM4O2Z7 DT Small molecular drug
DM4O2Z7 PC 2907
DM4O2Z7 MW 261.079
DM4O2Z7 FM C7H15Cl2N2O2P
DM4O2Z7 IC InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
DM4O2Z7 CS C1CNP(=O)(OC1)N(CCCl)CCCl
DM4O2Z7 IK CMSMOCZEIVJLDB-UHFFFAOYSA-N
DM4O2Z7 IU N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DM4O2Z7 CA CAS 50-18-0
DM4O2Z7 CB CHEBI:4027
DM4O2Z7 DE Solid tumour/cancer
DMT1I52 ID DMT1I52
DMT1I52 DN Cycloserine
DMT1I52 HS Approved
DMT1I52 SN D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
DMT1I52 TC Antiinfective Agents
DMT1I52 DT Small molecular drug
DMT1I52 PC 6234
DMT1I52 MW 102.09
DMT1I52 FM C3H6N2O2
DMT1I52 IC InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
DMT1I52 CS C1[C@H](C(=O)NO1)N
DMT1I52 IK DYDCUQKUCUHJBH-UWTATZPHSA-N
DMT1I52 IU (4R)-4-amino-1,2-oxazolidin-3-one
DMT1I52 CA CAS 68-41-7
DMT1I52 CB CHEBI:40009
DMT1I52 DE Tuberculosis; Bacterial infection; Obsessive compulsive disorder
DMJ4AWC ID DMJ4AWC
DMJ4AWC DN Cyclothiazide
DMJ4AWC HS Approved
DMJ4AWC SN Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMJ4AWC TC Antihypertensive Agents
DMJ4AWC DT Small molecular drug
DMJ4AWC PC 2910
DMJ4AWC MW 389.9
DMJ4AWC FM C14H16ClN3O4S2
DMJ4AWC IC InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
DMJ4AWC CS C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
DMJ4AWC IK BOCUKUHCLICSIY-UHFFFAOYSA-N
DMJ4AWC IU 3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMJ4AWC CA CAS 2259-96-3
DMJ4AWC CB CHEBI:31448
DMJ4AWC DE Congestive heart failure
DM8C43Q ID DM8C43Q
DM8C43Q DN Cycrimine
DM8C43Q HS Approved
DM8C43Q SN Cicrimina; Cycriminum; Pagitane; Cicrimina [INN-Spanish]; Cycriminum [INN-Latin]; Alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; (+-)-cycrimine; 1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q TC Antiparkinson Agents
DM8C43Q DT Small molecular drug
DM8C43Q PC 2911
DM8C43Q MW 287.4
DM8C43Q FM C19H29NO
DM8C43Q IC InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DM8C43Q CS C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O
DM8C43Q IK SWRUZBWLEWHWRI-UHFFFAOYSA-N
DM8C43Q IU 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q CA CAS 77-39-4
DM8C43Q CB CHEBI:59692
DM8C43Q DE Parkinson disease
DMUY2OR ID DMUY2OR
DMUY2OR DN Cynarin
DMUY2OR HS Approved
DMUY2OR SN 1,3-O-Dicaffeoylquinic acid; 19870-46-3; 1,3-Dicaffeoylquinic acid; Cynarin; 1,5-Dicaffeoylquinic acid; Cynarine; 1,5-di-O-Caffeoylquinic acid; 1,3-di-O-Caffeoylquinic acid; 30964-13-7; (1S,3R,4R,5R)-1,3-Bis[3-(3,4-dihydroxyphenyl)acryloyloxy]-4,5-dihydroxycyclohexanecarboxylic acid; (1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxy-cyclohexanecarboxylic acid; AC1O6FEM; 1,5-Dicaffeoylquinic-acid; 1,3-Dicaffeoyl quinic acid; 1,5-Dicaffeoylquinic acid ; CHEMBL478574; 1,5-DCQA
DMUY2OR DT Small molecular drug
DMUY2OR PC 5281769
DMUY2OR MW 516.4
DMUY2OR FM C25H24O12
DMUY2OR IC InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1
DMUY2OR CS C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O
DMUY2OR IK YDDUMTOHNYZQPO-RVXRWRFUSA-N
DMUY2OR IU (1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
DMUY2OR CA CAS 212891-05-9
DMUY2OR CB CHEBI:520
DMUY2OR DE Vibrio cholerae infection
DM92AH3 ID DM92AH3
DM92AH3 DN Cyproheptadine
DM92AH3 HS Approved
DM92AH3 SN Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
DM92AH3 CP Merck & Co
DM92AH3 TC Antihistamines
DM92AH3 DT Small molecular drug
DM92AH3 PC 2913
DM92AH3 MW 287.4
DM92AH3 FM C21H21N
DM92AH3 IC InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
DM92AH3 CS CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
DM92AH3 IK JJCFRYNCJDLXIK-UHFFFAOYSA-N
DM92AH3 IU 1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
DM92AH3 CA CAS 129-03-3
DM92AH3 CB CHEBI:4046
DM92AH3 DE Rhinitis
DMQXLD2 ID DMQXLD2
DMQXLD2 DN Cyproterone
DMQXLD2 HS Approved
DMQXLD2 SN Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
DMQXLD2 CP Schering-Plough
DMQXLD2 TC Anticancer Agents
DMQXLD2 DT Small molecular drug
DMQXLD2 PC 5284537
DMQXLD2 MW 374.9
DMQXLD2 FM C22H27ClO3
DMQXLD2 IC InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
DMQXLD2 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O
DMQXLD2 IK DUSHUSLJJMDGTE-ZJPMUUANSA-N
DMQXLD2 IU (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
DMQXLD2 CA CAS 2098-66-0
DMQXLD2 CB CHEBI:50742
DMQXLD2 DE Prostate cancer
DMSYFM8 ID DMSYFM8
DMSYFM8 DN Cysteamine
DMSYFM8 HS Approved
DMSYFM8 SN Becaptan; Cisteamina; Cystavision; Cysteamide; Cysteamin; Cysteinamine; Decarboxycysteine; Ethanethiolamine; Lambraten; Lambratene; MEA; Mecramine; Mercamin; Mercamine; Mercaptamin; Mercaptamina; Mercaptamine; Mercaptaminum; Mercaptoethylamine; Merkamin; Riacon; Thioethanolamine; Aminoethyl mercaptan; Cisteamina [Italian]; Cysteamine bitartate; L 1573; WR 347; Beta-Aminoethanethiol; Beta-Aminoethylthiol; Beta-MEA; Beta-Mercaptoethylamine; C-9500; Cysteamine (USAN); Cysteamine [USAN:BAN]; L-1573; MEA (mercaptan); Mercaptamina [INN-Spanish]; Mercaptamine (INN); Mercaptaminum [INN-Latin]; (2-Mercaptoethyl)amine; (Mercaptoethyl)ammonium toluene-p-sulphonate; 1-Amino-2-mercaptoethylamine; 2-AMINO-ETHANETHIOL; 2-Amino-1-ethanethiol; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; 2-Mercaptoethanamine; 2-Mercaptoethylamine; 2-Mercaptoethylamine, polymer-bound; 641022_ALDRICH
DMSYFM8 CP Mylan Pharmaceuticals Inc
DMSYFM8 TC Nephropathic cystinosis therapy
DMSYFM8 DT Small molecular drug
DMSYFM8 PC 6058
DMSYFM8 MW 77.15
DMSYFM8 FM C2H7NS
DMSYFM8 IC InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
DMSYFM8 CS C(CS)N
DMSYFM8 IK UFULAYFCSOUIOV-UHFFFAOYSA-N
DMSYFM8 IU 2-aminoethanethiol
DMSYFM8 CA CAS 60-23-1
DMSYFM8 CB CHEBI:17141
DMSYFM8 DE Nephropathic cystinosis
DMZD5QR ID DMZD5QR
DMZD5QR DN Cytarabine
DMZD5QR HS Approved
DMZD5QR SN Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
DMZD5QR CP Upjohn Corporation
DMZD5QR TC Anticancer Agents
DMZD5QR DT Small molecular drug
DMZD5QR PC 6253
DMZD5QR MW 243.22
DMZD5QR FM C9H13N3O5
DMZD5QR IC InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMZD5QR CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMZD5QR IK UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DMZD5QR IU 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMZD5QR CA CAS 147-94-4
DMZD5QR CB CHEBI:28680
DMZD5QR DE Acute lymphoblastic leukaemia
DMDI6R4 ID DMDI6R4
DMDI6R4 DN Dabigatran
DMDI6R4 HS Approved
DMDI6R4 SN Pradaxa (TN)
DMDI6R4 CP Boehringer Ingelheim
DMDI6R4 DT Small molecular drug
DMDI6R4 PC 216210
DMDI6R4 MW 471.5
DMDI6R4 FM C25H25N7O3
DMDI6R4 IC InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
DMDI6R4 CS CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
DMDI6R4 IK YBSJFWOBGCMAKL-UHFFFAOYSA-N
DMDI6R4 IU 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
DMDI6R4 CA CAS 211914-51-1
DMDI6R4 CB CHEBI:70752
DMDI6R4 DE Stroke
DMX6OE3 ID DMX6OE3
DMX6OE3 DN Dabrafenib
DMX6OE3 HS Approved
DMX6OE3 SN 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436
DMX6OE3 DT Small molecular drug
DMX6OE3 PC 44462760
DMX6OE3 MW 519.6
DMX6OE3 FM C23H20F3N5O2S2
DMX6OE3 IC InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
DMX6OE3 CS CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
DMX6OE3 IK BFSMGDJOXZAERB-UHFFFAOYSA-N
DMX6OE3 IU N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
DMX6OE3 CA CAS 1195765-45-7
DMX6OE3 CB CHEBI:75045
DMX6OE3 DE Melanoma
DMNPZL4 ID DMNPZL4
DMNPZL4 DN Dacarbazine
DMNPZL4 HS Approved
DMNPZL4 SN Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
DMNPZL4 CP Bayer Pharmaceuticals Corporation
DMNPZL4 TC Anticancer Agents
DMNPZL4 DT Small molecular drug
DMNPZL4 PC 135398738
DMNPZL4 MW 182.18
DMNPZL4 FM C6H10N6O
DMNPZL4 IC InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
DMNPZL4 CS CN(C)/N=N/C1=C(NC=N1)C(=O)N
DMNPZL4 IK FDKXTQMXEQVLRF-ZHACJKMWSA-N
DMNPZL4 IU 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
DMNPZL4 CA CAS 4342-03-4
DMNPZL4 CB CHEBI:94587
DMNPZL4 DE Melanoma
DMSFK9V ID DMSFK9V
DMSFK9V DN Daclatasvir
DMSFK9V HS Approved
DMSFK9V SN 1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
DMSFK9V CP Bristol-Myers Squibb
DMSFK9V DT Small molecular drug
DMSFK9V PC 25154714
DMSFK9V MW 738.9
DMSFK9V FM C40H50N8O6
DMSFK9V IC InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
DMSFK9V CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSFK9V IK FKRSSPOQAMALKA-CUPIEXAXSA-N
DMSFK9V IU methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSFK9V CA CAS 1009119-64-5
DMSFK9V CB CHEBI:82977
DMSFK9V DE Hepatitis C virus infection
DM6OZQV ID DM6OZQV
DM6OZQV DN Daclizumab
DM6OZQV HS Approved
DM6OZQV SN DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec
DM6OZQV CP Biogen
DM6OZQV DT Monoclonal antibody
DM6OZQV SQ Humanized Anti-CD25 Heavy Chain 1: QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Humanized Anti-CD25 Light Chain 1DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM6OZQV DE Multiple sclerosis
DMOH8VY ID DMOH8VY
DMOH8VY DN Dacomitinib
DMOH8VY HS Approved
DMOH8VY SN PF-00299804
DMOH8VY CP Pfizer
DMOH8VY DT Small molecular drug
DMOH8VY PC 11511120
DMOH8VY MW 469.9
DMOH8VY FM C24H25ClFN5O2
DMOH8VY IC InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
DMOH8VY CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
DMOH8VY IK LVXJQMNHJWSHET-AATRIKPKSA-N
DMOH8VY IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
DMOH8VY CA CAS 1110813-31-4
DMOH8VY CB CHEBI:91466
DMOH8VY DE Non-small-cell lung cancer
DM2YGNW ID DM2YGNW
DM2YGNW DN Dactinomycin
DM2YGNW HS Approved
DM2YGNW SN Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
DM2YGNW TC Anticancer Agents
DM2YGNW DT Small molecular drug
DM2YGNW PC 457193
DM2YGNW MW 1255.4
DM2YGNW FM C62H86N12O16
DM2YGNW IC InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
DM2YGNW CS C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
DM2YGNW IK RJURFGZVJUQBHK-IIXSONLDSA-N
DM2YGNW IU 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
DM2YGNW CA CAS 50-76-0
DM2YGNW CB CHEBI:27666
DM2YGNW DE Solid tumour/cancer
DMGMNH3 ID DMGMNH3
DMGMNH3 DN Dalbavancin
DMGMNH3 HS Approved
DMGMNH3 SN Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba
DMGMNH3 CP Pfizer
DMGMNH3 DT Small molecular drug
DMGMNH3 PC 16134627
DMGMNH3 MW 1816.7
DMGMNH3 FM C88H100Cl2N10O28
DMGMNH3 IC InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
DMGMNH3 CS CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
DMGMNH3 IK KGPGQDLTDHGEGT-SZUNQUCBSA-N
DMGMNH3 IU (2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid
DMGMNH3 CA CAS 171500-79-1
DMGMNH3 CB CHEBI:82721
DMGMNH3 DE Bacterial infection
DMM0PDO ID DMM0PDO
DMM0PDO DN Dalfampridine
DMM0PDO HS Approved
DMM0PDO SN Ampyra (TN)
DMM0PDO CP Acorda Therapeutics
DMM0PDO DT Small molecular drug
DMM0PDO PC 1727
DMM0PDO MW 94.11
DMM0PDO FM C5H6N2
DMM0PDO IC InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
DMM0PDO CS C1=CN=CC=C1N
DMM0PDO IK NUKYPUAOHBNCPY-UHFFFAOYSA-N
DMM0PDO IU pyridin-4-amine
DMM0PDO CA CAS 504-24-5
DMM0PDO CB CHEBI:34385
DMM0PDO DE Multiple sclerosis
DM4LTKV ID DM4LTKV
DM4LTKV DN Dalfopristin
DM4LTKV HS Approved
DM4LTKV SN 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE
DM4LTKV TC Antibiotics
DM4LTKV DT Small molecular drug
DM4LTKV PC 6323289
DM4LTKV MW 690.8
DM4LTKV FM C34H50N4O9S
DM4LTKV IC InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
DM4LTKV CS CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
DM4LTKV IK SUYRLXYYZQTJHF-VMBLUXKRSA-N
DM4LTKV IU (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
DM4LTKV CA CAS 112362-50-2
DM4LTKV CB CHEBI:4309
DM4LTKV DE Bacterial infection
DM6CLBN ID DM6CLBN
DM6CLBN DN Danaparoid
DM6CLBN HS Approved
DM6CLBN SN Orgaran (TN)
DM6CLBN CP Schering-Plough
DM6CLBN TC Anticoagulants
DM6CLBN DE Deep venous clot
DML8KTN ID DML8KTN
DML8KTN DN Danazol
DML8KTN HS Approved
DML8KTN SN Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
DML8KTN TC Fertility Agents
DML8KTN DT Small molecular drug
DML8KTN PC 28417
DML8KTN MW 337.5
DML8KTN FM C22H27NO2
DML8KTN IC InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
DML8KTN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
DML8KTN IK POZRVZJJTULAOH-LHZXLZLDSA-N
DML8KTN IU (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
DML8KTN CA CAS 17230-88-5
DML8KTN CB CHEBI:4315
DML8KTN DE Menorrhagia; Breast cancer
DM1D8XY ID DM1D8XY
DM1D8XY DN Dantrolene
DM1D8XY HS Approved
DM1D8XY SN Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CP Procter & Gamble
DM1D8XY TC Muscle Relaxants
DM1D8XY DT Small molecular drug
DM1D8XY PC 6914273
DM1D8XY MW 314.25
DM1D8XY FM C14H10N4O5
DM1D8XY IC InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
DM1D8XY CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]
DM1D8XY IK OZOMQRBLCMDCEG-VIZOYTHASA-N
DM1D8XY IU 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CA CAS 7261-97-4
DM1D8XY DE Hyperthermia
DM28UJG ID DM28UJG
DM28UJG DN Dapagliflozin
DM28UJG HS Approved
DM28UJG SN BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
DM28UJG CP AstraZeneca
DM28UJG DT Small molecular drug
DM28UJG PC 9887712
DM28UJG MW 408.9
DM28UJG FM C21H25ClO6
DM28UJG IC InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
DM28UJG CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
DM28UJG IK JVHXJTBJCFBINQ-ADAARDCZSA-N
DM28UJG IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM28UJG CA CAS 461432-26-8
DM28UJG CB CHEBI:85078
DM28UJG DE Type-2 diabetes
DM34TXO ID DM34TXO
DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO HS Approved
DM34TXO SN Saxagliptin Hydrochloride; Qtern
DM34TXO CP Astrazeneca
DM34TXO DT Small molecular drug
DM34TXO DE Type-2 diabetes
DMOXJKF ID DMOXJKF
DMOXJKF DN Dapiprazole
DMOXJKF HS Approved
DMOXJKF SN Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
DMOXJKF CP Abbott Laboratories
DMOXJKF TC Ophthalmologicals
DMOXJKF DT Small molecular drug
DMOXJKF PC 3033538
DMOXJKF MW 325.5
DMOXJKF FM C19H27N5
DMOXJKF IC InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
DMOXJKF CS CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
DMOXJKF IK RFWZESUMWJKKRN-UHFFFAOYSA-N
DMOXJKF IU 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
DMOXJKF CA CAS 72822-12-9
DMOXJKF CB CHEBI:51066
DMOXJKF DE Glaucoma/ocular hypertension
DM4LT8A ID DM4LT8A
DM4LT8A DN Dapsone
DM4LT8A HS Approved
DM4LT8A SN Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline
DM4LT8A TC Antiinflammatory Agents
DM4LT8A DT Small molecular drug
DM4LT8A PC 2955
DM4LT8A MW 248.3
DM4LT8A FM C12H12N2O2S
DM4LT8A IC InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
DM4LT8A CS C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
DM4LT8A IK MQJKPEGWNLWLTK-UHFFFAOYSA-N
DM4LT8A IU 4-(4-aminophenyl)sulfonylaniline
DM4LT8A CA CAS 80-08-0
DM4LT8A CB CHEBI:4325
DM4LT8A DE Pneumocystis pneumonia
DMFDQ3I ID DMFDQ3I
DMFDQ3I DN Daptomycin
DMFDQ3I HS Approved
DMFDQ3I SN Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102
DMFDQ3I PC 16134395
DMFDQ3I MW 1620.7
DMFDQ3I FM C72H101N17O26
DMFDQ3I IC DOAKLVKFURWEDJ-RWDRXURGSA-N
DMFDQ3I CS CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMFDQ3I IK 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMFDQ3I IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMFDQ3I CA CAS 103060-53-3
DMFDQ3I CB CHEBI:600103
DMFDQ3I DE Methicillin-resistant staphylococcus infection
DMKDU16 ID DMKDU16
DMKDU16 DN Daptomycin
DMKDU16 HS Approved
DMKDU16 SN Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox
DMKDU16 CP Cubist Pharmaceuticals
DMKDU16 TC Antibiotics
DMKDU16 DT Small molecular drug
DMKDU16 PC 16134395
DMKDU16 MW 1620.7
DMKDU16 FM C72H101N17O26
DMKDU16 IC InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMKDU16 CS CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMKDU16 IK DOAKLVKFURWEDJ-RWDRXURGSA-N
DMKDU16 IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMKDU16 CA CAS 103060-53-3
DMKDU16 CB CHEBI:600103
DMKDU16 DE Bacterial infection
DMKCIUZ ID DMKCIUZ
DMKCIUZ DN Daratumumab
DMKCIUZ HS Approved
DMKCIUZ CP Genmab Princeton, NJ
DMKCIUZ DT Antibody
DMKCIUZ DE Multiple myeloma
DMMJTYW ID DMMJTYW
DMMJTYW DN Darbepoetin alfa
DMMJTYW HS Approved
DMMJTYW SN Aranesp (TN)
DMMJTYW CP Amgen Inc
DMMJTYW TC Antianemic Agents
DMMJTYW SQ DB00012 sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DMMJTYW DE Anemia
DMWXLYZ ID DMWXLYZ
DMWXLYZ DN Darifenacin
DMWXLYZ HS Approved
DMWXLYZ SN Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)
DMWXLYZ CP Norvatis Phamaceuticals Corporation
DMWXLYZ TC Urinary antispasmodics
DMWXLYZ DT Small molecular drug
DMWXLYZ PC 444031
DMWXLYZ MW 426.5
DMWXLYZ FM C28H30N2O2
DMWXLYZ IC InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
DMWXLYZ CS C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
DMWXLYZ IK HXGBXQDTNZMWGS-RUZDIDTESA-N
DMWXLYZ IU 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
DMWXLYZ CA CAS 133099-04-4
DMWXLYZ CB CHEBI:391960
DMWXLYZ DE Overactive bladder
DMV7YFT ID DMV7YFT
DMV7YFT DN Darolutamide
DMV7YFT HS Approved
DMV7YFT SN 1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen
DMV7YFT CP Bayer Pharmaceuticals Whippany, NJ
DMV7YFT PC 67171867
DMV7YFT MW 398.8
DMV7YFT FM C19H19ClN6O2
DMV7YFT IC InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
DMV7YFT CS C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
DMV7YFT IK BLIJXOOIHRSQRB-PXYINDEMSA-N
DMV7YFT IU N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
DMV7YFT CA CAS 1297538-32-9
DMV7YFT DE Prostate cancer
DMN3GCH ID DMN3GCH
DMN3GCH DN Darunavir
DMN3GCH HS Approved
DMN3GCH SN 206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
DMN3GCH CP Tibotec
DMN3GCH TC Antiviral Agents
DMN3GCH DT Small molecular drug
DMN3GCH PC 213039
DMN3GCH MW 547.7
DMN3GCH FM C27H37N3O7S
DMN3GCH IC InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
DMN3GCH CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
DMN3GCH IK CJBJHOAVZSMMDJ-HEXNFIEUSA-N
DMN3GCH IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMN3GCH CA CAS 206361-99-1
DMN3GCH CB CHEBI:367163
DMN3GCH DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMJV2EK ID DMJV2EK
DMJV2EK DN Dasatinib
DMJV2EK HS Approved
DMJV2EK SN Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMJV2EK CP Bristol Myers Squibb
DMJV2EK TC Anticancer Agents
DMJV2EK DT Small molecular drug
DMJV2EK PC 3062316
DMJV2EK MW 488
DMJV2EK FM C22H26ClN7O2S
DMJV2EK IC InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMJV2EK CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMJV2EK IK ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMJV2EK IU N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMJV2EK CA CAS 302962-49-8
DMJV2EK CB CHEBI:49375
DMJV2EK DE Chronic myelogenous leukaemia; Multiple myeloma
DM74SVE ID DM74SVE
DM74SVE DN Dasiglucagon
DM74SVE HS Approved
DM74SVE SN UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha
DM74SVE CP Zealand Pharma
DM74SVE DT Peptide
DM74SVE PC 126961379
DM74SVE MW 3381.6
DM74SVE FM C152H222N38O50
DM74SVE IC InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1
DM74SVE CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DM74SVE IK RZRMFQMNPDPAIX-AJTOSFMRSA-N
DM74SVE IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-2-methylpropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM74SVE CA CAS 1544300-84-6
DM74SVE DE Hypoglycemia; Hyperinsulinemia
DMLDQFV ID DMLDQFV
DMLDQFV DN Dasotraline
DMLDQFV HS Approved
DMLDQFV SN SEP-225289; SEP-289; Triple reuptake inhibitors (depression), Sepracor
DMLDQFV CP Sunovion pharmaceuticals
DMLDQFV DT Small molecular drug
DMLDQFV PC 9947999
DMLDQFV MW 292.2
DMLDQFV FM C16H15Cl2N
DMLDQFV IC InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
DMLDQFV CS C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
DMLDQFV IK SRPXSILJHWNFMK-MEDUHNTESA-N
DMLDQFV IU (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DMLDQFV CA CAS 675126-05-3
DMLDQFV DE Mood disorder; Attention deficit hyperactivity disorder; Eating disorder
DMQUSBT ID DMQUSBT
DMQUSBT DN Daunorubicin
DMQUSBT HS Approved
DMQUSBT SN daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
DMQUSBT TC Anticancer Agents
DMQUSBT DT Small molecular drug
DMQUSBT PC 30323
DMQUSBT MW 527.5
DMQUSBT FM C27H29NO10
DMQUSBT IC InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
DMQUSBT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
DMQUSBT IK STQGQHZAVUOBTE-VGBVRHCVSA-N
DMQUSBT IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMQUSBT CA CAS 20830-81-3
DMQUSBT CB CHEBI:41977
DMQUSBT DE Acute myeloid leukaemia; Solid tumour/cancer; Kaposi sarcoma
DMC50ME ID DMC50ME
DMC50ME DN Debrisoquin
DMC50ME HS Approved
DMC50ME SN Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
DMC50ME TC Antihypertensive Agents
DMC50ME DT Small molecular drug
DMC50ME PC 2966
DMC50ME MW 175.23
DMC50ME FM C10H13N3
DMC50ME IC InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
DMC50ME CS C1CN(CC2=CC=CC=C21)C(=N)N
DMC50ME IK JWPGJSVJDAJRLW-UHFFFAOYSA-N
DMC50ME IU 3,4-dihydro-1H-isoquinoline-2-carboximidamide
DMC50ME CA CAS 1131-64-2
DMC50ME CB CHEBI:34665
DMC50ME DE Hypertension
DMSBRUW ID DMSBRUW
DMSBRUW DN Decamethonium
DMSBRUW HS Approved
DMSBRUW SN Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide
DMSBRUW TC Neuromuscular Depolarizing Agents
DMSBRUW DT Small molecular drug
DMSBRUW PC 2968
DMSBRUW MW 258.49
DMSBRUW FM C16H38N2+2
DMSBRUW IC InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
DMSBRUW CS C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DMSBRUW IK MTCUAOILFDZKCO-UHFFFAOYSA-N
DMSBRUW IU trimethyl-[10-(trimethylazaniumyl)decyl]azanium
DMSBRUW CA CAS 156-74-1
DMSBRUW CB CHEBI:41934
DMSBRUW DE Muscle spasm
DMQL8XJ ID DMQL8XJ
DMQL8XJ DN Decitabine
DMQL8XJ HS Approved
DMQL8XJ SN AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2′-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
DMQL8XJ TC Anticancer Agents
DMQL8XJ DT Small molecular drug
DMQL8XJ PC 451668
DMQL8XJ MW 228.21
DMQL8XJ FM C8H12N4O4
DMQL8XJ IC InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
DMQL8XJ CS C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
DMQL8XJ IK XAUDJQYHKZQPEU-KVQBGUIXSA-N
DMQL8XJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMQL8XJ CA CAS 2353-33-5
DMQL8XJ CB CHEBI:50131
DMQL8XJ DE Myelodysplastic syndrome
DM6ETS0 ID DM6ETS0
DM6ETS0 DN Deferasirox
DM6ETS0 HS Approved
DM6ETS0 SN Deferasirox; Deferasirox (Exjade); Deferasiroxum; Deferasiroxum [INN-Latin]; Exjade; V8G4MOF2V9; 201530-41-8; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; C21H15N3O4; CGP-72670; CHEBI:49005; DSSTox_CID_28522; DSSTox_RID_82794; ICL 670; ICL 670A; ICL-670; ICL-670A; ICL670; ICL670A; NCGC00181754-01; UNII-V8G4MOF2V9
DM6ETS0 PC 214348
DM6ETS0 MW 373.4
DM6ETS0 FM C21H15N3O4
DM6ETS0 IC BOFQWVMAQOTZIW-UHFFFAOYSA-N
DM6ETS0 CS C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IK C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DM6ETS0 CA C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 CB CHEBI:49005
DM6ETS0 DE Hyperphosphatemia
DMS2M7O ID DMS2M7O
DMS2M7O DN Deferiprone
DMS2M7O HS Approved
DMS2M7O SN Ferriprox (TN)
DMS2M7O CP ApoPharma
DMS2M7O DT Small molecular drug
DMS2M7O PC 2972
DMS2M7O MW 139.15
DMS2M7O FM C7H9NO2
DMS2M7O IC InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
DMS2M7O CS CC1=C(C(=O)C=CN1C)O
DMS2M7O IK TZXKOCQBRNJULO-UHFFFAOYSA-N
DMS2M7O IU 3-hydroxy-1,2-dimethylpyridin-4-one
DMS2M7O CA CAS 30652-11-0
DMS2M7O CB CHEBI:68554
DMS2M7O DE Thalassemia
DMTUKZH ID DMTUKZH
DMTUKZH DN Deferoxamine mesylate
DMTUKZH HS Approved
DMTUKZH SN Desferal
DMTUKZH CP Novartis Pharmaceuticals Corp
DMTUKZH DT Small molecular drug
DMTUKZH PC 62881
DMTUKZH MW 656.8
DMTUKZH FM C26H52N6O11S
DMTUKZH IC InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
DMTUKZH CS CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
DMTUKZH IK IDDIJAWJANBQLJ-UHFFFAOYSA-N
DMTUKZH IU N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid
DMTUKZH CA CAS 138-14-7
DMTUKZH CB CHEBI:31460
DMTUKZH DE Acute iron or aluminum toxicity
DMV0RNS ID DMV0RNS
DMV0RNS DN Deflazacort
DMV0RNS HS Approved
DMV0RNS SN C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927
DMV0RNS CP PTC Therapeutics
DMV0RNS DT Small molecular drug
DMV0RNS PC 189821
DMV0RNS MW 441.5
DMV0RNS FM C25H31NO6
DMV0RNS IC InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
DMV0RNS CS CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
DMV0RNS IK FBHSPRKOSMHSIF-GRMWVWQJSA-N
DMV0RNS IU [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
DMV0RNS CA CAS 14484-47-0
DMV0RNS CB CHEBI:135720
DMV0RNS DE Duchenne dystrophy
DM3O8QY ID DM3O8QY
DM3O8QY DN Degarelix
DM3O8QY HS Approved
DM3O8QY SN Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
DM3O8QY DT Small molecular drug
DM3O8QY PC 16136245
DM3O8QY MW 1632.3
DM3O8QY FM C82H103ClN18O16
DM3O8QY IC InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DM3O8QY CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DM3O8QY IK MEUCPCLKGZSHTA-XYAYPHGZSA-N
DM3O8QY IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM3O8QY CA CAS 214766-78-6
DM3O8QY CB CHEBI:135961
DM3O8QY DE Prostate cancer
DM4Q80H ID DM4Q80H
DM4Q80H DN Dehydroepiandrosterone sulfate
DM4Q80H HS Approved
DM4Q80H SN Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate
DM4Q80H PC 12594
DM4Q80H MW 368.5
DM4Q80H FM C19H28O5S
DM4Q80H IC InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DM4Q80H CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DM4Q80H IK CZWCKYRVOZZJNM-USOAJAOKSA-N
DM4Q80H IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DM4Q80H CA CAS 651-48-9
DM4Q80H CB CHEBI:16814
DM4Q80H DE Dyspareunia
DMVTU5Q ID DMVTU5Q
DMVTU5Q DN Delafloxacin Meglumine
DMVTU5Q HS Approved
DMVTU5Q SN Baxdela
DMVTU5Q CP Melinta Therapeutics
DMVTU5Q DT Small molecular drug
DMVTU5Q PC 11578213
DMVTU5Q MW 636
DMVTU5Q FM C25H29ClF3N5O9
DMVTU5Q IC InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
DMVTU5Q CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMVTU5Q IK AHJGUEMIZPMAMR-WZTVWXICSA-N
DMVTU5Q IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DMVTU5Q CA CAS 352458-37-8
DMVTU5Q DE Acute bacterial skin infection; Skin infection
DMXE76K ID DMXE76K
DMXE76K DN Delamanid
DMXE76K HS Approved
DMXE76K SN OPC-67683; Nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka; 2-nitroimidazole derivatives (tuberculosis), Otsuka
DMXE76K CP Otsuka pharmaceutical
DMXE76K DT Small molecular drug
DMXE76K PC 6480466
DMXE76K MW 534.5
DMXE76K FM C25H25F3N4O6
DMXE76K IC InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
DMXE76K CS C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
DMXE76K IK XDAOLTSRNUSPPH-XMMPIXPASA-N
DMXE76K IU (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole
DMXE76K CA CAS 681492-22-8
DMXE76K CB CHEBI:134742
DMXE76K DE Mycobacterium infection; Multi-drug resistant tuberculosis
DM7EUK3 ID DM7EUK3
DM7EUK3 DN Delapril
DM7EUK3 HS Approved
DM7EUK3 SN Adecut (TN)
DM7EUK3 CP Takeda
DM7EUK3 DT Small molecular drug
DM7EUK3 PC 5362116
DM7EUK3 MW 452.5
DM7EUK3 FM C26H32N2O5
DM7EUK3 IC InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1
DM7EUK3 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2
DM7EUK3 IK WOUOLAUOZXOLJQ-MBSDFSHPSA-N
DM7EUK3 IU 2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid
DM7EUK3 CA CAS 83435-66-9
DM7EUK3 CB CHEBI:135735
DM7EUK3 DE Cardiovascular disease
DM3NF5G ID DM3NF5G
DM3NF5G DN Delavirdine
DM3NF5G HS Approved
DM3NF5G SN DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
DM3NF5G CP Pfizer Pharmaceuticals
DM3NF5G TC Anti-HIV Agents
DM3NF5G DT Small molecular drug
DM3NF5G PC 5625
DM3NF5G MW 456.6
DM3NF5G FM C22H28N6O3S
DM3NF5G IC InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
DM3NF5G CS CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DM3NF5G IK WHBIGIKBNXZKFE-UHFFFAOYSA-N
DM3NF5G IU N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DM3NF5G CA CAS 136817-59-9
DM3NF5G CB CHEBI:119573
DM3NF5G DE Human immunodeficiency virus infection
DMAYEU1 ID DMAYEU1
DMAYEU1 DN Demecarium bromide
DMAYEU1 HS Approved
DMAYEU1 SN Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide
DMAYEU1 TC Parasympathomimetics
DMAYEU1 DT Small molecular drug
DMAYEU1 PC 5965
DMAYEU1 MW 716.6
DMAYEU1 FM C32H52Br2N4O4
DMAYEU1 IC InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2
DMAYEU1 CS CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-]
DMAYEU1 IK YHKBUDZECQDYBR-UHFFFAOYSA-L
DMAYEU1 IU trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide
DMAYEU1 CA CAS 56-94-0
DMAYEU1 CB CHEBI:4391
DMAYEU1 DE Open-angle glaucoma
DMZEPFJ ID DMZEPFJ
DMZEPFJ DN Demeclocycline
DMZEPFJ HS Approved
DMZEPFJ SN Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline
DMZEPFJ CP Patheon Pharmaceuticals Inc
DMZEPFJ TC Antibiotics
DMZEPFJ DT Small molecular drug
DMZEPFJ PC 54680690
DMZEPFJ MW 464.9
DMZEPFJ FM C21H21ClN2O8
DMZEPFJ IC InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1
DMZEPFJ CS CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMZEPFJ IK GUXHBMASAHGULD-SEYHBJAFSA-N
DMZEPFJ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMZEPFJ CA CAS 127-33-3
DMZEPFJ CB CHEBI:4392
DMZEPFJ DE Bronchitis; Acne vulgaris; Lyme disease
DMCZQGK ID DMCZQGK
DMCZQGK DN Demecolcine
DMCZQGK HS Approved
DMCZQGK SN colcemid; 1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one; demecolcine,colcemid, n-deacetyl-n-methylcolchicine, n-methyl-n-desacetylcolchicine; Demicolcine; NSC3096; 1,2,3,10-Tetramethoxy-7-(methylamino)-6,7-dihydrobenzo[a]heptalen-9(5H)-one; NCGC00166035-01; AC1L1EKK; MolMap_000011; SCHEMBL8160; AC1Q698E; CHEMBL433632; CTK8E8505; MolPort-003-846-192; 6,7-Dihydro-1,2,3,10-Tetramethoxy-7-(Methylamino) Benzo (alpha) Heptalen-9(5H)-one; HMS3374M04; HSCI1_000384; BBL027927; STL377913; CD0013
DMCZQGK DT Small molecular drug
DMCZQGK PC 220401
DMCZQGK MW 371.4
DMCZQGK FM C21H25NO5
DMCZQGK IC InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1
DMCZQGK CS CN[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DMCZQGK IK NNJPGOLRFBJNIW-HNNXBMFYSA-N
DMCZQGK IU (7S)-1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one
DMCZQGK CA CAS 477-30-5
DMCZQGK CB CHEBI:4393
DMCZQGK DE Solid tumour/cancer
DMMHR1U ID DMMHR1U
DMMHR1U DN Denileukin diftitox
DMMHR1U HS Approved
DMMHR1U CP Louisville
DMMHR1U TC Anticancer Agents
DMMHR1U SQ DB00004 sequence: MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DMMHR1U DE leukaemia; Non-small-cell lung cancer
DM8C3GN ID DM8C3GN
DM8C3GN DN Denopamine
DM8C3GN HS Approved
DM8C3GN SN Kalgut (TN)
DM8C3GN DT Small molecular drug
DM8C3GN PC 5311064
DM8C3GN MW 317.4
DM8C3GN FM C18H23NO4
DM8C3GN IC InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1
DM8C3GN CS COC1=C(C=C(C=C1)CCNC[C@@H](C2=CC=C(C=C2)O)O)OC
DM8C3GN IK VHSBBVZJABQOSG-INIZCTEOSA-N
DM8C3GN IU 4-[(1R)-2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol
DM8C3GN CA CAS 71771-90-9
DM8C3GN CB CHEBI:135359
DM8C3GN DE Cardiac disease
DMNI0KO ID DMNI0KO
DMNI0KO DN Denosumab
DMNI0KO HS Approved
DMNI0KO SN Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)
DMNI0KO CP Amgen
DMNI0KO DT Antibody
DMNI0KO SQ Denosumab OPGL-1 heavy chain sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Denosumab OPGL-1 light chain sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNI0KO DE Postmenopausal osteoporosis; Rheumatoid arthritis; Prostate cancer
DM3GYAL ID DM3GYAL
DM3GYAL DN Deoxycholic acid
DM3GYAL HS Approved
DM3GYAL SN (3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate
DM3GYAL DT Small molecular drug
DM3GYAL PC 222528
DM3GYAL MW 392.58
DM3GYAL FM C24H40O4
DM3GYAL IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM3GYAL CS CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
DM3GYAL IK KXGVEGMKQFWNSR-LLQZFEROSA-N
DM3GYAL IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3GYAL CA CAS 83-44-3
DM3GYAL CB CHEBI:28834
DM3GYAL DE Fat below the chin
DMYE5LJ ID DMYE5LJ
DMYE5LJ DN DEOXYCYTIDINE
DMYE5LJ HS Approved
DMYE5LJ SN Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
DMYE5LJ DT Small molecular drug
DMYE5LJ PC 13711
DMYE5LJ MW 227.22
DMYE5LJ FM C9H13N3O4
DMYE5LJ IC InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1
DMYE5LJ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O
DMYE5LJ IK CKTSBUTUHBMZGZ-SHYZEUOFSA-N
DMYE5LJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMYE5LJ CA CAS 951-77-9
DMYE5LJ CB CHEBI:15698
DMYE5LJ DE Acute myeloid leukaemia
DMRH7CV ID DMRH7CV
DMRH7CV DN Deserpidine
DMRH7CV HS Approved
DMRH7CV SN Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)
DMRH7CV TC Antihypertensive Agents
DMRH7CV DT Small molecular drug
DMRH7CV PC 8550
DMRH7CV MW 578.7
DMRH7CV FM C32H38N2O8
DMRH7CV IC InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
DMRH7CV CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DMRH7CV IK CVBMAZKKCSYWQR-WCGOZPBSSA-N
DMRH7CV IU methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMRH7CV CA CAS 131-01-1
DMRH7CV CB CHEBI:27478
DMRH7CV DE Hypertension
DM2TO9R ID DM2TO9R
DM2TO9R DN Desflurane
DM2TO9R HS Approved
DM2TO9R SN Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R TC Anesthetics
DM2TO9R DT Small molecular drug
DM2TO9R PC 42113
DM2TO9R MW 168.04
DM2TO9R FM C3H2F6O
DM2TO9R IC InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DM2TO9R CS C(C(F)(F)F)(OC(F)F)F
DM2TO9R IK DPYMFVXJLLWWEU-UHFFFAOYSA-N
DM2TO9R IU 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R CA CAS 57041-67-5
DM2TO9R CB CHEBI:4445
DM2TO9R DE Anaesthesia
DMT2FDC ID DMT2FDC
DMT2FDC DN Desipramine
DMT2FDC HS Approved
DMT2FDC SN Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
DMT2FDC CP Sanofi Aventis Us Llc
DMT2FDC TC Antidepressants
DMT2FDC DT Small molecular drug
DMT2FDC PC 2995
DMT2FDC MW 266.4
DMT2FDC FM C18H22N2
DMT2FDC IC InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
DMT2FDC CS CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DMT2FDC IK HCYAFALTSJYZDH-UHFFFAOYSA-N
DMT2FDC IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMT2FDC CA CAS 50-47-5
DMT2FDC CB CHEBI:47781
DMT2FDC DE Attention deficit hyperactivity disorder; Depression
DM2BTFN ID DM2BTFN
DM2BTFN DN Desirudin Recombinant
DM2BTFN HS Approved
DM2BTFN SN Iprivask
DM2BTFN CP Valeant Pharmaceuticals North America Llc
DM2BTFN TC Cardiovascular Agents
DM2BTFN DE Coagulation defect
DMB3ZSK ID DMB3ZSK
DMB3ZSK DN Deslanoside
DMB3ZSK HS Approved
DMB3ZSK SN Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
DMB3ZSK TC Antiarrhythmic Agents
DMB3ZSK DT Small molecular drug
DMB3ZSK PC 28620
DMB3ZSK MW 943.1
DMB3ZSK FM C47H74O19
DMB3ZSK IC InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
DMB3ZSK CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
DMB3ZSK IK OBATZBGFDSVCJD-LALPQLPRSA-N
DMB3ZSK IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMB3ZSK CA CAS 17598-65-1
DMB3ZSK CB CHEBI:31468
DMB3ZSK DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DM56YN7 ID DM56YN7
DM56YN7 DN Desloratadine
DM56YN7 HS Approved
DM56YN7 SN Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
DM56YN7 CP Schering-Plough
DM56YN7 TC Antiallergic Agents
DM56YN7 DT Small molecular drug
DM56YN7 PC 124087
DM56YN7 MW 310.8
DM56YN7 FM C19H19ClN2
DM56YN7 IC InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
DM56YN7 CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
DM56YN7 IK JAUOIFJMECXRGI-UHFFFAOYSA-N
DM56YN7 IU 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DM56YN7 CA CAS 100643-71-8
DM56YN7 CB CHEBI:291342
DM56YN7 DE Allergic rhinitis
DMS3GVE ID DMS3GVE
DMS3GVE DN Desmopressin
DMS3GVE HS Approved
DMS3GVE SN Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals
DMS3GVE CP Ferring Pharmaceuticals Inc
DMS3GVE DT Small molecular drug
DMS3GVE PC 5311065
DMS3GVE MW 1069.2
DMS3GVE FM C46H64N14O12S2
DMS3GVE IC InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
DMS3GVE CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMS3GVE IK NFLWUMRGJYTJIN-PNIOQBSNSA-N
DMS3GVE IU (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS3GVE CA CAS 16679-58-6
DMS3GVE CB CHEBI:4450
DMS3GVE DE Diabetic complication
DM27U4Y ID DM27U4Y
DM27U4Y DN Desogestrel
DM27U4Y HS Approved
DM27U4Y SN Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
DM27U4Y TC Contraceptive Agents
DM27U4Y DT Small molecular drug
DM27U4Y PC 40973
DM27U4Y MW 310.5
DM27U4Y FM C22H30O
DM27U4Y IC InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DM27U4Y CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
DM27U4Y IK RPLCPCMSCLEKRS-BPIQYHPVSA-N
DM27U4Y IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
DM27U4Y CA CAS 54024-22-5
DM27U4Y CB CHEBI:4453
DM27U4Y DE Contraception
DMTP2NJ ID DMTP2NJ
DMTP2NJ DN Desonide
DMTP2NJ HS Approved
DMTP2NJ SN Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide
DMTP2NJ TC Antiinflammatory Agents
DMTP2NJ DT Small molecular drug
DMTP2NJ PC 5311066
DMTP2NJ MW 416.5
DMTP2NJ FM C24H32O6
DMTP2NJ IC InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMTP2NJ CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O
DMTP2NJ IK WBGKWQHBNHJJPZ-LECWWXJVSA-N
DMTP2NJ IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMTP2NJ CA CAS 638-94-8
DMTP2NJ CB CHEBI:204734
DMTP2NJ DE Atopic dermatitis
DM4PXF6 ID DM4PXF6
DM4PXF6 DN Desoximetasone
DM4PXF6 HS Approved
DM4PXF6 SN Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
DM4PXF6 TC Antiinflammatory Agents
DM4PXF6 DT Small molecular drug
DM4PXF6 PC 5311067
DM4PXF6 MW 376.5
DM4PXF6 FM C22H29FO4
DM4PXF6 IC InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
DM4PXF6 CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
DM4PXF6 IK VWVSBHGCDBMOOT-IIEHVVJPSA-N
DM4PXF6 IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4PXF6 CA CAS 140218-14-0
DM4PXF6 CB CHEBI:691037
DM4PXF6 DE Inflammation
DMS0AFE ID DMS0AFE
DMS0AFE DN Desoxycorticosterone acetate
DMS0AFE HS Approved
DMS0AFE SN Doca
DMS0AFE CP Organon Usa Inc
DMS0AFE DT Small molecular drug
DMS0AFE PC 5952
DMS0AFE MW 372.5
DMS0AFE FM C23H32O4
DMS0AFE IC InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1
DMS0AFE CS CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMS0AFE IK VPGRYOFKCNULNK-ACXQXYJUSA-N
DMS0AFE IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMS0AFE CA CAS 56-47-3
DMS0AFE CB CHEBI:34671
DMS0AFE DE Discovery agent
DMSA4B3 ID DMSA4B3
DMSA4B3 DN Desoxycorticosterone pivalate
DMSA4B3 HS Approved
DMSA4B3 SN DOCP; DTMA; Cortexone M; Deoxycorticosterone pivalate; Deoxycorticosterone trimethylacetate; Deoxycortolone Pivalate; Deoxycortone pivalate; Deoxycortone trimethylacetate; Desoxycorticosterone trimethylacetate; Desoxycortone pivalate; Percorten M; Percorten Pivalate; Desoxycorticosterone pivalate (USP); Neodin-depositum; Percorten (TN); Corticosterone, deoxy-, pivalate (6CI,7CI); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; 11-Deoxycorticosterone pivalate; 11-Deoxycorticosterone, pivalate; 11-Deoxycorticosterone, pivalate (8CI); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate
DMSA4B3 TC Antiaddison Agents
DMSA4B3 DT Small molecular drug
DMSA4B3 PC 11876263
DMSA4B3 MW 414.6
DMSA4B3 FM C26H38O4
DMSA4B3 IC InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
DMSA4B3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C
DMSA4B3 IK VVOIQBFMTVCINR-WWMZEODYSA-N
DMSA4B3 IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMSA4B3 CA CAS 808-48-0
DMSA4B3 CB CHEBI:50782
DMSA4B3 DE Addison disease
DMEZFXR ID DMEZFXR
DMEZFXR DN Desoxyribonuclease
DMEZFXR HS Approved
DMEZFXR DE Female genital tract inflammation
DMJE6KO ID DMJE6KO
DMJE6KO DN Desvenalfaxine succinate
DMJE6KO HS Approved
DMJE6KO SN 386750-22-7; Desvenlafaxine succinate monohydrate; Desvenlafaxine (succinate hydrate); Desvenlafaxine succinate hydrate; Desvenlafaxine Succinate [USAN]; Desvenlafaxine succinate (USAN); O-desmethylvenlafaxine Succinate Monohydrate; Desvenlafaxine Succinate Monohydrate (O-Desmethylvenlafaxine Succinate Monohydrate); Pristiq (TN); AC1OCFPN; Desvenlafaxine(succinatehydrate); SCHEMBL1278407; CTK8E8387; HY-B0602A; MolPort-021-783-032
DMJE6KO CP Wyeth
DMJE6KO DT Small molecular drug
DMJE6KO PC 6918664
DMJE6KO MW 399.5
DMJE6KO FM C20H33NO7
DMJE6KO IC InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2
DMJE6KO CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O
DMJE6KO IK PWPDEXVGKDEKTE-UHFFFAOYSA-N
DMJE6KO IU butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate
DMJE6KO CA CAS 386750-22-7
DMJE6KO DE Fibromyalgia
DMHD4PE ID DMHD4PE
DMHD4PE DN Desvenlafaxine
DMHD4PE HS Approved
DMHD4PE SN Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233
DMHD4PE CP Wyeth
DMHD4PE DT Small molecular drug
DMHD4PE PC 125017
DMHD4PE MW 263.37
DMHD4PE FM C16H25NO2
DMHD4PE IC InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
DMHD4PE CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
DMHD4PE IK KYYIDSXMWOZKMP-UHFFFAOYSA-N
DMHD4PE IU 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
DMHD4PE CA CAS 93413-62-8
DMHD4PE CB CHEBI:83527
DMHD4PE DE Major depressive disorder; Menopause symptom
DMUPFLI ID DMUPFLI
DMUPFLI DN Deutetrabenazine
DMUPFLI HS Approved
DMUPFLI SN Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]
DMUPFLI CP Teva
DMUPFLI DT Small molecular drug
DMUPFLI PC 73437646
DMUPFLI MW 323.5
DMUPFLI FM C19H27NO3
DMUPFLI IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
DMUPFLI CS [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
DMUPFLI IK MKJIEFSOBYUXJB-VFJJUKLQSA-N
DMUPFLI IU (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMUPFLI CA CAS 1392826-25-3
DMUPFLI DE Tardive dyskinesia; Huntington disease
DMMWZET ID DMMWZET
DMMWZET DN Dexamethasone
DMMWZET HS Approved
DMMWZET SN Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
DMMWZET CP Swiss Pharma
DMMWZET TC Antiinflammatory Agents
DMMWZET DT Small molecular drug
DMMWZET PC 5743
DMMWZET MW 392.5
DMMWZET FM C22H29FO5
DMMWZET IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DMMWZET CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMMWZET IK UREBDLICKHMUKA-CXSFZGCWSA-N
DMMWZET IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMMWZET CA CAS 50-02-2
DMMWZET CB CHEBI:41879
DMMWZET DE Rheumatoid arthritis
DMIG8DW ID DMIG8DW
DMIG8DW DN Dexamethasone sodium phosphate
DMIG8DW HS Approved
DMIG8DW SN EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel
DMIG8DW CP Universita' Degli Studi Di Urbino
DMIG8DW DT Small molecular drug
DMIG8DW PC 16961
DMIG8DW MW 516.4
DMIG8DW FM C22H28FNa2O8P
DMIG8DW IC InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
DMIG8DW CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+]
DMIG8DW IK PLCQGRYPOISRTQ-FCJDYXGNSA-L
DMIG8DW IU disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
DMIG8DW CA CAS 2392-39-4
DMIG8DW CB CHEBI:4462
DMIG8DW DE Ataxia-telangiectasia
DMKVWGE ID DMKVWGE
DMKVWGE DN Dexbrompheniramine
DMKVWGE HS Approved
DMKVWGE SN Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine
DMKVWGE CP Schering Corp Sub Schering Plough Corp
DMKVWGE TC Antihistamines
DMKVWGE DT Small molecular drug
DMKVWGE PC 16960
DMKVWGE MW 319.24
DMKVWGE FM C16H19BrN2
DMKVWGE IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
DMKVWGE CS CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMKVWGE IK ZDIGNSYAACHWNL-HNNXBMFYSA-N
DMKVWGE IU (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMKVWGE CA CAS 132-21-8
DMKVWGE CB CHEBI:59269
DMKVWGE DE Hay fever
DMA8DPN ID DMA8DPN
DMA8DPN DN Dexchlorpheniramine maleate
DMA8DPN HS Approved
DMA8DPN SN Polaramine
DMA8DPN CP Schering Corp Sub Schering Plough Corp
DMA8DPN DT Small molecular drug
DMA8DPN PC 5281070
DMA8DPN MW 390.9
DMA8DPN FM C20H23ClN2O4
DMA8DPN IC InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1
DMA8DPN CS CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DMA8DPN IK DBAKFASWICGISY-DASCVMRKSA-N
DMA8DPN IU (Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMA8DPN CA CAS 2438-32-6
DMA8DPN CB CHEBI:4465
DMA8DPN DE Rhinitis
DMFYBD0 ID DMFYBD0
DMFYBD0 DN Dexibuprofen
DMFYBD0 HS Approved
DMFYBD0 SN (S)-(+)-Ibuprofen; 51146-56-6; DEXIBUPROFEN; S(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; d-Ibuproten; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (+)-(S)-p-Isobutylhydratropic acid; Seractil; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; UNII-671DKG7P5S; S-(+)-ibuprofen; (2S)-2-(4-isobutylphenyl)propanoic acid; CHEMBL175; 671DKG7P5S; CHEBI:43415; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; NCGC00016861-05
DMFYBD0 DT Small molecular drug
DMFYBD0 PC 39912
DMFYBD0 MW 206.28
DMFYBD0 FM C13H18O2
DMFYBD0 IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
DMFYBD0 CS C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
DMFYBD0 IK HEFNNWSXXWATRW-JTQLQIEISA-N
DMFYBD0 IU (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
DMFYBD0 CA CAS 51146-56-6
DMFYBD0 CB CHEBI:43415
DMFYBD0 DE Ankylosing spondylitis
DM1DBV5 ID DM1DBV5
DM1DBV5 DN Dexlansoprazole
DM1DBV5 HS Approved
DM1DBV5 SN dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole
DM1DBV5 CP Takeda
DM1DBV5 DT Small molecular drug
DM1DBV5 PC 9578005
DM1DBV5 MW 369.4
DM1DBV5 FM C16H14F3N3O2S
DM1DBV5 IC InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
DM1DBV5 CS CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DM1DBV5 IK MJIHNNLFOKEZEW-RUZDIDTESA-N
DM1DBV5 IU 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DM1DBV5 CA CAS 138530-94-6
DM1DBV5 CB CHEBI:135931
DM1DBV5 DE Non-erosive gastro-esophageal reflux disease; Erosive esophagitis; Peptic ulcer; NSAID-associated gastric ulcer
DM93L4X ID DM93L4X
DM93L4X DN Dexmedetomidine
DM93L4X HS Approved
DM93L4X SN Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CP Hospira
DM93L4X TC Hypnotics and Sedatives
DM93L4X DT Small molecular drug
DM93L4X PC 5311068
DM93L4X MW 200.28
DM93L4X FM C13H16N2
DM93L4X IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
DM93L4X CS CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C
DM93L4X IK CUHVIMMYOGQXCV-NSHDSACASA-N
DM93L4X IU 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CA CAS 113775-47-6
DM93L4X CB CHEBI:4466
DM93L4X DE Irritability
DMUQE2A ID DMUQE2A
DMUQE2A DN Dexmethylphenidate
DMUQE2A HS Approved
DMUQE2A SN Dexmethylphenidate; Dexmethylphenidate (INN); Dexmethylphenidate [INN]; Focalin; Focalin XR; M32RH9MFGP; Methyl D-phenidate; d-Methylphenidate; Attenade; Dex methylphenidate; d-threo-Methylphenidate; dex-methylphenidate; dexmethylphenidatum; dexmetilfenidato; threo-(+)-Methylphenidate; (+)-threo-Methylphenidate; 40431-64-9; CHEBI:51860; CHEMBL827; D-MPH; D-TMP; UNII-M32RH9MFGP; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
DMUQE2A PC 154101
DMUQE2A MW 233.31
DMUQE2A FM C14H19NO2
DMUQE2A IC DUGOZIWVEXMGBE-CHWSQXEVSA-N
DMUQE2A CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DMUQE2A IK 1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
DMUQE2A IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DMUQE2A CA CAS 40431-64-9
DMUQE2A CB CHEBI:51860
DMUQE2A DE Attention deficit hyperactivity disorder
DM8WBAH ID DM8WBAH
DM8WBAH DN Dexmethylphenidate hydrochloride
DM8WBAH HS Approved
DM8WBAH SN Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
DM8WBAH DT Small molecular drug
DM8WBAH PC 154100
DM8WBAH MW 269.77
DM8WBAH FM C14H20ClNO2
DM8WBAH IC InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
DM8WBAH CS COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
DM8WBAH IK JUMYIBMBTDDLNG-OJERSXHUSA-N
DM8WBAH IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
DM8WBAH CA CAS 19262-68-1
DM8WBAH DE Attention deficit hyperactivity disorder
DMD7X1O ID DMD7X1O
DMD7X1O DN Dexrazoxane
DMD7X1O HS Approved
DMD7X1O SN 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum; Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187
DMD7X1O CP Pfizer Pharmaceuticals
DMD7X1O TC Anticancer Agents
DMD7X1O DT Small molecular drug
DMD7X1O PC 71384
DMD7X1O MW 268.27
DMD7X1O FM C11H16N4O4
DMD7X1O IC InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
DMD7X1O CS C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
DMD7X1O IK BMKDZUISNHGIBY-ZETCQYMHSA-N
DMD7X1O IU 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
DMD7X1O CA CAS 24584-09-6
DMD7X1O CB CHEBI:50223
DMD7X1O DE Breast cancer; Chemoprotection; Respiratory tract disease
DMMIHVP ID DMMIHVP
DMMIHVP DN Dextroamphetamine
DMMIHVP HS Approved
DMMIHVP SN D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga
DMMIHVP CP GlaxoSmithKline
DMMIHVP TC Central Nervous System Stimulants
DMMIHVP DT Small molecular drug
DMMIHVP PC 5826
DMMIHVP MW 135.21
DMMIHVP FM C9H13N
DMMIHVP IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
DMMIHVP CS C[C@@H](CC1=CC=CC=C1)N
DMMIHVP IK KWTSXDURSIMDCE-QMMMGPOBSA-N
DMMIHVP IU (2S)-1-phenylpropan-2-amine
DMMIHVP CA CAS 51-64-9
DMMIHVP CB CHEBI:4469
DMMIHVP DE Narcolepsy; Attention deficit hyperactivity disorder
DMUDJZM ID DMUDJZM
DMUDJZM DN Dextromethorphan
DMUDJZM HS Approved
DMUDJZM SN Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)
DMUDJZM TC Analgesics
DMUDJZM DT Small molecular drug
DMUDJZM PC 5360696
DMUDJZM MW 271.4
DMUDJZM FM C18H25NO
DMUDJZM IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
DMUDJZM CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
DMUDJZM IK MKXZASYAUGDDCJ-NJAFHUGGSA-N
DMUDJZM IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMUDJZM CA CAS 125-71-3
DMUDJZM CB CHEBI:4470
DMUDJZM DE Cough
DMEHCY5 ID DMEHCY5
DMEHCY5 DN Dextromethorphan polistirex
DMEHCY5 HS Approved
DMEHCY5 CP Reckitt Benckiser Llc
DMEHCY5 PC 5464025
DMEHCY5 MW 352.3
DMEHCY5 FM C18H26BrNO
DMEHCY5 IC InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1
DMEHCY5 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br
DMEHCY5 IK MISZALMBODQYFT-URVXVIKDSA-N
DMEHCY5 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide
DMEHCY5 CA CAS 125-69-9
DMEHCY5 DE Dry cough
DM23HCX ID DM23HCX
DM23HCX DN Dextropropoxyphene
DM23HCX HS Approved
DM23HCX SN Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
DM23HCX TC Analgesics
DM23HCX DT Small molecular drug
DM23HCX PC 10100
DM23HCX MW 339.5
DM23HCX FM C22H29NO2
DM23HCX IC InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
DM23HCX CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C
DM23HCX IK XLMALTXPSGQGBX-GCJKJVERSA-N
DM23HCX IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
DM23HCX CA CAS 469-62-5
DM23HCX CB CHEBI:51173
DM23HCX DE Pain
DMBVEC7 ID DMBVEC7
DMBVEC7 DN Dextrothyroxine Sodium
DMBVEC7 HS Approved
DMBVEC7 SN Choloxin
DMBVEC7 CP Abbvie Inc
DMBVEC7 DT Small molecular drug
DMBVEC7 PC 23690433
DMBVEC7 MW 798.85
DMBVEC7 FM C15H10I4NNaO4
DMBVEC7 IC InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1
DMBVEC7 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)[O-])N.[Na+]
DMBVEC7 IK YDTFRJLNMPSCFM-UTONKHPSSA-M
DMBVEC7 IU sodium;(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
DMBVEC7 CA CAS 137-53-1
DMBVEC7 DE High blood cholesterol level
DMJDB0Y ID DMJDB0Y
DMJDB0Y DN Dezocine
DMJDB0Y HS Approved
DMJDB0Y SN SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol
DMJDB0Y TC Analgesics
DMJDB0Y DT Small molecular drug
DMJDB0Y PC 3033053
DMJDB0Y MW 245.36
DMJDB0Y FM C16H23NO
DMJDB0Y IC InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1
DMJDB0Y CS C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O
DMJDB0Y IK VTMVHDZWSFQSQP-VBNZEHGJSA-N
DMJDB0Y IU (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol
DMJDB0Y CA CAS 53648-55-8
DMJDB0Y CB CHEBI:4474
DMJDB0Y DE Pain
DMU3FGB ID DMU3FGB
DMU3FGB DN Dhaq diacetate
DMU3FGB HS Approved
DMU3FGB SN Mitoxantrone diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate
DMU3FGB TC Anticancer Agents
DMU3FGB DT Small molecular drug
DMU3FGB PC 51151
DMU3FGB MW 564.6
DMU3FGB FM C26H36N4O10
DMU3FGB IC InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4)
DMU3FGB CS CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO
DMU3FGB IK ZWCKUVMZBKQQRG-UHFFFAOYSA-N
DMU3FGB IU 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium;diacetate
DMU3FGB CA CAS 70711-41-0
DMU3FGB DE Solid tumour/cancer
DM08E9O ID DM08E9O
DM08E9O DN Diazepam
DM08E9O HS Approved
DM08E9O SN diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol; Diazepam (intranasal, epilepsy)
DM08E9O CP Archimedes Pharma Ltd
DM08E9O DT Small molecular drug
DM08E9O PC 3016
DM08E9O MW 284.74
DM08E9O FM C16H13ClN2O
DM08E9O IC InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DM08E9O CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DM08E9O IK AAOVKJBEBIDNHE-UHFFFAOYSA-N
DM08E9O IU 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM08E9O CA CAS 439-14-5
DM08E9O CB CHEBI:49575
DM08E9O DE Epilepsy
DML1538 ID DML1538
DML1538 DN Diazoxide
DML1538 HS Approved
DML1538 SN Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1
DML1538 TC Antihypertensive Agents
DML1538 DT Small molecular drug
DML1538 PC 3019
DML1538 MW 230.67
DML1538 FM C8H7ClN2O2S
DML1538 IC InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
DML1538 CS CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
DML1538 IK GDLBFKVLRPITMI-UHFFFAOYSA-N
DML1538 IU 7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DML1538 CA CAS 364-98-7
DML1538 CB CHEBI:4495
DML1538 DE Hypertension
DMF9G7L ID DMF9G7L
DMF9G7L DN Dibucaine
DMF9G7L HS Approved
DMF9G7L SN Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CP Novartis Pharmaceuticals Corp
DMF9G7L TC Anesthetics
DMF9G7L DT Small molecular drug
DMF9G7L PC 3025
DMF9G7L MW 343.5
DMF9G7L FM C20H29N3O2
DMF9G7L IC InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
DMF9G7L CS CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
DMF9G7L IK PUFQVTATUTYEAL-UHFFFAOYSA-N
DMF9G7L IU 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CA CAS 85-79-0
DMF9G7L CB CHEBI:247956
DMF9G7L DE Anaesthesia
DMH7IDQ ID DMH7IDQ
DMH7IDQ DN Dichlorphenamide
DMH7IDQ HS Approved
DMH7IDQ SN dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis; Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE
DMH7IDQ TC Antiglaucomic Agents
DMH7IDQ DT Small molecular drug
DMH7IDQ PC 3038
DMH7IDQ MW 305.2
DMH7IDQ FM C6H6Cl2N2O4S2
DMH7IDQ IC InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
DMH7IDQ CS C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
DMH7IDQ IK GJQPMPFPNINLKP-UHFFFAOYSA-N
DMH7IDQ IU 4,5-dichlorobenzene-1,3-disulfonamide
DMH7IDQ CA CAS 120-97-8
DMH7IDQ CB CHEBI:101085
DMH7IDQ DE Chronic glaucoma
DMPIHLS ID DMPIHLS
DMPIHLS DN Diclofenac
DMPIHLS HS Approved
DMPIHLS SN Diclofenac (sodium matrix patch, pain)
DMPIHLS CP Novartis Pharmaceuticals Corp
DMPIHLS TC Neurology Agents
DMPIHLS DT Small molecular drug
DMPIHLS PC 3033
DMPIHLS MW 296.1
DMPIHLS FM C14H11Cl2NO2
DMPIHLS IC InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
DMPIHLS CS C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMPIHLS IK DCOPUUMXTXDBNB-UHFFFAOYSA-N
DMPIHLS IU 2-[2-(2,6-dichloroanilino)phenyl]acetic acid
DMPIHLS CA CAS 15307-86-5
DMPIHLS CB CHEBI:47381
DMPIHLS DE Osteoarthritis
DM8EU0Z ID DM8EU0Z
DM8EU0Z DN Dicloxacillin
DM8EU0Z HS Approved
DM8EU0Z SN Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DM8EU0Z CP Sandoz Inc
DM8EU0Z TC Antibiotics
DM8EU0Z DT Small molecular drug
DM8EU0Z PC 18381
DM8EU0Z MW 470.3
DM8EU0Z FM C19H17Cl2N3O5S
DM8EU0Z IC InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DM8EU0Z CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DM8EU0Z IK YFAGHNZHGGCZAX-JKIFEVAISA-N
DM8EU0Z IU (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8EU0Z CA CAS 3116-76-5
DM8EU0Z CB CHEBI:4511
DM8EU0Z DE Bacterial infection
DMFQCB1 ID DMFQCB1
DMFQCB1 DN Dicumarol
DMFQCB1 HS Approved
DMFQCB1 SN Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3′-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin
DMFQCB1 TC Anticoagulants
DMFQCB1 DT Small molecular drug
DMFQCB1 PC 54676038
DMFQCB1 MW 336.3
DMFQCB1 FM C19H12O6
DMFQCB1 IC InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
DMFQCB1 CS C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
DMFQCB1 IK DOBMPNYZJYQDGZ-UHFFFAOYSA-N
DMFQCB1 IU 4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one
DMFQCB1 CA CAS 66-76-2
DMFQCB1 CB CHEBI:4513
DMFQCB1 DE Thrombosis; Bleeding disorder
DMZSDGX ID DMZSDGX
DMZSDGX DN Dicyclomine
DMZSDGX HS Approved
DMZSDGX SN Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride
DMZSDGX CP Peckforton Pharmaceuticals
DMZSDGX TC Anticholinergic Agents
DMZSDGX DT Small molecular drug
DMZSDGX PC 3042
DMZSDGX MW 309.5
DMZSDGX FM C19H35NO2
DMZSDGX IC InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
DMZSDGX CS CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
DMZSDGX IK CURUTKGFNZGFSE-UHFFFAOYSA-N
DMZSDGX IU 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
DMZSDGX CA CAS 77-19-0
DMZSDGX CB CHEBI:4514
DMZSDGX DE Functional bowel syndrome
DMI2QPE ID DMI2QPE
DMI2QPE DN Didanosine
DMI2QPE HS Approved
DMI2QPE SN didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927
DMI2QPE CP Bristol-Myers Squibb
DMI2QPE TC Anti-HIV Agents
DMI2QPE DT Small molecular drug
DMI2QPE PC 135398739
DMI2QPE MW 236.23
DMI2QPE FM C10H12N4O3
DMI2QPE IC InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
DMI2QPE CS C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
DMI2QPE IK BXZVVICBKDXVGW-NKWVEPMBSA-N
DMI2QPE IU 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMI2QPE CA CAS 69655-05-6
DMI2QPE CB CHEBI:490877
DMI2QPE DE Human immunodeficiency virus infection
DMBSXI0 ID DMBSXI0
DMBSXI0 DN Dienestrol
DMBSXI0 HS Approved
DMBSXI0 SN Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 TC Estrogens
DMBSXI0 DT Small molecular drug
DMBSXI0 PC 667476
DMBSXI0 MW 266.3
DMBSXI0 FM C18H18O2
DMBSXI0 IC InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+
DMBSXI0 CS C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\\C2=CC=C(C=C2)O
DMBSXI0 IK NFDFQCUYFHCNBW-SCGPFSFSSA-N
DMBSXI0 IU 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 CA CAS 13029-44-2
DMBSXI0 CB CHEBI:4518
DMBSXI0 DE Atrophic vaginitis
DM1TJ8F ID DM1TJ8F
DM1TJ8F DN Diethylcarbamazine
DM1TJ8F HS Approved
DM1TJ8F SN Bitirazine; Camin; Caracide; Carbamazine; Carbilazine; Caricide; Cypip; Decacide; Diaethylcarbamazinum; Diethylcarbamazinum; Dietilcarbamazina; Ethodryl; Luxuran; Notezine; Spatonin; Diethyl carbamazine; Ditrazine Base; Banocide (TN); Camin (TN); Carbilazine (TN); Caricide (TN); Cypip (TN); Diethylcarbamazine (INN); Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; Ethodryl (TN); FR-1031; Filaribits (TN); Forte (TN); Hetrazan (TN); Spatonin (TN); N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-diethyl-4-methylpiperazine-1-carboxamide; 1-Diethylcarbamyl-4-methylpiperazine; 84L
DM1TJ8F CP Lederle Laboratories Div American Cyanamid Co
DM1TJ8F TC Anthelmintics
DM1TJ8F DT Small molecular drug
DM1TJ8F PC 3052
DM1TJ8F MW 199.29
DM1TJ8F FM C10H21N3O
DM1TJ8F IC InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3
DM1TJ8F CS CCN(CC)C(=O)N1CCN(CC1)C
DM1TJ8F IK RCKMWOKWVGPNJF-UHFFFAOYSA-N
DM1TJ8F IU N,N-diethyl-4-methylpiperazine-1-carboxamide
DM1TJ8F CA CAS 90-89-1
DM1TJ8F CB CHEBI:4527
DM1TJ8F DE Lymphatic filariasis
DMN3UXQ ID DMN3UXQ
DMN3UXQ DN Diethylstilbestrol
DMN3UXQ HS Approved
DMN3UXQ SN Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol "2" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol
DMN3UXQ CP Bayer Pharmaceuticals Corp
DMN3UXQ TC Anticancer Agents
DMN3UXQ DT Small molecular drug
DMN3UXQ PC 448537
DMN3UXQ MW 268.3
DMN3UXQ FM C18H20O2
DMN3UXQ IC InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
DMN3UXQ CS CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
DMN3UXQ IK RGLYKWWBQGJZGM-ISLYRVAYSA-N
DMN3UXQ IU 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
DMN3UXQ CA CAS 56-53-1
DMN3UXQ CB CHEBI:41922
DMN3UXQ DE Gonorrheal vaginitis
DMI9PRJ ID DMI9PRJ
DMI9PRJ DN Diflorasone
DMI9PRJ HS Approved
DMI9PRJ SN Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
DMI9PRJ CP Pharmacia And Upjohn Co
DMI9PRJ TC Antiinflammatory Agents
DMI9PRJ DT Small molecular drug
DMI9PRJ PC 71415
DMI9PRJ MW 410.5
DMI9PRJ FM C22H28F2O5
DMI9PRJ IC InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
DMI9PRJ CS C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F
DMI9PRJ IK WXURHACBFYSXBI-XHIJKXOTSA-N
DMI9PRJ IU (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMI9PRJ CA CAS 2557-49-5
DMI9PRJ CB CHEBI:59750
DMI9PRJ DE Rosacea
DM7EN8I ID DM7EN8I
DM7EN8I DN Diflunisal
DM7EN8I HS Approved
DM7EN8I SN Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid
DM7EN8I CP Merck & Co
DM7EN8I TC Analgesics
DM7EN8I DT Small molecular drug
DM7EN8I PC 3059
DM7EN8I MW 250.2
DM7EN8I FM C13H8F2O3
DM7EN8I IC InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
DM7EN8I CS C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
DM7EN8I IK HUPFGZXOMWLGNK-UHFFFAOYSA-N
DM7EN8I IU 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
DM7EN8I CA CAS 22494-42-4
DM7EN8I CB CHEBI:39669
DM7EN8I DE Pain
DMMFVB3 ID DMMFVB3
DMMFVB3 DN Difluprednate
DMMFVB3 HS Approved
DMMFVB3 SN Durezol (TN)
DMMFVB3 CP Sirion
DMMFVB3 DT Small molecular drug
DMMFVB3 PC 443936
DMMFVB3 MW 508.5
DMMFVB3 FM C27H34F2O7
DMMFVB3 IC InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
DMMFVB3 CS CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C
DMMFVB3 IK WYQPLTPSGFELIB-JTQPXKBDSA-N
DMMFVB3 IU [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
DMMFVB3 CA CAS 23674-86-4
DMMFVB3 CB CHEBI:31485
DMMFVB3 DE Ocular pain
DMWVIGP ID DMWVIGP
DMWVIGP DN Digitoxin
DMWVIGP HS Approved
DMWVIGP SN Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]
DMWVIGP TC Antiarrhythmic Agents
DMWVIGP DT Small molecular drug
DMWVIGP PC 441207
DMWVIGP MW 764.9
DMWVIGP FM C41H64O13
DMWVIGP IC InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
DMWVIGP CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
DMWVIGP IK WDJUZGPOPHTGOT-XUDUSOBPSA-N
DMWVIGP IU 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMWVIGP CA CAS 71-63-6
DMWVIGP CB CHEBI:28544
DMWVIGP DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMQCTIH ID DMQCTIH
DMQCTIH DN Digoxin
DMQCTIH HS Approved
DMQCTIH SN digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin
DMQCTIH CP GlaxoSmithKline
DMQCTIH TC Antiarrhythmic Agents
DMQCTIH DT Small molecular drug
DMQCTIH PC 2724385
DMQCTIH MW 780.9
DMQCTIH FM C41H64O14
DMQCTIH IC InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
DMQCTIH CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
DMQCTIH IK LTMHDMANZUZIPE-PUGKRICDSA-N
DMQCTIH IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQCTIH CA CAS 20830-75-5
DMQCTIH CB CHEBI:4551
DMQCTIH DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMZIXU9 ID DMZIXU9
DMZIXU9 DN Dihydralazine
DMZIXU9 HS Approved
DMZIXU9 SN Dihydralazine sulfate; 7327-87-9; Dihydralazine sulphate; 1,4-Dihydrazinophthalazine sulfate; Depressan; Hydralazine sulfate; Ophthazin Sulfate; UNII-1C2B1W91NK; CCRIS 5386; Sulfate de dihydralazine [French]; 1,4-Dihydrazinylphthalazine Sulfate; EINECS 230-808-0; 1C2B1W91NK; Phthalazine, 1,4-dihydrazino-, sulfate (1:1); 1,4-Dihydrazinophthalazine hydrogen sulfate; W-104459; Sulfate de dihydralazine; 1,4-dihydrazinophthalazine sulfate(1:1); Dihydralazinsulfat; C8H10N6.H2O4S; Nepresol (TN); Dihydralazine Sulfate,(S); AC1Q6XE2
DMZIXU9 DT Small molecular drug
DMZIXU9 PC 10230
DMZIXU9 MW 190.21
DMZIXU9 FM C8H10N6
DMZIXU9 IC InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
DMZIXU9 CS C1=CC=C2C(=C1)C(=NN=C2NN)NN
DMZIXU9 IK VQKLRVZQQYVIJW-UHFFFAOYSA-N
DMZIXU9 IU (4-hydrazinylphthalazin-1-yl)hydrazine
DMZIXU9 CA CAS 484-23-1
DMZIXU9 CB CHEBI:134841
DMZIXU9 DE Hypertension
DMBXVMZ ID DMBXVMZ
DMBXVMZ DN Dihydroartemisinin
DMBXVMZ HS Approved
DMBXVMZ SN Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
DMBXVMZ DT Small molecular drug
DMBXVMZ PC 3000518
DMBXVMZ MW 284.35
DMBXVMZ FM C15H24O5
DMBXVMZ IC InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1
DMBXVMZ CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
DMBXVMZ IK BJDCWCLMFKKGEE-ISOSDAIHSA-N
DMBXVMZ IU (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
DMBXVMZ CA CAS 71939-50-9
DMBXVMZ CB CHEBI:135921
DMBXVMZ DE Malaria
DM5SQ1G ID DM5SQ1G
DM5SQ1G DN Dihydroergocristine
DM5SQ1G HS Approved
DM5SQ1G SN Nehydrin
DM5SQ1G CP Sanochemia Pharmazeutika AG
DM5SQ1G DT Small molecular drug
DM5SQ1G PC 107715
DM5SQ1G MW 611.7
DM5SQ1G FM C35H41N5O5
DM5SQ1G IC InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
DM5SQ1G CS CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5SQ1G IK DEQITUUQPICUMR-HJPBWRTMSA-N
DM5SQ1G IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5SQ1G CA CAS 17479-19-5
DM5SQ1G CB CHEBI:59912
DM5SQ1G DE Alcohol dependence
DM5IKUF ID DM5IKUF
DM5IKUF DN Dihydroergotamine
DM5IKUF HS Approved
DM5IKUF SN Migranal (TN)
DM5IKUF CP Pfizer Pharmaceuticals
DM5IKUF TC Antimigraine Agents
DM5IKUF DT Small molecular drug
DM5IKUF PC 10531
DM5IKUF MW 583.7
DM5IKUF FM C33H37N5O5
DM5IKUF IC InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
DM5IKUF CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5IKUF IK LUZRJRNZXALNLM-JGRZULCMSA-N
DM5IKUF IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5IKUF CA CAS 511-12-6
DM5IKUF CB CHEBI:4562
DM5IKUF DE Migraine
DM5D6WZ ID DM5D6WZ
DM5D6WZ DN Dihydroergotoxine
DM5D6WZ HS Approved
DM5D6WZ SN Ergotamine, dihydro, methanesulfonate (salt)
DM5D6WZ TC Vasodilator Agents
DM5D6WZ DT Small molecular drug
DM5D6WZ PC 6420006
DM5D6WZ MW 679.8
DM5D6WZ FM C34H41N5O8S
DM5D6WZ IC InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1
DM5D6WZ CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5CC6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
DM5D6WZ IK ADYPXRFPBQGGAH-WVVAGBSPSA-N
DM5D6WZ IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
DM5D6WZ CA CAS 11032-41-0
DM5D6WZ DE Alzheimer disease
DMFB97P ID DMFB97P
DMFB97P DN Dihydrotachysterol
DMFB97P HS Approved
DMFB97P SN Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol
DMFB97P TC Antihypoparathyroid Agents
DMFB97P DT Small molecular drug
DMFB97P PC 5311071
DMFB97P MW 398.7
DMFB97P FM C28H46O
DMFB97P IC InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1
DMFB97P CS C[C@H]\\1CC[C@@H](C/C1=C\\C=C\\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O
DMFB97P IK ILYCWAKSDCYMBB-OPCMSESCSA-N
DMFB97P IU (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
DMFB97P CA CAS 67-96-9
DMFB97P CB CHEBI:4591
DMFB97P DE Hypocalcemia
DMM1LG2 ID DMM1LG2
DMM1LG2 DN Dihydroxyacetone
DMM1LG2 HS Approved
DMM1LG2 SN 1,3-dihydroxyacetone; Dihydroxyacetone; 96-26-4; 1,3-Dihydroxypropan-2-one; Chromelin; 1,3-Dihydroxy-2-propanone; glycerone; Triulose; Viticolor; Soleal; Oxatone; Dihyxal; Oxantin; Otan; 2-Propanone, 1,3-dihydroxy-; 1,3-Dihydroxypropanone; 1,3-Dihydroxydimethyl ketone; NSC-24343; Ketochromin; Bis(hydroxymethyl) ketone; UNII-O10DDW6JOO; dihydroxy-acetone; 2-Propanone, 1,3-dihydroxy; BRN 1740268; CCRIS 4899; AI3-24477; Dihydroxyacetone [USP]; EINECS 202-494-5; O10DDW6JOO; 1,2-Dihydroxy-2-propanone; CHEBI:16016; RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 DT Small molecular drug
DMM1LG2 PC 670
DMM1LG2 MW 90.08
DMM1LG2 FM C3H6O3
DMM1LG2 IC InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2
DMM1LG2 CS C(C(=O)CO)O
DMM1LG2 IK RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 IU 1,3-dihydroxypropan-2-one
DMM1LG2 CA CAS 96-26-4
DMM1LG2 CB CHEBI:16016
DMM1LG2 DE Sunburn
DM8YXKW ID DM8YXKW
DM8YXKW DN Dihydroxyaluminium
DM8YXKW HS Approved
DM8YXKW SN (2-Aminoacetoxy)dihydroxyaluminum; Dihydroxyaluminium glycinate; Dihydroxyaluminum aminoacetate; 41354-48-7; Robalate; Prodexin; Hyperacid; Alilac; (Glycinato)dihydroxyaluminum; Alminate; (T-4)-(Glycinato-N,O)dihydroxyaluminum; Dihydroxyaluminum aminoacetate [USAN:USP]; C2H6AlNO4; Dihydroxoaluminium glycinat; Aluminum glycinate, AldrichCPR; DTXSID3044546; (Glycinato-N,O)dihydroxyaluminum; 51484-68-5 (proacid); MolPort-023-220-319; 13682-92-3 (Parent); (Glycinato)dihydroxyaluminum hydrate; EINECS 237-193-8; Aluminum, (glycinato-N
DM8YXKW TC Antiinflammatory Agents
DM8YXKW DT Small molecular drug
DM8YXKW PC 16683036
DM8YXKW MW 137.07
DM8YXKW FM C2H8AlNO4
DM8YXKW IC InChI=1S/C2H5NO2.Al.2H2O/c3-1-2(4)5;;;/h1,3H2,(H,4,5);;2*1H2/q;+1;;/p-1
DM8YXKW CS C(C(=O)O[Al])N.O.O
DM8YXKW IK RBNPZEHAODHBPZ-UHFFFAOYSA-M
DM8YXKW CA CAS 13682-92-3
DM8YXKW DE Skin inflammation
DMAI7ZV ID DMAI7ZV
DMAI7ZV DN Diltiazem
DMAI7ZV HS Approved
DMAI7ZV SN Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
DMAI7ZV CP Valeant International Barbados Srl
DMAI7ZV TC Antihypertensive Agents
DMAI7ZV DT Small molecular drug
DMAI7ZV PC 39186
DMAI7ZV MW 414.5
DMAI7ZV FM C22H26N2O4S
DMAI7ZV IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
DMAI7ZV CS CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMAI7ZV IK HSUGRBWQSSZJOP-RTWAWAEBSA-N
DMAI7ZV IU [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMAI7ZV CA CAS 56209-45-1
DMAI7ZV CB CHEBI:101278
DMAI7ZV DE Hypertension
DM264B3 ID DM264B3
DM264B3 DN Dimenhydrinate
DM264B3 HS Approved
DM264B3 SN Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
DM264B3 CP Carter-Horner Corp.
DM264B3 TC Antiemetics
DM264B3 DT Small molecular drug
DM264B3 PC 10660
DM264B3 MW 470
DM264B3 FM C24H28ClN5O3
DM264B3 IC InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)
DM264B3 CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DM264B3 IK NFLLKCVHYJRNRH-UHFFFAOYSA-N
DM264B3 IU 2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione
DM264B3 CA CAS 523-87-5
DM264B3 CB CHEBI:94848
DM264B3 DE Nausea
DM32YAI ID DM32YAI
DM32YAI DN Dimethindene
DM32YAI HS Approved
DM32YAI SN Dimethpyrindene; Dimethylpyrindene; Dimetindene; Dimetindeno; Dimetindenum; Fengel; Fenistil; Forhistal; Foristal; Pecofenil; Triten; Z 2001; Dimetindene (INN); Dimetindene [INN:BAN]; Dimetindeno [INN-Spanish]; Dimetindenum [INN-Latin]; Fenistil (TN); Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-(9CI); 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine
DM32YAI TC Antiallergic Agents
DM32YAI DT Small molecular drug
DM32YAI PC 21855
DM32YAI MW 292.4
DM32YAI FM C20H24N2
DM32YAI IC InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3
DM32YAI CS CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
DM32YAI IK MVMQESMQSYOVGV-UHFFFAOYSA-N
DM32YAI IU N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine
DM32YAI CA CAS 5636-83-9
DM32YAI CB CHEBI:135222
DM32YAI DE Respiratory allergy
DMXQKSL ID DMXQKSL
DMXQKSL DN Dinoprost Tromethamine
DMXQKSL HS Approved
DMXQKSL SN Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt
DMXQKSL TC Abortifacient Agents
DMXQKSL DT Small molecular drug
DMXQKSL PC 5282415
DMXQKSL MW 475.6
DMXQKSL FM C24H45NO8
DMXQKSL IC InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
DMXQKSL CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMXQKSL IK IYGXEHDCSOYNKY-RZHHZEQLSA-N
DMXQKSL IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DMXQKSL CA CAS 38562-01-5
DMXQKSL CB CHEBI:31502
DMXQKSL DE Abortion
DMTYOPD ID DMTYOPD
DMTYOPD DN Dinoprostone
DMTYOPD HS Approved
DMTYOPD SN Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
DMTYOPD CP Pfizer Pharmaceuticals
DMTYOPD TC Prostaglandins
DMTYOPD DT Small molecular drug
DMTYOPD PC 5280360
DMTYOPD MW 352.5
DMTYOPD FM C20H32O5
DMTYOPD IC InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
DMTYOPD CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMTYOPD IK XEYBRNLFEZDVAW-ARSRFYASSA-N
DMTYOPD IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMTYOPD CA CAS 363-24-6
DMTYOPD CB CHEBI:15551
DMTYOPD DE Medical abortion
DMXVU6D ID DMXVU6D
DMXVU6D DN Diphemanil Methylsulfate
DMXVU6D HS Approved
DMXVU6D SN Demotil; Diphemanil; Diphemanilum; Diphenatil; Diphenmethanil; Nivelon; Nivelona; Prantal; Prantil; Prentol; Talpran; Vagophemanil; Variton; Diphemanil methosulfate; Diphemanil methyl sulfate; Diphemanil methylsulphate; Diphemanil metilsulfate; Diphemanili metilsulfas; Diphenmanil methyl sulfate; Diphenmanil methylsulfate; Diphenmethanil methyl sulfate; Diphenmethanil methylsulfate; Metilsulfate de diphemanil; Metilsulfato de difemanilo; Prantal methylsulfate; Vagophemanil methyl sulfate; Ban-guard; Diphemanil methylsulfate [INN:BAN]; Diphemanil metilsulfate (INN); Diphemanili metilsulfas [INN-Latin]; Metilsulfate de diphemanil [INN-French]; Metilsulfato de difemanilo [INN-Spanish]; Prantal (TN); Ban-Guard (Veterinary); P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; P-(alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium
DMXVU6D TC Parasympatholytics
DMXVU6D DT Small molecular drug
DMXVU6D PC 6126
DMXVU6D MW 389.5
DMXVU6D FM C21H27NO4S
DMXVU6D IC InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMXVU6D CS C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-]
DMXVU6D IK BREMLQBSKCSNNH-UHFFFAOYSA-M
DMXVU6D IU 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium;methyl sulfate
DMXVU6D CA CAS 62-97-5
DMXVU6D CB CHEBI:59782
DMXVU6D DE Peptic ulcer
DMKQTBA ID DMKQTBA
DMKQTBA DN Diphenhydramine
DMKQTBA HS Approved
DMKQTBA SN diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl; Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM
DMKQTBA CP Johnson & Johnson
DMKQTBA TC Antiallergic Agents
DMKQTBA DT Small molecular drug
DMKQTBA PC 3100
DMKQTBA MW 255.35
DMKQTBA FM C17H21NO
DMKQTBA IC InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMKQTBA CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DMKQTBA IK ZZVUWRFHKOJYTH-UHFFFAOYSA-N
DMKQTBA IU 2-benzhydryloxy-N,N-dimethylethanamine
DMKQTBA CA CAS 58-73-1
DMKQTBA CB CHEBI:4636
DMKQTBA DE Meniere disease
DMHPWOM ID DMHPWOM
DMHPWOM DN Diphenidol
DMHPWOM HS Approved
DMHPWOM SN Avomol; Defenidol; Difenidol; Difenidolo; Difenidolum; Nometic; Vontrol; Difenidol HCl; Difenidolo [DCIT]; SKF 478; Difenidolum [INN-Latin]; Diphenidol [USAN:BAN]; SK-478; Diphenidol (USAN/INN); SK&F-478; Alpha,alpha-Diphenyl-1-piperidinebutanol; Diphenyl(3-(1-piperidyl)propyl)carbinol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride
DMHPWOM DT Small molecular drug
DMHPWOM PC 3055
DMHPWOM MW 309.4
DMHPWOM FM C21H27NO
DMHPWOM IC InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2
DMHPWOM CS C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMHPWOM IK OGAKLTJNUQRZJU-UHFFFAOYSA-N
DMHPWOM IU 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol
DMHPWOM CA CAS 972-02-1
DMHPWOM CB CHEBI:4638
DMHPWOM DE Nausea
DMO5SZX ID DMO5SZX
DMO5SZX DN Diphenoxylate
DMO5SZX HS Approved
DMO5SZX SN Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride
DMO5SZX CP Janssen Pharmaceutica
DMO5SZX TC Analgesics
DMO5SZX DT Small molecular drug
DMO5SZX PC 13505
DMO5SZX MW 452.6
DMO5SZX FM C30H32N2O2
DMO5SZX IC InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
DMO5SZX CS CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMO5SZX IK HYPPXZBJBPSRLK-UHFFFAOYSA-N
DMO5SZX IU ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
DMO5SZX CA CAS 915-30-0
DMO5SZX CB CHEBI:4639
DMO5SZX DE Diarrhea
DMW4X37 ID DMW4X37
DMW4X37 DN Diphenylpyraline
DMW4X37 HS Approved
DMW4X37 SN Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
DMW4X37 TC Antihistamines
DMW4X37 DT Small molecular drug
DMW4X37 PC 3103
DMW4X37 MW 281.4
DMW4X37 FM C19H23NO
DMW4X37 IC InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
DMW4X37 CS CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
DMW4X37 IK OWQUZNMMYNAXSL-UHFFFAOYSA-N
DMW4X37 IU 4-benzhydryloxy-1-methylpiperidine
DMW4X37 CA CAS 147-20-6
DMW4X37 CB CHEBI:59788
DMW4X37 DE Allergic rhinitis
DM0FSIM ID DM0FSIM
DM0FSIM DN Diphtheria-tetanus vaccine
DM0FSIM HS Approved
DM0FSIM SN Diphtheria-tetanus vaccine (im suspension), Finlay Institute
DM0FSIM CP Finlay Institute
DM0FSIM DT Vaccine
DM0FSIM DE Clostridium infection
DMH5W0G ID DMH5W0G
DMH5W0G DN Dipivefrin
DMH5W0G HS Approved
DMH5W0G SN AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
DMH5W0G CP Allergan Pharmaceutical
DMH5W0G TC Ophthalmologicals
DMH5W0G DT Small molecular drug
DMH5W0G PC 3105
DMH5W0G MW 351.4
DMH5W0G FM C19H29NO5
DMH5W0G IC InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3
DMH5W0G CS CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C
DMH5W0G IK OCUJLLGVOUDECM-UHFFFAOYSA-N
DMH5W0G IU [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
DMH5W0G CA CAS 52365-63-6
DMH5W0G CB CHEBI:4646
DMH5W0G DE Chronic open-angle glaucoma
DMXY30O ID DMXY30O
DMXY30O DN Dipyridamole
DMXY30O HS Approved
DMXY30O SN Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
DMXY30O CP FISCHER and ROCH
DMXY30O TC Vasodilator Agents
DMXY30O DT Small molecular drug
DMXY30O PC 3108
DMXY30O MW 504.6
DMXY30O FM C24H40N8O4
DMXY30O IC InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
DMXY30O CS C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMXY30O IK IZEKFCXSFNUWAM-UHFFFAOYSA-N
DMXY30O IU 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMXY30O CA CAS 58-32-2
DMXY30O CB CHEBI:4653
DMXY30O DE Hypertension
DM0D9YJ ID DM0D9YJ
DM0D9YJ DN Dirithromycin
DM0D9YJ HS Approved
DM0D9YJ SN Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin
DM0D9YJ TC Antibiotics
DM0D9YJ DT Small molecular drug
DM0D9YJ PC 6473883
DM0D9YJ MW 835.1
DM0D9YJ FM C42H78N2O14
DM0D9YJ IC InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1
DM0D9YJ CS CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O
DM0D9YJ IK WLOHNSSYAXHWNR-DWIOZXRMSA-N
DM0D9YJ IU (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
DM0D9YJ CA CAS 62013-04-1
DM0D9YJ CB CHEBI:474014
DM0D9YJ DE Bacterial infection
DM5SYZP ID DM5SYZP
DM5SYZP DN Disopyramide
DM5SYZP HS Approved
DM5SYZP SN Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CP Gd Searle Llc
DM5SYZP TC Antiarrhythmic Agents
DM5SYZP DT Small molecular drug
DM5SYZP PC 3114
DM5SYZP MW 339.5
DM5SYZP FM C21H29N3O
DM5SYZP IC InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
DM5SYZP CS CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
DM5SYZP IK UVTNFZQICZKOEM-UHFFFAOYSA-N
DM5SYZP IU 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CA CAS 3737-09-5
DM5SYZP CB CHEBI:4657
DM5SYZP DE Ventricular arrhythmias; Urinary incontinence
DMCL2OK ID DMCL2OK
DMCL2OK DN Disulfiram
DMCL2OK HS Approved
DMCL2OK SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMCL2OK CP Odyssey Pharmaceuticals
DMCL2OK TC Alcohol Deterrents
DMCL2OK DT Small molecular drug
DMCL2OK PC 3117
DMCL2OK MW 296.5
DMCL2OK FM C10H20N2S4
DMCL2OK IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMCL2OK CS CCN(CC)C(=S)SSC(=S)N(CC)CC
DMCL2OK IK AUZONCFQVSMFAP-UHFFFAOYSA-N
DMCL2OK IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMCL2OK CA CAS 97-77-8
DMCL2OK CB CHEBI:4659
DMCL2OK DE Alcohol dependence
DM4RK0G ID DM4RK0G
DM4RK0G DN Divalproex sodium
DM4RK0G HS Approved
DM4RK0G SN Delepsine; Depakote; Divalproate; Divalproex; Epilex; Epival; Sprinkle; Valcote; Valdisoval; Valparin; Depakote CP; Depakote ER; Depakote Sprinkle; Divalproex sodium [USAN]; Sodium divalproate; Sodium hydrogen divalproate; Valproate semisodique; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico; Valproato semisodico [Spanish]; Valproatum seminatricum; Valproatum seminatricum [Latin]; Abbott 50711; Abbott-50711; Depacon (TN); Depakote (TN); Depakote ER (TN); Divalproex sodium (USP); Epival (TN); Ergenyl Chrono (TN); Valance (TN); Valproate semisodium (INN); Divalproex sodium, Depakote, Epival; Natrium hydrogen bis(2-propylvalerat); Sodium hydrogen bis(2-propylpentanoate); Sodium hydrogen bis(2-propylvalerate); Valproic acid semisodium salt (2:1); Zalkote. (TN); Sodium hydrogen bis(2-propylvalerate), oligomer; Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1); Pentanoic acid, 2-propyl-, sodium salt (2:1); Pentanoic acid, 2-propyl-, sodium salt(2:1); 2-propylpentanoate
DM4RK0G CP Abbott Laboratories
DM4RK0G TC Anticonvulsants
DM4RK0G DT Small molecular drug
DM4RK0G PC 23663956
DM4RK0G MW 310.4
DM4RK0G FM C16H31NaO4
DM4RK0G IC InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1
DM4RK0G CS CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
DM4RK0G IK MSRILKIQRXUYCT-UHFFFAOYSA-M
DM4RK0G IU sodium;2-propylpentanoate;2-propylpentanoic acid
DM4RK0G CA CAS 76584-70-8
DM4RK0G CB CHEBI:4667
DM4RK0G DE Seizure disorder
DMD1B8Z ID DMD1B8Z
DMD1B8Z DN Dobutamine
DMD1B8Z HS Approved
DMD1B8Z SN Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CP Ben Venue Laboratories
DMD1B8Z TC Cardiotonic Agents
DMD1B8Z DT Small molecular drug
DMD1B8Z PC 36811
DMD1B8Z MW 301.4
DMD1B8Z FM C18H23NO3
DMD1B8Z IC InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
DMD1B8Z CS CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
DMD1B8Z IK JRWZLRBJNMZMFE-UHFFFAOYSA-N
DMD1B8Z IU 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CA CAS 34368-04-2
DMD1B8Z CB CHEBI:4670
DMD1B8Z DE Heart failure
DMS5IEB ID DMS5IEB
DMS5IEB DN Docarpamine
DMS5IEB HS Approved
DMS5IEB SN Tanadopa (TN)
DMS5IEB DT Small molecular drug
DMS5IEB PC 71137
DMS5IEB MW 470.5
DMS5IEB FM C21H30N2O8S
DMS5IEB IC InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
DMS5IEB CS CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC
DMS5IEB IK ZLVMAMIPILWYHQ-INIZCTEOSA-N
DMS5IEB IU [4-[2-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]ethyl]-2-ethoxycarbonyloxyphenyl] ethyl carbonate
DMS5IEB CA CAS 74639-40-0
DMS5IEB CB CHEBI:31513
DMS5IEB DE Hypertension
DMDI269 ID DMDI269
DMDI269 DN Docetaxel
DMDI269 HS Approved
DMDI269 SN EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
DMDI269 CP Sanofi-Aventis
DMDI269 TC Anticancer Agents
DMDI269 DT Small molecular drug
DMDI269 PC 148124
DMDI269 MW 807.9
DMDI269 FM C43H53NO14
DMDI269 IC InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
DMDI269 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
DMDI269 IK ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DMDI269 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDI269 CA CAS 114977-28-5
DMDI269 CB CHEBI:4672
DMDI269 DE Solid tumour/cancer
DMOHK1E ID DMOHK1E
DMOHK1E DN Docosanol
DMOHK1E HS Approved
DMOHK1E SN Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL
DMOHK1E CP Avanir Pharmaceuticals
DMOHK1E TC Antiviral Agents
DMOHK1E DT Small molecular drug
DMOHK1E PC 12620
DMOHK1E MW 326.6
DMOHK1E FM C22H46O
DMOHK1E IC InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DMOHK1E CS CCCCCCCCCCCCCCCCCCCCCCO
DMOHK1E IK NOPFSRXAKWQILS-UHFFFAOYSA-N
DMOHK1E IU docosan-1-ol
DMOHK1E CA CAS 661-19-8
DMOHK1E CB CHEBI:31000
DMOHK1E DE Herpes simplex virus infection
DMPN1TW ID DMPN1TW
DMPN1TW DN Dofetilide
DMPN1TW HS Approved
DMPN1TW SN Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE
DMPN1TW CP Pfizer Pharmaceuticals
DMPN1TW TC Antiarrhythmic Agents
DMPN1TW DT Small molecular drug
DMPN1TW PC 71329
DMPN1TW MW 441.6
DMPN1TW FM C19H27N3O5S2
DMPN1TW IC InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
DMPN1TW CS CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
DMPN1TW IK IXTMWRCNAAVVAI-UHFFFAOYSA-N
DMPN1TW IU N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
DMPN1TW CA CAS 115256-11-6
DMPN1TW CB CHEBI:4681
DMPN1TW DE Sinus rhythm disorder
DMMG26Z ID DMMG26Z
DMMG26Z DN Dolasetron
DMMG26Z HS Approved
DMMG26Z SN Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
DMMG26Z CP Aventis Pharmaceuticals Inc.
DMMG26Z TC Antiemetics
DMMG26Z DT Small molecular drug
DMMG26Z PC 3033818
DMMG26Z MW 324.4
DMMG26Z FM C19H20N2O3
DMMG26Z IC InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
DMMG26Z CS C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
DMMG26Z IK UKTAZPQNNNJVKR-AKJUYKBHSA-N
DMMG26Z IU [(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate
DMMG26Z CA CAS 115956-12-2
DMMG26Z CB CHEBI:94561
DMMG26Z DE Nausea
DMCZGRE ID DMCZGRE
DMCZGRE DN Dolutegravir
DMCZGRE HS Approved
DMCZGRE SN 1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
DMCZGRE CP GlaxoSmithKline
DMCZGRE DT Small molecular drug
DMCZGRE PC 54726191
DMCZGRE MW 419.4
DMCZGRE FM C20H19F2N3O5
DMCZGRE IC InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
DMCZGRE CS C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMCZGRE IK RHWKPHLQXYSBKR-BMIGLBTASA-N
DMCZGRE IU (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
DMCZGRE CA CAS 1051375-16-6
DMCZGRE CB CHEBI:76010
DMCZGRE DE Human immunodeficiency virus infection
DMBDPY0 ID DMBDPY0
DMBDPY0 DN Domperidone
DMBDPY0 HS Approved
DMBDPY0 SN Domperidon; Domperidona; Domperidonum; Motilium; Nauzelin; KW 5338; NCI299589; Costi (TN); D-122; Domperidona [INN-Spanish]; Domperidonum [INN-Latin]; HS-0067; KW-5338; Motilium (TN); Motillium (TN); Motinorm (TN); R 33,812; R-33812; R-33,812; Domperidone (JAN/USAN/INN); Domperidone [USAN:BAN:INN:JAN]; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CP Janssen Pharmaceutica
DMBDPY0 TC Antiemetics
DMBDPY0 DT Small molecular drug
DMBDPY0 PC 3151
DMBDPY0 MW 425.9
DMBDPY0 FM C22H24ClN5O2
DMBDPY0 IC InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
DMBDPY0 CS C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
DMBDPY0 IK FGXWKSZFVQUSTL-UHFFFAOYSA-N
DMBDPY0 IU 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CA CAS 57808-66-9
DMBDPY0 CB CHEBI:31515
DMBDPY0 DE Gastrointestinal disease
DMIYG7Z ID DMIYG7Z
DMIYG7Z DN Donepezil
DMIYG7Z HS Approved
DMIYG7Z SN Donepezil (transdermal patch, Alzheimer's disease)
DMIYG7Z CP Nitto Denko Corp
DMIYG7Z TC Neurology Agents
DMIYG7Z DT Small molecular drug
DMIYG7Z PC 3152
DMIYG7Z MW 379.5
DMIYG7Z FM C24H29NO3
DMIYG7Z IC InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
DMIYG7Z CS COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
DMIYG7Z IK ADEBPBSSDYVVLD-UHFFFAOYSA-N
DMIYG7Z IU 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
DMIYG7Z CA CAS 120014-06-4
DMIYG7Z CB CHEBI:53289
DMIYG7Z DE Alzheimer disease
DMPGUCF ID DMPGUCF
DMPGUCF DN Dopamine
DMPGUCF HS Approved
DMPGUCF SN Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
DMPGUCF CP Baxter Healthcare Corp Anesthesia And Critical Care
DMPGUCF TC Cardiotonic Agents
DMPGUCF DT Small molecular drug
DMPGUCF PC 681
DMPGUCF MW 153.18
DMPGUCF FM C8H11NO2
DMPGUCF IC InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
DMPGUCF CS C1=CC(=C(C=C1CCN)O)O
DMPGUCF IK VYFYYTLLBUKUHU-UHFFFAOYSA-N
DMPGUCF IU 4-(2-aminoethyl)benzene-1,2-diol
DMPGUCF CA CAS 51-61-6
DMPGUCF CB CHEBI:18243
DMPGUCF DE Parkinson disease; Hypotension
DMSCIKZ ID DMSCIKZ
DMSCIKZ DN Dopexamine
DMSCIKZ HS Approved
DMSCIKZ SN Dopacard (TN)
DMSCIKZ DT Small molecular drug
DMSCIKZ PC 55483
DMSCIKZ MW 356.5
DMSCIKZ FM C22H32N2O2
DMSCIKZ IC InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2
DMSCIKZ CS C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O
DMSCIKZ IK RYBJORHCUPVNMB-UHFFFAOYSA-N
DMSCIKZ IU 4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
DMSCIKZ CA CAS 86197-47-9
DMSCIKZ CB CHEBI:135507
DMSCIKZ DE Cardiac failure
DM9UCJK ID DM9UCJK
DM9UCJK DN Doripenem
DM9UCJK HS Approved
DM9UCJK SN Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CP Shionogi; penisula
DM9UCJK DT Small molecular drug
DM9UCJK PC 73303
DM9UCJK MW 420.5
DM9UCJK FM C15H24N4O6S2
DM9UCJK IC InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1
DM9UCJK CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O
DM9UCJK IK AVAACINZEOAHHE-VFZPANTDSA-N
DM9UCJK IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CA CAS 148016-81-3
DM9UCJK CB CHEBI:135928
DM9UCJK DE Urinary tract infection; Gram-positive bacterial infection
DM3XU74 ID DM3XU74
DM3XU74 DN Dornase Alfa
DM3XU74 HS Approved
DM3XU74 SN Pulmozyme (TN)
DM3XU74 CP Genentech
DM3XU74 TC Enzyme Replacement Agents
DM3XU74 SQ Dornase alfa sequence: LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK
DM3XU74 DE Cystic fibrosis
DMA17D0 ID DMA17D0
DMA17D0 DN Dorzolamide
DMA17D0 HS Approved
DMA17D0 SN Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
DMA17D0 CP Merck & Co
DMA17D0 TC Antihypertensive Agents
DMA17D0 DT Small molecular drug
DMA17D0 PC 5284549
DMA17D0 MW 324.4
DMA17D0 FM C10H16N2O4S3
DMA17D0 IC InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
DMA17D0 CS CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMA17D0 IK IAVUPMFITXYVAF-XPUUQOCRSA-N
DMA17D0 IU (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMA17D0 CA CAS 120279-96-1
DMA17D0 CB CHEBI:4702
DMA17D0 DE Open-angle glaucoma
DM78NWP ID DM78NWP
DM78NWP DN Dostarlimab
DM78NWP HS Approved
DM78NWP CP AnaptysBio; GlaxoSmithKline
DM78NWP DT Antibody
DM78NWP DE Endometrial cancer; Multiple myeloma; Breast cancer; Neoplasm
DMKE7L9 ID DMKE7L9
DMKE7L9 DN Doxacurium
DMKE7L9 HS Approved
DMKE7L9 SN Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride
DMKE7L9 CP Abbott Laboratories
DMKE7L9 TC Analgesics
DMKE7L9 DT Small molecular drug
DMKE7L9 PC 60169
DMKE7L9 MW 1035.2
DMKE7L9 FM C56H78N2O16+2
DMKE7L9 IC InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
DMKE7L9 CS C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C
DMKE7L9 IK GBLRQXKSCRCLBZ-UHFFFAOYSA-N
DMKE7L9 IU bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
DMKE7L9 CA CAS 133814-18-3
DMKE7L9 CB CHEBI:4706
DMKE7L9 DE Spasm
DMCYANK ID DMCYANK
DMCYANK DN Doxapram
DMCYANK HS Approved
DMCYANK SN Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)
DMCYANK TC Central Nervous System Stimulants
DMCYANK DT Small molecular drug
DMCYANK PC 3156
DMCYANK MW 378.5
DMCYANK FM C24H30N2O2
DMCYANK IC InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
DMCYANK CS CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
DMCYANK IK XFDJYSQDBULQSI-UHFFFAOYSA-N
DMCYANK IU 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
DMCYANK CA CAS 309-29-5
DMCYANK CB CHEBI:681848
DMCYANK DE Respiratory disease
DM9PLRH ID DM9PLRH
DM9PLRH DN Doxazosin
DM9PLRH HS Approved
DM9PLRH SN Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
DM9PLRH CP Pfizer Pharmaceuticals
DM9PLRH TC Antihypertensive Agents
DM9PLRH DT Small molecular drug
DM9PLRH PC 3157
DM9PLRH MW 451.5
DM9PLRH FM C23H25N5O5
DM9PLRH IC InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
DM9PLRH CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
DM9PLRH IK RUZYUOTYCVRMRZ-UHFFFAOYSA-N
DM9PLRH IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
DM9PLRH CA CAS 74191-85-8
DM9PLRH CB CHEBI:4708
DM9PLRH DE Hypertension
DMPI98T ID DMPI98T
DMPI98T DN Doxepin
DMPI98T HS Approved
DMPI98T SN Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin
DMPI98T CP Pfizer Pharmaceuticals
DMPI98T TC Antidepressants
DMPI98T DT Small molecular drug
DMPI98T PC 667477
DMPI98T MW 279.4
DMPI98T FM C19H21NO
DMPI98T IC InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
DMPI98T CS CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
DMPI98T IK ODQWQRRAPPTVAG-GZTJUZNOSA-N
DMPI98T IU (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
DMPI98T CA CAS 1668-19-5
DMPI98T DE Depression
DM6FG1P ID DM6FG1P
DM6FG1P DN Doxercalciferol
DM6FG1P HS Approved
DM6FG1P SN Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
DM6FG1P CP Genzyme
DM6FG1P DT Small molecular drug
DM6FG1P PC 5281107
DM6FG1P MW 412.6
DM6FG1P FM C28H44O2
DM6FG1P IC InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
DM6FG1P CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM6FG1P IK HKXBNHCUPKIYDM-CGMHZMFXSA-N
DM6FG1P IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM6FG1P CA CAS 54573-75-0
DM6FG1P CB CHEBI:4712
DM6FG1P DE Chronic kidney disease
DMEDKZH ID DMEDKZH
DMEDKZH DN Doxofylline
DMEDKZH HS Approved
DMEDKZH SN Ansimar (TN)
DMEDKZH CP ABC S.p.A.
DMEDKZH DT Small molecular drug
DMEDKZH PC 50942
DMEDKZH MW 266.25
DMEDKZH FM C11H14N4O4
DMEDKZH IC InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
DMEDKZH CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
DMEDKZH IK HWXIGFIVGWUZAO-UHFFFAOYSA-N
DMEDKZH IU 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
DMEDKZH CA CAS 69975-86-6
DMEDKZH CB CHEBI:94714
DMEDKZH DE Asthma
DMVP5YE ID DMVP5YE
DMVP5YE DN Doxorubicin
DMVP5YE HS Approved
DMVP5YE SN doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
DMVP5YE CP Sequus Pharmaceuticals Inc
DMVP5YE TC Anticancer Agents
DMVP5YE DT Small molecular drug
DMVP5YE PC 31703
DMVP5YE MW 543.5
DMVP5YE FM C27H29NO11
DMVP5YE IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
DMVP5YE CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMVP5YE IK AOJJSUZBOXZQNB-TZSSRYMLSA-N
DMVP5YE IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMVP5YE CA CAS 23214-92-8
DMVP5YE CB CHEBI:28748
DMVP5YE DE Solid tumour/cancer; Tumour; Breast cancer; Hepatocellular carcinoma
DM7ICNU ID DM7ICNU
DM7ICNU DN Doxycycline
DM7ICNU HS Approved
DM7ICNU SN Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline
DM7ICNU CP Collagenex
DM7ICNU TC Antiinflammatory Agents
DM7ICNU DT Small molecular drug
DM7ICNU PC 54671203
DM7ICNU MW 444.4
DM7ICNU FM C22H24N2O8
DM7ICNU IC InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
DM7ICNU CS C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DM7ICNU IK SGKRLCUYIXIAHR-AKNGSSGZSA-N
DM7ICNU IU (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM7ICNU CA CAS 564-25-0
DM7ICNU CB CHEBI:50845
DM7ICNU DE Chronic periodontitis; Advanced gum disease; Diabetic foot ulcer
DMKOXFE ID DMKOXFE
DMKOXFE DN Doxylamine
DMKOXFE HS Approved
DMKOXFE SN Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline
DMKOXFE CP Ion Healthcare
DMKOXFE TC Hypnotics and Sedatives
DMKOXFE DT Small molecular drug
DMKOXFE PC 3162
DMKOXFE MW 270.37
DMKOXFE FM C17H22N2O
DMKOXFE IC InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
DMKOXFE CS CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
DMKOXFE IK HCFDWZZGGLSKEP-UHFFFAOYSA-N
DMKOXFE IU N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
DMKOXFE CA CAS 469-21-6
DMKOXFE CB CHEBI:51380
DMKOXFE DE Morning sickness
DMGOXPQ ID DMGOXPQ
DMGOXPQ DN DP-VPA
DMGOXPQ HS Approved
DMGOXPQ SN TVA; RAP-valproate; SPD-421; Valproic acid prodrug, Shire; RAP-valproate, D-Pharm
DMGOXPQ CP D-Pharm Ltd
DMGOXPQ DE Bipolar disorder
DMF2JDG ID DMF2JDG
DMF2JDG DN Dromostanolone
DMF2JDG HS Approved
DMF2JDG SN Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone
DMF2JDG CP Eli Lilly And Co
DMF2JDG TC Anabolic Agents
DMF2JDG DT Small molecular drug
DMF2JDG PC 6011
DMF2JDG MW 304.5
DMF2JDG FM C20H32O2
DMF2JDG IC InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1
DMF2JDG CS C[C@@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)CC1=O)C
DMF2JDG IK IKXILDNPCZPPRV-RFMGOVQKSA-N
DMF2JDG IU (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMF2JDG CA CAS 58-19-5
DMF2JDG CB CHEBI:34838
DMF2JDG DE Mammary tumour
DMA8FS5 ID DMA8FS5
DMA8FS5 DN Dronedarone
DMA8FS5 HS Approved
DMA8FS5 SN Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
DMA8FS5 CP Sanofi-Synthelabo
DMA8FS5 DT Small molecular drug
DMA8FS5 PC 208898
DMA8FS5 MW 556.8
DMA8FS5 FM C31H44N2O5S
DMA8FS5 IC InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
DMA8FS5 CS CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
DMA8FS5 IK ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
DMA8FS5 IU N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
DMA8FS5 CA CAS 141626-36-0
DMA8FS5 CB CHEBI:50659
DMA8FS5 DE Angina pectoris; Atrial fibrillation
DM0DXA8 ID DM0DXA8
DM0DXA8 DN Droperidol
DM0DXA8 HS Approved
DM0DXA8 SN DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CP Janssen Pharmaceutica
DM0DXA8 TC Antipsychotic Agents
DM0DXA8 DT Small molecular drug
DM0DXA8 PC 3168
DM0DXA8 MW 379.4
DM0DXA8 FM C22H22FN3O2
DM0DXA8 IC InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
DM0DXA8 CS C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
DM0DXA8 IK RMEDXOLNCUSCGS-UHFFFAOYSA-N
DM0DXA8 IU 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CA CAS 548-73-2
DM0DXA8 CB CHEBI:4717
DM0DXA8 DE Nausea
DM1A9W3 ID DM1A9W3
DM1A9W3 DN Drospirenone
DM1A9W3 HS Approved
DM1A9W3 SN DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta
DM1A9W3 TC Contraceptive Agents
DM1A9W3 DT Small molecular drug
DM1A9W3 PC 68873
DM1A9W3 MW 366.5
DM1A9W3 FM C24H30O3
DM1A9W3 IC InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
DM1A9W3 CS C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C
DM1A9W3 IK METQSPRSQINEEU-HXCATZOESA-N
DM1A9W3 IU (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
DM1A9W3 CA CAS 67392-87-4
DM1A9W3 CB CHEBI:50838
DM1A9W3 DE Contraception
DM59JCN ID DM59JCN
DM59JCN DN Drotrecogin alfa
DM59JCN HS Approved
DM59JCN SN Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN)
DM59JCN CP Eli Lilly
DM59JCN TC Antisepsis Agents
DM59JCN SQ Heavy chain: LIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP >Light chainSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL
DM59JCN DE Cerebrovascular ischaemia; Severe sepsis
DM5YF4M ID DM5YF4M
DM5YF4M DN Droxidopa
DM5YF4M HS Approved
DM5YF4M SN droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-
DM5YF4M CP Chelsea Therapeutics
DM5YF4M DT Small molecular drug
DM5YF4M PC 92974
DM5YF4M MW 213.19
DM5YF4M FM C9H11NO5
DM5YF4M IC InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
DM5YF4M CS C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
DM5YF4M IK QXWYKJLNLSIPIN-JGVFFNPUSA-N
DM5YF4M IU (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
DM5YF4M CA CAS 23651-95-8
DM5YF4M CB CHEBI:31524
DM5YF4M DE Neurogenic orthostatic hypotension
DMXZRW0 ID DMXZRW0
DMXZRW0 DN DTI-015
DMXZRW0 HS Approved
DMXZRW0 SN Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics
DMXZRW0 CP Direct Therapeutics Inc
DMXZRW0 DT Small molecular drug
DMXZRW0 PC 2578
DMXZRW0 MW 214.05
DMXZRW0 FM C5H9Cl2N3O2
DMXZRW0 IC InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
DMXZRW0 CS C(CCl)NC(=O)N(CCCl)N=O
DMXZRW0 IK DLGOEMSEDOSKAD-UHFFFAOYSA-N
DMXZRW0 IU 1,3-bis(2-chloroethyl)-1-nitrosourea
DMXZRW0 CA CAS 154-93-8
DMXZRW0 CB CHEBI:3423
DMXZRW0 DE Liver cancer; Brain cancer
DMCIJBH ID DMCIJBH
DMCIJBH DN DU-176B
DMCIJBH HS Approved
DMCIJBH SN Edoxaban
DMCIJBH CP Daiichi Sankyo
DMCIJBH DT Small molecular drug
DMCIJBH PC 25022378
DMCIJBH MW 738.3
DMCIJBH FM C31H40ClN7O8S2
DMCIJBH IC InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
DMCIJBH CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O
DMCIJBH IK PSMMNJNZVZZNOI-SJILXJHISA-N
DMCIJBH IU N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate
DMCIJBH CA CAS 1229194-11-9
DMCIJBH CB CHEBI:85974
DMCIJBH DE Atrial fibrillation
DMYXBV3 ID DMYXBV3
DMYXBV3 DN Dulaglutide
DMYXBV3 HS Approved
DMYXBV3 SN GLP-1 analog
DMYXBV3 CP Eli Lilly
DMYXBV3 SQ Dulaglutide Sequence: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
DMYXBV3 DE Type-2 diabetes
DM9BI7M ID DM9BI7M
DM9BI7M DN Duloxetine
DM9BI7M HS Approved
DM9BI7M SN Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
DM9BI7M CP Eli Lilly
DM9BI7M TC Antidepressants
DM9BI7M DT Small molecular drug
DM9BI7M PC 60835
DM9BI7M MW 297.4
DM9BI7M FM C18H19NOS
DM9BI7M IC InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
DM9BI7M CS CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DM9BI7M IK ZEUITGRIYCTCEM-KRWDZBQOSA-N
DM9BI7M IU (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DM9BI7M CA CAS 116539-59-4
DM9BI7M CB CHEBI:36795
DM9BI7M DE Depression
DMOAD2Y ID DMOAD2Y
DMOAD2Y DN Dupilumab
DMOAD2Y HS Approved
DMOAD2Y SN REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
DMOAD2Y CP Regeneron/Sanofi
DMOAD2Y DT Antibody
DMOAD2Y DE Atopic dermatitis; Asthma
DM4PVDY ID DM4PVDY
DM4PVDY DN Durvalumab
DM4PVDY HS Approved
DM4PVDY CP AstraZeneca
DM4PVDY DT Monoclonal antibody
DM4PVDY SQ Durvalumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Durvalumab light chainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM4PVDY DE Pancreatic ductal carcinoma; Solid tumour/cancer; Biliary tract cancer; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Melanoma; Urothelial carcinoma
DMQ4TJK ID DMQ4TJK
DMQ4TJK DN Dutasteride
DMQ4TJK HS Approved
DMQ4TJK SN Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
DMQ4TJK CP GSK
DMQ4TJK TC Anticancer Agents
DMQ4TJK DT Small molecular drug
DMQ4TJK PC 6918296
DMQ4TJK MW 528.5
DMQ4TJK FM C27H30F6N2O2
DMQ4TJK IC InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
DMQ4TJK CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMQ4TJK IK JWJOTENAMICLJG-QWBYCMEYSA-N
DMQ4TJK IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMQ4TJK CA CAS 164656-23-9
DMQ4TJK CB CHEBI:521033
DMQ4TJK DE Benign prostatic hyperplasia; Prostate cancer
DMU6OFP ID DMU6OFP
DMU6OFP DN Dyclonine
DMU6OFP HS Approved
DMU6OFP SN Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone
DMU6OFP CP Astrazeneca Lp
DMU6OFP TC Anesthetics
DMU6OFP DT Small molecular drug
DMU6OFP PC 3180
DMU6OFP MW 289.4
DMU6OFP FM C18H27NO2
DMU6OFP IC InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
DMU6OFP CS CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
DMU6OFP IK BZEWSEKUUPWQDQ-UHFFFAOYSA-N
DMU6OFP IU 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
DMU6OFP CA CAS 586-60-7
DMU6OFP CB CHEBI:4724
DMU6OFP DE Pain
DMAKIDV ID DMAKIDV
DMAKIDV DN Dydrogesterone
DMAKIDV HS Approved
DMAKIDV SN Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI)
DMAKIDV CP Solvay Pharmaceuticals
DMAKIDV TC Progesterones
DMAKIDV DT Small molecular drug
DMAKIDV PC 9051
DMAKIDV MW 312.4
DMAKIDV FM C21H28O2
DMAKIDV IC InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1
DMAKIDV CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C
DMAKIDV IK JGMOKGBVKVMRFX-HQZYFCCVSA-N
DMAKIDV IU (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMAKIDV CA CAS 152-62-5
DMAKIDV CB CHEBI:31527
DMAKIDV DE Menstrual disorder
DM8DZC1 ID DM8DZC1
DM8DZC1 DN Dyphylline
DM8DZC1 HS Approved
DM8DZC1 SN Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline
DM8DZC1 TC Bronchodilator Agents
DM8DZC1 DT Small molecular drug
DM8DZC1 PC 3182
DM8DZC1 MW 254.24
DM8DZC1 FM C10H14N4O4
DM8DZC1 IC InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DM8DZC1 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DM8DZC1 IK KSCFJBIXMNOVSH-UHFFFAOYSA-N
DM8DZC1 IU 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DM8DZC1 CA CAS 479-18-5
DM8DZC1 CB CHEBI:4728
DM8DZC1 DE Acute bronchial asthma
DMJDYNQ ID DMJDYNQ
DMJDYNQ DN E-2007
DMJDYNQ HS Approved
DMJDYNQ SN Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
DMJDYNQ CP Eisai Co. Ltd.
DMJDYNQ DT Small molecular drug
DMJDYNQ PC 9924495
DMJDYNQ MW 349.4
DMJDYNQ FM C23H15N3O
DMJDYNQ IC InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
DMJDYNQ CS C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
DMJDYNQ IK PRMWGUBFXWROHD-UHFFFAOYSA-N
DMJDYNQ IU 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
DMJDYNQ CA CAS 380917-97-5
DMJDYNQ CB CHEBI:71013
DMJDYNQ DE Diabetic neuropathy; Parkinson disease
DMOF2C6 ID DMOF2C6
DMOF2C6 DN Ecallantide
DMOF2C6 HS Approved
DMOF2C6 SN FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea
DMOF2C6 CP Dyax Corp
DMOF2C6 DT Small molecular drug
DMOF2C6 PC 44152182
DMOF2C6 MW 7054
DMOF2C6 FM C305H442N88O91S8
DMOF2C6 IC InChI=1S/C305H442N88O91S8/c1-16-152(5)241-295(478)377-195(124-168-80-82-172(398)83-81-168)252(435)334-137-227(404)333-138-228(405)345-214-143-487-491-147-218-291(474)351-179(73-47-107-327-301(315)316)255(438)341-154(7)245(428)339-155(8)249(432)379-210(127-171-136-326-150-338-171)299(482)393-113-53-79-221(393)294(477)361-181(75-49-109-329-303(319)320)260(443)372-203(125-169-134-332-175-69-40-39-68-173(169)175)277(460)370-198(119-163-58-29-20-30-59-163)274(457)369-199(120-164-60-31-21-32-61-164)275(458)375-207(130-226(314)403)284(467)389-242(153(6)17-2)296(479)378-202(123-167-66-37-24-38-67-167)283(466)390-243(159(12)396)297(480)362-182(76-50-110-330-304(321)322)258(441)353-186(86-94-223(311)400)267(450)383-217(290(473)359-188(89-98-234(414)415)263(446)354-189(90-99-235(416)417)265(448)368-201(282(465)388-241)122-166-64-35-23-36-65-166)146-490-489-145-216(384-268(451)191(92-101-237(420)421)355-262(445)187(88-97-233(412)413)357-271(454)194(116-151(3)4)366-285(468)212(141-394)381-266(449)190(91-100-236(418)419)358-273(456)197(118-162-56-27-19-28-57-162)367-259(442)180(74-48-108-328-302(317)318)349-280(463)206(129-225(313)402)374-264(447)185(85-93-222(310)399)356-279(462)205(128-224(312)401)344-229(406)139-335-251(434)184(352-288(214)471)87-96-232(410)411)289(472)350-178(72-43-46-106-308)256(439)347-177(71-42-45-105-307)257(440)360-193(103-115-486-15)270(453)385-219(292(475)391-244(160(13)397)298(481)363-183(77-51-111-331-305(323)324)261(444)380-211(300(483)484)133-240(426)427)148-492-488-144-215(386-276(459)200(121-165-62-33-22-34-63-165)371-286(469)213(142-395)382-278(461)204(126-170-135-325-149-337-170)373-269(452)192(102-114-485-14)346-246(429)156(9)340-250(433)174(309)84-95-231(408)409)287(470)343-158(11)247(430)364-196(117-161-54-25-18-26-55-161)272(455)348-176(70-41-44-104-306)254(437)342-157(10)248(431)365-209(132-239(424)425)281(464)376-208(131-238(422)423)253(436)336-140-230(407)392-112-52-78-220(392)293(476)387-218/h18-40,54-69,80-83,134-136,149-160,174,176-221,241-244,332,394-398H,16-17,41-53,70-79,84-133,137-148,306-309H2,1-15H3,(H2,310,399)(H2,311,400)(H2,312,401)(H2,313,402)(H2,314,403)(H,325,337)(H,326,338)(H,333,404)(H,334,435)(H,335,434)(H,336,436)(H,339,428)(H,340,433)(H,341,438)(H,342,437)(H,343,470)(H,344,406)(H,345,405)(H,346,429)(H,347,439)(H,348,455)(H,349,463)(H,350,472)(H,351,474)(H,352,471)(H,353,441)(H,354,446)(H,355,445)(H,356,462)(H,357,454)(H,358,456)(H,359,473)(H,360,440)(H,361,477)(H,362,480)(H,363,481)(H,364,430)(H,365,431)(H,366,468)(H,367,442)(H,368,448)(H,369,457)(H,370,460)(H,371,469)(H,372,443)(H,373,452)(H,374,447)(H,375,458)(H,376,464)(H,377,478)(H,378,479)(H,379,432)(H,380,444)(H,381,449)(H,382,461)(H,383,450)(H,384,451)(H,385,453)(H,386,459)(H,387,476)(H,388,465)(H,389,467)(H,390,466)(H,391,475)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,483,484)(H4,315,316,327)(H4,317,318,328)(H4,319,320,329)(H4,321,322,330)(H4,323,324,331)/t152-,153-,154-,155-,156-,157-,158-,159-,160-,174-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,241-,242-,243-,244-/m0/s1
DMOF2C6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)[C@H](C)O)CC1=CC=CC=C1)[C@@H](C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O
DMOF2C6 IK VBGWSQKGUZHFPS-VGMMZINCSA-N
DMOF2C6 IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(1R,2aS,4S,5aS,8aS,11aR,13S,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,84S,87R,96S,99S)-22,42,45-tris(4-aminobutyl)-31-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-29a,72,78-tris(2-amino-2-oxoethyl)-14a,75-bis(3-amino-3-oxopropyl)-2a,23a,25,32a,35a,66-hexabenzyl-26a,99-bis[(2S)-butan-2-yl]-17a,41a,59a,69-tetrakis(3-carbamimidamidopropyl)-5a,8a,51,54,63,84-hexakis(2-carboxyethyl)-13,16-bis(carboxymethyl)-20a-[(1S)-1-hydroxyethyl]-60-(hydroxymethyl)-96-[(4-hydroxyphenyl)methyl]-50a-(1H-imidazol-5-ylmethyl)-38a-(1H-indol-3-ylmethyl)-19,28,53a,56a-tetramethyl-57-(2-methylpropyl)-39-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.04,8.0144,148]nonahexacontahectane-36-carbonyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]butanedioic acid
DMOF2C6 CA CAS 460738-38-9
DMOF2C6 DE Retina venous occlusion
DMSNVGB ID DMSNVGB
DMSNVGB DN Echothiophate Iodide
DMSNVGB HS Approved
DMSNVGB SN Echodide; Phospholine; Diethoxyphosphinylthiocholine iodide; ECOTHIOPATE IODIDE; Ecostigmini jodidum; Ecothiopati iodidum; Ecothiophate iodide; Ioduro de ecotiopato; Phospholine iodide; Diethoxyphosphoryl-thiocholine iodide; Echothiophate iodide (USP); Ecothiopati iodidum [INN-Latin]; Iodide, Echothiophate; Iodide, Ecothiopate; Iodide, Ecothiophate; Iodide, Phospholine; Iodure d'ecothiopate; Ioduro de ecotiopato [INN-Spanish]; Phospholine (the pharmaceutical); Phospholine Iodide (TN); Phospholine iodide (TN); Ecothiopate iodide (JP15/INN); Iodure d'ecothiopate [INN-French]; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; 217 MI; 217-mi
DMSNVGB CP Wyeth Pharmaceuticals
DMSNVGB TC Parasympathomimetics
DMSNVGB DT Small molecular drug
DMSNVGB PC 10547
DMSNVGB MW 383.23
DMSNVGB FM C9H23INO3PS
DMSNVGB IC InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1
DMSNVGB CS CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]
DMSNVGB IK OVXQHPWHMXOFRD-UHFFFAOYSA-M
DMSNVGB IU 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium;iodide
DMSNVGB CA CAS 513-10-0
DMSNVGB CB CHEBI:59849
DMSNVGB DE Chronic glaucoma
DMFSWGH ID DMFSWGH
DMFSWGH DN Econazole
DMFSWGH HS Approved
DMFSWGH SN Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMFSWGH CP Merz Pharmaceuticals Llc
DMFSWGH TC Antifungal Agents
DMFSWGH DT Small molecular drug
DMFSWGH PC 3198
DMFSWGH MW 381.7
DMFSWGH FM C18H15Cl3N2O
DMFSWGH IC InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2
DMFSWGH CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMFSWGH IK LEZWWPYKPKIXLL-UHFFFAOYSA-N
DMFSWGH IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMFSWGH CA CAS 27220-47-9
DMFSWGH CB CHEBI:82873
DMFSWGH DE Tinea versicolor; Cutaneous candidiasis; Tinea corporis; Tinea cruris; Tinea pedis
DMCRQHB ID DMCRQHB
DMCRQHB DN Edrophonium
DMCRQHB HS Approved
DMCRQHB SN EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium
DMCRQHB TC Antidotes
DMCRQHB DT Small molecular drug
DMCRQHB PC 3202
DMCRQHB MW 166.24
DMCRQHB FM C10H16NO+
DMCRQHB IC InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
DMCRQHB CS CC[N+](C)(C)C1=CC(=CC=C1)O
DMCRQHB IK VWLHWLSRQJQWRG-UHFFFAOYSA-O
DMCRQHB IU ethyl-(3-hydroxyphenyl)-dimethylazanium
DMCRQHB CA CAS 312-48-1
DMCRQHB CB CHEBI:251408
DMCRQHB DE Myasthenia gravis
DMCKL5V ID DMCKL5V
DMCKL5V DN Efalizumab
DMCKL5V HS Approved
DMCKL5V SN Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
DMCKL5V CP Roche
DMCKL5V TC Immunomodulatory Agents
DMCKL5V DT Antibody
DMCKL5V SQ Heavy Chain Variable Region: EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS >Light Chain Variable RegionDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR
DMCKL5V DE Psoriasis vulgaris; Renal transplantation
DMC0GSJ ID DMC0GSJ
DMC0GSJ DN Efavirenz
DMC0GSJ HS Approved
DMC0GSJ SN EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
DMC0GSJ TC Anti-HIV Agents
DMC0GSJ DT Small molecular drug
DMC0GSJ PC 64139
DMC0GSJ MW 315.67
DMC0GSJ FM C14H9ClF3NO2
DMC0GSJ IC InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
DMC0GSJ CS C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
DMC0GSJ IK XPOQHMRABVBWPR-ZDUSSCGKSA-N
DMC0GSJ IU (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
DMC0GSJ CA CAS 154598-52-4
DMC0GSJ CB CHEBI:119486
DMC0GSJ DE Human immunodeficiency virus infection
DMFA9MV ID DMFA9MV
DMFA9MV DN Efinaconazole
DMFA9MV HS Approved
DMFA9MV SN IDP-108; KP-103
DMFA9MV CP Dow
DMFA9MV DT Small molecular drug
DMFA9MV PC 489181
DMFA9MV MW 348.4
DMFA9MV FM C18H22F2N4O
DMFA9MV IC InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
DMFA9MV CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
DMFA9MV IK NFEZZTICAUWDHU-RDTXWAMCSA-N
DMFA9MV IU (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMFA9MV CA CAS 164650-44-6
DMFA9MV CB CHEBI:82718
DMFA9MV DE Fungal infection
DMJOQM3 ID DMJOQM3
DMJOQM3 DN Eflornithine
DMJOQM3 HS Approved
DMJOQM3 SN EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate
DMJOQM3 CP Sanofi-Aventis
DMJOQM3 TC Anticancer Agents
DMJOQM3 DT Small molecular drug
DMJOQM3 PC 3009
DMJOQM3 MW 182.17
DMJOQM3 FM C6H12F2N2O2
DMJOQM3 IC InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)
DMJOQM3 CS C(CC(C(F)F)(C(=O)O)N)CN
DMJOQM3 IK VLCYCQAOQCDTCN-UHFFFAOYSA-N
DMJOQM3 IU 2,5-diamino-2-(difluoromethyl)pentanoic acid
DMJOQM3 CA CAS 70052-12-9
DMJOQM3 CB CHEBI:41948
DMJOQM3 DE African trypanosomiasis; Trypanosomiasis
DMMUCG4 ID DMMUCG4
DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4 HS Approved
DMMUCG4 SN Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN); DOCOSAHEXAENOIC ACID
DMMUCG4 CP Omthera Pharmaceutials
DMMUCG4 DT Small molecular drug
DMMUCG4 PC 445580
DMMUCG4 MW 328.5
DMMUCG4 FM C22H32O2
DMMUCG4 IC InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMMUCG4 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMMUCG4 IK MBMBGCFOFBJSGT-KUBAVDMBSA-N
DMMUCG4 IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
DMMUCG4 CA CAS 6217-54-5
DMMUCG4 CB CHEBI:28125
DMMUCG4 DE Hypertriglyceridemia; Alzheimer disease
DMRDUC0 ID DMRDUC0
DMRDUC0 DN Elagolix sodium
DMRDUC0 HS Approved
DMRDUC0 SN Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336
DMRDUC0 CP AbbVie
DMRDUC0 PC 24785956
DMRDUC0 MW 653.6
DMRDUC0 FM C32H29F5N3NaO5
DMRDUC0 IC InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
DMRDUC0 CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
DMRDUC0 IK DQYGXRQUFSRDCH-UQIIZPHYSA-M
DMRDUC0 IU sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
DMRDUC0 CA CAS 832720-36-2
DMRDUC0 DE Endometriosis
DMS7OU8 ID DMS7OU8
DMS7OU8 DN Elapegademase
DMS7OU8 HS Approved
DMS7OU8 SN Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS
DMS7OU8 CP Leadiant Biosciences
DMS7OU8 DE Immunodeficiency; Adenosine deaminase defciency
DMJLE18 ID DMJLE18
DMJLE18 DN Elbasvir
DMJLE18 HS Approved
DMJLE18 SN Elbasvir; Elbasvir [USAN:INN]; Elbasvir(MK-8742); MK 8742; MK-8742; MK8742; SB16741; ZINC150588351; 1370468-36-2; 632L571YDK; A16855; CHEBI:132967; CHEMBL3039514; CS-5332; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; DB11574; EX-A2889; HY-15789; SCHEMBL17429773; UNII-632L571YDK
DMJLE18 PC 71661251
DMJLE18 MW 882
DMJLE18 FM C49H55N9O7
DMJLE18 IC BVAZQCUMNICBAQ-PZHYSIFUSA-N
DMJLE18 CS CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
DMJLE18 IK 1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
DMJLE18 IU methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMJLE18 CA CAS 1370468-36-2
DMJLE18 CB CHEBI:132967
DMJLE18 DE Viral hepatitis
DMW649X ID DMW649X
DMW649X DN Eletriptan
DMW649X HS Approved
DMW649X SN Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CP Pfizer Inc
DMW649X TC Antimigraine Agents
DMW649X DT Small molecular drug
DMW649X PC 77993
DMW649X MW 382.5
DMW649X FM C22H26N2O2S
DMW649X IC InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
DMW649X CS CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMW649X IK PWVXXGRKLHYWKM-LJQANCHMSA-N
DMW649X IU 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CA CAS 143322-58-1
DMW649X CB CHEBI:50922
DMW649X DE Migraine
DMSRZAO ID DMSRZAO
DMSRZAO DN Eliglustat tartrate
DMSRZAO HS Approved
DMSRZAO SN Fabrazyme (TN)
DMSRZAO CP Genzyme
DMSRZAO DT Small molecular drug
DMSRZAO PC 52918379
DMSRZAO MW 959.2
DMSRZAO FM C50H78N4O14
DMSRZAO IC InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1
DMSRZAO CS CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMSRZAO IK KUBARPMUNHKBIQ-VTHUDJRQSA-N
DMSRZAO IU N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid
DMSRZAO CA CAS 928659-70-5
DMSRZAO CB CHEBI:83353
DMSRZAO DE Metabolic disorder
DMZC6GT ID DMZC6GT
DMZC6GT DN Elliptinium acetate
DMZC6GT HS Approved
DMZC6GT SN Celiptium (TN)
DMZC6GT CP Sanofi
DMZC6GT DT Small molecular drug
DMZC6GT PC 42722
DMZC6GT MW 336.4
DMZC6GT FM C20H20N2O3
DMZC6GT IC InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4)
DMZC6GT CS CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-]
DMZC6GT IK BOMZMNZEXMAQQW-UHFFFAOYSA-N
DMZC6GT IU 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate
DMZC6GT CA CAS 58337-35-2
DMZC6GT DE Solid tumour/cancer
DMRCX8K ID DMRCX8K
DMRCX8K DN Eloctate
DMRCX8K HS Approved
DMRCX8K SN Recombinant human factor VIII-FC
DMRCX8K CP Biogen Idec
DMRCX8K DE Haemophilia A
DMA9REV ID DMA9REV
DMA9REV DN Elosulfase alfa
DMA9REV HS Approved
DMA9REV SN Vimizim
DMA9REV CP Biomarin
DMA9REV SQ Elosulfase-alfa: APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARNLLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLTFLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPFPGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWTVTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGKPNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARPQIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWWPPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQCLTPPESIPKKCLWSH
DMA9REV DE Mucopolysaccharidosis
DMEYHG9 ID DMEYHG9
DMEYHG9 DN Elotuzumab
DMEYHG9 HS Approved
DMEYHG9 SN BMS-901608
DMEYHG9 CP Bristol-Myers Squibb
DMEYHG9 DT Antibody
DMEYHG9 SQ Elotuzumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Elotuzumab light chainDIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMEYHG9 DE Multiple myeloma
DMOGFIX ID DMOGFIX
DMOGFIX DN Eltrombopag
DMOGFIX HS Approved
DMOGFIX SN Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
DMOGFIX CP GlaxoSmithKline
DMOGFIX DT Small molecular drug
DMOGFIX PC 135449332
DMOGFIX MW 442.5
DMOGFIX FM C25H22N4O4
DMOGFIX IC InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
DMOGFIX CS CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
DMOGFIX IK SVOQIEJWJCQGDQ-UHFFFAOYSA-N
DMOGFIX IU 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
DMOGFIX CA CAS 496775-61-2
DMOGFIX CB CHEBI:85010
DMOGFIX DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMYZ0P1 ID DMYZ0P1
DMYZ0P1 DN Eluxadoline
DMYZ0P1 HS Approved
DMYZ0P1 SN MuDelta
DMYZ0P1 CP Furiex pharmaceuticals
DMYZ0P1 DT Small molecular drug
DMYZ0P1 PC 11250029
DMYZ0P1 MW 569.6
DMYZ0P1 FM C32H35N5O5
DMYZ0P1 IC InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
DMYZ0P1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
DMYZ0P1 IK QFNHIDANIVGXPE-FNZWTVRRSA-N
DMYZ0P1 IU 5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
DMYZ0P1 CA CAS 864821-90-9
DMYZ0P1 CB CHEBI:85980
DMYZ0P1 DE Diarrhea-predominant irritable bowel syndrome
DMG9B1U ID DMG9B1U
DMG9B1U DN Elvitegravir
DMG9B1U HS Approved
DMG9B1U SN EVG
DMG9B1U DT Small molecular drug
DMG9B1U PC 5277135
DMG9B1U MW 447.9
DMG9B1U FM C23H23ClFNO5
DMG9B1U IC InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
DMG9B1U CS CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
DMG9B1U IK JUZYLCPPVHEVSV-LJQANCHMSA-N
DMG9B1U IU 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
DMG9B1U CA CAS 697761-98-1
DMG9B1U CB CHEBI:72289
DMG9B1U DE Human immunodeficiency virus infection
DMZG5WL ID DMZG5WL
DMZG5WL DN Emapalumab
DMZG5WL HS Approved
DMZG5WL SN emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
DMZG5WL CP Novimmune
DMZG5WL DT Antibody
DMZG5WL DE Primary haemophagocytic lymphohistiocytosis
DM36LAJ ID DM36LAJ
DM36LAJ DN Emedastine
DM36LAJ HS Approved
DM36LAJ SN Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
DM36LAJ TC Antiallergic Agents
DM36LAJ DT Small molecular drug
DM36LAJ PC 3219
DM36LAJ MW 302.4
DM36LAJ FM C17H26N4O
DM36LAJ IC InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
DM36LAJ CS CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
DM36LAJ IK KBUZBQVCBVDWKX-UHFFFAOYSA-N
DM36LAJ IU 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
DM36LAJ CA CAS 87233-61-2
DM36LAJ CB CHEBI:4779
DM36LAJ DE Allergic conjunctivitis
DMCOAVT ID DMCOAVT
DMCOAVT DN Emepronium
DMCOAVT HS Approved
DMCOAVT SN Emepronium Bromide; Restenacht; Cetiprin; Emeprone bromide; Emepron bromide; 3614-30-0; Emeproniumbromid [German]; Emepronium bromide [INN:BAN]; Emepronii bromidum [INN-Latin]; Bromure d'emepronium [INN-French]; Bromuro de emepronio [INN-Spanish]; EINECS 222-786-6; Ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide; Dimethylethyl(beta-benzhydrylisopropyl)ammonium bromide; C20H28N; Ammonium, ethyldimethyl(1-methyl-3,3-diphenylpropyl)-, bromide; Emeproniumbromid; Emepronii bromidum; Bromure d'emepronium; Bromuro de emep
DMCOAVT DT Small molecular drug
DMCOAVT PC 34055
DMCOAVT MW 282.4
DMCOAVT FM C20H28N+
DMCOAVT IC InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
DMCOAVT CS CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMCOAVT IK JEJBJBKVPOWOQK-UHFFFAOYSA-N
DMCOAVT IU 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium
DMCOAVT CA CAS 27892-33-7
DMCOAVT CB CHEBI:135169
DMCOAVT DE Urinary incontinence
DMCT2YF ID DMCT2YF
DMCT2YF DN Emetine
DMCT2YF HS Approved
DMCT2YF SN Emetine hydrochloride; EMETINE; 14198-59-5; MLS000028478; SMR000058444; NSC-33669; NSC33669; Emetine monohydrochloride; Opera_ID_1460; Cephaeline methyl ether HCl; AC1O7FP4; SCHEMBL636599; CHEMBL513000; DTXSID80424947; MolPort-004-964-890; Cephaeline methyl ether hydrochloride; NSC752340; AKOS024374935; NSC-752340; ST51014995; Emetan,7',10,11-tetramethoxy-, dihydrochloride; Q-100155; 10-[((1R)-6,7-dimethoxy(1,2,3,4-tetrahydroisoquinolyl))methyl](10S,11aS,9R)-9- ethyl-2,3-dimethoxy-5,6,7,11a-tetrahydropiperidino[2,1-a]isoquinolin
DMCT2YF DT Small molecular drug
DMCT2YF PC 10219
DMCT2YF MW 480.6
DMCT2YF FM C29H40N2O4
DMCT2YF IC InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1
DMCT2YF CS CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
DMCT2YF IK AUVVAXYIELKVAI-CKBKHPSWSA-N
DMCT2YF IU (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
DMCT2YF CA CAS 483-18-1
DMCT2YF CB CHEBI:4781
DMCT2YF DE Hepatitis virus infection
DM0AQ83 ID DM0AQ83
DM0AQ83 DN Emicizumab
DM0AQ83 HS Approved
DM0AQ83 CP Roche/Genentech
DM0AQ83 DT Antibody
DM0AQ83 DE Factor VIII deficiency
DMRF9YK ID DMRF9YK
DMRF9YK DN Empagliflozin
DMRF9YK HS Approved
DMRF9YK SN 864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
DMRF9YK CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMRF9YK DT Small molecular drug
DMRF9YK PC 11949646
DMRF9YK MW 450.9
DMRF9YK FM C23H27ClO7
DMRF9YK IC InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
DMRF9YK CS C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMRF9YK IK OBWASQILIWPZMG-QZMOQZSNSA-N
DMRF9YK IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9YK CA CAS 864070-44-0
DMRF9YK CB CHEBI:82720
DMRF9YK DE Type-1 diabetes
DMBMUWZ ID DMBMUWZ
DMBMUWZ DN Emtricitabine
DMBMUWZ HS Approved
DMBMUWZ SN Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
DMBMUWZ CP Gilead; Bristol-Myers Squibb
DMBMUWZ TC Anti-HIV Agents
DMBMUWZ DT Small molecular drug
DMBMUWZ PC 60877
DMBMUWZ MW 247.25
DMBMUWZ FM C8H10FN3O3S
DMBMUWZ IC InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
DMBMUWZ CS C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMBMUWZ IK XQSPYNMVSIKCOC-NTSWFWBYSA-N
DMBMUWZ IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMBMUWZ CA CAS 143491-57-0
DMBMUWZ CB CHEBI:31536
DMBMUWZ DE Human immunodeficiency virus infection; Hepatitis virus infection; Hepatitis B virus infection
DMNFUZR ID DMNFUZR
DMNFUZR DN Enalapril
DMNFUZR HS Approved
DMNFUZR SN Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CP Merck & Co
DMNFUZR TC Antihypertensive Agents
DMNFUZR DT Small molecular drug
DMNFUZR PC 5388962
DMNFUZR MW 376.4
DMNFUZR FM C20H28N2O5
DMNFUZR IC InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
DMNFUZR CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
DMNFUZR IK GBXSMTUPTTWBMN-XIRDDKMYSA-N
DMNFUZR IU (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CA CAS 75847-73-3
DMNFUZR CB CHEBI:4784
DMNFUZR DE Hypertension
DMFYAM1 ID DMFYAM1
DMFYAM1 DN Enalaprilat
DMFYAM1 HS Approved
DMFYAM1 SN Extract of ginger root; Ginger extract; Ginger root extract; Ginger, ext; LS-3194; Zingiber officinale extract; Zingiber officinale root extract; CCRIS 7641; EINECS 283-634-2; FEMA No. 2520; FEMA No. 2521; FEMA No. 2523; Ginger extract (Zingiber officinale); ginger, extract (zingiber officinale rosc.)
DMFYAM1 PC 6850776
DMFYAM1 MW 568.8
DMFYAM1 FM C35H52O6
DMFYAM1 IC QCVRFSPGUWEKFC-ILHSMLOTSA-N
DMFYAM1 CS CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC.CCCCCC(C)CC(=O)CCC1=CC(=C(C=C1)O)OC
DMFYAM1 IK 1S/C18H28O3.C17H24O3/c1-4-5-6-7-14(2)12-16(19)10-8-15-9-11-17(20)18(13-15)21-3;1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9,11,13-14,20H,4-8,10,12H2,1-3H3;7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b;8-7+
DMFYAM1 IU (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one;1-(4-hydroxy-3-methoxyphenyl)-5-methyldecan-3-one
DMFYAM1 CA CAS 84696-15-1
DMFYAM1 DE Essential hypertension
DMPRBQV ID DMPRBQV
DMPRBQV DN Enalaprilat
DMPRBQV HS Approved
DMPRBQV SN EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
DMPRBQV CP Merck & Co
DMPRBQV TC Antihypertensive Agents
DMPRBQV DT Small molecular drug
DMPRBQV PC 5462501
DMPRBQV MW 348.4
DMPRBQV FM C18H24N2O5
DMPRBQV IC InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
DMPRBQV CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O
DMPRBQV IK LZFZMUMEGBBDTC-QEJZJMRPSA-N
DMPRBQV IU (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMPRBQV CA CAS 76420-72-9
DMPRBQV CB CHEBI:4786
DMPRBQV DE Hypertension
DM8QXOC ID DM8QXOC
DM8QXOC DN Enasidenib
DM8QXOC HS Approved
DM8QXOC SN Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG
DM8QXOC PC 89683805
DM8QXOC MW 473.4
DM8QXOC FM C19H17F6N7O
DM8QXOC IC DYLUUSLLRIQKOE-UHFFFAOYSA-N
DM8QXOC CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DM8QXOC IK 1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DM8QXOC IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DM8QXOC CA CAS 1446502-11-9
DM8QXOC CB CHEBI:145374
DM8QXOC DE Acute myeloid leukaemia
DMPOU5H ID DMPOU5H
DMPOU5H DN ENASIDENIB MESYLATE
DMPOU5H HS Approved
DMPOU5H SN UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
DMPOU5H CP Celgene/Agios
DMPOU5H PC 90480031
DMPOU5H MW 569.5
DMPOU5H FM C20H21F6N7O4S
DMPOU5H IC InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
DMPOU5H CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
DMPOU5H IK ORZHZQZYWXEDDL-UHFFFAOYSA-N
DMPOU5H IU methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMPOU5H CA CAS 1650550-25-6
DMPOU5H DE Acute myeloid leukaemia
DM7RNP3 ID DM7RNP3
DM7RNP3 DN Enbrel
DM7RNP3 HS Approved
DM7RNP3 DE Arthritis
DM0YJSB ID DM0YJSB
DM0YJSB DN Enflurane
DM0YJSB HS Approved
DM0YJSB SN Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB TC Anesthetics
DM0YJSB DT Small molecular drug
DM0YJSB PC 3226
DM0YJSB MW 184.49
DM0YJSB FM C3H2ClF5O
DM0YJSB IC InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
DM0YJSB CS C(C(OC(F)F)(F)F)(F)Cl
DM0YJSB IK JPGQOUSTVILISH-UHFFFAOYSA-N
DM0YJSB IU 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB CA CAS 13838-16-9
DM0YJSB CB CHEBI:4792
DM0YJSB DE Anaesthesia
DMFS63G ID DMFS63G
DMFS63G DN Enfortumab
DMFS63G HS Approved
DMFS63G SN ASG-2ME
DMFS63G CP Astellas Northbrook, IL Seattle Genetics Bothell, WA
DMFS63G DT Antibody drug conjugate
DMFS63G DE Urothelial carcinoma
DM7YPM1 ID DM7YPM1
DM7YPM1 DN Enfuvirtide
DM7YPM1 HS Approved
DM7YPM1 SN Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd
DM7YPM1 CP Hoffmann-La Roche pharmaceutical company
DM7YPM1 TC Anti-HIV Agents
DM7YPM1 DT Small molecular drug
DM7YPM1 SQ DB00109 sequence: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
DM7YPM1 PC 24847866
DM7YPM1 MW 4565
DM7YPM1 FM C206H304N52O66
DM7YPM1 IC InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1
DM7YPM1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C
DM7YPM1 IK BWVBEUNZTQWGMR-CKVIKZOTSA-N
DM7YPM1 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM7YPM1 DE Human immunodeficiency virus infection
DMYTE6L ID DMYTE6L
DMYTE6L DN Enoxacin
DMYTE6L HS Approved
DMYTE6L SN Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-o